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Abstract 
Chronic obstructive pulmonary disease (COPD) is the 4th leading cause of death worldwide 
and accounts for the highest rate of hospital admissions in Canada.  The need for sensitive 
regional and surrogate measurements of lung structure and function in COPD continues to 
motivate the development of non-radiation based and sensitive imaging approaches, such as 
hyperpolarized helium-3 (3He) and xenon-129 (129Xe) magnetic resonance imaging (MRI).  
The static ventilation images acquired using these approaches allows us to directly visualize 
lung regions accessed by the hyperpolarized gas during a breath-hold, as well as quantify the 
regions without signal referred to as the percentage of the thoracic cavity occupied by 
ventilation defects (VDP).  The lung micro-structure can also be probed using diffusion-
weighted imaging which takes advantage of the rapid diffusion of 3He and 129Xe atoms to 
generate surrogate measurements of alveolar size, referred to as the apparent diffusion 
coefficient (ADC).  Here we evaluated COPD lung structure and function using 
hyperpolarized gas MRI measurements longitudinally, following treatment and in early 
disease.  In COPD ex-smokers, we demonstrated 3He VDP and ADC worsened significantly 
in only 2 years although there was no change in age-matched healthy volunteers, suggestive 
of disease progression.  We also evaluated COPD ex-smokers pre- and post-bronchodilator 
and showed regional improvements in gas distribution following bronchodilator therapy 
regardless of spirometry-based responder classification; the ADC measured in these same 
COPD ex-smokers also revealed significant reductions in regional gas trapping post-
bronchodilator.  Although 3He MRI has been more widely used, the limited global quantities 
necessitates the transition to hyperpolarized 129Xe, and therefore we directly compared 3He 
and 129Xe MRI in the same COPD ex-smokers and showed significantly greater gas 
distribution abnormalities for 129Xe compared to 3He MRI that were spatially and 
significantly related to lung regions with elevated ADC.  Finally, we demonstrated that ex-
smokers with normal spirometry but abnormal diffusion capacity of the lung for carbon 
monoxide (DLCO) had significantly worse symptoms, exercise capacity and 3He ADC than 
ex-smokers with normal DLCO.  These important findings indicate that hyperpolarized gas 
MRI can be used to improve our understanding of lung structural and functional changes in 
COPD. 
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CHAPTER 1  
1 INTRODUCTION 
Chronic Obstructive Pulmonary Disease (COPD), a common preventable and treatable 
disease, is characterized by persistent airflow limitation that is usually progressive and 
associated with an enhanced chronic inflammatory response in the airways and the lung 
to noxious particles or gases.1  The objective of Chapter 1 is to provide motivation for the 
work presented in the remaining chapters of this thesis, as well as to provide an overview 
of the current standard measurements of pulmonary function, the natural history and 
progression of lung function decline, the underlying disease mechanisms and finally 
discuss how nuclear medicine, computed tomography (CT) and magnetic resonance 
imaging (MRI) have been used to evaluate COPD and provide imaging biomarkers that 
can be used to evaluate disease progression and treatment response. 
1.1 Burden of COPD 
According to the World Health Organization estimates in 2004, 64 million people, or 
10% of the population, was suffering from COPD.2  Three million people died of COPD 
which equaled just over 5% of all global deaths and ranked COPD as the 4th leading 
cause of death worldwide.2;3  By the year 2030, it is predicted that COPD will increase to 
the 3rd leading cause of death worldwide, as shown in Figure 1-1.2  It is suggested that 
the projected increase in the global burden of COPD is due to the aging population and 
the increasing levels of tobacco smoking in many middle- and low-income countries.2   
Similarly, in Canada alone, respiratory disease is ranked the 3rd leading cause of death 
behind cardiovascular disease and cancer, and among all respiratory diseases that results 
in death, COPD is responsible for the greatest proportion of all deaths for both men and 
Figure 1-1 The top four leading causes of death in the world in 2004 and the predicted 
top four leading causes of death in 2030 compared 
Adapted from The global burden of disease:  2004 update, World Health Organization.2;3 
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women as shown in Figure 1-2.4  In addition to being a leading cause of death and 
disability,2 COPD also imposes significant healthcare costs with exacerbations of COPD, 
defined as COPD-related symptoms including one or more of the following lasting at 
least 3 days: cough, wheeze, dyspnea, or sputum production,5 accounting for the greatest 
proportion of the total COPD burden on the Canadian healthcare system.  The Canadian 
Institute for Health Information showed that in 2006, COPD accounted for the highest 
rate of hospital admission among the major chronic illnesses.6  This rate also included 
single and repeat hospitalizations indicating that there is a much higher readmission rate 
for COPD than any other chronic illness including angina, asthma, heart failure, diabetes 
and epilepsy, as shown in Figure 1-3.  A study by Mittmann and colleagues5 indicated 
that the average cost of an exacerbation requiring hospitalization in Canada was nearly 
$10,000, with an average length of stay of 10 days.  The authors also estimated that the 
national cost burden for the direct costs associated with COPD exacerbations ranged from 
$646 million to $736 million per annum.5  
Cigarette smoking has long been recognized as the most important risk factor for the 
development of COPD,7 greater than that of atmospheric pollution or occupational 
exposure, although the association between occupational exposure (airborne dusts, fumes 
and vapors) and COPD has been demonstrated independent of cigarette smoking.7-9  
Figure 1-2 Proportion of all deaths due to respiratory disease for men and women in 
Canada 
Adapted from the Life and Breath: Respiratory Disease in Canada 2007 report, Public 
Health Agency of Canada.4 
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Although there has been less evidence to support the association between second-hand 
smoke exposure and the risk of developing COPD,10;11 more recent studies suggest there 
is a causal relationship between exposure to second-and smoke and COPD.  There is also 
a genetic risk factor, alpha-1-antitrypsin deficiency, that has been shown to be associated 
with an increased risk of COPD.12;13  Other COPD risk factors have been suggested,1  
such as prior tuberculosis, socioeconomic status and asthma, however more work must be 
done to understand the effect of these and other risk factors on the development of COPD 
as COPD in those who have never smoked remains poorly understood.14 
Recent international epidemiological studies have reported prevalence estimates that 
suggest that approximately 9-10% of adults aged 40 years and older have COPD.14;15  
Importantly, this estimate is much higher than previous estimates15 and studies have 
shown that of these individuals that were determined to have COPD, only 19% had been 
Figure 1-3 Repeat Hospitalizations by Condition at First Admission 
This graph shows the number of patients with a single hospitalization, one repeat 
hospitalization and two or more repeat hospitalizations by condition at first admission.   
Reproduced with permission from the Canadian Institute for Health Information’s (CIHI) 
publication entitled Health Indicators 2008.6 
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previously diagnosed and were being treated.16  These studies indicate that the prevalence 
of COPD is much higher than previously believed and that the majority of the individuals 
that have the disease are not diagnosed and are not being treated.   
In the following section I will describe the structure and function of the lung, introduce 
the basic mechanisms by which this structure and function is abnormal in COPD, as well 
as describe the current gold standards for assessing lung function.  
1.2 The Respiratory System:  Structure and Function 
In humans, the respiratory system includes the oral and nasal cavities, the lungs, the 
conducting airways, the parts of the central nervous system concerned with the control of 
the muscles of respiration, and the chest wall structures.17;18  The respiratory system 
serves several functions, however, the main function of the respiratory system is to 
supply the tissues of our body with oxygen for cellular metabolism and to eliminate the 
carbon dioxide waste that is produced by cellular metabolism, and this process, known as 
gas exchange, occurs in the lungs.17-19  In this section I will discuss the process by which 
air moves from the environment, through the conducting zone and to the respiratory zone 
for gas exchange. 
1.2.1 The Airways:  Conducting Zone 
During inspiration, air passes through the nose or mouth into the pharynx.  The pharynx 
branches into two tubes:  the esophagus, which passes food to the stomach, and the 
larynx.  Air passes through the larynx into the trachea which then branches into the two 
main bronchi; one of which enters the left lung and the other the right lung.17-19  Within 
the lungs, air passes through more than 20 generations, or airway branches, and as the 
airway generation increases the airways become narrower, shorter and more numerous.  
As shown in Figure 1-4, the conducting zone extends from the top of the trachea 
(generation 0) to the terminal bronchioles (generation 16).20  These airways do not 
contain alveoli and therefore there is no gas exchange.17-19  However, following 
inspiration, some of the inhaled air remains in the conducting zone.  The air that resides 
within the conducting zone at the end of inspiration is known as the anatomic dead space.  
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The average anatomic dead space is approximately 150 ml in healthy adults,21 however, 
this volume has been shown to increase with age.22   
 
 
 
 
 
 
 
 
 
 
1.2.2 The Airways:  Respiratory Zone 
The terminal bronchioles branch into the respiratory bronchioles (generation 17-19), 
which marks the beginning of the respiratory zone.  Due to the large number of airway 
branching in the respiratory zone, the total cross sectional area of the airways increases 
rapidly (Figure 1-5).  Accordingly, the respiratory zone constitutes approximately 90% 
of the lung volume, while the airways and the blood vessels of the conducting zone 
constitute the remaining 10%.20  The respiratory bronchioles, as shown in Figure 1-4, 
have few alveoli lining their walls.  Finally, the respiratory bronchioles divide into the 
Figure 1-4  Schematic of the Human Airways   
The conducting zone of the lungs does not participate in gas exchange and extends 
from generation 0 to generation 16.  The respiratory zone is the site of gas exchange 
and extends from generation 17 to generation 23.  Adapted from West JB.  Respiratory 
Physiology:  the essentials, Ninth edition.19 
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alveolar ducts and the alveolar sacs.  The number of alveoli increases from the respiratory 
bronchioles to the alveolar sacs which consist entirely of alveoli.18  The part of the lung 
that branches from the respiratory bronchiole and includes the alveolar duct and sac is 
referred to as an acinus.  The acinus represents the functional respiratory unit of the lung 
where gas exchange occurs.   
 
 
 
 
 
 
 
1.2.3 Ventilation 
Ventilation is the process by which gas is brought from the environment to the blood-gas 
barrier.19  The volume of gas inhaled and exhaled with each breath, or during one 
respiratory cycle, is referred to as the tidal volume.  Total ventilation is defined as the 
volume of gas leaving the lung each minute.  Therefore, since the average person has a 
tidal volume of 500 ml and takes approximately 15 breaths/min,19 the volume of gas 
entering the lung each minute is 7500 ml/min.  However, as discussed above, the air that 
resides within the conducting zone at the end of inspiration does not participate in gas 
exchange.  Therefore, the volume of gas entering the lung each minute that participates in 
gas exchange, otherwise known as alveolar ventilation, is approximately 5250 ml/min.   
Figure 1-5 Schematic showing the rapid increase in the cross sectional area of the 
airways as the airway generation increases within the respiratory zone.   
Adapted from West JB.  Respiratory Physiology:  the essentials, Ninth edition.19 
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1.2.4 The Alveoli:  Site of Gas Exchange 
The alveoli are small air sacs at the end of the respiratory bronchioles where gas 
exchange occurs.  It has been estimated that there are approximately 480 million alveoli 
in the human lungs with a mean size of 4.2x106 μm3, or a diameter of roughly 200 μm23  
Within each alveoli, oxygen is transported from the alveoli to the pulmonary capillaries 
by diffusion.  The factors that determine the rate of diffusion of O2 from the alveoli to the 
pulmonary capillaries is described by Fick’s law for diffusion, as shown in equation (1): 
 (1) 
where A=surface area of the lung for diffusion, D=diffusion coefficient of gas, P1-
P2=partial pressure difference of the gas across the alveolar capillary membrane, and 
T=thichness across the alveolar capillary membrane.  Therefore, gas diffusion rate is 
directly proportional to the surface area of the lung, the diffusion coefficient of the gas 
and the partial pressure difference, and it is inversely proportional to the thickness across 
the lung membrane.   
The total surface area of an average adult’s lungs available for gas exchange is estimated 
to be approximately 70 m2.24  The gas in the alveoli follows the basic rule of a pressure 
gradient and diffuses from an area of high pressure within the alveoli (Partial Pressure of 
Oxygen, [PA02] > 100 mm Hg) to an area of low pressure within the pulmonary 
capillaries (PA02 = 40 mm Hg).25  The gas diffusion is slowed by the alveolar capillary 
membrane and the thickness of the alveolar capillary membrane of an average healthy 
adult is approximately 0.2-0.5 μm.17   
1.3 Established Tests of Lung Function 
Pulmonary function tests may be used in a hospital setting or a physician’s office to aid in 
the diagnosis and management of pulmonary diseases or in research studies.  These tests 
are used to evaluate overall lung function by measuring air flow or volume, symptoms or 
exercise capacity. 
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1.3.1 Pulmonary Function Tests 
Pulmonary Function tests measure the volume and flow of air during inspiration and 
expiration as well as provide information regarding gas exchange within the lung.   These 
measurements are used for clinical diagnosis of lung disease, for monitoring disease 
progression as well as for treatment recommendations in patients with respiratory disease. 
1.3.1.1 Spirometry 
 
Figure 1-6 Measurement of the Forced Expiratory Volume in 1 second (FEV1) and the 
Forced Vital Capacity (FVC)  
Body Plethysmograph (MedGraphics Corporation. 350 Oak Grove Parkway St. Paul, 
MN, USA) is used to measure airflows, lung volumes and capacities (A) and a schematic 
depicting the airflow curve used to measure FEV1 and FVC (B). 
 
Spirometry is a physiological test that measures how an individual inhales or exhales 
volumes of air as a function of time.26  The two most common spirometric measurements 
are the forced expiratory volume in 1 second (FEV1) and the forced vital capacity (FVC).  
As shown in Figure 1-6, these measurements are made while the subject is in the seated 
position in the Body Plethysmograph chamber.  The subject begins with tidal breathing 
and then is instructed to inhale maximally and then exhale as fast as possible and then 
continue to exhale as long as possible.  Following maximum inhalation, the volume that 
is exhaled in 1 second is the FEV1 and the total volume that could be maximally exhaled, 
following maximum inhalation, is the FVC.   
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According to the American Thoracic Society (ATS)/ European Respiratory Society 
(ERS) task force, an adequate test requires a minimum of three acceptable maneuvers be 
performed.26  An acceptable maneuver is one in which all three phases, defined as 1) 
maximal inspiration; 2) a “blast” of exhalation; and 3) continued complete exhalation to 
the end of test, were performed correctly and for the required duration.  The maneuvers 
must also be repeatable with the difference between the largest and the next largest FVC 
≤ 0.15 L.26 
In Canada, the Canadian Thoracic Society (CTS) clinical guidelines specify that 
spirometry measurements be used to diagnose asthma and COPD, and therefore 
spirometry should be conducted by trained and qualified personnel, to assure that 
ATS/ERS spirometry testing standards are met.27  However, even with technologists 
trained to meet these standards, spirometry is well-known to be difficult to perform in 
children and in those with lung disease.  
 
 
 
 
 
 
1.3.1.2 Plethysmography 
As shown in Figure 1-7, there are eight static lung volume and capacity measurements 
that can be determined using body plethysmography.  The definition of the lung volumes 
and capacity measurements are as follows:  tidal volume (TV) is defined as the volume of 
gas inhaled or exhaled during normal breathing; the inspiratory reserve volume (IRV) is 
the maximum volume of gas that can be inspired from the end of a normal inspiration; the 
expiratory reserve volume (ERV) is the maximum volume of gas that can be expired 
Figure 1-7  The Volumes and Capacities of the Lung Measured using Body 
Plethysmography 
Adapted from Respiratory Care: Principles and Practice.28 
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from the end of a resting expiration; the residual volume (RV) is the volume of gas 
remaining in the lungs after a maximal expiration; the vital capacity (VC) is the 
maximum volume of gas that can be exhaled from the lungs after a maximal inspiration 
or inhaled from a point of maximal exhalation; inspiratory capacity (IC) is the maximum 
volume of gas that can be inspired from the normal end-expiratory position; functional 
residual capacity (FRC) is the volume of gas remaining in the lungs at the end of a resting 
expiration; and, the total lung capacity (TLC) is the volume of gas in the lungs at the end 
of a maximal inspiration.28   
Clearly, many of these static volumes can be measured directly from normal breathing by 
instructing the subject to perform the four static positions:  maximal inhalation, end 
inspiration, end expiration, and maximal exhalation.  However, the gas remaining in the 
lung after a maximal expiration, known as the residual volume (RV), and the volume of 
gas in the lung after a normal expiration, known as the functional residual capacity 
(FRC), must be measured with body plethysmography using Boyle’s law.28  The subject 
is placed in an air-sealed plethysmograph chamber, as shown in Figure 1-6A, and 
breathes through a mouthpiece with a shutter.  At the end of a normal expiration the 
shutter closes and the subject is instructed to inhale.  As the subject tries to inhale, the 
pressure changes within the box and at the airway can be measured.  Since the box 
volume is known, the volume of gas in the lungs when the shutter was closed (FRC) can 
be calculated.   
1.3.1.3 Diffusing Capacity 
The diffusing capacity of the lung for carbon monoxide (DLCO) is another pulmonary 
function test that provides an indirect measure of diffusion of gases across the alveolar 
membrane into the blood.  The body plethysmograph, as shown in Figure 1-6A, with the 
attached Medgraphics gas analyzer allows DLCO to be measured.  DLCO is measured by 
instructing the subject to exhale to RV and then perform a maximum inhalation to TLC.  
As shown in Figure 1-8, during the inhalation the subject inhales a gas mixture that 
contains a very low concentration of carbon monoxide (CO) (0.3%) and helium (10%) 
with air; the subject is then instructed to hold their breath for 10 seconds before 
exhalation.29  The volume of gas exhaled is collected and analyzed.  The gas first exhaled 
11 
 
is discarded as it represents the anatomic dead space volume and is defined as 2.2 ml x kg 
body weight.29  The remaining volume is analyzed by comparing the exhaled 
concentrations of CO and helium to the inspired concentrations to determine the amount 
of CO diffusing across the alveolar membrane. 
 
 
 
 
 
 
 
 
 
 
 
According to the ATS/ERS task force, there should be at least two acceptable tests that 
meet the repeatability requirement of either being within 3 ml CO standard temperature 
(273 Kelvin), pressure (101.3 kPa, 760 mmHg) and dry (STPD)·min-1·mmHg-1 of each 
other or within 10% of the highest value.29  Factors that affect the DLCO include diseases 
that reduce the volume of pulmonary capillary blood such as anemia, and diseases that 
affect the area and thickness of the alveolar capillary membrane including emphysema, 
interstitial lung disease and pulmonary hypertension.29  Cigarette smoking has also shown 
to reduce DLCO30 and the ATS/ERS task force recommends that subjects refrain from 
smoking on the day the test is performed.29 
Figure 1-8  Measurement of the Diffusing Capacity of the Lung for Carbon Monoxide 
The subject inhales a mixture of 10% helium and 0.3% CO, holds his/her breath for 10 
seconds then exhales.  The anatomic dead space volume is discarded and the remaining 
alveolar sample is analyzed.  Adapted from West JB.  Respiratory Physiology:  the 
essentials, Ninth edition.19 
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Pulmonary function test measurements are usually interpreted by comparing measured 
values in individual subjects with the values that are predicted for healthy subjects based 
on age, sex, height and race, and expressing the observed value as a percent of 
predicted.31 
1.3.2 6 minute Walk Test 
The 6 minute walk test (6MWT) is a self-paced exercise test that measures the distance a 
subject can walk on a flat, hard surface in a period of 6 minutes.   The 6MWT is thought 
to reflect the functional exercise level for daily physical activities in subjects with 
respiratory disease.  The 6MWT has been used for measuring the efficacy of inhaled 
corticosteroids in the treatment of COPD.32  It has also been used as a measure of 
functional status for COPD subjects33 and the 6 minute walk distance (6MWD) has been 
demonstrated to correlate significantly with mortality.34-36   
1.3.3 St. George’s Respiratory Questionnaire 
The St. George’s Respiratory Questionnaire (SGRQ)37 is a questionnaire designed to 
measure impact on overall health, daily life, and perceived well-being in patients with 
obstructive airways disease.  The questionnaire contains three component scores:  
symptoms, activity and impact (on daily life), and a total score.  Scores range from 0 to 
100, with higher scores indicating more severe limitation.  In asthmatics and COPD 
subjects, the test-retest reproducibility has been determined to be high,38;39 and significant 
correlations have been shown between the SGRQ symptom score with frequency of 
wheeze, the SGRQ activity score with the 6MWD and between the SGRQ impact score 
with anxiety.38 
1.3.4 Other Pulmonary Function Tests 
The Global initiative for chronic Obstructive Lung Disease (GOLD)40 recommends the 
use of the Modified British Medical Research Council (mMRC)41 questionnaire or the 
COPD Assessment Test (CAT) for the assessment of COPD symptoms.  The mMRC 
questionnaire is grading system that is used to assess a patient’s level of dyspnea that 
range from Grade 0 (breathless with strenuous exercise) to Grade 4 (breathless when 
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dressing or undressing).  The mMRC score correlates with standard lung function 
measurements,42 the 6MWD43 and, importantly, predicts mortality better than evaluating 
disease severity using the FEV1.44 
The CAT is an 8-item questionnaire that assesses the impact of cough, sputum, dyspnea 
and chest tightness on health status.  The CAT scores range from 0 to 40 with the higher 
scores indicating a more severe impact of COPD symptoms on health status.45  CAT 
scores have been shown to correlate significantly with SGRQ scores in COPD.45;46 
Another test that has been recently developed uses four factors that were determined to 
have the strongest association with one-year morality, called the BODE index: the body 
mass index (B), the degree of airflow obstruction (O) measured using FEV1 as a 
percentage of the predicted value, dyspnea (D) measured from the score on the mMRC 
dyspnea scale, and exercise capacity (E) measured using the 6MWD.47  The BODE index 
after lung volume reduction surgery correlates with survival in COPD patients48 and has 
been shown to better predict hospitalization for COPD than FEV1 alone.49 
1.4 Lung Function Decline 
1.4.1 The Aging Lung 
As we age, the most important physiological changes that occur in the lung are, 1) 
decreased elastic recoil, 2) decreased compliance of the chest wall, and, 3) decreased 
strength of the respiratory muscles.50  The decline in elastic recoil of the lung with age is 
attributed to changes in the lung connective tissue,51 and the decrease in chest wall 
compliance is thought to occur due to structural changes within the rib cage, such as 
decalcification of the ribs, calcification of costal cartilage, changes in rib-vertebral 
articulations, changes in the shape of the chest, narrowing in intervertebral disk spaces 
and age-related osteoporosis, which all result in stiffening of the chest.50;51 Finally, 
respiratory muscle strength is known to decrease with age.  Respiratory muscle strength 
has been shown to be related to nutritional status, which is often poor in the elderly.  An 
age-related decrease in respiratory muscle strength is also related to a decrease in muscle 
mass and a decrease in the number of muscle fibres.50;52 
14 
 
Another important structural change that occurs during aging is the structural changes 
within lung parenchyma – known as “senile emphysema.”  Studies have demonstrated 
that homogeneous airspace size enlargement occurs over 60 years of age in the normal 
lungs, without a loss of alveolar attachments and chronic inflammation.53  It has also been 
demonstrated that there is thickening of alveolar walls and a reduction in the number of 
peripheral airways.53  A consequence of the reduction in supporting tissues around the 
airways is a tendency for the small airways to collapse at higher lung volumes.50 
The lung physiological changes that occur during aging result in changes in lung 
function.  Figure 1-9 shows the changes in lung volumes that occur during aging.  Early 
studies have shown that during normal aging, the RV increases while the TLC remains 
constant.54  The increase in RV that occurs with age is likely due to the decreased 
strength of the expiratory muscles and the tendency of the small airways to collapse.50  
There is also an increase in anatomic dead space that occurs during aging22 and this is 
thought to be due to calcification of the bronchial cartilage.  The DLCO is also been 
shown to decrease with age and this is likely a result of the decreased alveolar surface 
area as well as a decrease in the pulmonary capillary blood volume.55   
In the landmark study by Fletcher and Peto in 1977,56 airflow obstruction measured using 
FEV1 was evaluated for 103 men who were non-smokers aged 30-59.  As shown in 
Figure 1-10, FEV1 was shown to decline continuously with age.  However, this study 
was only performed in men and was cross-sectional.  Subsequent studies evaluating FEV1 
decline with age showed the rate of decline was greater in men than women,57 and the 
rate of decline was found to be much higher in longitudinal studies.58 
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1.4.2 COPD:  Accelerated Lung Aging  
As described in the previous section on risk factors for COPD, smoking cigarettes, 
although not the only risk factor, is the main source of inhaled noxic particles that leads 
to the development of COPD.40;59  However, not all smokers develop airflow limitation; 
early studies demonstrated that cigarette smoking is associated with inflammation in both 
the large and small airways60;61 and the lung parenchyma62 in smokers with normal FEV1.  
Although it is unclear why some smokers develop COPD while others do not, it is known 
that the inflammatory response in COPD is amplified63 and persists long after smoking 
cessation.64  Irreversible airflow limitation is the defining feature of COPD and is 
associated with “lesions that obstruct the small conducting airways, produce 
emphysematous destruction of the lung’s elastic recoil force, or both.”65  Importantly, the 
disease that occurs within the airways and the lung parenchyma are independent disease 
processes that may develop in tandem or in isolation.  In this section I will first introduce 
how COPD is diagnosed using spirometry and the natural history of COPD.  Finally, I 
will discuss the underlying disease mechanisms that are thought to be responsible for the 
functional lung changes. 
1.4.2.1 Diagnosis and Classification of COPD 
When COPD is suspected based on symptoms, such as dyspnea, chronic cough or sputum 
production, and/or a history of exposure to risk factors,59 airflow limitation is measured 
Figure 1-9  Lung volume changes that occur with age 
TCV = Thoracic Cavity Volume, VC = Vital Capacity, RV = Residual Volume.   
Adapted from Norris et. al. (1956).54 
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using spirometry and the presence of a post-bronchodilator FEV1/FVC <0.70 confirms 
the diagnosis of COPD.1;59  As shown in Table 1-1, COPD severity is determined 
according to the GOLD criteria, which uses specific spirometric cut-points that are 
obtained after inhalation of a short-acting bronchodilator in order to minimize 
variability.59 
Table 1-1  Classification of Severity of Airflow Limitation in COPD 
GOLD Stage Severity Post-Bronchodilator FEV1 Criteria 
GOLD Stage I Mild FEV1 ≥ 80% predicted 
GOLD Stage II Moderate 50% ≤ FEV1 < 80% predicted 
GOLD Stage III Severe 30% ≤ FEV1 < 50% predicted 
GOLD Stage IV Very Severe FEV1 < 30% predicted 
Adapted from the Global strategy for the diagnosis, management, and prevention of 
chronic obstructive pulmonary disease (Revised 2011), Global Initiative for Chronic 
Lung Disease1 
Although this approach has been introduced due to its diagnostic simplicity and ease of 
use in the primary care setting, the FEV1/FVC cut off has been acknowledged to 
potentially result in an over-diagnosis of COPD in the elderly,66 as well as under-
diagnosis of mild or early stage COPD.67  Moreover, there is only a weak correlation 
between GOLD spirometric severity classification and symptom scores reflecting health-
related quality of life.   
1.4.2.2 Natural History of Airflow Obstruction in COPD  
Figure 1-10 reproduces the landmark study by Fletcher and Peto56 that shows the 
different rates of lung function decline, as measured by FEV1, for healthy individuals that 
have never smoked in comparison with those individuals who were current cigarette 
smokers that exhibit the amplified inflammatory response that is associated with the 
development of COPD.  This study indicates that while the rate of decline of FEV1 in 
healthy non-smokers is 42±6 ml/year, this rate is accelerated to 47±3 ml/year in light 
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smokers and to 66±4 ml/year in heavy smokers.  Interestingly, this study also showed that 
the rate of FEV1 decline was slower in individuals that had quit smoking (32±4 ml/year), 
suggesting that decline in lung function can be slowed by smoking cessation.  However, 
as described previously, this was a cross-sectional study in men. 
The more recent longitudinal Lung Health Study68;69 also evaluated smokers that were 
randomized into three groups: a group of smokers who received no intervention, a group 
of smokers who received smoking cessation intervention, and a group of smokers who 
received smoking cessation intervention and bronchodilator therapy, and followed the 
subjects over 11 years.  In accordance with the findings by Fletcher and colleagues,56 this 
study found that men who quit smoking at the beginning of the study had a FEV1 decline 
of 30 ml/year while men who continued to smoke had an accelerated declined of 66 
ml/year.  In contrast to the study performed by Fletcher and colleagues,56 the Lung 
Healthy Study also evaluated women and showed that women who quit smoking at the 
beginning of the study had a FEV1 decline of 22 ml/year while women who continued to 
smoke declined by 54 ml/year.69  Interestingly, when decline in FEV1 was expressed as a 
percentage of the predicted normal value, there were no significant differences between 
the sexes.69 
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1.4.2.3 Chronic Bronchitis 
Chronic bronchitis is defined as “the presence of cough and sputum production for at 
least 3 months in each of two consecutive years.”1  Early work investigating chronic 
bronchitis attributed the mucous hypersecretion with thickening of the bronchial gland.70-
72  Reid70 reported that this thickness was related to gland hypertrophy and that there was 
a correlation between the amount of sputum produced and gland thickness.  It was later 
shown that chronic bronchitis was associated with bronchial inflammation.60  Mullen and 
colleagues60 demonstrated that smokers with chronic bronchitis had greater inflammation 
of the cartilaginous airways (> 4 mm in internal diameter) than smokers without chronic 
bronchitis, and that there was a significant correlation between inflammation of the 
cartilaginous airways and mucous gland thickness.  These data suggest that chronic 
cough and sputum production was associated with an inflammatory response due to the 
cigarette smoke in the cartilaginous (or central) airways.  Interestingly, it has also been 
demonstrated that this inflammatory response persists in the central airways of smokers 
who had quit but continued to report mucus hypersecretion.64 
Figure 1-10  Lung Function Decline  
Lung function declines in never-smokers during aging and declines at an accelerated rate 
in current smokers.  However, lung function declines return to normal rates following 
smoking cessation.  Adapted from Fletcher et. al. (1977).56 
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Much of this early work was performed in smokers with and without airflow limitation 
measured using FEV1 and therefore more recent studies have focused on evaluating 
whether there is a predictive relationship between the presence of chronic cough and 
sputum production and the future occurrence of COPD.  de Marco and colleagues73 
recently evaluated a group of young subjects, aged 20-45, with normal lung function over 
a period of approximately 9 years.  It was shown that at the baseline visit, 9% of subjects 
reported chronic cough and sputum production and of these subjects that reported 
persistent symptoms at follow-up, there was a threefold increased risk of developing 
COPD.73  Another study demonstrated that chronic cough and sputum production was 
associated with an increased decline in FEV1 and subsequent hospitalization due to 
COPD.74  
1.4.2.4 Small Airways Disease 
Based on the study by Weibel and Gomez20 it is known that as the airway generation 
increases, due to the dichotomous branching pattern of the airways, the number of 
airways rapidly increases and therefore the total cross-sectional area increases, as shown 
in Figure 1-5.   Although the smaller airways could be considered the major site of 
resistance in normal lungs based on Poiseuille’s equation that indicates that resistance in 
a single tube is inversely proportional to the radius of the tube to the 4th power, by 
inspection of the airways and according to Weibel’s data20 we must also consider the 
number of airways and their total cross-sectional area.  Although the radius of the 
airways decrease as airway generation increases, the number and cross-sectional area of 
the airways increases.17   Since these airways are arranged in parallel, the resistances are 
added as reciprocals and therefore the overall resistance is very small in the small 
airways.   
Early studies by Hogg and Macklem75 that directly measured small airway pressure using 
a retrograde catheter confirmed that in healthy subjects, the small airways contributed 
very little to the total airway resistance.   However, they also demonstrated that in 
subjects with mild and severe emphysema, as well as subjects with bronchiectasis and 
bronchiolitis that there was a marked increase in the resistance of the small airways (<2 
mm in diameter), while there was little or no change in total lung resistance.  The authors 
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observed that the bronchioles were often narrowed and occluded with mucus plugging 
and defined these changes in the small airways as “small airways disease,” where disease 
changes may occur without being detected by measuring total airway resistance or by 
FEV1.  Taken together, since the total resistance is determined largely by the more central 
airways, disease may accumulate in the small airways without being detected. 
It was later shown in histopathological studies that inflammation was present in the 
peripheral airways of smokers76 and that the most characteristic lesion in the small 
airways of smokers was respiratory bronchiolitis.61  However, these early reports did not 
perform spirometry in the smokers and therefore the subjects may or may not have had 
COPD.  A more recent study by Hogg and colleagues77 evaluated the pathology of the 
small airways in relation to COPD severity, as measured by the GOLD COPD stages 
(Table 1).1  These authors found that although the degree to which the lumen was filled 
with mucous was significantly correlated with the severity of COPD, the strongest 
parameter associated with progression of COPD from GOLD stage 0 to GOLD stage IV 
was with thickening of the airway wall.77  It was also shown that the extent of 
inflammation was significantly correlated with COPD severity.77  Figure 1-11A shows a 
normal small airway of a non-smoker in comparison with a small airway filled with 
mucus (Figure 1-11B), a small airway with thickened airway walls and a lumen partially 
filled with mucus (Figure 1-11C) and a small airway with wall thickening that is thought 
to restrict airway caliber with lung inflation (Figure 1-11D). 
1.4.2.5 Emphysema 
Emphysema was first described by Laennec in 1834.  He described emphysema of the 
lungs as “dilation of the air cells” that “may affect both lungs at the same time, one only, 
or a part of one or of both.”78  More recently, the National Heart, Lung, and Blood 
Institute defined emphysema as “a condition of the lung characterized by abnormal, 
permanent enlargement of airspaces distal to the terminal bronchiole, accompanied by the 
destruction of their walls, and without obvious fibrosis.”79  It is well known that smokers 
develop two distinct forms of emphysema:  centrilobular and panlobular emphysema.80-82  
Centrilobular emphysema results from dilation and destruction of the respiratory 
bronchioles, as shown in Figure 1-11E, and has been demonstrated to have a more 
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uneven pattern of tissue destruction, predominantly occurring in the upper lung lobes.  
Conversely, panlobular emphysema has a more homogenous pattern and is more likely to 
be associated with genetic disorders such as alpha-1 antitrypsin deficiency (Figure 1-
11F).81;82   Moreover, early studies indicated that there was a relationship between 
cigarette smoking and centrilobular emphysema, but not with panlobular emphysema.83  
Studies in smokers and non-smokers demonstrated that inflammatory cells play a role in 
the parenchyma tissue destruction in smokers,62 and that this cigarette smoke-induced 
inflammation is amplified in subjects with emphysema versus smokers without 
emphysema.63 
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Figure 1-11 Small Airways Disease and Emphysema in COPD 
A. Normal small airway.  B. Small airway containing plug of mucus.  C. Acutely 
inflamed airway with thickened wall in which the lumen is partly filled with an 
inflammatory exudate of mucus and cells.  D. Airway surrounded by connective tissue, 
which appears as if it might restrict normal enlargement of the lumen and unfolding of 
the epithelial lining that occurs with lung inflation.  E. Early lesions of centrilobular 
emphysema (CLE) that have destroyed central portions of several acini of a single 
secondary lobule. D. More even destruction of the lobule in panacinar emphysema.  
Reproduced with permission from Hogg (2004).65 
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1.5 Imaging Lung Structure and Function in COPD 
1.5.1 Chest X-ray  
Chest x-ray and x-ray computed tomography (CT) are the two most common lung 
imaging procedures performed.  Chest x-ray is often the first line imaging method 
because it is widely available, inexpensive, allows visualization of pulmonary structures, 
including the trachea, carina and major bronchi, mediastinum and hilar regions and the 
diaphragm, as shown in Figure 1-12, and has a relatively low radiation dose.84  In the 
posterior-anterior view, as shown in Figure 1-12A, the patient is upright with the x-ray 
source positioned so that the x-rays enter through the back (posterior lung) and the 
anterior surface of the chest is against the film holder.  The patient’s hands are place on 
their hips with the elbows rolled slightly forward so that the scapulae (or shoulder blades) 
are removed from the lung field.85  In the lateral view, as shown in Figure 1-12B, the 
patient is positioned with their side against the film with their arms over their head so that 
the arms are not in the lung field.85  The different lung structures described above can be 
depicted with a chest x-ray because the x-rays are attenuated differently by the various 
body tissues.  For example, the ribs show up as bright structures because they attenuate 
the x-rays more than the lung tissue, which are air-filled, and show up as dark regions in 
the image.  This is also the reason why the arms and the scapulae are removed from the 
lung field. 
The radiation dose associated with a typical chest x-ray is approximately 0.01 
millisieverts (mSv) which is equivalent to approximately 3 days of background 
radiation.85;86  Although there is very low radiation dose associated with chest x-ray, and 
identification of lung structures allows abnormalities in the lungs to be detected, such as 
increased translucency and flattening of the diaphragm which is commonly associated 
with gas trapping in respiratory diseases, the limitation of chest x-ray is that all anatomic 
structures are superimposed onto each other.  This results in difficulty diagnosing COPD 
and in particular for the early disease stages where disease-related structural changes may 
be subtle.  While there is some conflicting views on the utility of chest radiography in 
assessing COPD,87;88 and more specifically for the assessment of emphysema, a study 
comparing chest x-ray with a morphologic diagnosis of emphysema post-mortem 
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indicated that a diagnosis of emphysema using chest x-ray was made in only 16% of 
subjects that were pathologically proven to have mild to moderate emphysema and in 
only 42% of subjects with moderately severe to severe emphysema.88   
1.5.2 X-ray Computed Tomography  
Since its introduction in the early 1970s, CT scanning technology has become so 
advanced that it is now considered by many as the imaging technology of choice for 
many diseases.  As described above, a limitation of conventional x-ray imaging is that it 
provides a two-dimensional image of a three-dimensional object.  CT overcomes this 
limitation by acquiring the image in slices thereby providing images of three-dimensional 
objects.  Each slice in a CT image is composed of voxels and each voxel is assigned a CT 
value or Housfield unit (HU) based on the attenuation coefficient relative to water.  
Therefore, a voxel that contains water will have a value of 0 HU, while air will have a 
value of -1000 HU and tissues or structures that have a higher attenuation coefficient than 
water will have a positive HU value; bone has CT values up to 2000 HU.85   
Emphysema is characterized by airspace enlargement,79 and therefore the air-filled 
emphysematous regions in the lung will appear dark in CT images.  Figure 1-13A shows 
a central slice CT image for a healthy subject and a COPD subject with emphysema.  The 
Figure 1-12 Chest x-ray of a COPD subject  
Posterior-anterior chest x-ray (A) and lateral chest x-ray (B) for a 62-year-old male 
smoker.  Reproduced with permission from Parraga et. al (2007).89  
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air filled regions, including the trachea as well as the large left apical bullae in the COPD 
subject with emphysema appear dark in the image.  Early pathological correlative studies 
demonstrated that regions of the lung that visually appeared to be emphysematous on CT 
images were confirmed as emphysematous in post-mortem evaluations.90  Later, studies 
that used radiologist CT grading and pathological grading systems demonstrated that 
there were strong and statistically significant correlations between CT and pathology 
emphysema scores,91-93 however it was found that CT could not differentiate mild 
emphysema from normal parenchyma confirmed by pathology in some patients.92   
Although CT was demonstrated to be very accurate in the determination of the presence 
and extent of moderate to severe emphysema, with strong and significant correlations 
found with both pathology91-93 and measurements of airflow limitation and diffusion 
capacity,93 these early visual scoring systems were subjective and therefore there was 
considerable inter-observer and intra-observer variability.93  Because visual assessment 
was based on the presence of voxels with abnormally low attenuation, the extent of 
emphysema could be assessed by highlighting voxels within specified ranges of HU 
called “density masks.”94  Density mask emphysema scores were demonstrated to be 
comparable to visual emphysema scores and had strong and significant correlations with 
pathologic scores,94 and importantly, eliminated the inter-observer and intra-observer 
variability introduced by visual assessment.  Figure 1-13B shows the CT density mask 
with all voxels with attenuation values less than -950 HU highlighted in red.  Although 
there are several thresholds that have been introduced, and some contrasting results on 
which threshold is most appropriate,94-96 it has been demonstrated that the low attenuating 
areas quantified on CT are indicative of the lung tissue destruction that accompanies 
emphysema.   
Although strong and significant correlations between CT measurements of emphysema 
and diffusion capacity measurements have been reported, there have been only moderated 
correlations with measurements of airflow.93;95  This finding is not surprising given that 
measurements of airflow limitation (FEV1) are measuring the contributions of the loss of 
elastic recoil due emphysematous tissue destruction (emphysema) as well as airway 
narrowing and obstruction (chronic bronchitis and small airways disease).  Therefore, it is 
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also of great interest to obtain measurements of the airway dimensions from CT.  Figure 
1-14 shows an airway tree segmentation that was generated in three-dimensions from the 
CT image.  The cross-section of the airway of interest can then be identified and the 
airway dimensions can be measured.  Nakano and colleagues were the first to 
demonstrate that the percentage of the total airway (airway wall area plus lumen area) 
that was airway wall (wall area percent, WA%) significantly correlated with airflow 
limitation, but not DLCO, in COPD smokers independent of emphysema.97  However, 
these measurements were based on a large central airway and it is well known, as 
described above, that the major site of airflow limitation in COPD occurs in the small 
airways less than 2 mm in diameter.75  Accordingly, more recent studies have 
demonstrated that the correlation between CT wall area dimensions with airflow 
limitation was stronger for higher generation airways.98   
 
 
 
 
 
 
 
 
 
 
Figure 1-13 Coronal CT of a healthy smoker and a COPD ex-smoker 
The central slice coronal CT image (A) with the corresponding density mask with all voxels 
with attenuation values less than -950 HU highlighted in red (B) for a healthy subject and a 
COPD subject with emphysema. 
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Although thoracic CT is capable of measuring both emphysema and airways disease in 
COPD, CT is not without its costs and the field of medicine has observed a considerable 
increase in the number and type of CT scans performed for clinical investigation where 
now, in the United States, CT accounts for 24% of all radiation exposure and 50% of all 
medical radiation exposure.99  Importantly, the increase in CT scans was also observed in 
the paediatric population and a study by Mettler and colleagues100 reported that children 
aged 0-15 years old accounted for 11.2% of all CT scans performed.  This is a concern 
because the effective dose for a thoracic CT is approximately 8 mSV, which is equivalent 
to 400 chest x-rays or approximately 4 years of background radiation.85  In COPD, serial 
imaging is important for evaluating disease progression and response to treatment or 
intervention, and therefore the increase in radiation exposure from CT has been a major 
concern because there is an increased risk of radiation-induced cancer from the 
cumulative dose related to repeated CT investigations.101   
Figure 1-14 CT airway analysis of a COPD subject 
The airway tree segmentation in three-dimensions is obtained from the original CT 
image, with the surrounding lung parenchyma removed from view, to identify the 
airway of interest for measurement of the airway dimensions, as shown in red.  The 
airway tree and airway measurements were performed using the Pulmonary Workstation 
2.0 (VIDA Diagnostics, Inc., Coralville, IA).   
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1.5.3 Nuclear Medicine 
In their seminal study on the site and nature of airway obstruction in COPD, Hogg and 
colleagues stated that as a result of the obstruction of the small airways in the lung, there 
is a “strong likelihood that, at some stage, chronic obstructive airway disease causes 
significant abnormalities in the distribution of ventilation, and presumably in gas 
exchange.”75  Therefore, in COPD ventilation may be highly inhomogeneous across the 
lung or absent in certain lung regions all together.  Ventilation scintigraphy can be 
performed with radioaerosols or radioactive gases for visualization of the regional 
distribution of ventilation in the lung.102  Images can be acquired during the gas wash-in 
phase, at the “steady state” and during the gas wash-out phase.103  The breathing protocol 
utilized depends largely on the half-life of the isotope.  For example, the short half-life of 
Krypton-81m of 13 seconds limits its use for evaluating the gas in the wash-in or steady 
state phase as decay occurs prior to exhalation.103  Studies have demonstrated that 
subjects with abnormal pulmonary function tests also have abnormal aerosol deposition 
patterns,104 and smokers with reported symptoms and normal pulmonary function 
measurements often had abnormalities with xenon-133 or aerosol lung imaging,105;106 
suggesting that functional lung imaging may be more sensitive than spirometry for 
detecting early disease changes.  However, central aerosol deposition is often reported 
and may be caused by the large particle size or by abnormally rapid or shallow breathing 
patterns, or both.105  Taplin and colleagues105 showed that 10% of subjects having central 
deposition at one imaging time-point showed normal distribution 1-2 hours later.   
The lung attempts to match blood flow to ventilation to maintain optimal efficiency of 
gas exchange, and therefore subjects with ventilation abnormalities may have perfusion 
abnormalities as well.  Perfusion scintigraphy is often performed using technetium-99m 
(99mTc) labeled macro-aggregated albumin (MAA) injected in a peripheral vein.103  
Studies have shown that there is a significant correlation between perfusion and aerosol 
lung imaging106 suggesting that regional perfusion abnormalities are likely related to 
diminished ventilation within those areas. 
While lung scintigraphy acquires two-dimensional projection images, single photon 
emission tomography (SPECT) allows three-dimensional assessment of ventilation and 
29 
 
perfusion.  Studies have recently shown that ventilation/perfusion SPECT with 99mTc-
labled carbon (Technegas) is the aerosol of choice for COPD lung imaging, providing 
more homogeneous distribution within the lungs with less focal deposition in both larger 
and smaller airways.107  It was also recently demonstrated that the extent of 
ventilation/perfusion abnormalities in COPD subjects was significantly correlated with 
both spirometric measurements of lung function and with the extent of emphysema 
measured using CT, but not with COPD-related symptoms.108  Although 
ventilation/perfusion SPECT has been demonstrated to regionally evaluate abnormalities 
in COPD, it is limited by its low spatial resolution, long image acquisition times and the 
necessity for inhalation of a radioactive substance. 
1.6 Magnetic Resonance Imaging 
In contrast to other diagnostic imaging methods, magnetic resonance imaging (MRI) does 
not require the use of x-rays or other ionizing radiation, offering the potential for 
intensive serial and longitudinal studies in the same patient.  MRI is also becoming an 
important imaging tool because MRI can provide both structural and functional lung 
information.   
1.6.1 Conventional Proton MRI 
MRI is an imaging tool that provides unique tissue contrast with high spatial and 
temporal resolution.  However, despite these very practical advantages, MRI of the lung 
has some unique technical challenges.  Figure 1-15 illustrates the lower visibly obvious 
information content provided by conventional proton (1H) MRI as compared to chest CT 
for evaluating COPD.  Using conventional 1H MRI alone, without special attention to 
echo time, the thoracic cavity appears as a black hole because in the normal lung, tissue 
density (and consequently 1H density) is relatively low in comparison to gas density.  
Second, the 1H MRI lung tissue signal is degraded due to the air-tissue interfaces that 
introduce microscopic magnetic field inhomogeneities.109  Third, the signal is further 
degraded by respiratory and cardiac motion because of the relatively slow image 
acquisition time relative to CT.  Therefore, the application of conventional 1H MRI for 
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the detection of structural abnormalities in the lung has not progressed beyond the 
research setting, even though there is great potential for its use.110 
 
 
 
 
 
 
To overcome these shortcomings, numerous studies have endeavoured to develop more 
sensitive 1H MRI techniques for lung imaging, including ultra-short echo time (UTE) 
methods,111-113 oxygen-enhanced MRI114-124 and Fourier decomposition methods.125-129  
Although experience is limited in COPD, MRI of cystic fibrosis has been shown to be 
comparable to CT for identifying morphological changes, such as bronchiectasis, 
bronchial wall thickening, mucus plugging, air fluid level, consolidation and 
segmental/lobar destruction.130  Although it is clear that MRI lacks the spatial resolution 
achieved by CT to identify the more subtle morphological changes that are likely to occur 
in mild disease,130 the advantage of MRI is that assessment of lung function is also 
possible.  Oxygen-enhanced MRI allows regional visualization of oxygen diffusion from 
the alveoli into the capillaries,114 and initial studies in COPD demonstrated measurements 
of oxygen enhancement can differentiate between healthy volunteers and subjects with 
pulmonary emphysema,120 and showed strong and significant correlations with 
FEV1120;122 and DLCO in subjects with emphysema.119;120;122  Fourier decomposition MRI 
allows lung perfusion and ventilation to be assessed, with no contrast enhancement, and 
preliminary studies demonstrated that Fourier decomposition MRI is feasible and 
reproducible in respiratory disease. 125-129  These previous studies suggest that oxygen-
Figure 1-15 Comparison of CT and Conventional MRI in a COPD subject 
Yellow arrows point to a large left upper lobe bullae that is not as visually obvious with 
MRI as CT. 
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enhanced MRI and Fourier decomposition MRI have the potential to provide 
reproducible structural and functional measurements in COPD. 
1.1. Hyperpolarized Noble Gas MRI 
 Over the last two decades, MRI using inhaled hyperpolarized noble gases helium-3 
(3He)131-144 and xenon-129 (129Xe)145;146 have been shown to provide structural and 
functional measurements in healthy volunteers as well as subjects with a range of 
respiratory conditions.  These approaches are based on the serendipitous finding of Albert 
and colleagues145 in 1994 that showed the potential of inhaled hyperpolarized or 
magnetized noble gas for pulmonary MRI.  Albert and colleagues145 recognized that 
polarization of 3He and 129Xe gases could be enormously enhanced through spin-
exchange with an optically pumped alkali metal vapour – rubidium.147  Albert 
demonstrated that gas-phase collisions between 129Xe and the polarized rubidium atoms 
resulted in the transfer of angular momentum from the rubidium valence electron to the 
129Xe nucleus and thereby increased the signal by ~100 000 times.145  Although the first 
investigations utilized the isotope 129Xe,145;146 the field quickly transitioned to 3He due to 
the nearly 3-fold higher gyromagnetic ratio (3He: 32.4 MHz/T, 129Xe: 11.8 MHz/T) and 
higher enrichment – both of which contribute to a greater MRI signal with 3He than 
129Xe.  Importantly, excellent subject safety and tolerability across a wide spectrum of 
volunteers has been reported with both 3He148and 129Xe MRI.142;149   
1.1.1. Biomarkers 
Hyperpolarized gas MR imaging allows the quantification of several structural/functional 
components of the lung, commonly referred to as “biomarkers”.  The most established 
measurements are the ventilation defect percent150;151 and the apparent diffusion 
coefficient (ADC).152-154  Figure 1-16 shows the static ventilation images and the 
corresponding ADC maps for a representative subject with normal lung function in 
contrast with three representative COPD subjects with varying lung function.   
1.1.1.1. Ventilation Defect Measurements 
32 
 
Early in vivo studies in humans obtained these “spin density” or “static ventilation” 
images in healthy subjects and demonstrated homogenous signal intensity within the 
lung, with clear delineation of the diaphragm, heart, chest wall and blood vessels, which 
appeared as signal voids in the images.155-157  The 1st 3He MRI investigation in COPD 
was performed by Kauczor and colleagues131 and they demonstrated heterogeneous signal 
intensity and ventilation abnormalities or “defects,” which were thought to represent local 
hypoventilation or non-ventilated regions of the lung.  Subsequent studies also 
demonstrated extensive ventilation defects in subjects with severe emphysema that 
corresponded to defects seen on xenon-133 ventilation (wash-in) scintigraphy.132  A 
larger study evaluating hyperpolarized 3He MRI with xenon-133 scintigraphy also found 
fairly good concordance between the two modalities for depiction ventilation 
abnormalities in 15 subjects.158   
Although the first 3He MRI ventilation analyses were based on a radiologist’s 
interpretation of the ventilated lung regions,132;158-160 more recent investigations have 
utilized scoring and manual volumetric analysis approaches.89;150;151;158;160-170  Using these 
quantitative approaches it was demonstrated that ventilation defect measurements were 
highly reproducible in COPD for same day evaluations as well as for the images acquired 
one week later.89   Importantly, 3He ventilation defect measurements in COPD were also 
shown to correlate significantly with spirometric measurements of airflow limitation.151 
1.1.2. Apparent Diffusion Coefficient 
Another type of hyperpolarized gas MR image that is commonly acquired uses diffusion-
weighted MRI.  Hyperpolarized gas diffusion-weighted MRI is sensitive to the self-
diffusion of the gas atoms within the lung microstructure.  During the diffusion time 
interval, the hyperpolarized gas atoms diffuse by Brownian motion and the walls of the 
alveolar structures act as barriers by restricting the gas atoms motion or displacement.  
Therefore, an “apparent” diffusion coefficient (ADC) can be derived that reflects the 
level of restriction of the gas atoms within the airways and airspaces of the lung.  It is 
important to note that in contrast to 3He, 129Xe gas is capable of transmembrane diffusion 
across the alveolar wall, providing both measurements of alveolar size and 
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transmembrane diffusion kinetics;134-146 in contrast 3He gas is biologically inert and 
therefore it cannot be passively transported across intact biological tissues and 
membranes.   
Importantly, both 3He and 129Xe ADC measurements have been demonstrated to 
significantly correlate with age,140;171 with standard measurements of pulmonary 
function140;152;172;173 and with CT emphysema measurements.169;172-174  The 3He ADC has 
been more extensively evaluated and was shown to be highly reproducible89;163;175;176 and 
significant correlations with histology measurements of airspace size have been 
demonstrated.177  Abnormally elevated 3He ADC has also been reported in asymptomatic 
smokers without COPD,174;178 suggesting that 3He ADC provides a way to sensitively 
measure regional lung tissue destruction in early disease.   
Another advantage of hyperpolarized gas MR diffusion-weighted imaging is that by 
changing the diffusion time and gradient strength, different features of the lung micro-
structure may be evaluated.  For example, short-range diffusion experiments are most 
sensitive to changes in local microstructure (e.g. alveolar destruction), while long-range 
diffusion experiments are sensitive to the connections between airways and larger lung 
structures and possibly collateral ventilation in COPD.179;180  Moreover, obtaining 
diffusion-weighted images at multiple b-values, measurements of the geometric 
parameters at the level of the alveoli can be made.181-184 
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Figure 1-16 Hyperpolarized 3He MRI Static Ventilation Image and ADC Map in a 
Healthy ex-smoker and COPD ex-smokers 
Healthy ex-smoker is a 70 yr old male: FEV1=101%pred, FEV1/FVC=0.75; COPD 
subject 1 (S1) is a 74 yr old male: FEV1=86%pred, FEV1/FVC=0.54; COPD S2 is a 
72 yr old female: FEV1=64%pred, FEV1/FVC=0.65; COPD S3 is a 60 yr old female: 
FEV1=50%pred, FEV1/FVC=0.38. 
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1.7 Thesis Hypotheses and Objectives 
Hyperpolarized 3He MRI provides high spatial and temporal resolution images of the 
lung air spaces in subjects with COPD.  These images allow us to directly visualize the 
lung regions accessed by the hyperpolarized gas during a breath-hold, as well as the 
regions of the lung not accessed which appear as signal voids and are referred to as 
“ventilation defects.”  The lung micro-structure can also be probed using diffusion-
weighted imaging which takes advantage of the rapid 3He and 129Xe atom Brownian 
motion to generate surrogate measurements of alveolar size.  Since the establishment of 
inhaled gas MRI for pulmonary imaging in 1994, there have been significant 
advancements in the type and scope of images that can be acquired, however, in order for 
broader translation of this imaging technology to occur, and for the potential translation 
of hyperpolarized gas MRI for clinical use, it must be demonstrated that these 
measurements relate to clinically meaningful outcomes.  The overarching objective of 
this thesis was to generate hyperpolarized gas MRI measurements and measurement tools 
for the regional quantitative evaluation of hyperpolarized gas MRI with sufficient 
precision to evaluate COPD disease progression and treatment response.  Another 
important step in the broader translation of this imaging technology is transitioning to 
129Xe MRI, and comparison of hyperpolarized 129Xe with 3He MRI is important in order 
to realize the potential of 129Xe MRI for respiratory research.  The specific objectives and 
hypotheses tested in each chapter of this thesis are described below. 
To better understand the potential for hyperpolarized 3He MRI to provide quantitative 
longitudinal COPD endpoints,  the objective of Chapter 2 was to quantitatively evaluate a 
small group of COPD ex-smokers and healthy volunteers over 2 years using 
hyperpolarized 3He MRI.  As described above, much of our current understanding of the 
natural history of COPD arises from the landmark study of Fletcher and colleagues56 who 
showed that lung function measured using FEV1 declines as we age, and that this decline 
is accelerated in smokers with COPD; in ex-smokers, however, they showed that this 
decline in FEV1 returned to normal rates.  Therefore, based on the Fletcher curve 
prediction, we hypothesized that the longitudinal changes in 3He MRI measurements in 
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the COPD ex-smokers would be similar to those observed in elderly healthy never-
smokers.   
This previous work evaluating longitudinal changes in 3He MRI measurements was 
performed using manual segmentation approaches, which clearly increases segmentation 
time and, importantly, introduces the potential for inter- and intra-observer variability.  
For serial evaluation of 3He MRI it is critical that the change measured over time 
represents physiological change that has occurred and is not due to measurement error.  
Therefore, the objective of Chapter 3 was to generate a semi-automated segmentation 
method for 3He MRI to enable its use in longitudinal and serial studies, and to compare 
the reproducibility and spatial agreement of the developed semi-automated segmentation 
algorithm to manual segmentation.  We hypothesized that semi-automated measurements 
would not be statistically significantly different from manual measurements and have 
significantly reduced inter- and intra-observer variability. 
Using the segmentation algorithm developed in Chapter 3, the objective of Chapter 4 was 
to evaluate a group of COPD subjects using 3He MRI prior to and immediately following 
bronchodilator therapy.  A significant bronchodilator response is currently defined as an 
increase in post-bronchodilator spirometry, however, based on the findings in Chapter 2 
we hypothesized that 3He MRI would provide the necessary sensitivity as well as 
precision to detect any potential regional functional lung changes after bronchodilator 
therapy in COPD subjects regardless of spirometry based responder classification.   
In the same group of COPD ex-smokers evaluated using 3He MRI pre- and post-
bronchodilator therapy in Chapter 4, the objective of Chapter 5 was to further evaluate 
the regional effects of bronchodilator administration in COPD using 3He MRI ADC 
measurements.  Regional evaluation of tissue micro-structure using 3He MRI ADC would 
provide important insight into the lung alterations that accompany the improvements in 
regional 3He gas distribution after bronchodilator administration that were previously 
observed.  In order to do this we first developed image registration/segmentation methods 
for quantifying ADC in the lung regions newly ventilated post-bronchodilator.  We 
hypothesized that the regions of the lung that were newly ventilated following 
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bronchodilator therapy were not more emphysematous than the remaining lung tissue, 
and that the 3He ADC could measure significant reductions in regional gas trapping 
following bronchodilator therapy.   
Despite the unique potential of 3He MRI and the previous work demonstrating its 
potential for use in evaluating COPD outcomes, the broader adoption of hyperpolarized 
gas MRI requires a transition from 3He gas, which has limited and unpredictable global 
quantities and high cost, to 129Xe gas, which is substantially more abundant in nature 
existing in measurable quantities in the atmosphere.  The objective of Chapter 6 was to 
quantitatively compare hyperpolarized 3He and 129Xe MRI acquired within a few minutes 
in healthy volunteers and subjects with COPD, and to evaluate the correlations between 
3He and 129Xe MRI measurements with standard measurements of pulmonary function.  
We hypothesized that the different properties of 129Xe gas would result in significant 
differences in 129Xe compared to 3He gas distribution measurements in COPD but not in 
healthy volunteers.     
To better understand the morphological determinants for the ventilation differences 
observed between hyperpolarized 3He and 129Xe MRI in COPD in Chapter 6, the 
objective of Chapter 7 was to evaluate the same group of COPD subjects using the image 
registration/segmentation methods for quantifying ADC on a regional basis developed in 
Chapter 5.  We hypothesized that emphysematous regions in the lung would more readily 
fill with 3He as compared to 129Xe gas, leading to decreased 129Xe MRI ventilation.   
While it is important to demonstrate that 3He MRI measurements relate to important 
clinical outcomes, such as disease progression and treatment response, another goal of 
imaging is to identify early disease changes.  The objective of Chapter 8 was to evaluate 
and compare well-established clinical, physiological and emerging imaging 
measurements in ex-smokers with normal spirometry and abnormal DLCO with a group of 
ex-smokers with normal spirometry and DLCO and ex-smokers with GOLD stage I 
COPD.  We hypothesized that ex-smokers with normal spirometry but abnormal DLCO 
would have significantly worse symptoms, exercise capacity and 3He MRI ADC than ex-
smokers with normal DLCO. 
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The objective of Appendix A was to establish imaging measurement reproducibility in 
adult cystic fibrosis subjects over a short period of time (7 ± 2 days) in the absence of 
therapeutic intervention using hyperpolarized 3He MRI.  We hypothesized that 3He MRI 
would provide the necessary and sufficient spatial and temporal sensitivity to detect day-
to-day changes in lung function.   
A case report of a COPD ex-smoker that was evaluated serially over 4 years using 
hyperpolarized 3He MRI, twice prior to and twice following an acute exacerbation 
requiring hospitalization is provided in Appendix B.  Based on our previous studies 
demonstrating the high sensitivity of 3He MRI for measuring improvements in the 
absence of FEV1 improvements, we hypothesized that following hospitalization and 
treatment, visibly obvious improvements in 3He gas distribution would be observed prior 
to improvements in FEV1.   
Finally, in the last chapter of this thesis I will provide an overview and summary of the 
important findings and conclusions of Chapters 2-8.  I will also address the study specific 
limitations as well as general limitations of the hyperpolarized gas MRI studies 
presented, and provide some potential solutions.  Finally, based on the findings and 
limitations discussed, I will outline a roadmap for future hyperpolarized gas MRI studies. 
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CHAPTER 2  
To better understand the potential for hyperpolarized 3He MRI to provide quantitative 
longitudinal COPD endpoints, here we quantitatively evaluated a small group of COPD 
ex-smokers and healthy volunteers over 2 years using hyperpolarized 3He MRI.   
The contents of this chapter have been previously published in Radiology and permission 
to reproduce the article was granted by the Radiological Society of North America 
(RSNA®) and is provided in Appendix C. 
M Kirby, L Mathew, A Wheatley, GE Santyr, DG McCormack and G Parraga.  Chronic 
Obstructive Pulmonary Disease:  Longitudinal Hyperpolarized 3He MR Imaging.  
Radiology 2010; 256(1): 280-9. 
2 Longitudinal Hyperpolarized 3He Magnetic Resonance 
Imaging of COPD 
2.1 Introduction 
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and 
mortality affecting at least 600 million people worldwide.1  It is the world’s fourth 
leading cause of death, and the most common chronic, terminal respiratory disease.2  Due 
to the heterogeneous nature of COPD, studies of its natural history and progression are 
complex, typically requiring large study sample sizes and long durations to obtain 
relevant longitudinal endpoints.  Accordingly, much of our current understanding of the 
natural history of COPD arises from the landmark study of Fletcher and colleagues,3 and 
based on the cross-sectional spirometry measurements of the forced expiratory volume in 
one second (FEV1).  The current functional definition of COPD4 is also based on FEV1 
and changes in FEV1 over time are still the most widely-accepted measure of COPD 
progression.  However, a number of limitations of spirometry for the diagnosis, 
classification and longitudinal monitoring of COPD are motivating the development of 
new COPD measurements5 including those derived from non-invasive imaging.6;7  For 
example, high resolution multi-detector x-ray computed tomography (CT)8-11 has been 
recently used to identify phenotypes of both emphysema and airway disease12-14 and 
detects statistically significant COPD changes over relatively short periods of time.15   
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Hyperpolarized helium-3 (3He) magnetic resonance imaging (MRI) has recently emerged 
as another research method for the evaluation of COPD.16-20  In particular, previous work 
showed that the 3He apparent diffusion coefficient (ADC)16;21-23 was a sensitive 
measurement of emphysematous destruction19;23;24 and airspace size16;17;25;26, correlating 
with pulmonary function (FEV1 and DLCO),27 as well as histological measurements of 
lung surface area.28  Importantly, 3He MRI ADC is also age-dependent,29 and reflects 
differences in patient anatomical position,30 disease severity31 and smoking history.32  
Quantitative focal 3He MRI ventilation defects have also been shown in COPD,24;32-34 and 
these reflect differences in subject age35 and disease status.20  To better understand the 
potential for hyperpolarized 3He MRI to provide quantitative longitudinal COPD 
endpoints, we designed a pilot longitudinal 3He MRI study of COPD.  The objective of 
this study was to quantitatively evaluate a small pilot group of COPD ex-smokers and 
healthy volunteers over 2 years using hyperpolarized 3He MRI.   
2.2 Materials and Methods 
2.2.1 Subjects 
Twenty subjects were enrolled from the general population of the local tertiary health 
care center as previously described.20  All subjects provided written informed consent to 
the study protocol approved by the local research ethics board and Health Canada and the 
study was compliant with the Personal Information Protection and Electronic Documents 
Act (PIPEDA, Canada) and the Health Insurance Portability and Accountability Act 
(HIPAA, USA).  COPD subjects were enrolled who were ex-smokers between the ages 
of 50-70, with a clinical diagnosis of COPD and were categorized according to the 
Global initiative for chronic Obstructive Lung Disease (GOLD) criteria,4 with a smoking 
history of at least 10-pack-years and fewer than three COPD exacerbations within the last 
12 months.  Exacerbations during the follow-up period were defined as hospitalization 
for COPD or the patient’s first-time need for antibiotic or prednisone therapy and these 
were reported from hospital records,36 subject charts and additionally verified in a 
telephone interview with the subject after follow-up imaging was completed.  COPD 
subjects were excluded during a screening visit if post-salbutamol FEV1 was greater than 
3%.  Healthy elderly volunteers were enrolled (same age range as the COPD subjects) 
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who had a smoking history of <1 pack–year with no smoking in the previous 25 years, 
and with no history of previous chronic or current respiratory disease.  All tests and 
imaging were performed at baseline and at 26 months ± 2 (standard deviations). 
2.2.2 Pulmonary Function Tests 
Spirometry was performed using an ndd EasyOne spirometer (ndd Medizintechnik AG, 
Zurich, CH) reporting FEV1 and forced vital capacity (FVC) with a minimum of three 
acceptable spirometry maneuvers with the best FEV1 and FVC selected for analysis 
according to American Thoracic Society guidelines.37  Whole body plethysmography was 
performed using a MedGraphics’ Elite Series stand-alone body plethysmograph 
(MedGraphics Corporation. 350 Oak Grove Parkway St. Paul, MN USA) for the 
measurement of total lung capacity (TLC), inspiratory capacity (IC), residual volume 
(RV), and functional residual capacity (FRC).   
2.2.3 Imaging  
Subjects were screened for MRI and coil compatibility (inner diameter of elliptical coil = 
50cm) prior to scanning, and digital pulse oximetry was used to monitor arterial blood 
oxygenation levels during MR breathhold scanning.  A turn-key, spin-exchange polarizer 
system (HeliSpin™, GEHC, Durham, NC) was used to polarize 3He gas to 30-40%, as 
previously described.38  Doses of hyperpolarized 3He gas (5 mL per kilogram of body 
weight) were administered in 1 L plastic bags (Tedlar®, Jensen Inert Products, Coral 
Springs, FL) diluted with ultrahigh purity, medical grade nitrogen (Spectra Gases, Alpha, 
NJ).  Polarization of the diluted dose was quantified by a polarimetry station (GENC, 
Durham, NC) immediately prior to 3He gas administration to subject. 
MRI was performed on a whole body 3.0 Tesla Excite 12.0 MRI system (GEHC, 
Milwaukee, WI USA).  1H images were acquired prior to 3He MRI  during breath-hold of 
a 1 L 4He/N2 mixture from FRC;33 diffusion-weighted imaging and ventilation or spin 
density imaging were also performed during breath-hold of a 1 L 3He/N2 mixture from 
FRC.33  All scanning was completed within approximately 7-10 minutes of subjects first 
lying in the scanner.   
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2.2.4 Image Analysis 
The signal-to-noise ratio (SNR) for all images acquired was determined by calculating 
the mean pixel value within a 10 x 10 voxel region of interest (ROI) for four 
representative ROI within the lung parenchyma, and dividing by the standard deviation of 
the mean pixel values for noise inside a ROI of the same size at the corners of the image 
where there was no lung structure.  SNR was determined for each slice and then averaged 
to obtain a single SNR value for each subject and time-point.  Images were analyzed in a 
controlled image visualization environment with room lighting levels equivalently 
established for all image analysis sessions.   
ADC maps were processed using in-house software programmed in the IDL Virtual 
Machine platform (Research Systems Inc., Denver, CO) as previously described33 with b 
= 1.6 s/cm2.  Spin density images were examined for analysis of ventilation defects in all 
coronal slices by two expert observers (MK and LM) blinded to subject identity, disease 
status, and time point, as well as the other observer’s measurements.  As previously 
described,39 a ventilation defect was identified by each observer independently as any 
lung region of diminished signal intensity but not those areas of signal loss associated 
with the pulmonary vascular structures, heart, hilum and mediastinum.  Images were 
reviewed such that 3He and 1H images were visible on a digital workstation monitor 
system (consisting of identical 19 inch flat panel monitors).  Manual segmentation of 
ventilation defects was performed using custom-designed image visualization software 
which also provided a method for two-dimensional rigid single point image registration 
(1H and 3He slices) based on the carina, facilitating the manual segmentation of 
ventilation defects in all slices.  Ventilation defect volume (VDV) and thoracic cavity 
volume (TCV) were recorded following manual segmentation of 3He and 1H images 
respectively, and used to calculate ventilation defect percent (VDP).16;25;26;40  VDV was 
derived from the manually segmented ventilation defect area for each slice and this was 
multiplied by the slice thickness; VDV for all slices was summed to obtain a whole lung 
(WL) VDV.  For the center slice (CS), which is the middle slice acquired that clearly 
shows the carina and two main bronchi, VDV was also manually segmented and 
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reported.  Additionally, WL and CS measurements were recorded for TCV for calculation 
of both WL and CS VDP, as well as for ADC. 
2.2.5 Statistical Methods 
For 3He MRI ventilation measurements, observer reproducibility was evaluated for 2 
different observers using the interclass correlation coefficient (ICC), coefficient of 
variation (COV) and linear regression (r2) using SPSS 16.00 (SPSS Inc., LEAD 
Technologies Inc. Chicago, IL, USA).  Comparison of baseline and follow-up means 
were performed using a Wilcoxon matched pairs two-tailed t-test using SPSS 16.00.  The 
relationship between changes in 3He MRI measurements and changes in pulmonary 
function measurements at follow-up were determined using linear regression and 
Spearman correlation coefficients using GraphPad Prism version 4.00 (GraphPad 
Software Inc, San Diego California, USA).  The relationship between the changes in 3He 
MRI VDV and smoking history was also determined using linear regression and 
Spearman correlation coefficients using GraphPad Prism version 4.00.  A Holm-
Bonferroni correction41 was used for multiple paired t-tests and all correlations.  The 
Holm-Bonferroni adjusted p-values were determined by ordering p-values from smallest 
to largest, with the smallest p-value multiplied by k, where k is the number of hypotheses 
to be tested.  If the resulting modified p-value was less than α (Type I error rate) the 
hypothesis was rejected.  The next smallest p-value was then multiplied by k-1 and the 
new modified p-value was compared to α.  This process was repeated until the modified 
p-value could not be rejected.  In all statistical analyses, results were considered 
significant when the probability of making a Type I error was less than 5% (p < 0.05).  A 
retrospective sample size ( n ) calculation was also performed to detect a signficant 
change (δ) in FEV1 with α = 0.05 and power β = 0.80 and where SD is standard deviation;  
accordingly, Zα = 1.96 and Zβ = 0.2, and n was calculated according to Equation 2-1:42 
2
22)(2
δ
βα SDZZn
+
=  
(1) 
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2.3  Results 
Demographic characteristics are provided in Table 2-1.  All COPD subjects were non-
smokers at baseline with a mean smoking history of 47 ± 22 pack-years (range = 11 - 85 
pack-years) and mean years not-smoking at baseline of 11 ± 10 years (range = 10 weeks - 
34 years).  Three subjects experienced a single COPD exacerbation each over the follow-
up period.   
Table 2-2 shows mean and median WL and CS hyperpolarized 3He MRI measurements 
for the healthy never-smokers and COPD subjects.  The absolute change and annualized 
rates of change of FEV1 and hyperpolarized 3He MRI measurements for COPD subjects 
are provided in Table 2-3.  For ADC, annualized rate of change for ex-smokers with 
COPD was 0.01 cm2/s and that for never-smokers was 0.002 cm2/s.  There was no 
significant association between the changes in image SNR and the changes in ADC (r=-
.51, p=.12) and VDV (r=-.17, p=.55).  Inter-observer reproducibility of 3He MRI VDV 
was previously evaluated for 3 different observers and this was the same as intra-observer 
variability (COV=10%, unpublished results).  For two observers, inter-observer 
reproducibility was assessed for WL VDV (ICC=.93, COV=38% and r2=.84 (p<.0001)) 
and WL VDP (ICC=.91, COV=43% and r2=0.81 (p<.0001)).  Figure 2-S1 shows the 
relationship between ventilation defect measurements for Observer 1 and Observer 2; 
WL VDV (r2=.84, p<.0001) and WL VDP (r2=.81, p<.0001).  The change at follow-up 
for Observer 1 and Observer 2 were significantly correlated for WL VDV (r2=.51, 
p=.0004) and WL VDP (r2=.39, p=.007). We provide the change in WL VDV and WL 
VDP for each observer and the mean for both observers in Table 2-S1 within the online 
supplement, and throughout the main body of the manuscript a single observer’s results 
are described.  Table 2-S2 is also provided in the online supplement and shows a subject 
listing of baseline and follow-up pulmonary function and 3He MRI measurements.   
Wilcoxon matched pairs two-tailed t-tests indicated that all 3He MRI measurements were 
significantly different at follow-up for COPD subjects.  There was also no significant 
change observed in FEV1%predicted for the COPD subjects at follow-up.   For healthy 
never-smokers, there was no detectable change in any pulmonary function or imaging 
measurement.  The changes detected in the COPD ex-smokers were significantly 
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different than the changes measured in the healthy volunteers for WL VDV (p=.04) and 
WL VDP (p=.01), but not significantly different for WL ADC (p=.96) or FEV1 (p=.21). 
Table 2-1 Subject Demographics 
 Healthy Never-smokers 
(n=5) 
COPD Ex-smokers 
(n=15) 
 Baseline Follow-up Baseline Follow-up 
Age yrs  
(±SD) [range] 
69 
(6) [58-74] 
72 
(6) [61-76] 
68 
(6) [59-75] 
70 
(5) [61-77] 
Male Sex 2 2 8 8 
Body Mass Index 25 25 28 27 
(±SD) [range] 
FEV1 L (±SD) 
(2) [24-29] 
2.77 (1.01) 
(2) [23-28] 
2.62 (0.93) 
(5) [19-38] 
1.51 (0.63) 
(5) [18-37] 
1.43 (0.56) 
FEV1 % (±SD) 110 (23) 107 (23) 53 (15) 52 (15) 
FEV1/FVC % (±SD) 77 (4) 78 (15) 45 (14) 49 (16) 
IC % (±SD) 106 (18) - 88 (23) 82 (22) 
RV % (±SD) 95 (15) - 157 (48) 132 (33) 
FRC % (±SD) 101 (12) - 145 (65) 131 (33) 
TLC % (±SD) 105 (12) - 109 (17) 105 (10) 
FEV1= Forced Expiratory Volume in 1s, FVC= Forced Vital Capacity, IC= Inspiratory 
Capacity, RV= Reserve Volume, FRC= Functional Residual Capacity, TLC= Total Lung 
Capacity, SD=Standard Deviation 
 
Table 2-2  3He MRI ADC and Ventilation Defect Measurements at Baseline and Follow-
up 
 Healthy Never-smokers 
(n=5) 
COPD Ex-smokers 
(n=15) 
 Baseline 
Mean/Median 
Follow-up 
Mean/Median 
Baseline 
Mean/Median 
Follow-up 
Mean/Median 
WL ADC (±SD) cm2/s 0.27/0.25 
(0.02) 
0.29/0.29 
(0.03) 
0.43/0.45 
(0.08) 
0.46/0.46 
(0.07) 
CS ADC (±SD) cm2/s 0.28/0.27 
(0.02) 
0.28/0.30 
(0.03) 
0.44/0.45 
(0.09) 
0.47/0.46 
(0.08) 
WL VDV (±SD) L 0.023/0.006 
(0.04) 
0.020/0.017 
(0.02) 
0.52/0.24 
(0.54) 
0.92/0.77 
(0.93) 
CS VDV (±SD) L 0.003/0.000 
(0.005) 
0.002 /0.001 
(0.002) 
0.056/0.023 
(0.053) 
0.11/0.11 
(0.11) 
WL VDP (±SD) % 
CS VDP (±SD) % 
0.5/0.2 (0.9) 
0.6/0.2 (0.9) 
0.5/0.5 (0.4) 
0.4/0.2 (0.4) 
9/6 (9) 
9/11 (13) 
16/15 (14) 
16/16 (22) 
ADC=Apparent Diffusion Coefficient, VDV=Ventilation Defect Volume, 
VDP=Ventilation Defect Percent, CS=Center Slice, WL= Whole Lung, SD=Standard 
Deviation 
67 
 
Table 2-3 Annualized changes in pulmonary function and 3He MRI measurements for 
COPD subjects at follow-up 
 Absolute 
Change 
Annualized Rate of 
Change (/year) 
Significance of difference 
p* p** 
FEV1 (%) -1 -0.4 0.97 0.97 
WL ADC (cm2/s) 0.02 0.01 0.01 0.02 
CS ADC (cm2/s) 0.03 0.01 0.004 0.02 
WL VDV (L)  0.4 0.20 0.007 0.03 
CS VDV (L)  0.05 0.03 0.003 0.02 
WL VDP (%)  7 4 0.0009 0.006 
CS VDP (%) 7 3 0.01 0.03 
FEV1=Forced Expiratory Volume in 1s, ADC=Apparent Diffusion Coefficient, 
VDV=Ventilation Defect Volume, VDP=Ventilation Defect Percent, CS=Center Slice, 
WL= Whole Lung 
* Wilcoxon matched pairs two-tailed t-tests, ** Holm-Bonferroni adjusted significance 
values 
Figure 2-1 shows ventilation images, ADC maps and ADC histograms for two 
representative healthy never-smokers at baseline and follow-up.  Figure 2 shows 
ventilation images, ADC maps and histograms for two representative COPD subjects at 
baseline and follow-up. 
68 
 
Table 2-4 shows Spearman correlation coefficients for the changes in FEV1 (absolute and 
%predicted) with 3He MRI ADC, VDV and VDP for COPD subjects.  As shown in Figure 
2-3, the change in FEV1 (absolute) showed a significant negative association with the 
change in CS VDV (r=-.70, p=.02), CS VDP (r=-.70, p=0.03), but not ADC.  TCV was 
calculated for all subjects from the thoracic cavity 1H MRI and for all subjects, the 
change in TCV was significantly correlated with the change in TLC measured using 
plethysmography (r=.81, p=.001).  Figure 2-4 shows the relationships between COPD 
patient smoking history (pack-years smoking) with the changes in 3He MRI VDV and 
FEV1.  There was no significant correlation between pack-years smoking and the change 
in FEV1 (r=.05, p=.83), and the relationship between pack-years smoking and WL VDV 
was moderate, but once corrected for multiple tests, this relationship was on the threshold 
Figure 2-1 Representative hyperpolarized 3He MR at baseline and follow-up in healthy 
never-smokers 
Left panel subject 1001 58 year old male: top panel is baseline and bottom panel is 
follow-up:  
(A) ventilation image (B), ADC map (C) and ADC histogram. 
Right panel subject 1007 73 year old male: top panel is baseline and bottom panel is 
follow-up:  
(A) ventilation image (B), ADC map (C) and ADC histogram. 
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of significance (WL VDV [r=.52, p=.02, uncorrected, p=.06 Holm Bonferroni 
corrected]). 
  
Table 2-4 Relationship between changes in FEV1 and 3He MRI measurement changes for 
COPD subjects over time 
 Spearman Correlation Coefficients 
 FEV1 L   (p/p*) FEV1%predicted   (p/p*) 
WL ADC (cm2/s) -0.02   (0.93/0.93) 0.17   (0.56/1.0) 
CS ADC (cm2/s) -0.06   (0.84/1.0) 0.15   (0.60/0.60) 
WL VDV (L)  -0.56   (0.03/0.09) -0.53   (0.04/0.12) 
CS VDV (L)  -0.70   (0.003/0.02) -0.67   (0.007/0.04) 
WL VDP (%)  -0.60   (0.02/0.08) -0.55   (0.03/0.12) 
CS VDP (%) -0.70   (0.005/0.03) -0.70   (0.005/0.03) 
FEV1=Forced Expiratory Volume in 1s, ADC=Apparent Diffusion Coefficient, 
VDV=Ventilation Defect Volume, VDP=Ventilation Defect Percent, CS=Center Slice, 
WL= Whole Lung 
* Holm-Bonferroni adjusted significance values 
Figure 2-2 Representative hyperpolarized 3He MR VDV and ADC changes during 
follow-up in COPD 
Left panel subject 3004 75 year old male stage III COPD: top panel is baseline and 
bottom panel is follow-up: (A) ventilation image (B), ADC map (C) and ADC histogram 
Right panel subject 2009 61 year old male stage II COPD: top panel is baseline and 
bottom panel is follow-up: (A) ventilation image (B), ADC map (C) and ADC histogram 
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Figure 2-4 Relationship 
between 3He MRI VDV, FEV1 
and smoking history 
Scatterplot showing the 
relationship between smoking 
history and change in WL VDV 
(r=.52, p=.02/p=.06 Holm 
Bonferroni corrected) and 
change in FEV1%predicted (r=.05, 
p=.83).   
Figure 2-3 Relationship between 3He MRI 
measurements and changes in FEV1 
Scatterplots show the relationship between 
changes in FEV1 and changes in center slice 
(CS) ventilation defect volume (VDV), CS 
ventilation defect percent (VDP) and WL 
apparent diffusion coefficient (ADC).  The 95% 
confidence intervals for the regressions are 
shown as dotted lines.  (A) Changes in FEV1 
showed a significant negative correlation with 
changes in CS VDV (r=-.70, p=.02), and (B) CS 
VDP (r=-.70, p=.03).  (C) Changes in FEV1 
showed no significant correlation with changes 
in WL ADC. 
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2.4 Discussion 
Several observations were made in this small longitudinal pilot study.  First, we observed 
that mean 3He ADC, VDV and VDP significantly increased during the 26 month follow-
up period in the 15 COPD ex-smokers whereas pulmonary function measurements did 
not significantly change over the same period of time.  Based on the previously reported 
and pioneering epidemiological findings of Fletcher and colleagues,3 as well as the more 
recent tiotropium intervention trial,43 we were not surprised to find that in COPD ex-
smokers, FEV1 did not significantly change.  Indeed, this study was not powered to detect 
such changes in FEV1 over a 2 year timeframe; a retrospective power analysis shows that 
a sample size of approximately 1000 COPD and 1000 healthy volunteers would be 
required to detect significant change in FEV1 in this study.  Unlike the Fletcher curve 
prediction that longitudinal changes in hyperpolarized 3He measurements in the COPD 
ex-smokers would be similar to those observed in elderly healthy never-smokers, we 
observed an annualized rate of change in 3He MRI ADC of 0.01 cm2/s/y -an order of 
magnitude greater than the rate previously reported (0.001cm2/s/y) for healthy non-
smokers in a cross-sectional multi-center study at 1.5T,29 and for the healthy never-
smokers reported in this study (0.002 cm2/s/y).  Additionally, we observed no significant 
change in 3He MRI ADC, ventilation defect measurements or in pulmonary function 
measurements for the healthy never-smokers at follow-up.  These preliminary 
longitudinal findings suggest that regional disease markers derived from non-invasive 
imaging methods can be used in a small number of COPD subjects over short time 
periods, to quantitatively detect significant changes.   
We also showed that the change in 3He MRI VDV and VDP indicated a significant 
inverse correlation with the change in FEV1, whereas the change in ADC showed no such 
relationship.  This result suggests that 3He MRI ventilation defect measurements may be 
more predictive of airflow limitation than 3He MRI ADC, which necessitating further 
testing of this hypothesis. Although we observed statistically significant improvements in 
FEV1 <20 mL in five COPD subjects, we did not observe a corresponding improvement 
in 3He MR imaging-derived measurements over this time period.  On the contrary, for 
these five subjects we observed a statistically significant increase in 3He MRI ADC 
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(p=.02) and no change in ventilation measurements.  We believe this discordant finding 
highlights the sensitivity of using both ventilation and ADC measurements in detecting 
disease changes in COPD.  In a related finding, Ohara and colleagues15 showed the 
significant inverse correlation between annual changes in FEV1 and the CT measurement 
of wall area percent (WA% - a surrogate of airway wall thickness) and similar to our 
results, there was no significant relationship between the change in FEV1 and emphysema 
(percent low attenuation areas, %LAA).  It is important to note that for five of the 15 
COPD subjects evaluated in this pilot analysis, both imaging and spirometry suggested 
disease progression.  This finding generates a number of hypotheses for testing in larger 
or longer imaging studies of COPD progression evaluating the relationship between 
exacerbations, treatment changes and changes in quality of life with imaging and 
pulmonary function measurements.  Future COPD studies that include hyperpolarized 
3He MRI will likely focus on a critical balance between longitudinal time frame and finite 
numbers of subjects because of the relative complexity of these studies and the prediction 
for increased costs and decreased availability of 3He gas for clinical research.44  
Nevertheless, the preliminary findings of this pilot hyperpolarized 3He MRI longitudinal 
study provide clear guidance for future COPD imaging studies using established and 
emerging imaging tools such as optical coherence tomography,45 oxygen enhanced and 
proton MRI methods46;47 and hyperpolarized xenon-129 MRI.   
Finally, we showed in an exploratory analysis, the potential relationship between 
smoking history and changes in 3He MRI VDV but not with changes in FEV1.  We note 
that previous cross-sectional studies suggest ongoing inflammation in ex-smokers with 
COPD3;29 and that smoking history correlated with current inflammatory markers such as 
eosinophils48 and vascular endothelial growth factor49 supporting the hypothesis that 
there is a predictive relationship between pack-years and inflammation post smoking 
cessation.  The results of this exploratory analysis of 3He MRI changes and smoking 
history generate important hypotheses that future studies should explore in more detail. 
Although this pilot study reports significant increases in 3He MRI measurements in just 
over two years, we must acknowledge a number of specific limitations of our approach.  
We recognize that the relatively small group of COPD subjects and healthy never-
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smokers that were evaluated, and the relatively short period of follow-up compared to 
other COPD longitudinal studies5 certainly limits the applicability of our results.  The 
small sample size necessitates cautious interpretation of the results as well as the future 
requirement for larger studies to test the hypotheses generated.  For example, because of 
the small number of healthy volunteers and COPD subjects evaluated, significant 
differences were not detected for pulmonary function measurements in either group.  In 
addition, although we have previously demonstrated that ventilation defects are highly 
reproducible,20 the lack of longitudinal information regarding the variability of 
ventilation defects necessitates that the findings of this study be interpreted with caution.  
It is also important to note that although this pilot study showed that ex-smoking COPD 
patients differed from elderly never-smokers, it was not designed to show the relationship 
between the significant imaging changes and more established clinical measurements of 
COPD worsening.  To make the important conclusion that 3He MRI measurements are 
specifically related to clinical measurements of COPD worsening, future work in longer 
or larger studies must show that the detected 3He MRI changes occurred in patients who 
had measureable clinical changes.  Nevertheless, the results suggest that 3He MRI 
provides a sensitive method for the detection of the lung structural and functional 
changes that accompany COPD longitudinally.  In future, larger studies that directly 
compare 3He MRI and other well-established clinical measurements of COPD 
progression will be required in order to better understand the relationship between 3He 
measurements and other changes that occur in COPD over time.  Additionally, a 
comparison of COPD ex-smokers, healthy smokers and COPD current smokers may help 
to establish and directly compare rates of lung structural and functional decline.  It will 
also be critical to track patient exacerbations and changes in treatment over longer 
periods of time to probe potential treatment effects with imaging.  We also acknowledge 
that for this pilot study, we limited the COPD cohort to those with minimal FEV1 
reversibility, although clearly many COPD subjects have varying degrees of FEV1 
reversibility which necessitates further work in such patients.  CT images were not 
prospectively acquired for this study and therefore, our results cannot be directly 
compared to more established CT measurements such as LAA% (a measurement of the 
extent of emphysema), or WA% (a measurement of airway wall thickness).  Clearly, a 
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direct comparison of CT and hyperpolarized 3He derived measurements in the same 
subjects will allow for a better understanding of differences in measurement sensitivity 
these imaging modalities provide.  Previous work has shown significant correlations 
between ADC and the measurement of the diffusion capacity of carbon monoxide 
(DLCO).32  A direct comparison here would have provided another quantitative measure 
of global emphysematous changes in these subjects.  It is also important to note that 
while Woods and colleagues have previously shown the significant correlation between 
3He ADC and histological measurements of emphysema,28 we have not yet determined 
the underlying pathology that results in 3He ventilation defects we observe, which may be 
a result of small airway occlusion, mucous plugs, airway wall thickening and 
inflammation or bullous disease.  Related to this is the fact that there is significant 
information in regions of intermediate signal intensity and in both hyper- and hypo-
intense signal regions that have not yet been quantitatively or spatially exploited.  The 
development and validation of 3He image analysis techniques that quantify heterogeneous 
signal information are required in the future to fully characterize the important ventilation 
information contained in the image.  Whether regions of diminished ventilation and 
emphysema develop independently and the extent to which one leads to the other cannot 
be ascertained by this preliminary longitudinal study and is yet to be determined in other 
longitudinal imaging studies.  Importantly however, our group previously described the 
high reproducibility of 3He ventilation defects in COPD,20 suggesting that the significant 
changes measured here may be due to changes in lung morphology or function and not 
due to the variability of the imaging or measurement technique, nor due to short-term 
changes in small airway diameter or patency.    
In summary, in this small pilot study of COPD ex-smokers, we detected significant lung 
changes using 3He MRI that occurred over a relatively short period of time, perhaps 
before FEV1 changes could be detected or perhaps because such longitudinal changes 
occurred within the FEV1 silent zones, where disease might have accumulated without 
detection. 
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2.6 Supplementary Tables 
Table 2-S1 Hyperpolarized 3He MRI ventilation measurement observer reproducibility 
 Mean Difference at Follow-up (Significance) 
 Observer 1  Observer 2  Mean (Observers 1 & 2)  
WL VDV (L) 0.30 (0.007) 0.41 (0.02)  0.35 (0.004)  
WL VDP (%) 5.0 (0.002)  6.2 (0.04)  5.6 (0.01)  
VDV=ventilation defect volume, VDP=ventilation defect percent 
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Table 2-S2-2 Baseline and follow-up subject listing of pulmonary function test results and 3He MRI measurements 
 Pulmonary Function 
Measurements 
(Baseline/Follow-up) 
3He MRI Measurements 
(Baseline/Follow-up) 
Subject Age 
(yr) 
Pack-
year 
(yr) 
FEV1 
(%) 
FEV1/ 
FVC 
RV 
(%) 
TLC (L) ADC 
(cm2/s) 
Dw 
SNR 
TCV (L) VDV (L) VDP 
(%) 
SV 
SNR 
2001 73 39 64/71 50/54 148/100 4.67/5.12 .50/.55 64/37 6.57/4.32 0.03/0.10 0.4/2.2 233/153 
2002 74 11 51/53 41/49 157/127 4.88/4.53 .41/.44 52/25 3.95/3.84 0.24/0.55 6.0/14.3 183/196 
2003 71 72 80/71 61/54 132/126 8.10/7.79 .29/.37 49/18 6.01/5.18 0.04/0.34 0.7/6.3 136//61 
2004 72 40 58/51 46/42 139/131 5.65/5.74 -/.60 51/31 6.06/4.53 1.59/1.08 26.3/23.8 51/169 
2005 72 30 62/38 48/37 164/- 7.93/- .40/.40 44/27 6.96/6.57 0.622.25 9.0/34.2 90/113 
2006 62 52 62/62 53/51 116/71 5.19/5.49 .49/.48 56/42 4.70/4.22 0.09/0.23 1.9/5.4 125/148 
2007 68 24 66/66 77/89 116/124 4.30/5.04 .46/.44 12/17 4.08/3.47 0.04/0.16 1.1/4.6 37/39 
2008 59 65 59/68 50/70 174/141 8.09/7.53 .36/.38 48/42 6.11/5.07 0.03/0.09 0.5/1.9 162/118 
2009 61 85 68/64 60/62 132/120 8.31/7.88 .30/.36 27/29 7.62/5.20 0.19/1.09 2.5/21.0 53/33 
3001 74 52 43/56 29/42 265/157 9.6/7.45 .50/.55 45/28 6.57/6.28 1.23/1.21 18.6/19.3 115/102 
3002 62 49 35/43 29/38 212/170 8.58/7.37 .44/.47 56/26 6.23/6.18 0.59/1.28 9.5/20.8 75/142 
3004 75 20 41/45 46/48 94/113 6.01/5.88 .34/.38 40/18 4.86/4.19 0.16/0.22 3.4/5.3 90/102 
3005 65 66 42/42 32/30 210/- 6.56/- .47/.48 60/50 5.54/5.30 0.57/0.77 10.3/14.5 145/155 
3008 71 70 32/23 37/34 193/200 8.37/8.01 .47/.48 32/14 5.72/6.79 1.40/3.50 24.5/51.5 72/24 
3009 62 30 27/33 23/32 431/237 9.64/6.70 .58/.58 27/27 6.10/5.62 0.99/0.98 16.2/17.5 93/131 
FEV1=Forced Expiratory Volume in 1s, FVC=Forced Vital Capacity, RV=Reserve Volume, TLC=Total Lung Capacity, 
ADC=Apparent Diffusion Coefficient, Dw=Diffusion-weighted image, SNR=Signal-to-Noise Ratio, TCV=Thoracic Cavity 
Volume, VDV=Ventilation Defect Volume, VDP=Ventilation Defect Percent, SV=Static Ventilation Image 
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2.7 Supplementary Figures 
 
 
 
 
Figure 2-S1 Relationship between VDV and VDP for Observer 1 and Observer 2 
Scatterplots show the relationship for Observers 1 and 2 whole lung (WL) ventilation 
defect volume (VDV) and ventilation defect percent (VDP). The 95% confidence 
intervals for the regressions are shown as dotted lines.  (Ai) Observer 1 and 2 VDV 
(r2=.84, p<.0001) and (Aii) Observer 1 and 2 VDP (r2=.81, p<.0001).  The change at 
follow-up for Observer 1 and Observer 2 are significantly correlated for VDV (r2=.51, 
p=.0004) (Bi) and VDP (r2=.39, p=.007) (Bii).   
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CHAPTER 3  
A limitation of the longitudinal study performed in Chapter 2 was that 3He MRI 
measurements were performed using manual segmentation approaches, which clearly 
increases segmentation time and, importantly, introduces the potential for inter- and 
intra-observer variability.  Here we generated a semi-automated segmentation method 
for 3He MRI to enable its use in longitudinal and serial studies. 
The contents of this Chapter have been previously published in Academic Radiology and 
permission to reproduce the article was granted by John Wiley and Sons and is provided 
in Appendix C. 
M Kirby, M Heydarian, S Svenningsen, A Wheatley, DG McCormack R Etemad-Rezai 
and G Parraga.  Hyperpolarized 3He Magnetic Resonance Functional Imaging 
Semiautomated Segmentation.  Acad. Radiol. 2012; 19(2):141—52. 
3 Hyperpolarized 3He Magnetic Resonance Imaging Semi-
automated Segmentation 
3.1 Introduction 
Pulmonary hyperpolarized helium-3 (3He) magnetic resonance imaging (MRI) is a 
functional imaging method that detects ventilation abnormalities in elderly never-
smokers1 and patients with chronic obstructive pulmonary disease (COPD),2-9 asthma,10-
13 cystic fibrosis (CF),14-16 radiation-induced lung injury,17;18 and lung transplant 
recipients.19;20  Over the last few years, this approach has been enhanced by 
improvements in laser optical pumping techniques,21 parallel imaging,22 single-scan 
acquisition of ventilation and diffusion-weighted images,23 single-scan acquisition of 
ventilation and 1H MRI anatomical images24 and dynamic imaging.25;26  While this large 
body of work has advanced the scope and type of functional images that can be acquired, 
there have been fewer improvements related to image analysis methods.27-29  As we move 
forward with functional noble gas imaging and transition to hyperpolarized xenon-129 
(129Xe) MRI, a less expensive and more readily available approach, image analysis 
methods are urgently required for quantitative evaluation across a wide variety of 
respiratory diseases. 
Previous 3He functional/ventilation analyses were based on a radiologist’s interpretation 
of the ventilated lung regions,27;30 and quantification of ventilation defects was performed 
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using scoring1;8;11 and volumetric analysis approaches.1;8  While in these studies, imaging 
measurements were correlated with well-established measures of disease, a limitation of 
manual methods is the inherent reliance upon highly trained observers that increases 
segmentation time and introduces the potential for inter- and intra-observer variability.  
Although straightforward automated threshold methods have been used for segmentation 
of ventilation,27 automated segmentation of the 3He ventilation defects themselves, 
previously demonstrated by Tustison et. al.28 as a feature that differentiated asthma and 
healthy subject images, has proven to be much more difficult.  Subjects with severe 
obstructive disease, such as COPD or asthma, have numerous ventilation defects that 
appear in 3He images as signal voids.  Hyperinflation is also commonly observed in 
obstructive lung disease due in part to gas trapping and therefore changes in the thoracic 
cavity shape vary from patient to patient and within individual patients over time.  Thus, 
segmentation of ventilation defects likely requires an understanding of the relationship 
between 3He functional information with the anatomy of the thoracic cavity derived from 
proton (1H) MRI.  Furthermore, because there appear to be regions with 3He signal voids, 
as well as regions of hypo- and hyper-intensity, segmentation methods are required for 
the visually different classes of 3He MRI signal.    
Therefore, our objective was to develop a semi-automated segmentation method by 
applying two well-established image segmentation approaches, seeded region-growing31 
for segmentation of the thoracic cavity from 1H  MRI and K-means clustering32 to 
classify 3He MRI pixel intensities as previously investigated,29;33;34 to generate 3He MRI 
ventilation measurements.  The combination of these well-established and widely used 
segmentation methods allows for quantification and characterization of the important 
ventilation information contained in the image.  3He MRI segmentation methods must 
have high intra-observer and inter-observer reproducibility across a variety of respiratory 
diseases and subjects.  Therefore, here we evaluated the reproducibility as well as the 
spatial and quantitative relationships between manual and semi-automated functional 
measurements in subjects with asthma, COPD and CF.   
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3.2 Materials and Methods 
3.2.1 Subjects 
All subjects provided written informed consent to protocols approved by Health Canada 
and a local research ethics board.  COPD subjects were ex-smokers, with a clinical 
diagnosis of COPD and categorized according to the Global initiative for chronic 
Obstructive Lung Disease (GOLD) criteria,35 with a smoking history of at least 10-pack-
years as previously described.5  Adult asthmatics between 18-50 years of age were 
enrolled with FEV1%pred > 60% with a physician diagnosis of asthma and adult CF 
subjects (18-40 years of age) were also enrolled with FEV1%pred > 50% . 
3.2.2 Image Acquisition 
MRI was performed on a whole body 3.0 Tesla Excite 12.0 MRI system (GEHC, 
Milwaukee, WI USA) with broadband imaging capability as previously described,1 and 
3He MRI was enabled using a single channel, rigid elliptical transmit/receive chest coil 
(RAPID Biomedical GmbH, Wuerzburg Germany).  Pulse oximetry was used to measure 
arterial oxygen saturation (SaO2) for all subjects during scanning sessions and considered 
an adverse event occurred when SaO2 decreased below 88% continuously for ≥  15 
seconds at any time during the scanning session.  Study withdrawal was required when 
SaO2 decreased to 80% for 10 seconds or longer.   It is important to note that we 
endeavoured to minimize the potential for differences in the levels of inspiration between 
the breath-hold scans for each subject by: 1) training and practice for all subjects prior to 
MRI related to the inspiration breath-hold maneuver from functional residual capacity 
(FRC), and, 2) continuous coaching and monitoring at the MR bedside by a pulmonary 
function technologist during all inspiration breath-hold scans. 
Conventional 1H MRI was performed prior to hyperpolarized 3He MRI with subjects 
scanned during 1.0 L breath-hold of 4He/N2 using the whole body radiofrequency (RF) 
coil and 1H fast spoiled gradient recalled echo sequence (16s total data acquisition, 
repetition time (TR) / echo time (TE) / flip angle = 4.7 ms / 1.2 ms / 30o, field-of-view 
(FOV) = 40 × 40 cm, matrix 256 × 128, 14 slices, 15 mm slice thickness, 0 gap), as 
previously described.1 
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Prior to 3He MRI, a polarizer system (HeliSpin™, GEHC, Durham, NC) was used to 
polarize 3He gas to 30—40 % and doses (5 mL/kg body weight) were administered in 1.0 
L Tedlar bags diluted with ultrahigh purity, medical grade nitrogen (Spectra Gases, 
Alpha, NJ).  As previously described,1 hyperpolarized 3He MRI coronal static ventilation 
images were acquired during breath-hold of a 1L 3He/N2 mixture (14s data acquisition, 
TR / TE / flip angle = 4.3 ms / 1.4 ms / 7o, bandwidth = 31.25, FOV = 40 × 40 cm, matrix 
128 × 128, 14 slices, 15 mm slice thickness, 0 gap). 
3.2.3 Manual Segmentation 
Manual segmentation was repeated five times to estimate observer reliability using the 
approximation method developed by Walter et. al.36  All subjects were first randomized 
and subsequently manually segmented by a single observer blinded to subject identity 
and disease status, and all subjects measurements were repeated five times each (15 
subjects × 5 repetitions = 75 image datasets).  To minimize memory bias, at least 24 
hours was required between repetition rounds and randomization of subject image 
datasets was performed between each repetition round.  The observer (MK) had three 
years experience performing manual 3He MRI segmentation having been trained by an 
experience chest radiologist (RER).  As previously described,1 ventilation volume (VV)30 
was recorded following manual segmentation of the ventilated lung regions and 
ventilation defect volume (VDV)1;8 was recorded following manual segmentation of the 
3He MRI focal ventilation defects, using custom-designed image visualization software,37 
providing a method for two-dimensional rigid single point image registration (1H and 3He 
slices) based on fiducial markers located on the carina.  As previously described,38 a 
ventilation defect was identified by the observer as any lung region of diminished signal 
intensity but not including those areas of signal loss associated with the pulmonary 
vascular structures, heart, hilum and mediastinum.  
3.2.4 Semi-automated Segmentation:  Overview of Method 
Multi-step segmentation software was generated using MATLAB R2007b (The 
Mathworks Inc., Natick, Massachusetts).  All subjects, following randomization, were 
segmented using the semi-automated method by two observers blinded to subject identity 
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and disease status, and measurements were repeated five times each (15 subjects × 5 
repetitions × 2 observers = 150 image datasets).  To minimize memory bias, at least 24 
hours was required between repetition rounds.  The observer (blinded) had one year 
experience developing and performing semi-automated 3He MRI segmentation, and the 
observer (blinded) had 1 month experience performing semi-automated 3He MRI 
segmentation.  Figure 3-1 provides a summary of our method.  Briefly, 3He MR images 
(Step 1) were segmented automatically using a hierarchical version of K-means 
clustering algorithm,32 and 1H MR images were segmented automatically using a seeded 
region-growing algorithm (SRGA)31 (Step 2).  1H MR segmented images were 
registered39 to 3He MR segmented images (Step 3) to differentiate the ventilation defects 
from the background and therefore generating a 3He voxel cluster map, with clusters 
ranging from 1 to 5, representing gradations of signal intensity from no signal (Cluster 1, 
C1) and hypo-intense signal (C2) to hyper-intense signal (C5).  This approach was first 
tested in a training dataset of 5 COPD subjects (5 subjects × 10 slices = 50 image slices) 
for comparison to manual segmentation.  Results from the training dataset indicated that 
the semi-automated algorithm completed all tasks with image signal-to-noise-ratio 
(SNR)≥ 13, and this was the case for nearly all but the most anterior slices for each 
subject.  The combination of 4 initial clusters and re-clustering the initial C1 yielding a 
total of 5 clusters provided the best qualitative correlation with manual expert observer 
(chest radiologist) results.  We also quantitatively compared K-means with the initial user 
input of 4 to 10 clusters and the hierarchical K-means approach (4 initial clusters and re-
clustering the initial C1) with manual segmentation on the training dataset, and 
determined that hierarchical K-means provided the highest correlation and lowest Bland-
Altman bias with manual segmentation and was subsequently used for the testing dataset 
(Supplementary Table, Table 3-S1). 
3.2.5 3He MRI Automated Segmentation:  K-means Clustering 
Algorithm 
3He MRI of obstructive (COPD and asthma) and restrictive (CF) lung disease are 
typically characterized by heterogeneous 3He MRI signal intensity that reflect gas 
distribution heterogeneity during the inspiration breath-hold scan.  The expert observer 
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typically can distinguish between 4 visually apparent classes of 3He MRI signal – signal 
void, hypo-intense (or partial volume), normal intensity, and hyper-intense signal.  For 
this reason, a hierarchical K-means clustering method,32 similar to previously described 
methods for 3He MRI segmentation,29;33;34 was used to partition the signal intensity 
frequency distribution histogram into 4 clusters, based on an expert chest radiologist’s 
interpretation of the clinical meaning of the visible signal intensity differences.  Because 
the first round of K-means clustering resulted in a single cluster C1 that included both 
signal void and hypo-intense regions (partial volumes and/or partially ventilated 
volumes), K-means clustering was re-applied to the C1 to separate signal void from the 
hypo-intense signal regions.   This was accomplished in three steps as follows:  1) K-
means with four clusters was initially applied to the 3He image, 2) K-means with four 
clusters was then re-applied to C1, 3) the first two clusters from step 2 were merged to 
represent the background and ventilation defects and the last two clusters from step 2 
were merged to represent the hypo-intense signal regions.  For both steps 1 and 2, a 
standard initialization method was performed to produce the initial centroids by dividing 
the full pixel range of 0-255 into four equal regions: 0-63, 64-127, 128-191, 192-255, and 
selecting the interval center as the centroid for each cluster.     
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3.2.6 1H MRI Automated Segmentation:  Seeded Region-growing 
In conventional 1H MRI anatomical images, low 1H density in the lung produces a weak 
MR signal, thus providing sufficient contrast for segmentation methods such as a seeded 
region-growing algorithm (SRGA)31 to segment the contour of the thoracic cavity to 
differentiate ventilation defects from the edge of the lung.  Prior to application of SRGA, 
all 1H images were pre-processed to protect the region-growing algorithm from leaking 
into regions extending beyond the lung boundary with similar signal intensities.  Pre-
processing of the 1H images was performed using a 2D radially symmetric Gaussian low-
pass filter of size 15×15 with standard deviation 2.0.  The images were then converted to 
a binary mask using a threshold that was selected equal to the half the maximum intensity 
of the first cluster of K-mean clustering with four clusters.  Seed points were then 
automatically selected in both the left and right lungs of the binary mask by finding the 
Figure 3-1 Schematic of 3He semi-automated segmentation methodology   
Semi-automated segmentation was accomplished in three steps: 1) hierarchical K-means 
clustering of 3He MR images into 5 clusters where cluster 1 (C1) represented regions of 
ventilation defect and background, and cluster 2 to cluster 5 (C2-C5) represented 
gradations of signal intensity/ventilation, 2) 1H MRI segmentation using seeded region-
growing algorithm, and 3) landmark-based registration of 1H and 3He MRI segmentation 
to differentiate the ventilation defects from the background, and therefore generating a 
3He voxel cluster map. 
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columns in the image binary mask that contained 20 vertically adjacent pixels.  A 
morphological closing algorithm with a structuring element disk of radius equal to 15 
(function imclose in MATLAB) was applied to fill areas within the segmented left and 
right lung separately.   
3.2.7 Landmark-based Image Registration 
Because of the extensive coaching to minimize the potential for differences in the levels 
of inspiration between the breath-hold scans for all subjects, 3He and 1H images were 
registered using a landmark-based image affine registration approach.39  Briefly, the 
center slices, defined as the 2D MR slice that clearly showed the carina and primary 
bronchi, were first displayed side-by-side.  Three to seven fiducial markers were selected 
on the 3He image based on the carina, trachea, and primary bronchi, as well as any other 
distinguishing features located within the lung or near the lung periphery such as 
pulmonary vessels and regions near the diaphragm.  The same landmarks were selected in 
the same order on the 1H image.  Geometric operations consisting of rotation, translation 
and scaling (same in both x and y directions) were used to transform the 1H image to 
align it with the corresponding landmarks selected in the 3He image.  The same 
transformation map was applied to the remaining 1H MR image slices.  3He VDV was 
generated using the lowest signal intensity cluster (C1) and 3He VV was generated as the 
sum of the remaining clusters (C2-C5). 
3.2.8 Statistical Analysis 
A two-way analysis of variance (ANOVA) was performed for comparison of manual and 
semi-automated volume measurements with segmentation method and repetition (5 
repeated measurements) treated as within subject factors using SPSS 16.00 (SPSS Inc., 
Chicago, IL, USA LEAD Technologies, Inc., Chicago, IL).  The relationship between 
manual and semi-automated segmentation was also determined using linear regression 
(r2) and Pearson correlation coefficients (r) and the agreement between the methods was 
determined using Bland-Altman analysis using GraphPad Prism version 4.00 (GraphPad 
Software Inc, San Diego, CA, USA).  Intra-observer and inter-observer reproducibility 
was determined for manual and semi-automated segmentation results using the 
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coefficient of variation (CV), calculated as the standard deviation (SD) of the five 
measurements divided by the mean.  Two-way random effects single measure intra-class 
correlation coefficients (ICC) (absolute agreement) were also determined for the five 
repeated measurements for both manual and semi-automated segmentation using SPSS 
16.00.  The 95% confidence intervals (CI) for CV and ICC were determined using the 
Modified McKay’s method40 using SPSS version 16.00.  To compare the reproducibility 
of manual and semi-automated measurements, approximate tests were performed by 
examining the overlap in 95% CI.  The smallest detectable difference (SDD), defined as 
the smallest difference that can be measured with prospectively determined confidence 
not due to measurement error (variability), was calculated using the manual and semi-
automated five repeated 3He measurements according to Eliasziw et. al.41 and shown in 
Equation 3-1: 
raSEMzSDD int2α≥  (1) 
where αz  is 1.96 corresponding to a significance level of α =.05 and raSEM int  is the 
standard error of measurement due to intra-observer variability and was calculated as 
shown in Equation 3-2: 
2
int ˆ eraSEM σ=  (2) 
where 2ˆ eσ  is the intra-observer repeated measures variance.  The Dice coefficient 
42, 
calculated as the area of the intersection of two datasets divided by the average area of 
the two sets, was determined to measure the agreement or similarity between each of the 
five repeated measurements for both manual and semi-automated segmentation (5 
repetitions = 10 comparisons), as well as between each of the repeated manual and semi-
automated segmentation measurements (5 repetitions for manual and semi-automated = 
25 comparisons) as shown in Equation 3-3: 
BA
BA
BADice
+
∩
=
2
),(  (3) 
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where A and B are the two data sets.  For semi-automated segmentation, two observers 
performed all measurements and therefore the mean Dice coefficient for the two 
observers was used.  In all statistical analyses, results were considered significant when 
the probability of making a Type I error was less than 5% (p < 0.05).   
3.3 Results 
Demographic characteristics are provided in Table 3-1 for 15 subjects in total including 
five subjects with asthma (n=3 males, mean age=36 (±13), range=20-53), five subjects 
with COPD (n=2 males, mean age=67 (±6), range=61-77) and five subjects with CF (n=2 
males, mean age=25 (±9), range=20-41).  COPD subjects were GOLD stage II (n=1) and 
GOLD stage III (n=4).   
Figure 3-2 shows the centre coronal 3He MRI slice, where the trachea and two main 
bronchi are clearly visible, for each of two representative asthma, COPD and CF 
subjects; 3He ventilation displayed in red registered to the greyscale 1H MRI of the 
thorax, with the segmentation results obtained by manual and semi-automated 
segmentation.  It is important to note that manual segmentation of the 3He images 
required approximately 60 to 90 minutes for all slices per subject, whereas semi-
automated 3He segmentation required approximately four to eight minutes of supervised 
computational time for all slices per subject. 
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Table 3-1 Subject Demographics 
 
Parameter 
All (n=15) 
(±SD) [range] 
Asthma (n=5) 
(±SD) [range] 
COPD (n=5) 
(±SD) [range] 
CF (n=5) 
(±SD) [range] 
Age yrs 43 (20) [20-77] 36 (13) [20-53] 67 (6) [61-77] 25 (9) [20-41] 
Male Sex 7 3 2 2 
BMI kg·m-
2  
26 (4) [18-30] 27 (3) [21-30] 26 (5) [18-30] 25 (3) [21-29] 
FEV1%pred 69 (23) [31-108] 91 (16) [72-108] 42 (11) [31-61] 74 (4) [69-79] 
FVC %pred 87 (12) [65-110] 96 (13) [77-110] 78 (11) [65-90] 87 (1) [85-89] 
FEV1/FVC 64 (18) [27-86] 77 (8) [65-86] 41 (9) [27-51] 73 (6) [65-80] 
TLC %pred 114 (21) [94-175] 
‡ 
100 (5) [97-108] 129 (27) [106-
175] 
111 (12) [94-120] 
† 
IC %pred 101 (18) [71-138] 
‡ 
113 (15) [98-
138] 
86 (11) [71-96] 104 (18) [90-128] 
† 
FRC %pred 121 (44) [65-243] 
‡ 
88 (15) [65-107] 164 (45) [132-
243] 
109 (23) [88-139] 
† 
RV %pred 157 (55) [82-285] 
‡ 
108 (29) [82-
144] 
195 (53) [143-
285] 
172 (42) [109-
197]† 
SD=Standard Deviation, BMI=Body Mass Index, FEV1= Forced Expiratory Volume in 
1s, %pred=Percent Predicted, FVC= Forced Vital Capacity, TLC= Total Lung Capacity, 
IC= Inspiratory Capacity, FRC= Functional Residual Capacity, RV= Reserve Volume, 
†n=4, ‡n=14 
 
Table 3-2 shows the mean whole lung 3He volume measurements for manual and semi-
automated segmentation.  There was no significant difference between manual VDV and 
semi-automated VDV (C1) for asthma, COPD and CF subjects (p=.10).  There was also 
no significant difference between manual VV and semi-automated VV (C2-C5) for 
asthma, COPD and CF (p=.48). 
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Figure 3-2 Manual and semi-automated segmentation results for representative 
asthma, COPD and CF subjects.   
3He MRI center slice registered to 1H MRI, 3He VDV and VV mask generated by 
manual segmentation, and 3He cluster map generated by semi-automated 
segmentation for two representative asthma, COPD and CF subjects. 
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Table 3-2 Manual and semi-automated 3He volume measurements 
 
Parameter 
All 
(n=15) 
Asthma 
(n=5) 
COPD 
(n=5) 
CF 
(n=5) 
Manual 
VDV L (±SD) 0.92 (0.80) 0.13 (0.15) 1.40 (0.68) 1.23 (0.74) 
VV L (±SD)  4.19 (0.53) 4.37 (0.34) 4.12 (0.73) 4.08 (0.52) 
Semi-automated 
VDV L* (±SD) 0.76 (0.55) 0.26 (0.19) 1.26 (0.45) 0.76 (0.45) 
VV L* (±SD) 4.26 (0.61) 4.43 (0.83) 3.99 (0.90) 4.37 (1.05) 
C2 L (±SD) 0.66 (0.17) 0.51 (0.06) 0.80 (0.07) 0.68 (0.20) 
C3 L (±SD) 1.77 (0.41) 1.64 (0.43) 1.81 (0.35) 1.86 (0.50) 
C4 L (±SD) 1.27 (0.33) 1.55 (0.17) 0.98 (0.32) 1.28 (0.22) 
C5 L (±SD) 0.56 (0.20) 0.73 (0.17) 0.41 (0.16) 0.54 (0.13) 
SD=Standard Deviation, VDV=Ventilation Defect Volume, VV=Ventilation Volume, 
C2=Cluster 2, C3=Cluster 3, C4=Cluster 4, C5=Cluster 5. 
*Semi-automated VDV=Cluster 1, Semi-automated VV=Sum of Clusters 2-5 
 
Figure 3-3 shows the correlations and Bland-Altman plots between manual and semi-
automated VDV.  Manual VDV was significantly and highly correlated with semi-
automated VDV for asthma (r=.89, p<.0001), COPD (r=.84, p<.0001) and CF subjects 
(r=.89, p<.0001).  Bland-Altman analysis indicated that there was negligible bias between 
manual and semi-automated VDV for asthma (bias=-0.01±0.01L), COPD 
(bias=0.01±0.05L), and CF subjects (0.05±0.04L). 
Figure 3-4 shows the correlations and Bland-Altman plots between manual and semi-
automated VV.  Manual VV was significantly and highly correlated with semi-automated 
VV for asthma (r=.99, p<.0001), COPD (r=.91, p<.0001) and CF subjects (r=.84, 
p<.0001).  Bland-Altman analysis indicated that there was negligible bias for manual and 
semi-automated VV for asthma (bias=-0.003±0.02L), COPD (bias=0.01±0.04L) and CF 
subjects (-0.03±0.06L). 
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Table 3-3 shows the intra-observer reproducibility of 3He volume measurements for 
manual and semi-automated segmentation for all subjects.  Intra-observer reproducibility 
was significantly higher for semi-automated VDV compared to manual VDV as indicated 
by the non-overlapping 95% CI for both CV (manual: CV=12%, 95% CI=9%-19%, semi-
automated: CV=5%, 95% CI=4%-8%) and ICC (manual: ICC=.98, 95% CI=.96-.99, 
semi-automated: ICC=1.00, 95% CI=.99-1.00).  Intra-observer reproducibility was also 
significantly higher for semi-automated VV compared to manual VV as indicated by the 
non-overlapping 95% CI for both CV (manual: CV=4%, 95% CI=3%-7%, semi-
Figure 3-3 Correlations and Bland-Altman plots between manual and semi-automated 
VDV for all slices.   
A Manual VDV was significantly correlated with semi-automated VDV for asthma 
(r=.89, p<.0001, r2=.80, p<.0001, y=0.87x+0.02), COPD (r=.84, p<.0001, r2=.70, 
p<.0001, y=0.69x+0.03), and CF subjects (r=.89, p<.0001, r2=.79, p<.0001, 
y=0.61x+0.001).  B The mean difference (±SD) between manual and semi-automated 
VDV was -0.01L±0.01L (lower limit=-0.03L, upper limit=-0.0006L), 0.01L±0.05L 
(lower limit=-0.08L, upper limit=-0.10L), and 0.05L±0.04L (lower limit=-0.03L, upper 
limit=-0.12L) for asthma, COPD, and CF subjects, respectively.  Solid lines indicate the 
mean difference and dotted lines indicate the 95% limits of agreement. 
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automated: CV=.2%, 95% CI=.2%-.4%) and ICC (manual: ICC=.90, 95% CI=.81-.96, 
semi-automated: ICC=1.00, 95% CI=1.00-1.00). 
Table 3-3 Intra-observer reproducibility of manual and semi-automated 3He volume 
measurements 
 
Parameter 
All 
(n=15) 
Asthma 
(n=5) 
COPD 
(n=5) 
CF 
(n=5) 
Manual 
VDV CV % [95% 
CI]  
12 [9-19] 9 [5-26] 9 [5-25] 12 [7-36] 
 ICC [95% CI]  0.98 [0.96-
0.99] 
0.99 [0.98-
1.00] 
0.97 [0.90-
1.00] 
0.96 [0.87-
1.00] 
VV CV % [95% 
CI]  
4 [3-7] 2 [1-5] 5 [3-13] 6 [3-16] 
 ICC [95% CI]  0.90 [0.81-
0.96] 
0.96 [0.85-
1.00] 
0.94 [0.68-
0.99] 
0.83 [0.56-
0.98] 
Semi-Automated 
VDV* CV % [95% 
CI]  
5 [4-8] 6 [4-18] 4 [3-13] 4 [2-11] 
 ICC [95% CI] 1.00 [0.99-
1.00] 
0.99 [0.97-
1.00] 
0.98 [0.95-
1.00] 
1.00 [0.98-
1.00] 
VV* CV % [95% 
CI]  
0.2 [0.2-0.4] 0.2 [0.1-0.5] 0.2 [0.0-0.1] 0.4 [0.2-1.1] 
 ICC [95% CI] 1.00 [1.00-
1.00] 
1.00 [1.00-
1.00] 
1.00 [1.00-
1.00] 
1.00 [1.00-
1.00] 
   C2 CV % [95% 
CI]  
0.6 [0.5-1] 1 [0.5-2] 0.3 [0.2-1] 1 [0.5-2] 
 ICC [95% CI] 1.00 [1.00-
1.00] 
0.99 [0.97-
1.00] 
1.00 [1.00-
1.00] 
1.00 [1.00-
1.00] 
   C3 CV % [95% 
CI]  
0.3 [0.2-0.5] 0.2 [0.1-0.6] 0.2 [0.1-0.3] 0.5 [0.3-1] 
 ICC [95% CI] 1.00 [1.00-
1.00] 
1.00 [1.00-
1.00] 
1.00 [0.99-
1.00] 
1.00 [0.99-
1.00] 
   C4 CV % [95% 
CI]  
0.1 [0.1-0.2] 0.1 [0.0-0.2] 0.1 [0.1-0.4] 0.2 [0.1-0.6] 
 ICC [95% CI] 1.00 [1.00-
1.00] 
1.00 [0.99-
1.00] 
1.00 [1.00-
1.00] 
1.00 [0.99-
1.00] 
   C5 CV % [95% 
CI]  
0.1 [0.0-0.1] 0.1 [0.0-0.2] 0.0 [0.0-0.1] 0.1 [0.1-0.2] 
 ICC [95% CI] 1.00 [1.00-
1.00] 
1.00 [1.00-
1.00] 
1.00 [1.00-
1.00] 
1.00 [1.00-
1.00] 
VDV=Ventilation Defect Volume, VV=Ventilation Volume, CV=Coefficient of 
Variation, ICC=Intraclass Correlation Coefficient, CI=Confidence Interval, C2=Cluster 
2, C3=Cluster 3, C4=Cluster 4, C5=Cluster 5. 
*Semi-automated VDV=Cluster 1, Semi-automated VV=Sum of Clusters 2-5 
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Table 3-4 shows the inter-observer reproducibility of 3He volume measurements for 
semi-automated segmentation for all subjects.  For the two observers, CV was low 
(VDV: CV=7%, 95% CI=5%-11%, VV: CV=.4%, 95% CI=.3%-.6%) and ICC was high 
(VDV: ICC=.96, 95% CI=.76-.99, VV: ICC=1.00, 95% CI=.83-1.00) across all three 
respiratory diseases evaluated.  
Table 3-4 Inter-observer reproducibility of semi-automated 3He volume measurements 
 
Parameter 
All 
(n=15) 
Asthma 
(n=5) 
COPD 
(n=5) 
CF 
(n=5) 
VDV* CV % [95% 
CI]  
7 [5-11] 12 [7-37] 6 [4-17] 5 [3-15] 
 ICC [95% CI] 0.96  
[0.76-0.99] 
0.95  
[0.02-1.00] 
0.94  
[0.43-0.99] 
0.97  
[0.41-1.00] 
VV* CV % [95% 
CI]  
0.4 [0.3-0.6] 0.2 [0.1-0.6] 0.2 [0.1-0.7] 0.5 [0.3-1.5] 
 ICC [95% CI] 1.00  
[0.83-1.00] 
0.99  
[0.60-1.00] 
1.00  
[0.79-1.00] 
1.00  
[0.85-1.00] 
     C2 CV % [95% 
CI]  
1 [0.6-1] 1 [1-3] 0.5 [0.3-1] 1 [1-3] 
 ICC [95% CI] 0.99  
[0.54-1.00] 
0.92  
[0.03-0.99] 
0.98  
[0.08-1.00] 
0.99  
[0.25-1.00] 
     C3 CV % [95% 
CI]  
0.5 [0.3-0.7] 0.3 [0.2-0.9] 0.3 [0.2-0.8] 0.6 [0.4-1.9] 
 ICC [95% CI] 1.00  
[0.92-1.00] 
1.00  
[0.96-1.00] 
1.00  
[0.78-1.00] 
1.00  
[0.98-1.00] 
     C4 CV % [95% 
CI]  
0.2 [0.2-0.3] 0.1 [0.1-0.2] 0.2 [0.1-0.6] 0.3 [0.9-0.2] 
 ICC [95% CI] 1.00 
 [1.00-1.00] 
1.00  
[1.00-1.00] 
1.00  
[1.00-1.00] 
1.00  
[1.00-1.00] 
     C5 CV % [95% 
CI]  
0.1 [0.1-0.2] 0.1 [0.1-0.2] 0.0 [0.0-0.1] 0.1 [0.1-0.4] 
 ICC [95% CI] 1.00  
[1.00-1.00] 
1.00  
[1.00-1.00] 
1.00  
[1.00-1.00] 
1.00  
[1.00-1.00] 
VDV=Ventilation Defect Volume, VV=Ventilation Volume, CV=Coefficient of 
Variation, ICC=Intraclass Correlation Coefficient, CI=Confidence Interval, C2=Cluster 
2, C3=Cluster 3, C4=Cluster 4, C5=Cluster 5. 
*Semi-automated VDV=Cluster 1, Semi-automated VV=Sum of Clusters 2-5 
Table 3-5 shows the SDD for measurements obtained by manual and semi-automated 
segmentation.  For manual segmentation, the SDD or the minimum change that could be 
measured confidently in individual asthma, COPD and CF subjects that were not due to 
technological or observer measurement variability (measurement error) was 310mL and 
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480mL for 3He VDV and VV, respectively.  For the semi-automated method, the SDD or 
the minimum change that could be measured confidently in individual asthma, COPD 
and CF subjects was 110mL and 30mL for 3He VDV and VV, respectively. 
Table 3-5 Smallest detectable difference for manual and semi-automated segmentation 
 
Parameter 
All 
(n=15) 
Asthma 
(n=5) 
COPD 
(n=5) 
CF 
(n=5) 
Manual 
VDV L (±SD) 0.31 0.03 0.34 0.42 
VV L (±SD)  0.48 0.20 0.52 0.63 
Semi-automated 
VDV* L (±SD) 0.11 0.05 0.16 0.08 
VV* L (±SD) 0.03 0.02 0.02 0.05 
C2 L (±SD) 0.01 0.01 0.01 0.02 
C3 L (±SD) 0.02 0.01 0.01 0.02 
C4 L (±SD) 0.01 0.00 0.00 0.01 
C5 L (±SD) 0.00 0.00 0.00 0.00 
VDV=Ventilation Defect Volume, VV=Ventilation Volume, C2=Cluster 2, C3=Cluster 
3, C4=Cluster 4, C5=Cluster 5. 
*Semi-automated VDV=Cluster 1, Semi-automated VV=Sum of Clusters 2-5 
Table 3-6 shows the Dice coefficients for manual and semi-automated segmentation.  
Dice coefficients (D) were higher for repeated semi-automated segmentation than for 
repeated manual segmentation measurements for both VDV (manual: D=.71; semi-
automated: D=.88) and VV (manual: D=.95; semi-automated: D=1.00). The Dice 
coefficient for manual and semi-automated VDV was 0.44 and the Dice coefficient for 
manual and semi-automated VV was 0.91. 
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Table 3-6 Dice coefficients for manual and semi-automated segmentation 
 
Parameter 
All 
(n=15) 
Asthma 
(n=5) 
COPD 
(n=5) 
CF 
(n=5) 
Manual –  Manual 
VDV  0.71 (0.09)† 0.69 (0.12) - 0.74 (0.05) 
VV  0.95 (0.03)† 0.97 (0.00) - 0.92 (0.02) 
Semi-automated – Semi-automated 
VDV* 0.88 (0.06) 0.82 (0.03) 0.92 (0.04) 0.89 (0.06) 
VV* 1.00 (0.00) 1.00 (0.00) 1.00 (0.00) 1.00 (0.00) 
Manual – Semi-automated 
VDV 0.36 (0.20) 0.15 (0.15) 0.52 (0.10)** 0.42 (0.11) 
VV 0.90 (0.06) 0.95 (0.01) 0.88 (0.08) 0.87 (0.04) 
*Semi-automated VDV=Cluster 1, Semi-automated VV=Sum of Clusters 2-5, †One 
repetition of manual segmentation 
3.4 Discussion 
In contrast to the homogenous 3He MRI signal intensity observed in healthy subjects with 
normal lung function, 3He MRI of subjects with respiratory disease results in 
heterogeneous signal intensity throughout the lung, which may be a result of small airway 
occlusion, mucous plugs, airway wall thickening and inflammation or bullous disease.  
Related to this, is the fact that there is significant functional information in the regions of 
middle-intensity, and both hyper- and hypo-intense signal regions that have not yet been 
quantitatively or spatially exploited.  The development and validation of 3He image 
analysis techniques, or the use of widely available and well established image processing 
algorithms, that quantify heterogeneous signal information are required to fully 
characterize the important ventilation information contained in the image, and may 
enable a better understanding of the physiological changes that occur in disease 
longitudinally and in response to treatment.  Here we evaluated the spatial and 
quantitative agreement of a semi-automated segmentation method with manual 
segmentation for the evaluation of 3He and 1H MRI of asthma, COPD and CF subjects 
and report: 1) 3He manual and semi-automated VDV and VV measurements that were not 
statistically significantly different, and were significantly correlated with good 
agreement, 2) significantly higher intra-observer reproducibility for semi-automated 
compared to manual measurements and high inter-observer reproducibility, 3) smallest 
detectable differences that were lower for semi-automated measurements, and, 4) high 
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Dice coefficients for manual and semi-automated VV, indicating excellent spatial 
overlap. 
3He MRI measurements for asthma, COPD and CF subjects generated by manual and 
semi-automated segmentation were not significantly different and were significantly and 
strongly correlated and in good agreement.   A small but insignificant bias was detected 
by Bland-Altman analysis that may be due to the manual observers’ tendency to classify 
hypo-ventilated areas as defects in some subjects and in some image slices and not in 
others, or the inclusion of regions of signal loss associated with the pulmonary vascular 
structures, not included with manual segmentation,38 by the K-means approach.  
However, it is important to note that the inclusion of pulmonary vascular structures as 
ventilation defects may not be a critical consideration for serial studies.  The 
improvement in segmentation time afforded by the semi-automated approach and the 
finding that the lung can be reliably segmented in a number of respiratory diseases, 
demonstrates the potential for 3He MRI segmentation in large scale, multi-centre clinical 
evaluations. 
We also observed that intra-observer reproducibility of the 3He measurements was 
significantly higher for semi-automated segmentation compared to the manual approach, 
and inter-observer reproducibility was high for the semi-automated method and higher 
than previously reported manual results.43  Clearly, segmentation methods that provide 
high intra-/inter-observer reproducibility are required for future studies involving large 
subject numbers and multiple research centers such that reliable measurements can be 
obtained from multiple observers independent of the level of experience.  To better 
understand if the improvements in measurement reproducibility afforded by semi-
automated segmentation could be translated to practical use, the SDD was determined for 
both manual and semi-automated measurements, and the semi-automated method 
developed here reported a lower SDD as compared to manual results.  For serial studies it 
is important to be confident that the changes measured between imaging time-points are 
not due to measurement error.  Therefore, future 3He serial studies should utilize 
segmentation methods with low measurement error to detect the important functional 
measurement changes that occur following intervention or during disease progression.  
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Furthermore, the excellent reproducibility and very low SDD for 3He VV suggests that 
this measurement could be utilized in future studies for the analysis of treatment effects 
in individual subjects. 
Finally, we demonstrated high Dice coefficients between the semi-automated and manual 
segmentation results.  This finding suggests that along with the higher intra- and inter-
observer reproducibility of the volume measurements obtained by the semi-automated 
method, the segmentation results are also highly spatially reproducible.  However, we 
also reported low Dice coefficients between the manual and semi-automated VDV 
segmentation results for the asthma subjects and moderate Dice coefficients for the 
COPD and CF subjects.  The lack of spatial correspondence between the two methods, 
particularly in the asthma subjects, is likely due to the small size of the ventilation 
defects.  It should be noted that K-means clustering is a histogram-based segmentation 
approach, thus very small areas of signal void may be included as defects by the semi-
automated method but overlooked due to the small size by the manual observer.  
Therefore, the excellent spatial and quantitative agreement between manual and semi-
automated segmentation suggests that semi-automated or automated segmentation 
methods are important for future 3He imaging studies and should be utilized as we 
transition to 129Xe MRI. 
Although the semi-automated 3He segmentation method is very promising, we must 
acknowledge that the physiological rationale for selecting the initial cluster number was 
based on the expert observer’s visual assessment, and not based on a more objective 
approach.  However, we have previously evaluated K-means with the initial user input of 
4 to 10 clusters and the hierarchical K-means approach described here, and determined 
that hierarchical K-means provided the highest correlation and lowest Bland-Altman bias 
with manual segmentation.   
In conclusion, we employed a straightforward combination of previously developed, 
well-described and widely available methods, namely hierarchical K-means, seeded 
region-growing and non-rigid registration, to 3He MRI to enable semi-automated 
segmentation of the  unique functional information this method provides.  Reproducible 
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and robust segmentation methods that can be applied across many respiratory conditions 
are urgently needed for larger scale pulmonary functional MRI studies. 
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3.6 Supplementary Tables 
Table 3-S3-1 Comparison of 3He VDV and VV generated by manual segmentation with 
K-means clustering with 4 to 10 clusters and hierarchical K-means using Pearson 
correlation coefficients and Bland-Altman analysis 
  
 
 
Pearson Correlation 
Coefficients 
Bland-Altman 
Analysis 
Parameter r p-value Bias Lower CI Upper CI 
VDV L 4 Clusters 0.67 0.0001 -0.08 -0.06 0.21 
 5 Clusters 0.79 0.0001 -0.04 -0.06 0.14 
 6 Clusters 0.73 0.0001 -0.02 -0.09 0.14 
 7 Clusters 0.75 0.0001 -0.01 -0.10 0.12 
 8 Clusters 0.80 0.0001 -0.004 -0.10 0.09 
 9 Clusters 0.76 0.0001 -0.01 -0.12 0.10 
 10 Clusters 0.76 0.0001 -0.02 -0.12 0.09 
 Hierarchical K-means 0.84 0.0001 -0.006 -0.10 0.08 
VV L 4 Clusters 0.80 0.0001 -0.09 -0.22 0.03 
 5 Clusters 0.89 0.0001 -0.06 -0.15 0.04 
 6 Clusters 0.88 0.0001 -0.04 -0.14 0.06 
 7 Clusters 0.89 0.0001 -0.03 -0.12 0.07 
 8 Clusters 0.91 0.0001 -0.01 -0.11 0.08 
 9 Clusters 0.88 0.0001 -0.007 -0.11 0.09 
 10 Clusters 0.88 0.0001 -0.001 -0.10 0.10 
 Hierarchical K-means 0.91 0.0001 -0.01 -0.10 0.08 
 
VDV=Ventilation Defect Volume, VV=Ventilation Volume, r=Pearson correlation 
coefficient, CI=95% Confidence Interval. 
Significance (p<.05). 
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CHAPTER 4  
Using the segmentation algorithm developed in Chapter 3, here we evaluated a group of 
COPD subjects using 3He MRI prior to and immediately following bronchodilator 
therapy. 
The contents of this Chapter have been previously published in Radiology and permission 
to reproduce the article was granted by the Radiological Society of North America 
(RSNA®) and is provided in Appendix C. 
M Kirby, L Mathew, M Heydarian, R Etemad-Rezai, DG McCormack and G Parraga. 
Evaluating Bronchodilator Effects in Chronic Obstructive Pulmonary Disease Quantified 
using Hyperpolarized Helium-3 Magnetic Resonance Imaging. Radiology 2011; 
261(1):283-92. 
4 Chronic Obstructive Pulmonary Disease:  Quantification 
of Bronchodilator Effects by using Hyperpolarized 3He 
MR Imaging 
4.1 Introduction 
Chronic obstructive pulmonary disease (COPD) is characterized by progressive 
expiratory flow limitation that develops due to the combined effects of large and small 
airway dysfunction, and increased lung compliance due to the permanent destructive 
changes of emphysema.1  Gas trapping and dynamic lung hyperinflation are major 
consequences of decreased expiratory airflow that often lead to many of the disabling 
symptoms associated with COPD, such as dyspnea and limitation of exercise capacity.2;3  
After smoking cessation, bronchodilators are the first-line therapy in the symptomatic 
management of COPD,3 and assessment of acute response to bronchodilators is often 
based on spirometry measurements of the forced expiratory volume in 1 s (FEV1).  While 
spirometry provides the most common primary endpoint for clinical trials evaluating 
therapeutic response, relatively poor correlations have been reported between FEV1 and 
other clinical measurements of COPD.4-6  In other words, symptomatic relief following 
bronchodilators often occurs with only modest improvements in FEV1,7-9 underscoring 
the apparent discordance between spirometry and COPD symptoms, quality of life and 
functional measurements.   
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The discordance between spirometry and COPD symptoms, as well as the limitation of 
standard measures of expiratory airflow for evaluating the regional nature of 
bronchodilator response is motivating the evaluation of new methods,10;11 including those 
derived from non-invasive imaging.12-15  For example, Computed Tomography (CT) has 
been used to evaluate changes in airway morphology after administration of 
salbutamol12;13 and tiotropium,14;15 and showed greater post-bronchodilator response in 
COPD patients with mainly airways disease compared to those with mainly 
emphysema.16  Additionally, a recent single photon emission computed tomography 
(SPECT)-CT and multiple breath nitrogen washout study17 reported no significant change 
in ventilation heterogeneity after tiotropium administration.   
Pulmonary magnetic resonance imaging (MRI) using hyperpolarized helium-3 (3He) has 
emerged as a functional imaging method providing high spatial and temporal resolution18-
23 images of the lung.  Regional ventilation abnormalities are clearly visualized as 
decreased 3He signal in the lung that can be scored or quantified as a ventilation defect 
percent (VDP)19 or percent ventilated volume (PVV).24  3He MRI ventilation 
abnormalities have been previously evaluated in COPD,25-30 with measurements that are 
sensitive to the pathological changes that accompany COPD,24  have high same-day and 
short-term reproducibility,20;21 and detect significant longitudinal changes over two years 
before changes in FEV1 are observed.18  Because of previous reproducibility20;21 and 
longitudinal findings,18 we hypothesized that 3He MRI would provide the necessary and 
sufficient spatial and temporal sensitivity as well as precision to detect any potential 
regional functional lung changes after bronchodilator therapy.  Therefore, our aim was to 
evaluate short-acting bronchodilator effects in COPD using hyperpolarized 3He MRI, 
spirometry and plethysmography.   
4.2 Materials and Methods 
4.2.1 Subjects 
All subjects provided written informed consent to the study protocol approved by the 
local research ethics board and Health Canada, and the study was compliant with the 
Personal Information Protection and Electronic Documents Act (PIPEDA, Canada) and 
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the Health Insurance Portability and Accountability Act (HIPAA, USA).  The use of an 
onsite 3He gas polarizer (HelispinTM; GE Healthcare, Durham, NC) was provided to 
Robarts Research Institute through an agreement with GE Healthcare for which we pay 
$100,000 ($CDN) annually.   
Fourteen subjects with a clinical diagnosis of COPD who were ex-smokers with a 
smoking history of at least 10-pack-years, and were GOLD stage II-IV were enrolled.  
Subjects were required to withhold both short-acting and long-acting bronchodilators the 
morning of the study.  Pre-bronchodilator MRI was performed immediately following 
pulmonary function tests; post-bronchodilator MRI and pulmonary function tests were 
performed 25 minutes (±2 minutes) after administration of 400 μg salbutamol 
(Salbutamol Sulphate USP; Apo-Salvent CFC Free Inhalation Aerosol, Apotex Inc., 
Toronto, Ontario/Canada) inhaled via a spacer device.   
4.2.2 Pulmonary Function Tests 
Spirometry was performed using an ndd EasyOne spirometer (ndd Medizintechnik AG, 
Zurich, CH) according to the American Thoracic Society (ATS) guidelines.  Static lung 
volumes and diffusing capacity of carbon monoxide (DLCO) were measured using body 
plethysmography (MedGraphics Corporation. 350 Oak Grove Parkway St. Paul, MN 
USA).   
4.2.3 Image Acquisition 
MRI was performed on a whole body 3.0 Tesla Excite 12.0 MRI system (GEHC, 
Milwaukee, WI USA) with broadband imaging capability as previously described21 and 
3He MRI was enabled using a single channel, rigid elliptical transmit/receive chest coil 
(RAPID Biomedical GmbH, Wuerzburg Germany).  It is important to note that we 
endeavored to minimize the potential for differences in the levels of inspiration between 
the breath-hold scans for each subject by: 1) training and practice for all subjects prior to 
MRI related to the inspiration breath-hold maneuver from functional residual capacity 
(FRC), and, 2) continuous coaching and monitoring at the MR bedside by a pulmonary 
function technologist during all inspiration breath-hold scans.  Because of this extensive 
coaching, no correction for differences in inspiration levels between breath-hold scans for 
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individual subjects was required.  Pulse oximetry was used to measure arterial oxygen 
saturation (Sa02) for all subjects during scanning sessions and considered an adverse 
event occurred when Sa02 decreased below 88% at any time during the scanning session.  
Study withdrawal was required when Sa02 decreased to 80% for 10 seconds or longer.  
Conventional 1H MRI was performed prior to hyperpolarized 3He MRI with subjects 
scanned during 1.0 L breath-hold of 4He/N2 using the whole body radiofrequency (RF) 
coil and 1H fast spoiled gradient recalled echo sequence (16s total data acquisition, 
repetition time (TR) / echo time (TE) / flip angle = 4.7 ms / 1.2 ms / 30o, field-of-view 
(FOV) = 40 × 40 cm, matrix 256 × 128, 14 slices, 15 mm slice thickness, 0 gap), as 
previously described.21 
Prior to 3He MRI, a polarizer system (HeliSpin™, GEHC, Durham, NC) was used to 
polarize 3He gas to 30—40 % and doses (5 mL/kg body weight) were administered in 1.0 
L Tedlar bags diluted with ultrahigh purity, medical grade nitrogen (Spectra Gases, 
Alpha, NJ).  As previously described,21 hyperpolarized 3He MRI coronal static ventilation 
images were acquired during breath-hold of a 1L 3He/N2 mixture (14s data acquisition, 
TR / TE / flip angle = 4.3 ms / 1.4 ms / 7o, bandwidth = 31.25 kHz, FOV = 40 × 40 cm, 
matrix 128 × 128, 14 slices, 15 mm slice thickness, 0 gap). 
4.2.4 Image Analysis 
3He MRI pulmonary ventilation semi-automated segmentation was performed using 
custom software generated using MATLAB R2007b (The Mathworks Inc., Natick, MA, 
USA), as previously described.31  Briefly, and as shown in the schematic in Figure 4-1, 
3He MR images were evaluated using K-means cluster analysis,32 similar to previously 
described methods for 3He MRI segmentation,33-35 to classify the 3He MRI voxel 
intensity values into clusters ranging from 1 to 5, representing gradations of signal 
intensity from no signal (Cluster 1, C1) and hypo-intense signal (Cluster 2, C2) to hyper-
intense signal (Cluster 5, C5), and generating a 3He voxel cluster map (Figure 1B).  To 
obtain the external contour of the thoracic cavity to differentiate ventilation defects (C1) 
from the edge of the lung, 1H MR images were segmented using a seeded region-growing 
algorithm36 and registered to the 3He MR ventilation images as previously described.37  
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VDP was generated using ventilation defect volume (VDV or C1) normalized to the 
thoracic cavity volume as previously described.19  For the remaining ventilation clusters, 
the segmented 1H thoracic cavity volume was used to generate cluster percent 
representing a normalized 3He cluster volume for the lung.  All measurements were 
performed by the same observer (MK) blinded to subject and time point with time point 
randomized to reduce any potential measurement bias.  The observer (MK) had three 
years experience performing manual 3He MRI segmentation and one year experience 
developing and performing semi-automated 3He MRI segmentation.  Reproducibility of 
the semiautomated method was determined on the basis of the pre- salbutamol 
intraobserver variability of five repeated measurements for five COPD subjects.  The 
smallest detectable difference (SDD), or the minimum change in 3He measurements that 
could be measured confidently in individual patients-not due to observer measurement 
variability, for five of the COPD subjects was 2% for VDP and 0.4%, 1%, 0.6%, and 
0.3% for clusters 2–5, respectively. 
4.2.5 Statistical Methods 
Multivariate analysis of variance (MANOVA) and repeated measures analysis of 
variance (ANOVA) was performed for comparison of pre- and post-salbutamol 
pulmonary function and lung volume measurements using SPSS 16.00 (SPSS Inc., 
Chicago, IL, USA LEAD Technologies, Inc., Chicago, IL).  A two-way mixed design 
Figure 4-1 Overview of 3He MRI pulmonary ventilation semi-automated segmentation 
3He MRI (A) and 3He cluster map (B) generated by semi-automated cluster analysis and 
segmentation for all slices.  3He ventilation defect volume (VDV)=cluster 1, ventilation defect 
percent (VDP)=cluster 1 normalized to the thoracic cavity volume. 
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ANOVA was used to determine the interactions between subjects and treatment, imaging 
slice and treatment, as well as bronchodilator response group and treatment for all 3He 
MRI measurements using SPSS 16.00.  Effect size (ES) calculations allow the magnitude 
of an effect to be compared between disparate types of measurements.38 Therefore, for 
comparison of the magnitude of the treatment effect between pulmonary function and 
imaging measurements, treatment ES was calculated as the ratio of the mean difference 
between pre- and post-salbutamol measurements and the pooled standard deviation for all 
subjects, calculated using Hedges’ g as shown in Equation 4-1: 
2
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where prex  and postx  are the mean pre- and post-salbutamol measurement for all 
subjects, respectively, preSD and postSD  are the standard deviations of the pre- and post-
salbutamol measurements for all subjects, respectively, and pren  and postn  are the 
number of subjects evaluated pre- and post-salbutamol, respectively. The SDD, defined 
as the smallest difference that can be measured with prospectively determined confidence 
that is not due to measurement error (variability), was calculated for five repeated pre-
salbutamol 3He VDP measurements according to Eliasziw et. al.39 and shown in 
Equation 4-2: 
raSEMzSDD int2α≥  (2) 
where αz  is 1.96 corresponding to a significance level of α =.05 and raSEM int  is the 
standard error of measurement due to intra-observer variability and is calculated as 
shown in Equation 4-3: 
2
int ˆ eraSEM σ=  (3) 
where 2ˆ eσ  is the intra-observer repeated measures variance.  Linear regression (r
2) and 
Spearman correlation coefficients (r) were used to determine the relationships between 
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pulmonary function and 3He MRI measurements using GraphPad Prism version 4.00 
(GraphPad Software Inc version 4.00, San Diego, CA, USA).  In all statistical analyses, 
results were considered significant when the probability of making a Type I error was 
less than 5% (p < 0.05).   
4.3 Results 
Demographic characteristics are provided in Table 4-1 for 14 COPD ex-smokers (GOLD 
Stage II n=5; GOLD Stage III n=8; GOLD Stage IV n=1).   
Table 4-2 shows mean pulmonary function and 3He MRI measurements for all subjects 
and Table 4-S1 provides a subject listing of all measurements.  Statistically significant 
post-salbutamol changes were observed for FEV1 (p=.001, ES=.22), TLC (p=.04, ES=-
.34), and FRC (p=.03, ES=-.10).   
Table 4-1 Subject Demographics 
 All Subjects (±SD) [range] 
(n=14) 
Age yrs  70 (6) [61-77] 
Males 70 (6) [61-77] 
Females 71 (6) [64-77] 
Male Sex 8 
BMI kg·m-2  24.9 (3.8) [17.6-31.4] 
FEV1 L 1.23 (0.50) [0.63-2.18] 
FEV1%pred 45 (12) [28-61] 
FVC L 2.98 (0.83) [1.52-4.44] 
FVC %pred 83 (12) [65-107] 
FEV1/FVC 41 (10) [22-60] 
TLC L 7.12 (1.27) [4.82-8.96] 
TLC %pred 122 (20)[101-175] 
IC L 2.21 (0.54) [1.39-3.09] 
IC %pred 83 (16) [58-108] 
FRC L 4.89 (1.22) [3.14-7.27] 
FRC %pred 155 (42) [110-243] 
RV L 3.83 (0.94) [2.63-5.25] 
RV %pred 170 (53) [104-285] 
DLCO%pred 43 (19) [20-89] 
SD=Standard Deviation, BMI=Body Mass Index, FEV1= Forced Expiratory Volume in 
1s, %pred=Percent Predicted, FVC= Forced Vital Capacity, TLC= Total Lung Capacity, 
IC= Inspiratory Capacity, FRC= Functional Residual Capacity, RV= Reserve Volume, 
DLCO=Carbon Monoxide Diffusion Capacity of the lung. 
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Table 4-2 Pre- and post-salbutamol measurements 
 
 
Parameter 
Pre-
Salbutamol 
(n=14) 
Post-
Salbutamol 
(n=14) 
Significance of 
Difference 
(p) 
Effect 
Size 
 
Pulmonary Function Measurements   
FEV1 L (±SD) 1.23 (0.50) 1.35 (0.57) 0.001+ 0.22 
FVC L (±SD) 2.98 (0.83) 3.06 (0.85) 0.46+ 0.10 
TLC L (±SD) 7.05 (1.22) 6.62 (1.26)† 0.04+ -0.35 
IC L (±SD) 2.15 (0.58) 2.02 (0.66) † 0.39+ -0.21 
FRC L (±SD) 4.89 (1.22) 4.61 (1.22) † 0.03+ -0.23 
RV L (±SD) 3.79 (0.91) 3.59 (0.85) † 0.23+ -0.23 
Hyperpolarized 3He MRI   
VDP  % (±SD) 28 (7) 24 (9) <0.0001‡ -0.50 
Cluster 2 % (±SD) 15 (2) 14 (2) 0.01‡ -0.50 
Cluster 3 % (±SD) 31 (5) 32 (5) 0.03‡ 0.20 
Cluster 4 % (±SD) 19 (4) 22 (5) <0.0001‡ 0.66 
Cluster 5 % (±SD) 8 (3) 9 (3) 0.02‡ 0.33 
FEV1= Forced Expiratory Volume in 1s, FVC= Forced Vital Capacity, TLC= Total Lung 
Capacity, IC= Inspiratory Capacity, FRC= Functional Residual Capacity, RV= Reserve 
Volume, VDP=Ventilation Defect Percent, †n=13 
+Repeated measures ANOVA, ‡Two-way mixed design repeated measures ANOVA. 
Figure 4-2 shows two of the central coronal 3He MRI slices, where the trachea and two 
main bronchi are clearly visible with 3He ventilation displayed in red, registered to the 
greyscale 1H MRI of the thorax for each of five representative subjects (S1 and 
S2=GOLD II, S3 and S4=GOLD III and S5=GOLD IV) before and after salbutamol 
administration.  The change in 3He gas distribution after salbutamol is readily apparent in 
the right and left apical regions for S1 and S5 and right mid apex for S3, whereas there is 
little change visible for S2 and S4 for the two slices shown.  To ensure that the increased 
distribution of 3He gas post-salbutamol administration was not due to differences in the 
volume of polarized gas administered at each time-point, we calculated the total pixel 
intensity for each lung image, including the trachea and major airways, from the image 
pixel intensity frequency histograms, as well as the total moles of polarized gas delivered 
for each subject time-point (data not shown).  These estimations showed that the amount 
of polarized gas administered and inhaled was not significantly different between time-
points (p=.87).  The signal-to-noise ratio for each pre- and post-salbutamol image pair 
was also not statistically significantly different (p=.12).  To minimize the potential of 
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introducing intensity variations due to B1-field inhomogeneity, subjects were located in 
the same position within the coil between imaging time-points. 
   
 
 
 
 
 
 
Figure 4-2 3He MRI pre- and post-salbutamol 
Pre- and post-salbutamol 3He MRI (red) registered to coronal thoracic 1H MRI (grey 
scale) for five representative COPD subjects. Two center slices for GOLD Stage II 
COPD (S1, S2), GOLD Stage III (S3, S4), and GOLD Stage IV COPD (S5). 
120 
 
Table 4-2 shows mean normalized pre- and post-salbutamol 3He measurements and 
Table 4-S2 (online) shows the mean pre- and post-salbutamol 3He volume and signal 
intensity measurements.  There was a significant decrease in VDP following salbutamol 
administration (p<.0001, ES=-.50), and there was no relationship between post-
salbutamol changes in VDP and image slice (as a region of interest) (p=.30), indicating 
no bias for any measurable changes with respect to image slice.  Following salbutamol 
administration, there was a significant decrease in 3He C2 (p=.01, ES=-.50), and 
significant increases in 3He C3 (p=.03, ES=-.20), C4 (p<.0001, ES=-.66) and C5 (p=.02, 
ES=-.33).  Based on the pre-salbutamol intra-observer variance, the SDD or the minimum 
change in 3He measurements that could be measured confidently in individual subjects -
not due to observer measurement variability for five of the COPD subjects (n=1 stage II, 
n=4 stage III) was 2% for VDP and 0.4%, 1%, 0.6% and 0.3% for C2-5, respectively. 
As shown in Figure 4-3, there were significant and moderate Spearman correlations 
between baseline 3He VDP and post-salbutamol changes in FEV1 (r=-.77, p=.001) and 
between baseline FEV1%pred and post-salbutamol changes in FEV1 (r=.56, p=.04).  There 
was also a significant correlation between the changes measured in 3He C2 and changes 
in FEV1 (r=-.62, p=.02) and FVC (r=-.59, p=.03). 
Figure 4-3 Correlation between baseline FEV1 %pred and VDP and the post-salbutamol 
change in FEV1.   
BL FEV1%pred is significantly correlated with Δ FEV1 (r=.60, r2=.36, p=.02, y=0.006x-
0.13) (A), BL VDP is significantly correlated with Δ FEV1 (r=-.68, r2=.46, p=.008, y=-
0.01x+0.42) (B).  Dotted lines indicate the 95% confidence intervals. 
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Recently published ATS and European Respiratory Society (ERS) guidelines define a 
significant bronchodilator response as an increase in post-salbutamol FEV1 and/or FVC 
greater than 200mL and 12%.40 Accordingly, five subjects were classified as 
bronchodilator responders (BR) and nine subjects were classified as bronchodilator non-
responders (BNR).  As shown in Tables 4-3, and Table 4-S1, mean reductions in VDP 
and C2, and corresponding increases in C3-5 were demonstrated for both BR and BNR 
subjects.  As shown in Figure 4-4, VDP was significantly lower for BR compared to 
BNR at baseline and post bronchodilator (p=.03).  As depicted by the parallel slopes for 
pre- and post-salbutamol measurements shown in Figure 4, there was no significant 
difference between BR and BNR for post-salbutamol change in 3He MRI (VDP, C2-5, 
p>.05).  It is important to point out that there was a single BNR subject that showed a 
240ml and 12% improvement in FEV1 (just missing the greater than 12% change in FEV1 
requirement for BR), and when this subject was re-categorized as BR the reported results 
remained the same.  It is also worth noting that there were no significant differences 
between BR and BNR for baseline FEV1 (p=.44) or DLCO (p=1.00).  
 
  
 
 
 
 
 
 
 
 
Figure 4-4 Mean changes in VDP for BR 
and BNR.   
3He VDP pre- and post-salbutamol for BR 
(black) and BNR (grey).  Means 
calculated for all subject slices and error 
bars are 95% confidence intervals of the 
mean.   
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Table 4-3 Subject listing of changes in spirometry and 3He MRI measurements after 
salbutamol administration 
Subject Spirometry 3He MRI 
 ∆ FEV1 ∆ FVC ∆ VDP ∆ C2 ∆ C3 ∆ C4 ∆ C5 
 L %* L %* % % % % % 
All Subjects 
 0.12 10 0.07 2 -4 -1 1 3 1 
BR 
1 0.14 11 0.46 14 2 -1 -1 0 0 
3 0.18 16 0.42 13 2 -1 0 0 -2 
5 0.32 15 0.36 10 -14 -2 2 9 5 
7 0.18 25 0.24 16 0 1 1 0 -1 
10 0.27 22 0.49 21 -11 -4 4 6 4 
ALL 0.22 11 0.36 14 -4 -1 1 3 1 
BNR 
2 0.02 2 -0.01 0 0 0 1 0 -1 
4 0.04 6 -0.25 -11 2 -1 0 -1 -1 
6 0.00 0 -0.32 -12 3 -1 -2 0 -1 
8 -0.06 -7 -0.07 -3 -6 -3 3 5 1 
9 0.24 12 0.35 9 -2 0 -2 2 2 
11 0.08 9 0.11 3 -8 0 -5 9 4 
12 0.06 8 -0.08 -4 -20 -2 10 10 2 
13 0.13 9 0.07 2 -3 -1 -1 2 3 
14 0.07 4 -0.76 -17 -6 1 7 0 -2 
ALL 0.06 5 -0.11 -3 -5 -1 1 3 1 
*%=Percent change from baseline absolute value in litres 
BR=Bronchodilator Responder, BNR=Bronchodilator Non-Responder 
Significant bronchodilator response defined as an increase in FEV1 and/or FVC greater 
than 200mL and 12% from pre-salbutamol values according to ATS/ERS 40. 
 
4.4 Discussion 
In this pilot functional MRI evaluation of bronchodilator effects in COPD, we made a 
number of observations and report the following: 1) significant post-bronchodilator 
improvements in both spirometry and 3He MRI measurements of gas distribution, and 
their effect sizes, 2) a significant relationship between 3He VDP and changes in FEV1 
post-salbutamol, and, 3) changes in 3He MRI post-bronchodilator that were not 
significantly different for BR and BNR subgroups. 
First, and as might be expected from previous work that demonstrated modest 
improvements in lung function in patients with COPD following bronchodilator 
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therapy,7;10;11;41-43 we observed statistically significant changes in mean FEV1, FRC, and 
TLC.  At the same time, significant decreases in 3He MRI VDP and C2 and significant 
improvements in 3He MRI C3-5 were measured, suggesting regional gas distribution 
improvements throughout the lung.  Additionally, the 3He gas distribution changes 
occurred in different slices for each subject with no detected bias for specific regions of 
gas distribution improvements.  This finding is in agreement with a recent CT study15 that 
demonstrated regionally dispersed airway wall structural alterations post-bronchodilator.  
Moreover, when ES was evaluated, which allows the magnitude of the treatment effect to 
be compared between disparate types of measurements, 3He MRI measurements provided 
greater ES than FEV1.  We also observed an overall mean change in VDP and all 3He 
ventilation cluster measurements greater than the SDD indicating that the measured 
improvement in 3He distribution post-salbutamol was not due to measurement error or 
lack of reproducibility.  Although this study did not include a control arm, it is important 
to note that 11 of the 14 subjects evaluated here previously participated in a 
reproducibility study20 approximately 2 years prior to pre- and post-salbutamol imaging.  
In this previous study, the mean change in VDV for these subjects, approximately 7 
minutes after scan, was 1 mL – not a significant or clinically relevant change.  For the 
same 11 subjects reported here, the mean change in 3He VDV (C1) was 62 mL.  Taken 
together, these results strongly suggest that the changes following treatment observed 
here were not due to either scan-rescan variability or the intra-observer variability of the 
measurement technique.  We must also point out that although this is the first reported 
study demonstrating improvements in 3He gas distribution following bronchodilator 
therapy in COPD, previous 3He MRI studies have demonstrated changes in 3He gas 
distribution following bronchial provocation tests with methacholine in asthma and 
following therapy in cystic fibrosis subjects.25-29  Taken together, these imaging-based 
treatment response studies indicate that functional MRI may be considered for evaluating 
new respiratory therapies in clinical trials. 
Second, we also observed a significant negative correlation between the baseline VDP 
and changes in FEV1 post-salbutamol, and a significant positive correlation between 
baseline FEV1 and changes in FEV1.  These results suggest that subjects demonstrating 
the greatest improvement in FEV1 post-salbutamol were those with milder disease.  A 
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recent CT study also evaluated a large number of COPD ex-smokers as part of the 
National Emphysema Treatment Trial and in accordance with our MRI results, 
demonstrated that significant bronchodilator reversibility was more likely in patients with 
higher FEV1.44 
Finally, we detected post-bronchodilator improvements in 3He VDP and gas distribution 
that were not significantly different for the five BR and nine BNR subjects.  Based on 
this imaging finding, it appears that even COPD patients without a clinically relevant 
improvement in FEV1 show improved regional gas distribution, post-bronchodilator.  In 
fact, both groups showed the same mean improvement in 3He MRI measurements.    This 
important finding suggests that measurements derived from non-invasive imaging detect 
functional lung changes that enable a better understanding of the COPD lung and its 
regional response to therapy which may be important for drug development and drug 
treatment trials in COPD.  Future functional MRI studies with larger sample sizes will 
help to confirm and extend these important findings.  
We acknowledge that this pilot study is limited by the small number of subjects studied 
and the fact that the analysis was restricted mainly to subjects with stage II and III 
COPD.  Another limitation is the lack of a true reference standard for the measurement of 
treatment effects in COPD, such as dyspnea scores and measurements of exercise 
tolerance for direct comparison to 3He MRI measurements to evaluate the clinical 
meaning of the imaging changes.  In other words, whether improvements in gas 
distribution are related to clinical or symptomatic improvement remains to be established 
in a larger study.  We note that subjects were provided training for inspiration breath-hold 
scanning, they performed practice breath-holds and received coaching during breath-hold 
MRI.  Clearly, reproducible and comparable breath-hold volumes is critically important 
for acute and chronic therapy repeated studies.  We also acknowledge that although 3He 
MRI ventilation defect measurements have been previously reported to have high same-
day reproducibility20 in the majority of subjects included in this study, the prospective 
inclusion of a control group would have strengthened the conclusion that changes post-
salbutamol observed here were directly attributable to bronchodilator treatment.  Another 
important consideration is the high cost and limited access of 3He gas, however, it is 
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important to note that hyperpolarized 129Xe MRI is a less expensive and more readily 
available approach. 
In conclusion, our results suggest that noninvasive pulmonary functional 3He MRI 
provides a way to measure acute treatment effects by quantifying 3He gas distribution 
before and after therapy.  
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4.6 Supplementary Tables 
Table 4-S4-1 Subject listing of pre- and post-salbutamol pulmonary function and hyperpolarized 3He MRI measurements 
Subject 
Pre-Salbutamol Post-Salbutamol 
Pulmonary Function Tests Hyperpolarized 3He MRI Pulmonary Function Tests Hyperpolarized 3He MRI 
FEV1  
(L) 
FVC 
(L) 
TLC 
(L) 
IC 
(L)  
FRC 
(L) 
RV 
(L) 
VDP  
(%) 
C2  
(%) 
C3  
(%) 
 C4  
(%) 
C5  
(%) 
FEV1 
(L) 
FVC 
(L) 
TLC 
(L) 
IC 
(L)  
FRC 
(L) 
RV 
(L) 
VDP  
(%) 
C2  
(%) 
C3  
(%) 
 C4  
(%) 
C5  
(%) 
1 1.26 3.22 7.7 2.56 5.15 4.02 27 14 32 19 7 1.4 3.68 7.37 2.71 4.67 3.82 29 13 31 20 7 
2 1.13 3.13 7.45 1.39 6.06 4.1 38 10 20 20 12 1.15 3.12 7.56 1.34 6.22 4.63 38 10 20 20 11 
3 1.16 3.18 7.59 1.85 5.57 4.02 23 14 37 20 6 1.34 3.6 7.74 1.93 5.81 3.99 25 14 38 20 4 
4 0.63 2.31 7.66 1.69 5.97 5.25 36 15 31 13 5 0.67 2.06 6.7 1.31 5.39 4.36 38 14 30 12 5 
5 2.18 3.65 7.88 3.08 4.8 2.95 26 15 26 23 11 2.5 4.01  - - - - 11 13 28 31 16 
6 1.04 2.69 5.8 2.03 3.77 3.14 34 13 29 17 7 1.04 2.37 5.25 1.73 3.52 2.77 37 13 27 17 6 
7 0.72 1.52 4.82 1.39 3.43 3.09 23 15 32 20 9 0.9 1.76 4.71 1.61 3.1 2.76 23 16 32 20 8 
8 0.88 2.23 6.51 2.09 4.42 3.92 31 18 33 14 5 0.82 2.16 6.41 1.97 4.44 4.08 25 15 36 18 6 
9 2.06 4.06 8.19 3.09 5.1 4.06 13 14 38 25 10 2.3 4.41 7.53 3.06 4.48 3.08 11 14 36 27 12 
10 1.22 2.28 5.3 2.17 3.14 2.86 26 20 32 17 6 1.49 2.77 4.9 2.23 2.67 2.16 15 16 37 23 9 
11 0.85 3.87 8.96 1.7 7.27 5.11 31 15 35 14 5 0.93 3.98 8.31 1.77 6.54 4.66 23 15 30 23 9 
12 0.71 2.27 7.6 1.75 5.85 5.11 37 17 28 13 5 0.77 2.19 5.9 1.09 4.82 3.52 17 16 38 23 7 
13 1.4 2.92 5.61 2.39 3.22 2.63 20 14 35 23 8 1.53 2.99 5.49 2.26 3.23 2.52 17 13 34 25 12 
14 1.92 4.44 7.59 2.93 4.66 2.81 29 13 25 22 10 1.99 3.68 8.19 3.19 5.01 4.3 24 14 32 22 8 
FEV1= Forced Expiratory Volume in 1s, FVC= Forced Vital Capacity, TLC= Total Lung Capacity, IC= Inspiratory Capacity, 
FRC= Functional Residual Capacity, RV= Reserve Volume, VDP=Ventilation Defect Percent, C2=Cluster 2, C3=Cluster 3, 
C4=Cluster 4, C5=Cluster 
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Table 4-S4-2 Pre- and post-salbutamol 3He volume and signal intensity measurements 
 
Parameter 
Pre-Salbutamol Post-Salbutamol 
Volume (L) SI (x1012) Volume (L) SI (x1012) 
VDV (±SD) 1.76 (0.54) 0.48 (0.22) 1.51 (0.71) 0.60 (0.31) 
Cluster 2 (±SD) 0.92 (0.16) 1.18 (0.20) 0.87 (0.18) 1.72 (0.28) 
Cluster 3 (±SD) 1.93 (0.53) 2.63 (0.69) 1.98 (0.42) 3.86 (1.00) 
Cluster 4 (±SD) 1.16 (0.34) 5.25 (0.89) 1.33 (0.34) 7.68 (1.31) 
Cluster 5 (±SD) 0.48 (0.18) 8.73 (1.11) 0.53 (0.20) 11.86 (1.59) 
SI=Signal Intensity, VDV=Ventilation Defect Volume 
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CHAPTER 5  
In the same group of COPD ex-smokers evaluated using 3He MRI pre- and post-
bronchodilator therapy in Chapter 4, here we further evaluated the regional effects of 
bronchodilator administration in COPD using 3He MRI ADC.   
The contents of this Chapter have been previously published in the Journal of Applied 
Physiology and permission to reproduce the article was not required by The American 
Physiological Society.   
M Kirby, M Heydarian A Wheatley, R Etemad-Rezai, DG McCormack and G Parraga.  
Evaluating Bronchodilator Effects in Chronic Obstructive Pulmonary Disease using 
Diffusion-Weighted Hyperpolarized Helium-3 Magnetic Resonance Imaging.  J. Appl. 
Physiol. 2012; 112(4):651-7. 
5 Evaluating Bronchodilator Effects in Chronic 
Obstructive Pulmonary Disease using Diffusion-weighted 
Hyperpolarized Helium-3 Magnetic Resonance Imaging 
5.1 Introduction 
Chronic obstructive pulmonary disease (COPD) is characterized by progressive 
expiratory flow limitation that develops as a result of the lung’s inflammatory response to 
inhaled toxic gases and particles, primarily from tobacco smoke.1  Airflow limitation may 
be caused by a number of factors such as lumen occlusion via mucus plugs,2 structural 
alteration of the airway wall resulting in encroachment of the airway wall into the airway 
lumen3;4 and/or a loss of elastic recoil within the lung parenchyma due to emphysematous 
tissue destruction that leads to reduced tethering forces stabilizing the airways at forced 
expiration.5  The prolongation of the time constants for lung emptying results in 
numerous physiological and functional consequences including hyperinflation and gas 
trapping as well as ventilation abnormalities that lead to many of the disabling symptoms 
associated with COPD, such as dyspnea and limitation of exercise capacity.6;7 
Administration of short-acting beta-agonist bronchodilators is first-line therapy in the 
symptomatic management of COPD8 and this is thought to decrease airway smooth 
muscle tone thereby improving lung emptying during expiration.9  While improvements 
in airflow limitation and reductions in lung hyperinflation following bronchodilator 
administration have been previously shown,10-12 there is still little understanding about 
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the regional nature of bronchodilator response in COPD.  In this regard, pulmonary 
magnetic resonance imaging (MRI) using hyperpolarized helium-3 (3He) provides high 
spatial and temporal resolution in vivo images of 3He gas distribution within lung in 
COPD subjects.13-21  In COPD ex-smokers we previously observed significant 
improvements in the regional distribution of 3He gas after bronchodilator 
administration,22 however, it was unclear whether these regional improvements were 
related to physiological or symptomatic improvements.  The measurement of the 3He 
apparent diffusion coefficient (ADC) has been demonstrated to be highly reproducible23-
25 and is sensitive to changes in the lung microstructure and airspace size,20;26;27 
correlating with spirometry,28 diffusing capacity of carbon monoxide (DLCO),29 multi-
slice CT measurements of emphysema,30 as well as lung surface area measurements.31  
3He MRI ADC measurements are also age-dependent,32 and reflect GOLD classification 
of disease severity,13 smoking history,29 and detects gas trapping within the dependent 
lung regions in COPD.33 
We hypothesized that the improvements in 3He gas distribution we previously observed 
after bronchodilation in COPD may be the direct source of symptomatic relief following 
therapy.  To help test this hypothesis, here we aimed to evaluate hyperpolarized 3He MRI 
ADC as a surrogate of the extent of emphysematous tissue destruction within the newly 
ventilated lung regions (post-bronchodilator) and to evaluate regional gas trapping 
following bronchodilator administration.  We evaluated lung microstructural 
measurements using regional 3He MRI ADC in COPD before and after bronchodilator 
administration,22 after developing image registration/segmentation methods for 
quantifying ADC in the lung regions newly ventilated post-bronchodilator.   
5.2 Materials and Methods 
5.2.1 Subjects 
All subjects were enrolled in a 3He MRI study of the acute effects of salbutamol 
administration22 in which written informed consent to the protocol approved by the local 
research ethics board and Health Canada was provided, and the study was compliant with 
the Personal Information Protection and Electronic Documents Act (PIPEDA, Canada) 
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and the Health Insurance Portability and Accountability Act (HIPAA, USA).  COPD 
subjects were enrolled who were ex-smokers between the ages of 50-85, with a clinical 
diagnosis of COPD and were categorized according to the global initiative for chronic 
obstructive lung disease (GOLD) criteria,1 with a smoking history of at least 10 pack-
years.  Subjects were required to withhold short-acting bronchodilators the morning of 
their study visit.  Pre-bronchodilator MRI was performed immediately following 
pulmonary function tests, and post-bronchodilator MRI was performed 25 minutes (±2 
minutes) after administration of 400 μg salbutamol inhaled via a spacer device.  Digital 
pulse oximetry was used to measure arterial oxygen saturation (Sa02) during scanning 
sessions and a hypoxic adverse event was defined as a decrease in Sa02 below 88% at any 
time during imaging.  Study withdrawal was required when Sa02 decreased to 80% for 10 
s or longer.  
5.2.2 Pulmonary Function Tests 
Spirometry was performed using an ndd EasyOne spirometer (ndd Medizintechnik AG, 
Zurich, CH) reporting forced expiratory volume in 1 second (FEV1) and forced vital 
capacity (FVC) with a minimum of three acceptable spirometry maneuvers with the best 
FEV1 and FVC selected for analysis according to the American Thoracic Society (ATS) 
guidelines.  Total lung capacity (TLC), inspiratory capacity (IC), functional residual 
capacity (FRC) and residual volume (RV) were measured using body plethysmography 
(MedGraphics Corporation, 350 Oak Grove Parkway St. Paul, MN USA).   
5.2.3 Image Acquisition 
MRI was performed on a whole body 3.0 Tesla Excite 12.0 MRI system (GEHC, 
Milwaukee, WI USA) with broadband imaging capability as previously described.34  All 
helium imaging employed a whole body gradient set with maximum gradient amplitude 
of 1.94 G/cm and a single channel, rigid elliptical transmit/receive chest coil (RAPID 
Biomedical GmbH, Wuerzburg Germany).  The basis frequency of the coil was 97.3 
MHz and excitation power was 3.2 kW using an AMT 3T90 RF power amplifier (GEHC, 
Milwaukee WI USA).  Subjects were positioned supine in the MR scanner and Sa02 was 
used to monitor arterial blood oxygenation levels during all MRI maneuvers.  For both 1H 
137 
 
and 3He MRI, subjects were instructed by a pulmonary function technologist to inhale a 
gas mixture from a 1.0 L Tedlar bag (Jensen Inert Products, Coral Springs, FL) from 
FRC, and image acquisition was performed under breath-hold conditions –a period of 8 
to 15s.   
Coronal proton (1H) MRI was performed prior to hyperpolarized 3He MRI with subjects 
scanned during breath-hold after inspiration of a 1.0 L 4He/N2 gas mixture using the 
whole body radiofrequency (RF) coil and 1H fast spoiled gradient recalled echo sequence 
(16s total data acquisition, repetition time (TR) / echo time (TE) / flip angle = 4.7 ms / 
1.2 ms / 30o, field-of-view (FOV) = 40 x 40 cm, matrix 256 x 128, 14 slices, 15 mm slice 
thickness, 0 gap), as previously described.35 
Prior to 3He MRI, a polarizer system (HeliSpin™, GEHC, Durham, NC) was used to 
polarize 3He gas to 30—40 %.  As previously described,36 hyperpolarized 3He MRI 
diffusion-weighted images were acquired in breath-hold after inspiration of a 1.0 L 
3He/N2 mixture (does 5 mL/kg body weight) using a fast gradient-echo method (FGRE) 
with centric k-space sampling.  Two interleaved images were acquired (14s total data 
acquisition, TR/TE/flip angle = 7.6 ms/3.7 ms/8o, FOV = 40 x 40 cm, matrix 128 x 128, 7 
slices, 30 mm slice thickness), with and without additional diffusion sensitization (G = 
1.94 G/cm, rise and fall time = 0.5 ms, gradient duration = 0.46 ms, Δ = 1.46 ms, b = 1.6 
s/cm2). 
5.2.4 Image Analysis 
3He MRI ADC analysis was performed using MATLAB R2007b (The Mathworks Inc., 
Natick, MA, USA).  To ensure ADC was generated for voxels corresponding to 
ventilated lung regions, k-means cluster algorithm,36 previously developed for 3He MRI 
segmentation,22;37;38 was applied to the non-diffusion-weighted images to obtain a binary 
mask for each slice.  The resulting binary masks were applied to the corresponding non-
diffusion-weighted images, and the ADC maps were generated on a voxel-by-voxel basis 
according to Equation 5-1: 
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

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S
b
ADC 0ln1  
(1) 
where 0S  is the segmented non-diffusion-weighted image, S  is the diffusion-weighted 
image and b = 1.6 s/cm2.   
An overview of the 3He MRI analysis methodology is provided in Figure 5-1.  To 
minimize the potential for differences in the levels of inspiration between pre- and post-
salbutamol imaging, extensive coaching was performed between the breath-hold scans 
for all subjects.  Pre- and post-salbutamol ADC maps were registered using landmark-
based image registration.  Briefly, the center slice defined as the slice that clearly showed 
the carina and primary bronchi, was identified in the non-diffusion-weighted images for 
each imaging time-point and displayed side-by-side.  Fiducial markers were identified on 
both the pre- and post-salbutamol 3He images based on the carina and a translation 
operation was used to transform the post-salbutamol image for registration with the 
corresponding landmark in the pre-salbutamol image.  The resultant transformation was 
then applied to the 3He ADC maps for all slices.  The trachea and visible major airways 
were removed semi-automatically using a region of interest tool (function roipoly in 
MATLAB) permitting ADC calculation within the lung parenchyma. 
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Whole lung (WL) ADC values were determined for each slice and then averaged to 
obtain a single ADC for each subject.  Following registration of the pre- and post-
salbutamol ADC maps, the lung regions of interest (ROI) with 3He signal at both time-
points were identified as the intersection of the pre- and post-salbutamol maps; mean 
ADC within those ROI was generated for each slice and then averaged to obtain a 
previously ventilated ADC (ADCP) for both pre-salbutamol and post-salbutamol 
conditions.  Lung ROI with 3He signal at both time-points were used as a binary 
ventilation mask on the post-salbutamol ADC maps to calculate mean ADC in newly 
ventilated ROI post-salbutamol (ADCN).  To ensure that ADC estimates were generated 
for the newly ventilated lung regions post-salbutamol, and to minimize the contribution 
of patient movement or breath-hold mismatch between imaging time-points, we used a 
morphological closing algorithm on the post-salbutamol ADC maps (function imclose in 
Figure 5-1  3He MRI Image Analysis Methodology 
Subject is 74 yrs old female with Stage II COPD (FEV1 =47%pred, FVC=92%pred, 
FEV1/FVC=39%, DLCO=20%pred).  3He ADC maps pre- and post-salbutamol, binary 
ventilation mask of lung regions of interest (ROI) with 3He signal at both time-points 
following registration of pre- and post-salbutamol ADC maps, 3He ADC maps for the 
previously ventilated (ADCP) lung ROI pre- and post-salbutamol, and 3He ADC maps for 
newly ventilated (ADCN) lung ROI post-salbutamol with the CT density masks to outline 
areas with attenuation values less than -950 HU.  CT images were acquired 19 months 
following pre- and post-salbutamol imaging. 
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MATLAB) with a disked-shaped structuring element with radius=1.  The resultant binary 
masks were applied to the ADC maps of the newly ventilated regions post-salbutamol, 
and mean ADCN was determined. 
5.2.5 Statistical Methods 
All statistical analyses were performed using IBM SPSS Statistics 19.0 (IBM Inc., 
Chicago, IL).  Multivariate analysis of variance (MANOVA) and repeated measures 
analysis of variance (ANOVA) were performed for comparison of pre- and post-
salbutamol pulmonary function measurements.  Statistical comparisons of mean pre- and 
post-salbutamol WL ADC and ADCP measurements were performed using a two-way 
mixed design repeated measures ANOVA with imaging time-point (pre- and post-
salbutamol) treated as the within-subject factor and subject treated as the between-
subjects factor.  Comparison between ADCP and ADCN post-salbutamol were also 
performed using a two-way mixed design repeated measures ANOVA with region of 
interest (previously ventilated or newly ventilated post-salbutamol) treated as the within-
subject factor and subject treated as the between-subjects factor.  Anatomical differences 
in ADC within the regions of the lung ventilated at both time-points were quantified by 
determining the mean ADC in the most posterior slice and by calculating the absolute 
difference in ADC between the most anterior and the most posterior slice (ΔAP).  
Comparisons between mean ADC in the most posterior slice and ΔAP pre- and post-
salbutamol were determined using a two-tailed Wilcoxon signed rank t-test.  Spearman 
correlation coefficients were used to determine the relationship between ADC and 
pulmonary function measurements.  In all statistical analyses, results were considered 
significant when the probability of making a Type I error was less than 5% (p < 0.05).   
5.3 Results 
All subjects completed both scanning sessions and there were no serious or severe breath-
hold related or other adverse events reported, nor were there any other adverse events that 
required subjects to withdraw from the study.  Table 5-1 shows study subject 
demographics and mean pulmonary function measurements (n=3 Stage II, n=6 Stage III, 
and n=1 Stage IV) before and after salbutamol administration.  Statistically significant 
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post-salbutamol changes were observed for FEV1 (p=.007), TLC (p=.02), FRC (p=.02) 
and RV (p=.02). 
Table 5-1 Subject Demographics 
 
Parameter 
Pre-Salbutamol 
(±SD) [range] 
(n=10) 
Post-Salbutamol 
(±SD) [range] 
(n=10) 
Significance of 
Difference (p)* 
Age yrs  70 (6) [61-77] - 
Male Sex 4 - 
BMI kg·m-2  25 (4) [18-30] - 
FEV1 L 1.11 (0.42) [0.63-2.06] 1.23 (0.49) [0.67-2.30] 0.007 
FVC L 2.67 (0.71) [1.52-4.06] 2.80 (0.86) [1.76-4.41] 0.20 
FEV1/FVC 0.41 (0.09) [0.27-0.53] 0.45 (0.12) [0.32-0.70] 0.08 
TLC L  6.68 (1.21) [4.82-8.19] 6.20 (1.12) [4.71-7.74] 0.02 
IC L 2.10 (0.49) [1.39-3.09] 1.99 (0.60) [1.09-3.06] 0.23 
FRC L 4.56 (1.11) [3.14-5.97] 4.21 (1.04) [2.67-5.81] 0.02 
RV L  3.81 (0.89) [2.63-5.25] 3.31 (0.75) [2.16-4.36] 0.02 
BMI=Body Mass Index, FEV1=Forced Expiratory Volume in 1s, FVC=Forced Vital 
Capacity, TLC=Total Lung Capacity, IC=Inspiratory Capacity, FRC=Functional 
Residual Capacity, RV=Reserve Volume 
*Repeated measures ANOVA   
 
Figure 5-2 shows representative 3He ADC maps pre- and post-salbutamol for a single 
subject and arrows identify visually obvious alterations in gas distribution.  Figure 5-3A 
shows mean pre- and post-salbutamol 3He MRI ADC measurements for all subjects.  
There was no significant difference detected for WL ADC post-salbutamol (p=.516).  As 
shown in Table 5-2, no significant correlations were detected between the change in WL 
ADC post-salbutamol and the change in pulmonary function measurements.  However, 
there was a significant correlation between pre-salbutamol WL ADC and the change in 
IC (r=-.68, p=.03). 
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Table 5-2 Correlation between the post-salbutamol change in ADC and the change in 
pulmonary function measurements 
 
Parameter 
Spearman Correlation Coefficients (r) 
WL ADC (cm2/s) WL ADCp (cm2/s) 
TLC L 0.515 (0.133) 0.782 (0.011) 
IC L 0.139 (0.707) 0.285 (0.427) 
FRC L 0.636 (0.054) 0.806 (0.007) 
RV L 0.479 (0.166) 0.733 (0.020) 
 
Figure 5-4 shows for two representative COPD subjects the WL pre- and post-
salbutamol ADC maps and the newly ventilated ADCN maps post-salbutamol.  There was 
no statistically significant difference between ADCN and ADCP post-salbutamol 
(ADCP=.506±.072cm2/s, ADCN=.504±.082 cm2/s, p=1.00), nor were there any significant 
interactions between the ADCN and ADCP post-salbutamol (p=.18), indicating no 
significant change in ADC within the newly ventilated lung areas following 
administration of salbutamol. 
Figure 5-2 3He WL ADC pre-salbutamol and post-salbutamol. 
Subject is a 64 year old male with Stage III COPD (pre-salbutamol:  FEV1=38%pred, 
FVC=73%pred, TLC=115%pred, FRC=147%pred, RV=179%pred, DLCO=41%pred; post-
salbutamol:  FEV1=43%pred, FVC=84%pred, TLC=110%pred, FRC=133%pred, 
RV=170%pred).  Pre- and post-salbutamol WL ADC maps with the corresponding mean 
ADC measurement shown below for each image slice. 
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For ADCp measurements, there was a statistically significant decrease detected post-
salbutamol (p=.013) (Figure 3A).  As shown in Figure 5-3B, the mean ADC in the most 
posterior slice was significantly lower post-salbutamol (p=.049).  Additionally, ΔAP was 
significantly higher post-salbutamol (p=.020), indicating that there was a difference in the 
mean ADC in the AP direction following bronchodilator therapy (Figure 3C).  As shown 
in Table 5-2 and Figure 5-5, Spearman correlation coefficients indicate that the post-
salbutamol change in ADCp was significantly correlated with the change in TLC (r=.782, 
p=.011), FRC (r=.806, p=.007) and RV (r=.733, p=.020).    
Figure 5-3 Regional 3He MRI ADC 
Mean WL ADC measurements, mean WL ADC for the previously ventilated (ADCP) 
lung regions of interest (ROI), mean ADPP for the most anterior and posterior slices, and 
the absolute change in ADCP for the most anterior to the most posterior slice (ΔAP) pre- 
and post-salbutamol for all subjects (A).  Mean ADCP pre- and post-salbutamol for the 
most anterior and most posterior slices.  Error bars are the standard error of the mean (B).  
Mean ΔAP for ADCP pre- and post-salbutamol.  Error bars are the standard error of the 
mean (C). 
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Figure 5-4 Regional 3He MRI ADC 
WL center slice 3He ADC maps pre-and post-salbutamol, 3He ADC maps for newly 
ventilated (ADCN) lung ROI post-salbutamol, and CT density masks to outline areas 
with attenuation values less than -950 HU, for a 74 yrs old female and a 64 year old 
male both with Stage III COPD.  CT images were acquired 15 months following pre- 
and post-salbutamol imaging for the 74 yr old subject and 28 months following pre- 
and post-salbutamol imaging for the 64 yr old subject. 
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5.4 Discussion 
We previously evaluated COPD ex-smokers using hyperpolarized 3He MRI before and 
after bronchodilator administration and provided evidence of significant and visually 
obvious regional improvements in 3He gas distribution following bronchodilator 
therapy.22  Here, we extend these previous findings and explore the relationship of 
regional hyperpolarized 3He ADC measurements in the pre- and post-bronchodilator lung 
ROI.  We aimed to determine if the newly ventilated regions were different than lung 
ROI participating in ventilation before bronchodilation and based on previous 
histological findings,31 we used the 3He MRI ADC as a surrogate measurement of tissue 
microstructure.  We made a number of observations and report the following: 1) mean 
WL ADC did not change post-salbutamol, 2) mean ADC in newly ventilated lung regions 
post-salbutamol was not different than mean ADC in previously ventilated lung regions, 
3) mean ADC in previously ventilated lung regions was significantly different 
(improved) post-salbutamol, and, 4) ADC anterior-posterior gradients significantly 
improved post-salbutamol.  
First, we observed no significant change in WL ADC measurements following 
salbutamol administration, and this finding suggests that the alveolar structures that are 
Figure 5-5 Correlations between the post-salbutamol change in 3He ADCp and 
pulmonary function measurements. 
ΔADCp was significantly correlated with ΔTLC (r=.782, p=.011, r2=.387, p=.055, 
y=26.99x-0.30) (A), ΔFRC (r=.806, p=.007, r2=.604, p=0.008, y=23.13x-0.19) (B) and 
ΔRV (r=.733, p=.020, r2=0.379, p=0.039, y=28.91x-0.31) (C). Dotted lines represent the 
95% confidence intervals for the regressions. 
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probed by the 3He gas post-salbutamol are not more emphysematous than the other lung 
ROI probed by the 3He gas pre-salbutamol.  In other words, this finding indicates that the 
bronchodilator was delivered primarily to the more normal lung regions.  However, the 
3He ADC has been previously demonstrated to be sensitive to gas trapping in the 
dependent lung regions33 that may lead to a reduction in the ADC measurement post-
bronchodilator.  Because we observed no change in WL ADC post-salbutamol we 
developed methods to determine regional ADC as a way to tease apart the potential 
combinations of reduced hyperinflation and gas redistribution to lung ROI with greater 
emphysematous destruction. 
We applied these image processing methods and post-salbutamol observed no significant 
difference between mean ADC in the newly ventilated lung ROI (ADCN) and mean ADC 
in the previously ventilated ROI (ADCP), indicating that the lung ROI that participated in 
gas distribution following administration of salbutamol were not more emphysematous 
than lung ROI participating in gas distribution before salbutamol administration.  These 
findings must be interpreted with an understanding of the limitations of the relatively 
large voxel size (3.2mm x 3.2mm x 30mm) in this analysis and these images that reflect 
the contributions of approximately 70,000 alveoli, estimated based on the mean size of a 
single normal alveolus to be 6102.4 −x cm3 as previously described.39  Additionally, the 
contribution of subject motion between imaging time-points and the volume of gas within 
the lungs during the breath-hold imaging may have contributed to measurement 
uncertainty.  Nevertheless, we have previously evaluated the ADC measurement within 
one week with no treatment (scan, 7-day rescan)19 and determined that the estimated 
standard uncertainty (standard deviation) of both the WL ADC and the center slice ROI 
ADC measurement in Stage II and Stage III COPD subjects was 0.001cm2/s, indicating 
that the ADC measurement in subjects with moderate to severe disease was remarkably 
reproducible.  A previous study evaluating asthma subjects using 3He MRI and multi-
detector CT demonstrated that there was a regional association between 3He MRI 
ventilation abnormalities and CT measurements of gas trapping.40  Although it is 
plausible in the current study that emphysematous tissue destruction may have reduced 
the tethering or stabilization of the airways at forced expiration5 resulting in trapped gas 
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and ventilation defects in severe COPD subjects, our findings suggest that defect regions 
that become ventilated in response to bronchodilators do not reflect more severe 
emphysema.  Moreover, these results indicate that the bronchodilator acted on the 
obstructed small airways directly, allowing improvements in gas trapping and regional 
hyperinflation, and not on airways obstructed due to surrounding emphysema.  As shown 
in Figure 5-3, both emphysematous and healthy regions of the lung participated in gas 
distribution post-salbutamol.  We must acknowledge that the very small number of newly 
ventilated voxels in the post-salbutamol images may lead to biased ADC values due to a 
low signal-to-noise ratio (SNR),41 although this would have generated a bias towards 
higher ADC and this was not observed in the current study.  To minimize the potential 
for bias, we used a morphological closing algorithm to remove the contribution of small 
isolated voxels to the mean ADC value and an SNR threshold greater than 15 for ADC 
generation was used as previously described.41 
We also observed a statistically significant reduction (improvement) in mean ADCP post-
salbutamol.  This small but significant improvement may be explained by both a 
reduction in the physical size of the airspaces due to the increased distribution of the 3He 
gas (thereby effectively diluting the 1L dose) and bronchodilator-induced reduction in 
lung hyperinflation.  To determine whether the significant change in ADCP was related to 
a reduction in lung hyperinflation, we compared the anatomical distribution of ADC 
values pre- and post-salbutamol.  As previously described,33 airspaces are less 
compressible in COPD compared to healthy subjects in the dependent lung likely because 
of gas trapping.  We detected a statistically significant increase in ΔAP and decreased 
mean ADCP in the most posterior slice post-salbutamol, suggesting that bronchodilator 
administration improved the expiratory time constants which in turn allowed the 
dependent lung regions to empty more completely.  Moreover, as demonstrated in our 
previous study,22 there was no bias for any measurable changes in the distribution of 3He 
gas post-salbutamol with respect to image slice, indicating that the reduction in mean 
ADCP within the dependent lung regions was not due to increased gas distribution in 
these regions.  The significant correlation detected between the change in ADCP and 
changes in TLC, FRC and RV post-salbutamol lends support to the hypothesis that the 
reduction in ADCP post-salbutamol was related to a reduction in gas trapping.   
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We recognize that this work was limited by the small number of subjects and the fact that 
the analysis was restricted mainly to subjects with moderate to severe COPD.  Therefore, 
caution should be exercised in extrapolating these results to the general COPD population 
and more specifically to patients with mild and very severe disease.  An important 
limitation of 3He MRI is that large regions of the lung are not ventilated or are poorly 
ventilated preventing calculation of the ADC within these regions, and this may be due to 
small airway occlusion, mucous plugs, airway wall thickening and inflammation, severe 
emphysema or bullous disease.   We also acknowledge that without the inclusion of 
dyspnea scores and measurements of exercise tolerance for comparison to 3He MRI, the 
clinical meaning of the imaging changes remains unclear.  In other words, the changes in 
ADC measures post-salbutamol are related to clinical or symptomatic improvement 
remains to be established in a larger study. The lack of validation by an imaging 
reference method, such as computed tomography (CT) or proton MRI with ultra-short 
echo times, is also a limitation of this work.  Clearly, the direct comparison of functional 
and structural 3He MRI, proton UTE MRI, CT and symptomatic measurements will allow 
for a better understanding of the improvements in 3He gas distribution observed after 
bronchodilator administration.  It must also be noted that 3He MRI ADC provides 
structural information not only at the scale of the alveoli, probing emphysematous tissue 
destruction, but also at the scale of the alveolar ducts and the respiratory and terminal 
bronchioles,27 thus restriction to diffusion will differ in each of these structures and 
alveoli diffusion will be more restricted than diffusion in the bronchioles.  An important 
point related to this is the issue of collateral ventilation.  In patients with emphysema 
there is substantial collateral ventilatory pathways,42 including the pores of Kohn, canals 
of Lambert and the interbroncial communications of Martin.  Although with the very 
short diffusion times utilized in this study where the atoms are likely to be confined to the 
alveoli and acinar structures, measurements of 3He diffusion over longer times and 
distances are likely sensitive to collateral ventilation paths,43;44 which are significant in 
patients with emphysema.  A better understanding of collateral ventilation and collateral 
pathways is required and noninvasive imaging measurements such as 3He MRI ADC may 
be useful for treatment planning, such as bronchoscopic airway bypass, and evaluating 
treatment effects.  Reproducible and comparable breath-hold volumes are critically 
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important for acute and chronic therapy repeated studies and therefore training and 
instruction for inspiration breath-hold scanning was performed during breath-hold MRI.   
Although 3He MRI has limited access and high cost which has thus far restricted 
translation of this functional imaging method, 129Xe MRI is a less expensive and more 
readily available approach with which these reported findings can be directly tested.  
In summary, this study demonstrated that 3He MRI provides a noninvasive approach for 
the evaluation of regional structure-function measurements after bronchodilator 
administration in COPD subjects.  Lung micro-structure in ROI that participate in gas 
distribution only after bronchodilator administration was not more emphysematous than 
ROI participating in gas distribution before bronchodilator use.  We also demonstrated 
that regional ADC reflect significant changes in the anterior-posterior gradient following 
bronchodilator therapy and this is possibly related to a reduction in regional gas trapping.  
The regional evaluation of hyperpolarized 3He MRI ADC provides insights into regional 
lung microstructure for lung ROI that participate in 3He gas distribution after 
bronchodilator administration. 
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CHAPTER 6  
The limited and unpredictable global supply of 3He necessitates the transition to 129Xe 
gas, however a direct comparison of hyperpolarized 3He and 129Xe MRI acquired in the 
same subjects is required in order for us to better understand the potential of 129Xe MRI 
in respiratory research.  Here we quantitatively compared 3He and 129Xe MRI acquired 
in the same healthy volunteers and subjects with COPD.    
The contents of this Chapter have been previously published in Radiology and permission 
to reproduce the article was granted by the Radiological Society of North America 
(RSNA®) and is provided in Appendix C. 
M  Kirby, S Svenningsen, A Owrangi, A Wheatley, A Farag, A Ouriadov, GE Santyr, R 
Etemad-Rezai, HO Coxson, DG McCormack and G Parraga.  Hyperpolarized Helium-3 
and Xenon-129 Magnetic Resonance Imaging in Healthy Volunteers and Subjects with 
Chronic Obstructive Pulmonary Disease.  Radiology. 2012;265(2):600-10. 
6 Hyperpolarized 3He and 129Xe MR Imaging in Healthy 
Volunteers and Patients with Chronic Obstructive 
Pulmonary Disease 
6.1 Introduction 
Magnetic resonance imaging (MRI) using hyperpolarized noble gases, such as helium-3 
(3He) and xenon-129 (129Xe), provides a way to acquire high spatial and temporal 
resolution pulmonary images.1-4  Hyperpolarized 3He MRI has dominated for the 
evaluation of gas distribution and tissue abnormalities in healthy volunteers5 and in 
patients with chronic obstructive pulmonary disease (COPD),6-9 asthma,10-14 cystic 
fibrosis,15-18 radiation-induced lung injury,19;20 and lung transplant.21;22  Numerous studies 
have shown that 3He MRI in COPD is highly reproducible,6;23-25 sensitive to early lung 
micro-structural changes,1;26-31 and significantly correlates with established 
measurements of pulmonary function,1;32 multi-slice computed tomography (CT) 
measurements32 and histology measurements of emphysema.33  Furthermore, longitudinal 
3He MRI of COPD has highlighted the sensitivity of the method to progressive 
worsening8;34 and shown regional improvements post-bronchodilator.35;36 
Unfortunately, despite the unique potential of 3He MRI, clinical translation has not 
occurred in part because of limited and unpredictable global quantities and high cost.  
129Xe gas, on the other hand, is substantially more abundant in nature existing in 
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measurable quantities in the atmosphere and it is relatively inexpensive.  Although 
hyperpolarized 129Xe MRI is technically challenging because of its nearly 3-fold lower 
gyromagnetic ratio and lower enrichment, considerable improvements in 129Xe gas 
polarization and imaging methods37 have been achieved since the first clinical studies 
were reported.38-40  Recently, the tolerability of a 1.0L inhaled dose of 129Xe and 
diffusion-weighted MRI measurements were reported in COPD and healthy subjects.39;40  
These important results suggested that 129Xe MRI may be very useful for examining 
structural and functional abnormalities in COPD and also generated numerous hypotheses 
to test.   In this investigation, we hypothesized that the different properties of 129Xe gas 
would result in significant differences in 129Xe compared to 3He ventilation defect percent 
(VDP) in COPD but not in healthy volunteers.  Accordingly, here our objective was to 
quantitatively compare hyperpolarized 3He and 129Xe MRI acquired within a few minutes 
in healthy volunteers and subjects with COPD, and to evaluate the correlations between 
3He and 129Xe MRI measurements with spirometry and plethysmography. 
6.2 Materials and Methods 
6.2.1 Subjects 
All subjects provided written informed consent to the study protocol approved by the 
local research ethics board and Health Canada, and the study was compliant with the 
Personal Information Protection and Electronic Documents Act (PIPEDA, Canada) and 
the Health Insurance Portability and Accountability Act (HIPAA, USA).  COPD subjects 
were ex-smokers 50-85 years of age, with a smoking history of at least 10 pack-years.   
Pack-year was defined as the number of cigarette packs smoked per day multiplied by the 
number of years smoked.  Healthy volunteers were enrolled who had no history of 
previous chronic or current respiratory disease.  For all subjects, mean age was 71±8 yrs, 
and mean age for men was 71±9 yrs and for women 72±6 yrs. 
6.2.2 Pulmonary Function Tests 
Spirometry was performed using an ndd EasyOne spirometer (ndd Medizintechnik AG, 
Zurich, CH) according to the American Thoracic Society (ATS) guidelines.41  Static lung 
volumes and diffusing capacity of carbon monoxide (DLCO) were measured using body 
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plethysmography (MedGraphics Corporation. 350 Oak Grove Parkway St. Paul, MN 
USA).   
6.2.3 Image Acquisition 
MRI was performed on a whole body 3.0 Tesla Discovery 750MR (General Electric 
Health Care, Milwaukee, WI) MRI system with broadband imaging capability as 
previously described.6 Subjects were instructed to inhale a gas mixture from a 1.0 L 
Tedlar® bag (Jensen Inert Products, Coral Springs, New Jersey, USA) from functional 
residual capacity (FRC), and image acquisition was performed in 8-15s under breath-hold 
conditions.  It is important to note that we endeavored to minimize the potential for 
differences in the levels of inspiration between the breath-hold scans for each subject by: 
1) training and practice for all subjects prior to MRI related to the inspiration breath-hold 
maneuver from FRC, and, 2) continuous coaching and monitoring at the MR bedside by a 
pulmonary function technologist during all inspiration breath-hold scans.   
Conventional 1H MRI was performed prior to hyperpolarized 129Xe and 3He MRI with 
subjects scanned during 1.0L breath-hold of ultrahigh purity, medical grade nitrogen (N2) 
(Spectra Gases, Alpha, NJ) using the whole body radiofrequency (RF) coil and 1H fast 
spoiled gradient-recalled-echo sequence as previously described.6  Theoretical diffusion 
coefficients for the 3He/N2 and 129Xe/4He 50/50 mixtures were generated adopting 
assumptions previously described.42 
Hyperpolarized 3He MRI was enabled using a linear bird-cage transmit/receive chest coil 
(RAPID Biomedical GmbH, Wuerzburg Germany).  A turnkey system (HeliSpin™) was 
used to polarize 3He gas to 30—40% and doses (5mL/kg body weight) were administered 
in 1.0L Tedlar® bags diluted with N2.  Hyperpolarized 3He MRI coronal static ventilation 
images and diffusion-weighted (DW) images were acquired during breath-hold of a 1.0L 
3He/N2 mixture as previously described.6 
Hyperpolarized 129Xe MRI was enabled using a custom-made, unshielded quadrature-
asymmetric bird-cage coil model tuned to 35.34MHz similar to previous approaches43 
and as previously described.44  129Xe gas (86% enriched) was polarized to 10—60% using 
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a turn-key polarizer (XeBox-E10, Xemed LLC, New Hampshire, USA).  Doses of 
hyperpolarized 129Xe gas were dispensed directly into the pre-rinsed 1.0L Tedlar® bags 
pre-filled with 4He to generate a 50/50 mixture.  Polarization of the diluted dose was 
quantified by a Polarimeter (GEHC, Durham, NC).  129Xe MRI coronal static ventilation 
images were acquired using a 3D fast gradient-recalled-echo (FGRE) sequence with 
centric phase-encoding ordering in the y direction and normal sampling in the z direction 
during breath-hold of the 1.0 L 129Xe/4He mixture (14s data acquisition, TE/TR/flip angle 
= 1.50 ms/6.7 ms/variable flip angle, bandwidth = 15.63 kHz, FOV = 40 × 40 cm, matrix 
128 × 128, 14 slices, 15 mm slice thickness, 0 gap).  DW images were obtained using a 
2D FGRE sequence with centric phase-encoding ordering.  Two interleaved images (16s 
total data acquisition, TE/TR/flip angle = 10 ms/13.5 ms/9o, bandwidth = 31.25 kHz, 
FOV = 40 x 40 cm, matrix 128 x 80, 7 slices, 30 mm slice thickness, 0 gap), with and 
without additional diffusion sensitization with b = 12 s/cm2 (maximum gradient 
amplitude (G) = 2.90 G/cm, gradient rise and fall time = 0.5 ms, gradient separation = 2 
ms, gradient duration = 2.0 ms, diffusion time = 5 ms).  The diffusion time of 5ms for 
129Xe MRI was selected based on the theoretical background for optimal gradient 
sequence parameters45 and previous findings demonstrating its sensitivity to alveolar 
enlargement.46  All scanning was completed within approximately 5 minutes of subjects 
first lying in the scanner.  Also, based on the calculations for the theoretical diffusion 
coefficients for 3He and 129Xe and the diffusion times used, the characteristic diffusion 
length for 3He (~490μm) is comparable to 129Xe (~460μm), indicating similar spatial 
length scales are being investigated. 
CT was performed on a 64-slice Lightspeed VCT scanner (GE Healthcare, Milwaukee, 
WI USA) using a detector configuration of 64×0.625 mm, 120 kVp, 100 effective mA, 
tube rotation time of 500 ms and a pitch of 1.0.  A single spiral acquisition of the entire 
lung was acquired from the apex to the base with subjects in the supine position and in 
breath-hold after inhalation of a 1.0L Tedlar® bag of N2 from FRC.  Reconstruction of the 
data was performed using a slice thickness of 1.25 mm with a standard convolution 
kernel.   
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6.2.4 Image Analysis 
3He and 129Xe MRI semi-automated segmentation was performed, similar to approaches 
that have been previously described for quantification of lung volumes,47 using custom 
software generated using MATLAB R2007b (The Mathworks Inc., Natick, MA, USA), 
as previously described.48  3He MRI of COPD is typically characterized by heterogeneous 
signal intensity that reflects gas distribution heterogeneity during the inspiration breath-
hold scan.  To compare the distribution of both 3He and 129Xe gases within the lung, we 
segmented the 3He and 129Xe images based on the pixel signal intensity.  Briefly, 3He and 
129Xe MRI static ventilation images were segmented using a K-means approach49 that 
classified voxel intensity values into five clusters ranging from signal void (cluster 1, C1 
or ventilation defect volume (VDV)) and hypo-intense (cluster 2 or partial volume) to 
hyper-intense signal (cluster 5), and therefore generating a gas distribution cluster-map.  
For delineation of the ventilation defect boundaries, a seeded region-growing algorithm50 
was used to segment the 1H MR images of the thoracic cavity for registration to the 
cluster-map and 3He and 129Xe VDP 7 were generated by VDV normalized to the thoracic 
cavity volume.  3He and 129Xe non-diffusion-weighted (NDW) images were also 
segmented using the same approach where NDW images were segmented using K-means 
and registered to the corresponding 1H MRI slices for calculation of VDP.49  Apparent 
diffusion coefficient (ADC) analysis was performed as previously described.36  The 
signal-to-noise ratio (SNR) for all 3He and 129Xe static ventilation and NDW and DW 
images were determined by calculating the mean voxel value within a 5 x 5 cm2 voxel 
region of interest (ROI) for four representative ROI within the lung parenchyma, and 
dividing by the standard deviation of the voxel values for noise inside for four 
representative ROI of the same size within the image background where there was no 
lung structure.  The ROI within the lung parenchyma and the image background were 
selected independently for each slice, with exception of diffusion-weighted imaging 
where the ROI was selected independently for each NDW image slice, and the 
coordinates of the lung ROI were applied to the diffusion-weighted image slice.  SNR 
was determined for each slice and then averaged to obtain a single SNR value for each 
subject.  CT measurements were performed using MATLAB R2007b; the relative area 
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with attenuation values below −950 HU (RA 950) and the 15th percentile (HU15%) were 
generated from the frequency distribution of Hounsfield units.  
6.2.5 Statistical Methods 
Multivariate analysis of variance (ANOVA) and a one-way ANOVA were performed 
using IBM SPSS Statistics 20.0 (SPSS Inc., Chicago, IL, USA).  A paired two-tailed t-
test was used for statistical comparison for normally distributed data and a two-tailed 
Wilcoxon signed rank test was used for statistical comparison for non-normally 
distributed data for tests between 3He and 129Xe VDP, ADC, and SNR using GraphPad 
Prism version 4.00 (GraphPad Software Inc, San Diego, CA, USA).  Normality was 
determined using a Shapiro-Wilk test using IBM SPSS Statistics 20.0.  A two-way 
mixed-effects repeated measures ANOVA was used to determine the interactions for 
VDP measured from both 3He and 129Xe MRI and imaging slice using SPSS 20.0.   The 
agreement between 3He and 129Xe VDP was evaluated using Bland-Altman plots51 
generated using GraphPad Prism version 4.00. Linear regression (r2) and Pearson 
correlation coefficients (r) were used to determine the relationships between and imaging 
and other measurements using GraphPad.  Correlation coefficients were compared52 by 
calculating the Fisher’s z’ transformation for each r as shown in Equation 6-1: 
 (1) 
where r is the correlation coefficient for 3He MRI (rHe) and 129Xe MRI (rXe).  The Z value 
was then calculated using Equation 6-2: 
 
 
(2) 
where zHe is the z’ of rHe, zHe is the z’ of rXe and n equals the number of subjects 
compared.  A Holm-Bonferroni correction53 was used for multiple paired t-tests and all 
correlations.  The Holm-Bonferroni adjusted p-values were determined by ordering p-
values from smallest to largest, with the smallest p-value multiplied by k, where k is the 
number of hypotheses to be tested.  If the resulting modified p-value was less than α 
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(Type I error rate) the hypothesis was rejected.  The next smallest p-value was then 
multiplied by k minus 1 and the new modified p-value was compared to α.  This process 
was repeated until the modified p-value could not be rejected.  In all statistical analyses, 
results were considered significant when the probability of making a Type I error was 
less than 5% (p < 0.05).   
6.3 Results 
All imaging procedures and maneuvers were well-tolerated and there were no serious or 
severe adverse events reported.  There was a single adverse event reported by a single 
COPD subject (headache seven hours after completion of MRI that resolved without 
treatment) and this was judged not-related to 3He or 129Xe gas inhalation; the details of 
the safety and tolerability of 129Xe MRI for this study are reported elsewhere54 and 
tolerability of a 1.0L 129Xe dose (versus the 50/50 mixture used here) was previously 
reported.40  Table 6-1 shows subject demographics and pulmonary function 
measurements for eight healthy volunteers and 10 COPD subjects (GOLD Class I n=1; 
GOLD Class II n=6; GOLD Class III n=2; GOLD Class IV n=1).55   The two subject 
groups were significantly different with respect to FEV1, FEV1/FVC, RV, RV/TLC, IC, 
FRC and DLCO; there were no significant differences between the groups with respect to 
age, sex or BMI. 
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Table 6-1 Subject Demographics 
 Healthy Volunteers 
(n=8) 
COPD 
(n=10) 
Significance of 
Difference (p) 
Age yrs (±SD) 67 (10) 74 (4) 0.10 
  Men 63 (11) 75 (4) - 
  Women 71 (7) 73 (6) - 
Male Sex n (±SD) 4 8 0.32 
BMI kg·m-2  (±SD) 25.9 (2.2) 25.4 (5.0) 0.79 
Pack-years yrs (±SD) 0 (0) 62 (15) - 
FEV1 % pred  (±SD) 107 (13) 57 (24) <0.001 
FVC % pred (±SD) 106 (13) 91 (19) 0.08 
FEV1/FVC (±SD) 0.75 (.04) 0.46 (.14) <.0001 
TLC % pred (±SD) 106 (11) 115 (8) 0.09 
RV % pred (±SD) 105 (19) 159 (46) 0.007 
RV/TLC (±SD) 0.39 (0.10) 0.53 (0.14) 0.03 
IC % pred (±SD) 120 (25) 85 (31) 0.02 
FRC % pred (±SD) 95 (13) 141 (35) 0.002 
DLCO % pred (±SD) 103 (13) 41 (17)† <.0001 
SD=Standard Deviation, BMI=Body Mass Index, FEV1= Forced Expiratory Volume in 
1s, %pred=Percent Predicted, FVC= Forced Vital Capacity, TLC= Total Lung Capacity, 
RV= Reserve Volume, IC= Inspiratory Capacity, FRC= Functional Residual Capacity, 
DLCO=Carbon Monoxide Diffusion Capacity of the lung.  †n=7.   
Significance of difference (p<.05) determined using a multivariate analysis of variance.  
Fisher’s exact test was performed for categorical variables. 
 
Figure 6-1 shows the two central coronal 3He and 129Xe MRI slices, where the trachea 
and two main bronchi are clearly visible, with 3He gas distribution displayed in red and 
129Xe gas distribution displayed in purple registered to the grey-scale 1H MRI of the 
thorax for each of three representative healthy volunteers and three COPD subjects.  For 
the COPD subjects, regions of signal void are observed in 129Xe MRI not qualitatively 
apparent in 3He MRI; these regions are readily observed in the right mid apex for COPD 
S1 and the right and left apical regions for COPD S2 and S3 for the two slices shown in 
Figure 6-1.   
 
 
 
163 
 
Figure 6-1 3He and 129Xe MRI static ventilation images of healthy volunteers and subjects 
with COPD 
3He and 129Xe MRI of the two coronal centre slices, where the trachea and two main bronchi 
are clearly visible, with 3He gas distribution displayed in red and 129Xe gas distribution 
displayed in purple registered to the greyscale 1H MRI of the thorax for each of three 
representative healthy volunteers (S1: 75 yr old female, FEV1=93%pred, FEV1/FVC=70%; 
S2: 57 yr old male, FEV1=95%pred, FEV1/FVC=72%; S3: 51 yr old male, FEV1=120%pred, 
FEV1/FVC=83%) and three COPD subjects (S1: 77 yr old female, FEV1=50%pred, 
FEV1/FVC=20%; S2: 68 yr old female, FEV1=59%pred, FEV1/FVC=53%; S3: 71 yr old 
male, FEV1=107%pred, FEV1/FVC=58%). 
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Figure 6-2 shows the strong and statistically significant correlations between whole lung 
(WL) 3He and 129Xe VDP (r=.91, p<.0001) and 3He and 129Xe ADC (r=.97, p<.0001). 
Although 3He and 129Xe VDP were significantly correlated, Bland-Altman analysis 
indicates that there was a 9±8% bias (95% limit of agreement: -25%-7%) for higher VDP 
for 129Xe MRI.  Table 6-2 shows mean 3He and 129Xe MRI gas distribution and ADC 
measurements.  129Xe VDP was statistically significantly greater than 3He VDP for the 
COPD subjects (p=.0003, uncorrected; p=.03, Holm-Bonferroni corrected), and 129Xe 
signal intensity cluster C3 (p=.002, uncorrected; p=.002 Holm-Bonferroni corrected) was 
significantly different.  For healthy volunteers, there was no significant difference 
between 129Xe and 3He VDP (p=.56), however there was a significant difference in C4 
(p=.008, uncorrected) although following Holm-Bonferroni correction this difference was 
no longer significant (p=.06).  For both groups, there was no relationship between the 
difference in 3He and 129Xe VDP and image slice (p=.99), indicating no bias for 
differences between 3He and 129Xe VDP for any specific image slice.   To better 
understand the potential impact of any difference in pulse sequence parameters for 129Xe 
(3D acquisition) and 3He (2D acquisition) MRI gas distribution measurements, we 
compared 3He and 129Xe VDP measured from NDW images, both acquired using 2D 
FGRE sequences.  No significant difference was observed between 129Xe VDP (3D) and 
129Xe VDP measured from NDW images for the healthy volunteers and the COPD 
subjects (p=.87) and 3He VDP (2D) and 129Xe VDP measured from NDW images were 
not significantly different for healthy volunteers (p=.50) however they were significantly 
different for COPD subjects (p=.002).  This result is in agreement with the 2D 3He and 
3D 129Xe MRI results that showed there was no difference between 3He and 129Xe VDP 
for healthy volunteers, but for COPD subjects 129Xe VDP was significantly greater than 
3He VDP.  Mean SNR was significantly lower for 129Xe MRI (33±17) as compared to 
3He MRI (56±25, p<.0001), however importantly there was no significant correlation for 
the difference between 3He and 129Xe SNR and the difference between 3He and 129Xe 
VDP (r=.26, p=.30).  
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Table 6-2 3He and 129Xe MRI Measurements 
 Healthy Volunteers (n=8) COPD (n=10) 
 3He 
MRI 
129Xe 
MRI 
SDif* (p) 3He 
MRI 
129Xe 
MRI 
SDif* (p) 
Gas Distribution  
VDP % 
(±SD) 
4 (2) 4 (4) 0.56 (1.00) 20 (10) 34 (13) 0.003 (0.03) 
C2 % (±SD) 10 (1) 11 (5) 0.94 (0.94) 14 (2) 15 (3) 0.30 (1.00) 
C3 % (±SD) 36 (5) 26 (10) 0.08  
(0.48) 
34 (5) 22 (6) 0.002 (0.002) 
C4 % (±SD) 34 (2) 40 (2) 0.008  
(0.06) 
23 (7) 20 (9) 0.05 (0.35) 
C5 % (±SD) 16 (5) 19 (3) 0.22  
(1.00) 
10 (4) 9 (4) 0.50 (1.00) 
ADC cm2/s 
(±SD) 
0.246 
(0.021) 
0.053 
(0.002)† 
0.002  
(0.02) 
0.481 
(0.121) 
0.079 
(0.015) 
<0.0001 
(0.001) 
VDP=Ventilation Defect Percent, 2=Cluster 2, C3=Cluster 3, C4=Cluster 4, C5=Cluster 
5, ADC=Apparent Diffusion Coefficient 
SDif=Significance of difference (p<.05) determined using a two-tailed Wilcoxon signed 
rank test for gas distribution measurements and a two-tailed paired t-test for ADC 
measurements.  
* Holm-Bonferroni adjusted significance values in parentheses 
†n = 3 
Figure 6-2 Relationship between 3He MRI and 129Xe MRI VDP and ADC 
A) 3He VDP was significantly and positively correlated with 129Xe VDP (r=.91, 
p<.0001, r2=.82, p<.0001, y=1.4x+2.7). 
B) The mean bias (±SD) between 3He and 129Xe VDP was -9±8% (lower limit=-25%, 
upper limit=7%).  Solid lines indicate the mean difference and dotted lines indicate 
the 95% limits of agreement. 
C) 3He ADC was significantly and positively correlated with 129Xe ADC (r=.97, 
p<.0001, r2=.93, p<.0001, y=0.11x+0.03). 
Dotted lines represent the 95% confidence intervals of the regression line. 
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As shown in Table 6-2, WL hyperpolarized 3He and 129Xe ADC was significantly 
different for the healthy volunteers (p=.002) and the COPD subjects (p<.0001).   Mean 
SNR for 3He MRI DW and NDW was 36±16 and 64±29, respectively, and for 129Xe MRI 
DW and NDW were 11±6, and 28±19, respectively.   
Table 6-3 Relationships between 3He and 129Xe MRI with pulmonary function 
measurements 
  Pearson Correlation Coefficients r (p/p**) 
 3He VDP % 129Xe VDP % 3He ADC cm2/s 129Xe ADC cm2/s 
FEV1 % pred 
-0.84 
(<.0001/<.0001) 
-0.89 
(<.0001/.001) 
-0.75 
(.0007/.002) 
-0.67  
(.01/.01) 
FEV1/FVC 
-0.84 
(<.0001/.001)* 
-0.95 
(<.0001/.001)* 
-0.86 
(<.0001/.001) 
-0.77  
(.002/.004) 
DLCO % pred -0.83 
(.0001/.001)† 
-0.92 
(<.0001/.001) † 
-0.95 
(<.0001/.001)‡ 
-0.93 
(<.0001/.001)¥ 
Significance of difference (p<.05) between 3He and 129Xe MRI correlation coefficients 
for each r were calculated using the Fisher’s z transformation. *p=.01 
** Holm-Bonferroni adjusted significance values 
†n=15, ‡n = 13, ¥n = 10 
 
Table 6-3 shows Pearson correlations for 3He and 129Xe VDP and ADC with pulmonary 
function measurements.  There were significant and similar correlations for 3He and 
129Xe MRI VDP with FEV1, although the relationship between VDP and FEV1/FVC was 
significantly stronger for 129Xe MRI (p=.01).   There were also significant and similar 
correlations for 3He and 129Xe MRI ADC and DLCO (Table 6-3).  Figure 6-3 shows the 
significant and strong relationships for 3He and 129Xe ADC with RA950 (r=.90, p=.0005) 
and HU15% (r=-.91, p=.0003) for COPD subjects only.    
Theoretical diffusion coefficients were generated as previously described42 for 3He/N2 
and 129Xe/4He and are summarized in Table 6-S1.  The 3He-N2 diffusion coefficient in air 
was 0.826cm2/s, whereas for 129Xe-4He, the diffusion coefficient in air was 0.211cm2/s 
and for air, the self-diffusion coefficient of air was 0.218cm2/s.   
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6.4  Discussion 
We evaluated 3He and 129Xe MRI acquired within approximately five minutes in healthy 
subjects with and without COPD, and made a number of observations:  1) significant and 
strong correlations were observed between 3He and 129Xe MRI VDP, although visually 
and quantitatively 129Xe MRI VDP was worse than 3He MRI VDP in COPD, but not in 
healthy subjects, 2) significant and strong correlations were observed that were similar 
for 3He and 129Xe VDP with FEV1, but significantly stronger between 129Xe VDP and 
FEV1/FVC, and, 3) a significant and strong correlation was observed between 3He and 
129Xe ADC, both of which showed similar and significant correlations with DLCO and CT 
measurements of emphysema. 
Figure 6-3 Relationships between 3He and 129Xe MRI ADC with CT measurements 
A) CT HU15 was significantly correlated with 3He ADC (r=-.91, p=.0003, r2=.83, 
p=.0003, y=-225x-839) and 129Xe ADC (r=-.91, p=.0003, r2=.82, p=.0003, y=-1815x-
803).   
B) CT RA950 was significantly correlated with 3He ADC (r=.90, p=.0005, r2=.80, 
p=.0003, y=105x-32) and 129Xe ADC (r=.87, p=.001, r2=.76, p=.001, y=821x-47).   
Dotted lines represent the 95% confidence intervals of the regression line. 
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First, in COPD subjects, 129Xe MRI gas distribution was qualitatively more regionally 
heterogeneous than 3He MRI.  This was not the case in healthy volunteers, where 129Xe 
and 3He MRI showed homogeneous gas distribution and very low VDP that was not 
significantly different.  The visually obvious differences between 129Xe and 3He were 
also quantitatively different with 129Xe VDP significantly greater (worse) than 3He VDP 
in COPD subjects, but not healthy volunteers.  Importantly, these differences could not be 
attributed to differences in the pulse sequences used, nor was there a bias detected for 
specific anterior-posterior slices dominating this result.  This unexpected result leads to 
the simple question: why are these measurements different in COPD?  Some explanations 
might derive from the different gases themselves.  In COPD, significant airflow 
limitation is thought to occur in the small conducting airways <2mm in diameter56 
increasing airway resistance with the potential for regional and preferential 129Xe gas 
limitation to the distal airways.  Another important consideration relates to the terminal 
and respiratory bronchioles, where diffusion dominates, and the lower diffusion 
coefficient of 129Xe relative to 3He may result in slower gas movement into the distal 
diseased lung regions.   Another important consideration is the role of collateral 
ventilation in COPD.  The lower atomic mass and higher diffusivity of 3He relative to 
129Xe may allow for regions of the lung that are not ventilated to gradually fill with 3He 
over the time course of the breath-hold scan as has been shown recently by Marshall et. 
al.57  Our finding that ventilation defect percent was greater for 129Xe MRI than 3He MRI, 
both with 129Xe 3D and 2D image acquisition, suggests that the lower diffusivity of 129Xe 
may slow the process of delayed/collateral ventilation beyond a realistic single breath-
hold time.  To try to better understand the properties of the two gases inhaled, we 
generated theoretical diffusion coefficients as previously described42 for 3He diluted with 
N2  and air and 129Xe diluted with 4He and air and compared these to the theoretical self-
diffusion coefficient of air.  Taken together, these results indicated that air has a similar 
estimated diffusion coefficient as 129Xe diluted with 4He+air (within 3%), and both 
diffusion coefficients are much lower than the estimated diffusion coefficient of 3He 
diluted with N2+air.  Although the exact etiology that may explain the differences 
between the 129Xe and 3He MRI gas distributions in COPD are not yet established, it is 
possible that the differences in diffusion coefficients might provide part of the reason for 
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these observed differences and that different gas mixtures may be helpful in probing 
different airway and parenchymal abnormalities.  For example, the larger 129Xe VDP in 
COPD might reflect the fact that airway narrowing is less easily penetrated by 129Xe/ 4He. 
Second, we reported significant and similar correlations between 3He and 129Xe VDP 
with spirometry for all subjects, however the correlation coefficient was significantly 
stronger for 129Xe VDP with FEV1/FVC.  We note that during expiration in COPD, 
airway narrowing is caused by the combination of many factors, including small-airway 
wall thickening and obliteration, and collapse of airways secondary to the loss of lung 
tissue within the lungs.  FEV1/FVC is reduced in subjects with severe COPD and asthma, 
and has been reported to be sensitive to airway narrowing and bronchoconstriction.58  The 
finding that the 129Xe VDP correlation with FEV1/FVC was stronger than 3He VDP lends 
support to the notion that the differences in diffusion coefficients of the gases might be 
helpful in probing different airway and parenchymal abnormalities.   
Finally, we also reported strong and significant correlations between 3He and 129Xe ADC 
in the same subjects and similar correlation coefficients between 3He and 129Xe ADC 
with DLCO and CT measurements.  The relationship between 129Xe ADC and spirometry 
measurements for b=12s/cm2 has been previously reported39 in COPD subjects and 
healthy volunteers and similar correlation coefficients for FEV1%pred and FEV1/FVC 
were observed here.  However, we reported slightly higher ADC values for both healthy 
volunteers and COPD ex-smokers and this may be due to the differences in the inspired 
gas mixtures between the two different studies.   We note that in the previously published 
study, a 1.0L 129Xe dose was used and as shown in Table E1, the estimated diffusion 
coefficient of 129Xe in air was 0.138cm2/s in comparison to 129Xe diluted with 4H and air 
that was used in this study with an estimated diffusion coefficient of 0.211cm2/s.  In 
addition, the strong correlations between 129Xe with 3He ADC and the strong and similar 
correlations between both 129Xe and 3He ADC with CT measurements of emphysema 
suggest that 129Xe diffusion-weighted imaging with b=12s/cm2 is sensitive to lung micro-
structural abnormalities.  The comparable results we observed with 3He and 129Xe ADC 
suggest that both methods are probing similar spatial dimensions which is important since 
the choice of diffusion-weighted gradient can influence the measured ADC.  We must 
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also note that the COPD subjects investigated here showed varying degrees of 
emphysema, with DLCO ranging from 17%pred to 67%pred, indicating that 129Xe MRI as 
employed in this study provided a way to measure varying degrees of emphysema.  
Future studies comparing 129Xe ADC with different b-values to 3He ADC and CT 
emphysema measurements, as well as comparing the 129Xe ADC anterior-posterior 
gradients with different b-values, which has been previously shown using 3He MRI to 
change following treatment in COPD,36 are required to determine the differences the 
diffusion-weighting provides for probing the lung microstructure. 
We recognize that there were a small number of subjects used in this study and that most 
of the subjects evaluated had moderate to severe COPD.  We must also acknowledge that 
because all of these measurements and tests were performed in the same small subject 
group, extrapolation of these results to a general COPD population cannot be confirmed 
until studies with larger sample sizes are performed.  Another limitation is the difference 
in pulse sequences used for 3He and 129Xe MRI.  However, results obtained using NDW 
images, both acquired using 2D FGRE sequences, were in agreement with the 2D 3He 
and 3D 129Xe MRI acquisition results indicating that there was no difference between 3He 
and 129Xe VDP for the healthy volunteers, however for COPD subjects 129Xe VDP was 
greater than 3He VDP.   
In summary, in healthy volunteers and COPD subjects there were strong correlations 
between 129Xe and 3He ADC but significant differences in 129Xe and 3He gas distribution 
in COPD reflecting differences in the gases as well as physiological/anatomical 
abnormalities in COPD not seen in healthy volunteers.    
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6.6 Appendix 
Experimental measurements of the diffusion coefficient of 129Xe (83% enriched) and air 
have been previously reported by Kaushik et. al.,39 however the theoretical diffusion 
coefficient of 129Xe diluted with 4He and air has not been reported.  Using the 
assumptions described in Chen et. al.,42 we estimated the diffusion coefficient of 129Xe 
diluted with 4He and air and the diffusion coefficient of 3He diluted with N2 and air as 
well as the diffusion coefficient of the main gases (N2 and 02) and air.   
The diffusion coefficient of gases A and B may be estimated using the following 
Equation 6-3 
 as previously described:42  
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(1) 
where MA and MB are the respective molecular weights of gas A and B, k is Boltzmann’s 
constant, T is the absolute temperature, Ρ is the pressure, ΩD is the collision integral for 
diffusion between molecules,59 σAB is the characteristic length (mean free path of a 
molecule)59 and fD is a correction term and can be considered to equal 1. 
Table 4 shows the estimated self-diffusion coefficients of 3He, 4He, 129Xe, N2 and air, as 
well as the estimated diffusion coefficient of 129Xe diluted with 4He and air and in 
addition, the diffusion coefficient of 3He diluted with N2 and air.  The estimated self-
diffusion coefficient of air at 310K and 1 atm was 0.218 cm2/s.  The estimated diffusion 
coefficient of 129Xe diluted with 4He and air was 0.211 cm2/s and for 3He diluted with N2 
and air the diffusion coefficient was 0.826 cm2/s. 
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Table 6-S6-1 Theoretical Diffusion Coefficients 
 
Parameter 3He 4He 129Xe N2 Air 
 
129Xe-
(4He-
Air) 
3He-
(N2-
Air) 
3He-
Air 
 
129Xe-
Air 
 
M (g/mol) 3 4 129 28 28.85 - - - - 
σ (A) 2.551 2.551 4.047 3.798 3.711 3.5050 3.1745 3.131 3.879 
/k (K) 
10.22 10.22 231.0 71.4 78.6 61.7984 27.6857 28.3424 134.747 
kT/  
30.34 30.33 1.342 4.3417 3.944 5.0163 11.1971 10.9377 2.3006 
ΩD 0.6225 0.6225 1.257 0.8689 0.8879 0.8425 0.7282 0.7310 1.0264 
D0 (cm2/s) 2.04 1.77 0.061 0.216 0.218 0.211 0.826 0.858 0.138 
Note:   = energy parameter 
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CHAPTER 7  
To better understand the morphological determinants for the ventilation differences 
observed between hyperpolarized 3He and 129Xe MRI in COPD in Chapter 6, here we 
evaluated the same group of COPD subjects using diffusion-weighted MRI. 
The contents of this Chapter have been previously published in the Journal of Applied 
Physiology and permission to reproduce the article was not required by The American 
Physiological Society.   
M Kirby, S Svenningsen, N Kanhere, A Owrangi, A Wheatley, HO Coxson, GE Santyr, 
NAM Paterson, DG McCormack and G Parraga.  Regional Visualisation of 
Hyperpolarized Helium-3 and Xenon-129 Magnetic Resonance Imaging Ventilation: 
Differences in COPD and Relationship to Emphysema.  JAP 
doi:10.1152/japplphysiol.01206.2012.  [Epub ahead of print Dec 13 2012]. 
7 Pulmonary Ventilation Visualized using Hyperpolarized 
Helium-3 and Xenon-129 Magnetic Resonance Imaging:  
Differences in COPD and Relationship to Emphysema 
7.1 Introduction 
In chronic obstructive pulmonary disease (COPD), irreversible airflow limitation is a 
consequence of increased time constants for lung emptying related to airway 
narrowing/occlusion as well as loss of elastic recoil due to emphysematous tissue 
destruction.1  Magnetic resonance imaging (MRI) using hyperpolarized helium-3 (3He) 
provides high spatial and temporal resolution images of pulmonary ventilation and 
ventilation abnormalities2-4 and with the recent advances in polarization physics,5-8 
hyperpolarized xenon-129 (129Xe) MRI now also provides high resolution images of 
pulmonary ventilation and transmembrane diffusion.6;9-20  The lung micro-structure can 
also be probed using diffusion-weighted MRI, which takes advantage of the rapid 3He 
and 129Xe atom Brownian motion to generate apparent diffusion coefficients 
(ADC),11;12;16;21-24 now a well-established surrogate measurement of alveolar 
dimensions.25  In a small group of COPD subjects it was also recently demonstrated that 
there were significantly greater ventilation abnormalities measured using 129Xe as 
compared to 3He gas and this was not observed in healthy age-matched subjects.26  
Moreover, in this previous work, some COPD subjects had greater 3He-129Xe ventilation 
181 
 
differences than others, suggesting that patient-specific, disease-related mechanisms 
might be responsible for this difference.  
We still do not have a clear understanding of the etiology of noble gas MRI ventilation 
defects, nor their relationship to patient symptoms, exercise capacity or other outcomes; it 
is also unclear what the structural determinants or mechanisms are behind the differences 
between 3He and 129Xe ventilation in COPD.  A large number of studies have 
investigated the convective and diffusive gas transport within the lung using multiple-
breath washout studies27-30 and it is clear from this previous work that there are many 
factors affecting ventilation distribution within the lung including the inhaled gas 
physical properties.  For example, gas density and viscosity affect flow resistance and 
this itself is dependent on airway lumen dimensions.31  In the small airways (<2mm in 
diameter) where flow is fully laminar, viscosity provides the main influence on flow 
resistance.  However, in the large airways where turbulent flow dominates, resistance is 
mainly affected by gas density.  The major site of airflow limitation in COPD occurs 
within the small conducting airways 32 and therefore it is predicted that the gas viscosity 
would be the most important gas physical property affecting flow resistance.  However, 
both the greater density and viscosity of 129Xe gas (pure 129Xe gas has approximately 40 
times greater density and 1.5 times greater viscosity than pure 3He gas)33;34 may result in 
greater resistance to flow regardless of the location of airway abnormalities, and therefore 
may contribute to greater 129Xe ventilation abnormalities in comparison to 3He MRI in 
COPD.  Another potential mechanism responsible for 3He-129Xe ventilation differences in 
COPD is the presence of emphysema and the effects of collateral ventilation.35  In 
emphysema, lung tissue compliance is increased and resistance to flow through 
obstructed airways is higher than through collateral pathways.36;37    
To provide a better understanding of the clinical or physiological meaning of MRI-
derived ventilation abnormalities, we investigated the relationship between emphysema 
and airway wall morphology with differences observed between hyperpolarized 3He and 
129Xe MRI gas distribution.  As a first step, here we evaluated a small group of COPD 
subjects26 and hypothesized that emphysematous lung regions would more readily fill 
with 3He as compared to 129Xe gas under the same physiological conditions.  In other 
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words, lung regions that could not be accessed by 129Xe gas would be more 
emphysematous, leading to decreased 129Xe MRI ventilation.  To test this hypothesis, we 
evaluated regional 3He ADC using image registration/segmentation methods38 and x-ray 
computed tomography (CT) measurements of airway wall thickness and emphysema to 
probe the structure-function relationships in lung regions accessed by both gases and 
those that were accessed only by 3He gas.   
7.2 Materials and Methods 
7.2.1 Subjects 
We enrolled 10 COPD subjects in a hyperpolarized 3He and 129Xe MRI study26 and they 
provided written informed consent to a protocol approved by the local research ethics 
board and Health Canada, which was compliant with the Personal Information Protection 
and Electronic Documents Act (PIPEDA, Canada) and the Health Insurance Portability 
and Accountability Act (HIPAA, USA).  COPD subjects were ex-smokers 50-85 years of 
age and were categorized according to the Global initiative for chronic Obstructive Lung 
Disease (GOLD) criteria 1, with a smoking history of at least 10 pack-years.   
7.2.2 Pulmonary Function Tests 
Spirometry was performed using an EasyOne spirometer (ndd Medizintechnik AG, 
Zurich, CH) according to the American Thoracic Society (ATS) guidelines.39  Static lung 
volumes and the diffusing capacity for carbon monoxide (DLCO) were measured using a 
whole body plethysmograph (MedGraphics Corporation. 350 Oak Grove Parkway St. 
Paul, MN USA).  All spirometry and plethysmography measurements were performed 
approximately 1 hour following administration of 400 μg salbutamol inhaled via a spacer 
device.   
7.2.3 Image Acquisition 
MRI was performed on a whole body 3.0 Tesla Discovery 750MR (General Electric 
Health Care, Milwaukee, WI) MRI system.40  Subjects were instructed to inhale a gas 
mixture from a 1.0 L Tedlar® bag (Jensen Inert Products, New Jersey, USA) from 
functional residual capacity (FRC), and image acquisition was performed during a 8-15s 
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breath-hold.  To minimize the potential for differences in the levels of inspiration 
between 3He and 129Xe MRI, extensive coaching was performed prior to the imaging 
sessions to ensure subjects could inspire the entire bag and throughout the duration of all 
imaging sessions.  To ensure that each inhalation was performed from FRC, the subjects 
were instructed to perform two tidal breaths prior to inhalation from the bag.  The order 
of 3He and 129Xe MRI acquisition was also randomized for each subject. 
3He gas was polarized to 30—40% (HeliSpin™) and doses (5mL/kg body weight) were 
administered in 1.0L Tedlar® bags diluted with medical grade nitrogen (N2) (Spectra 
Gases, Alpha, NJ).  3He MRI diffusion-weighted images were acquired using a fast 
gradient-recalled-echo (FGRE) sequence immediately following inhalation of the 3He/N2 
gas mixture during breath-hold conditions.40  Two interleaved images were acquired (14s 
total data acquisition, repetition time (TR)/echo time (TE)/flip angle = 7.6 ms/3.7 ms/8o, 
field of view (FOV) = 40 x 40 cm, matrix 128 x 128, 7 slices, 30 mm slice thickness, 0 
gap), with and without additional diffusion sensitization with b = 1.6 s/cm2 (gradient 
amplitude (G) = 1.94 G/cm, rise and fall time = 0.5 ms, gradient duration = 0.46 ms, 
diffusion time = 1.46 ms).  129Xe gas was polarized to 10—60% (XeBox-E10, Xemed 
LLC, New Hampshire, USA) and doses (50/50 129Xe/4He) were administered in 1.0L 
Tedlar® bags.  129Xe MRI diffusion-weighted images were acquired using a FGRE 
sequence immediately following inhalation of the 129Xe/4He gas mixture.26  129Xe gas was 
diluted with 4He instead of N2 to try to reduce the differences in the physical properties of 
the inhaled 3He and 129Xe gas mixtures and better mimic the mixture of gaseous oxygen 
in air.  Two interleaved images (16s total data acquisition, TE/TR/flip angle = 10 
ms/13.5 ms/1o, FOV = 40 x 40 cm, matrix 128 x 80, 7 slices, 30 mm slice thickness, 0 
gap), with and without additional diffusion sensitization with b = 12 s/cm2 (G = 2.90 
G/cm, rise and fall time = 0.5 ms, gradient duration = 2.0 ms, diffusion time = 5 ms).26  A 
low dose CT was performed on a 64-slice Lightspeed VCT scanner (GEHC, Milwaukee, 
WI USA) as previously described.26 
7.2.4 Image Analysis 
Hyperpolarized 3He and 129Xe MRI ADC maps were generated from diffusion-weighted 
and non-diffusion-weighted images as previously described using MATLAB R2007b 
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(The Mathworks Inc., Natick, MA, USA).38  To ensure ADC was generated for voxels 
corresponding to ventilated lung regions, the non-diffusion-weighted images were 
segmented to obtain a binary mask for each slice.  The resulting binary masks were 
applied to the corresponding non-diffusion-weighted images, and the ADC maps were 
generated on a voxel-by-voxel basis.  An overview of the image analysis methodology 
adapted from38 is provided in Figure 7-1.  3He and 129Xe ADC maps were registered 
using landmark-based image registration.  The trachea and visible major airways were 
removed semi-automatically permitting ADC calculation within the lung parenchyma.  A 
single ADC value was calculated for each subject by averaging the mean ADC for each 
slice to obtain a whole lung slice-average (WL) ADC.  Following registration of the 3He 
and 129Xe ADC maps, the lung regions of interest (ROI) within the ADC maps accessed 
by both gases were identified as the intersection (regions of overlap) of the 3He and 129Xe 
ADC maps; mean ADC within those ROI was generated for each slice and then averaged 
to obtain a mean 3He ADC value accessed by both gases (ADCHX).  Lung ROI accessed 
by both 3He and 129Xe were used as a binary mask on the 3He ADC maps to calculate 
mean ADC in 3He only ROI (ADCHO).  It is important to note that no lung regions were 
accessed only by 129Xe gas.  3He and 129Xe ventilation volume (VV)41 was generated by 
summing the voxels in the segmented non-diffusion-weighted image following the 
removal of the trachea and visible major airways. 
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CT airway and emphysema analysis was performed using VIDA’s Pulmonary 
Workstation 2.0 (VIDA Diagnostics, Inc., Coralville, IA).  Wall area percentage (WA%) 
and lumen area (LA) was measured for the 3rd to 7th generation airways.42  The extent of 
emphysema was estimated using lowest 15th percentile point of the CT lung density 
histogram (HU15%).43   
7.2.5 Density and Viscosity Estimates 
The density and viscosity of the inspired 29Xe gas diluted with 4He and the inspired 3He 
gas diluted with N2 as well as the density and viscosity of the pulmonary gases were 
estimated.  The density of gases may be estimated using Equation 7-1: 
 (1) 
Figure 7-1 Regional 3He and 129Xe MRI image analysis methodology.  
3He and 129Xe apparent diffusion coefficient (ADC) maps, binary mask of lung regions of 
interest (ROI) probed by both 3He and 129Xe following registration of 3He and 129Xe 
ADC maps, 3He and 129Xe ADC maps for lung ROI probed by both 3He and 129Xe 
(ADCHX), and 3He ADC maps for 3He only lung ROI (ADCHO) with the computed 
tomography (CT) density masks to outline areas with attenuation values <-950 HU.  
Subject is 73 yrs old male with Stage IV chronic obstructive pulmonary disease (COPD):  
forced expiratory volume in 1 s (FEV1)=26%pred, forced vital capacity (FVC)=66%pred, 
FEV1/FVC=29%.   
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where M is the molar mass, P is the pressure, R is the universal gas constant and T is the 
absolute temperature.  The density of a mixture of gases A and B may be estimated using 
Equation 7-2: 
 (2) 
where  and  are the densities of gases A and B, and   and  are the volumes of 
gases A and B.  The viscosity of gases may be estimated using the Chapman-Enskog 
viscosity equation, as previously described33 and shown below in Equation 7-3: 
 (3) 
where M is the molecular weight, T is the absolute temperature, ΩD is the collision 
integral for diffusion between molecules34 and σC is the collision diameter.  The viscosity 
of a mixture of gases A and B may be estimated using Equation 7-4: 
 (4) 
where  and  are the mole fractions of gases A and B, MA and MB are the molecular 
weights of gases A and B and and  are the respective viscosities of gases A and B.  
This equation was selected because it can represent with reasonable accuracy the 
viscosity of a gas mixture at low or moderate pressures.  For the viscosity calculations of 
the 3He-N2 mixture, we used the average volume of 3He gas given to each subject 
(390mL) to determine the mole fraction which was approximately 40/60, and for the 
129Xe-4He mixture it was 50/50.  We also calculated the characteristic diffusion length 
(L1) of the gases and gas mixtures using Equation 7-5: 
 (5) 
where D0 is the diffusion coefficient and Δ is the diffusion time. 
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Density and viscosity calculations for the 3He-N2 and 129Xe-4He gas mixtures 
administered at 310K and 1 atm are provided in Table 7-1.  The estimated density of 
3He-N2 mixture and 129Xe-4He mixture was 0.61kg/m3 and 2.65kg/m3, respectively, and 
the estimated viscosity of 3He-N2 mixture and 129Xe-4He mixture was 1.99x10-4P and 
2.55x10-4P, respectively.   The estimated characteristic diffusion length for the 3He-N2 
mixture and 129Xe-4He mixture was 460μm and 490μm, respectively.  The calculations 
for the estimated diffusion coefficient of 129Xe diluted with 4He and air and the diffusion 
coefficient of 3He diluted with N2 and air were reported elsewhere26 and shown in Table 
7-1. 
Table 7-1 Density and Viscosity Estimates 
Parameter 3He 4He 129Xe N2 Air 129Xe-4He 3He-N2 
M (g/mol) 3 4 129 28 28.85 - - 
σ (A) 2.551 2.551 4.047 3.798 3.711 3.505 3.175 
ΩD 0.623 0.623 1.257 0.869 0.888 0.843 0.728 
D0 (cm2/s) 2.04 1.77 0.061 0.216 0.218 0.211* 0.826* 
L1 (μm) 770† 720† 250‡ 460‡ 470‡ 460‡ 490† 
μ x 10-4 (P) 2.033 2.321 2.593 1.984 2.064 2.552 1.993 
ρ (kg/m3) 0.118 0.157 5.071 1.101 1.140 2.651 0.6095 
M=molecular weight, σ=collision diameter, Ω D=collision integral for diffusion between 
molecules, D0=diffusion coefficient, L1=characteristic diffusion length, μ=viscosity, 
ρ=density. 
* The diffusion coefficient of 129Xe diluted with 4He and air and the diffusion coefficient 
of 3He diluted with N2 and air (21). 
† diffusion time=1.46ms, ‡diffusion time=5ms 
7.2.6 Statistical Methods 
A two-way mixed-effects repeated measures analysis of variance (ANOVA) was used to 
determine the interaction between 3He and 129Xe VV as well as the interaction between 
3He ADC for lung ROI ventilated by both gases (ADCHX) and by 3He gas only (ADCHO) 
using IBM SPSS Statistics 20.0 (SPSS Inc., Chicago, IL, USA).  Linear regression (r2) 
and Pearson correlation coefficients (r) were used to determine the relationships for the 
difference between 3He and 129Xe VV with CT HU15%, spirometry and ADCHO using 
GraphPad Prism version 4.00 (GraphPad Software Inc, San Diego, CA, USA).  In all 
statistical analyses, results were considered significant when the probability of making a 
Type I error was less than 5% (p < 0.05).   
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7.3 Results 
Table 7-2 shows subject demographics and pulmonary function measurements for all 10 
COPD ex-smokers (GOLD Class I n=1; GOLD Class II n=6; GOLD Class III n=2; 
GOLD Class IV n=1).   
Table 7-3 shows a subject listing of mean 3He and 129Xe WL ADC and VV, as well as 
regional ADC measurements.  As previously described in the same group of subjects 
using static ventilation images,26 3He VV derived from non-diffusion-weighted images 
was significantly greater than 129Xe VV (3He VV=5.17L, 129Xe VV=4.34L, p<.0001).  
There was a significant interaction for VV between inhaled gas (3He and 129Xe) and 
subject (p=.04) and this finding may indicate that some COPD subjects had greater 3He 
and 129Xe ventilation differences than others.  Importantly, the difference between 3He 
and 129Xe SNR was not significantly correlated with the difference between 3He and 
129Xe VV (r=-.25, p=.48).   
Figure 7-2 shows 3He and 129Xe ADC maps for all slices for two representative subjects.  
Visually obvious differences in ventilation between 3He and 129Xe MRI were apparent in 
the subject with higher mean ADC for all slices, but to a much lesser extent in the subject 
with moderate ADC values.   
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Table 7-2 Subject listing of pulmonary function measurements 
Subjects 
 
Age 
(yrs) 
Sex 
 
BMI 
(kg·m-2) 
FEV1 
(%pred) 
FVC 
(%pred) 
FEV1/FVC 
 
TLC 
(%pred) 
RV 
(%pred) 
RV/TLC 
 
IC 
(%pred) 
FRC 
(%pred) 
DLCO 
(%pred) 
1 77 F 19.8 50 76 0.50 114 156 0.63 86 135 22 
2 78 M 26.5 59 82 0.52 102 145 0.52 89 112 - 
3 79 M 23.1 52 104 0.36 114 151 0.51 69 153 50 
4 76 M 30.6 77 104 0.54 114 140 0.45 128 102 - 
5 73 M 20.8 26 66 0.29 111 229 0.77 27 189 - 
6 77 M 18.4 34 94 0.26 132 221 0.63 54 201 17 
7 68 F 23.7 59 86 0.53 115 121 0.45 121 110 43 
8 76 M 29.6 35 84 0.31 123 205 0.60 70 168 44 
9 67 M 32.1 75 82 0.68 105 134 0.42 92 117 67 
10 71 M 29.8 107 135 0.58 115 86 0.27 109 121 42 
ALL 
(±SD) 
74 
(4) 
 
 
25.4  
(5.0) 
57  
(24) 
91 
(19) 
0.46  
(0.14) 
115 
(8) 
159 
(46) 
0.53 
(0.14) 
85 
(31) 
141 
(35) 
41 
(17)† 
SD=Standard Deviation, BMI=Body Mass Index, FEV1= Forced Expiratory Volume in 1s, %pred=Percent Predicted, FVC= 
Forced Vital Capacity, TLC= Total Lung Capacity, RV= Reserve Volume, IC= Inspiratory Capacity, FRC= Functional 
Residual Capacity, DLCO=Carbon Monoxide Diffusion Capacity of the lung.  †n=7 
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Table 7-3 3He and 129Xe MRI WL and Regional ADC for all subjects 
 
WL 3He MRI WL 129Xe MRI 
Regional 3He ADC 
(cm2/s) 
Subject 
VV 
(L) 
ADC 
(cm2/s) 
VV 
(L) 
ADC 
(cm2/s) 
ADCHX 
(cm2/s) 
ADCHO 
(cm2/s) 
1 4.25 0.608 3.70 0.095 0.600 0.645 
2 5.13 0.312 5.09 0.058 0.306 0.329 
3 6.03 0.534 4.99 0.086 0.511 0.620 
4 5.16 0.332 4.90 0.057 0.320 0.381 
5 6.06 0.575 4.80 0.092 0.572 0.600 
6 5.86 0.622 4.43 0.087 0.610 0.643 
7 5.05 0.503 4.39 0.086 0.508 0.474 
8 6.24 0.479 4.50 0.080 0.466 0.508 
9 3.10 0.290 2.85 0.057 0.274 0.297 
10 4.83 0.527 3.77 0.085 0.529 0.536 
ALL 
(±SD) 
5.17‡ 
(0.97) 
0.478 
(0.124) 
4.34‡ 
(0.71) 
0.078 
(0.015) 
0.470† 
(0.125) 
0.503† 
(0.119) 
WL=Whole lung, VV=Ventilation Volume, ADC=Apparent Diffusion Coefficient, 
ADCHX= lung regions of interest with signal at both 3He and 129Xe time-points, ADCHO= 
lung regions of interest with signal during the 3He breath-hold only. 
‡ Denotes p-value < 0.0001 for comparison between WL 3He and 129Xe MRI VV  
† Denotes p-value < 0.0001 for comparison between Regional 3He ADCHX and 3He 
ADCHO 
 
Figure 7-3 shows the 3He and 129Xe ADC maps as well as the ADC map for the ROI 
ventilated only by 3He for a subject with moderately severe COPD.  As shown in Table 
7-3, regional analysis showed that mean ADC for those regions only accessed by 3He gas 
(ADCHO=0.503±0.119cm2/s) was significantly greater than mean ADC for those regions 
accessed by both 3He and 129Xe gas (ADCHX=0.470±0.125cm2/s, p<.0001).  Moreover, to 
ensure that 129Xe ventilation abnormalities in regions of emphysema were not due to 
signal attenuation within those regions in the diffusion-weighted images, we compared 
ventilation measured from the non-diffusion-weighted images (non-diffusion-weighted 
129Xe VV=4.27±0.76L) and the ADC maps and determined there was no significant 
ventilation difference (ADC map 129Xe VV=4.31±0.69L, p=.80).  To determine whether 
airways leading to regions accessed only by 3He gas might be abnormally thickened or 
obstructed we compared the lung side with the greatest difference between 3He and 129Xe 
ventilation with the lung side with the lower 3He-129Xe difference and observed no 
significant difference in WA% (ΔWA%=1%, p=.64) or LA (ΔLA=6.7mm2, p=.33).    
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In Figure 7-4, the differences between 3He and 129Xe VV are shown and these were 
significantly correlated with CT HU15% (r=-.65, p=.04) and mean 3He ADCHO (r=.70, 
p=.02).  However, there was no significant correlation for the difference between 3He and 
129Xe VV with CT WA% (r=-.34, p=.33) for all airway generations or for each of the 3rd 
to 7th generation airways individually. There was also a significant correlation for the 
Figure 7-2 3He and 129Xe ADC maps for two representative subjects with slices in the 
anterior-to-posterior direction   
A. Subject is 78 yrs old male with Stage II chronic obstructive pulmonary disease 
(COPD):  forced expiratory volume in 1 s (FEV1)=59%pred, forced vital capacity 
(FVC)=82%pred, FEV1/FVC=52%, relative area with attenuation values below 
−950 HU (RA950)=36.70, lowest 15th percentile (HU15)=-975.   
B. Subject is a 73 yr old male with Stage IV COPD:  FEV1=26%pred, FVC=66%pred, 
FEV1/FVC=29%, RA950=5.00, HU15=-930.   
The CT density mask shown in green is in the bottom panel for each slice to 
highlight the areas with attenuation <-950HU. 
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difference between 3He and 129Xe VV with FEV1/FVC (r=-.79, p=.007), but not with 
FEV1 (r=-.48, p=.16) or DLCO (r=-.37, p=.41). 
 
 
Figure 7-3 Regional 3He and 129Xe ADC 
3He and 129Xe ADC maps with the ADC map for the ROI ventilated only by 3He 
registered to the binary ADC map for those regions accessed by both 3He and 129Xe 
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7.4 Discussion 
Hyperpolarized noble gas MRI has been developed over the last two decades because it 
has the potential for clinical translation, providing quantitative microstructural and 
dynamic pulmonary functional information and measurements.  However, while 3He MRI 
allows the acquisition of very high quality images, the global availability and costs are 
motivating a transition to hyperpolarized 129Xe MRI.  Recently, a pilot study performed 
with both 3He and 129Xe MRI showed there were visually obvious and quantitatively 
greater gas distribution abnormalities for 129Xe MRI in COPD subjects but not healthy 
elderly never-smokers.26  The reasons for the difference were not clear and so in the 
current evaluation we investigated emphysema as a contributor to the observed 
differences in 3He and 129Xe ventilation.  Accordingly, here we report:  1) significantly 
greater 3He ADC in regions only accessed by 3He gas (ADCHO) as compared to regions 
accessed by both gases (3He ADCHX), and, 2) a significant relationship between the 
Figure 7-4 Correlation for the difference between 3He and 129Xe VV and CT HU15% 
Threshold 
A. The difference between 3He and 129Xe VV was significantly correlated with the 
extent of emphysema as assessed by CT using HU15% threshold (r=-65, p=.04, 
r2=.42, p=.04, y=-34.4x-919.2). 
B. The difference between 3He and 129Xe VV was significantly correlated with mean 
ADC in the 3He only regions of interest (ADCHO) (r=.70, p=.02, r2=.50, p=.02, 
y=3.1x-0.7). 
Dotted lines represent the 95% confidence intervals. 
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difference in 3He and 129Xe VV and the extent of emphysema assessed by CT but not 
with CT airway wall thickness (WA%) measurements. 
We observed that mean 3He ADC in pulmonary ROI accessed only by 3He gas were 
elevated relative to the mean 3He ADC in the remaining lung.  This finding suggests that 
more emphysematous or damaged lung was more readily filled with 3He as compared to 
129Xe gas for the duration of the breath-hold imaging performed in this study.  We 
acknowledge, however, that SNR was lower for 129Xe than with 3He MRI,26 and therefore 
there is the potential for regions of the lung with reduced signal intensity to appear as 
ventilation defects in low SNR 129Xe images.  However, for this investigation, we 
observed that the difference between 3He and 129Xe SNR was not significantly correlated 
with the difference between 3He and 129Xe VV.  Moreover, to ensure that 129Xe 
ventilation abnormalities in regions of emphysema were not due to signal attenuation 
within those regions in the diffusion-weighted images, we compared ventilation 
measured from the non-diffusion-weighted images and the ADC maps and determined 
there was no significant ventilation difference.  We think, therefore, that it is unlikely that 
this finding is due to SNR alone and another possible explanation for this observation is 
that the highly diffusive and less dense and viscous 3He gas may readily access the 
slower-filling emphysematous lung during the inhalation period and the breath-hold 
interval.  Alternatively, the 3He gas may fill emphysematous lung regions via collateral 
channels.  Collateral channels have been identified in emphysema35 and although 
resistance to flow through collateral channels is high in the normal lung, in emphysema 
resistance to flow through collateral channels is lower than through obstructed airways.37  
Collateral ventilation has been demonstrated with 3He MRI44;45 and more recently, 
indirect, non-airway dependent or collateral ventilation was directly visualized using 3He 
MRI in COPD46 within a single breath-hold.  For 129Xe gas, however, it is likely that 
there are longer time constants for gas filling in emphysematous regions; 129Xe gas with 
its lower diffusion coefficient would diffuse much more slowly into these 
emphysematous regions than 3He and therefore have a much shorter diffusion distance 
due to the short breath-hold duration, which may contribute to lower 129Xe signal 
intensity in regions of significant emphysema.  Accordingly, we calculated the 
characteristic diffusion length for the 129Xe/4He and 4He/N2 gas mixtures and showed that 
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the characteristic diffusion length for the 129Xe atoms is smaller than that for the 3He 
atoms.  Regardless of the exact mechanisms that are in play, the finding of significant 
emphysema in lung regions probed only with 3He gas suggests that these lung regions 
cannot be penetrated by 129Xe gas in the same timeframe.   
Importantly, we previously showed that the mixture of 129Xe/4He gas administered in this 
study better approximates the self-diffusion coefficient of oxygen mixed with air in the 
lung,26 suggesting that 129Xe MRI ventilation may be a better estimate of ground truth 
pulmonary ventilation.  The 3He/N2 gas mixture has a lower density and viscosity than 
air, and studies have previously demonstrated that inspiring oxygen mixed with helium 
reduces airway resistance by decreasing turbulent flow.47  This interesting finding 
suggests that inhaled 3He gas and its mixtures may be less sensitive to peripheral airway 
obstruction.  Clearly, there are advantages to utilizing inhaled gases such as 129Xe and 
mixtures thereof that may have increased sensitivity to airway obstruction and 
emphysema for targeted treatments and interventions.  On the other hand, the increased 
density/viscosity and lower diffusion coefficient of 129Xe may limit signal from those 
regions of the lung most affected by emphysema or receiving collateral flow.  Clearly, 
both gases provide application-specific advantages.  
Importantly, we did not detect a significant correlation for the difference in 3He and 129Xe 
ventilation and WA%.  However, we cannot ascertain whether this might be the case 
regionally, wherein specific airways leading to regions accessed only by 3He gas might 
be abnormally thickened or obstructed.  In other words, it is possible that the whole lung 
estimates of WA% might not be representative of regional differences.  We investigated 
this possibility by regionally comparing the lung side with the greatest difference 
between 3He and 129Xe ventilation with the lung side with the lower 3He-129Xe difference 
and observed no significant difference in WA% or lumen area.  However, we must also 
acknowledge that for some subjects, the lung region that showed a 3He-129Xe ventilation 
difference was very small and this may have also contributed to the lack of significant 
relationship observed with WA%.   
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A large number of studies have investigated convective and diffusive gas transport within 
the lung using multiple-breath washout studies27-30 and modeling48 and it is evident from 
these previous studies that the inhaled gas physical properties are important factors 
affecting ventilation distribution within the lung.  Clearly there is significant work to be 
done to better understand how the different properties of 3He and 129Xe gas affect 
ventilation distribution and most importantly, what information these differences in 
ventilation distribution provide us regarding the sensitivity of the different gases and their 
mixtures for detecting airway and ventilation abnormalities.  Directly visualizing the 
distribution of the gases using mixtures of 3He and 129Xe with well-controlled viscosities 
and densities during a breath-hold in the same subjects using time-resolved imaging 
sequences, as was recently performed with 3He MRI,46 could certainly be utilized to test 
some of our important hypotheses regarding delayed/collateral ventilation within 
emphysematous lung regions in COPD subjects.  Moreover, while several modeling 
studies have aimed to evaluate gas transport in the lung using 3He and 129Xe,49;50 more 
studies of this nature are required to fully understand the role of the gas properties on 
regional ventilation distribution with noble gas MRI as well as to determine the gas 
mixture that best approximates the distribution of typical room air within the lung.   
We recognize that this work was limited by the small number of subjects evaluated 
meaning that extrapolation of these results to a general COPD population cannot be 
confirmed until studies with larger sample sizes are performed.  This study was also 
limited by the different diffusion times and b-values that were utilized for 3He and 129Xe 
image acquisition, and therefore we may be probing different lung structures.  Previous 
studies have demonstrated that greater diffusion time results in greater diffusion distances 
and there is therefore the potential to probe a fundamentally different spatial scale.51  
However, significant and strong correlations have been previously observed between 3He 
and 129Xe ADC,26 suggesting that both methods are probing similar spatial dimensions.  
In addition, the acquisition of clinical measurements, such as dyspnea scores and 
measurements of exercise tolerance, for direct comparison to 3He and 129Xe MRI 
measurements may have aided in determining the clinical meaning of these differences.  
Future studies should aim to evaluate the differences between 3He and 129Xe MRI in 
197 
 
terms of their relationships with clinical measurements as well as the relative sensitivities 
for detecting improvements following treatment or interventions.   
In summary, we used regional hyperpolarized 3He and 129Xe ADC image 
registration/segmentation methods to quantify ADC in the lung regions accessed by both 
gases and the lung regions accessed by 3He gas only.  We reported a significantly greater 
mean ADC in the lung regions accessed by 3He gas only than in the remaining lung 
tissue, and a significant relationship between the difference in 3He and 129Xe VV and 
emphysema.  In COPD, the lower resistance to flow within emphysematous lung regions 
is a potential determinant of the differences observed in 3He and 129Xe ventilation defects.   
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CHAPTER 8  
While it is important to demonstrate that 3He MRI measurements relate to important 
clinical outcomes, such as disease progression and treatment response, another goal of 
imaging is to identify early disease changes.  Here we evaluated well-established clinical, 
physiological and emerging imaging measurements in ex-smokers with normal 
spirometry and abnormal DLCO as well as a group of ex-smokers with normal spirometry 
and DLCO and ex-smokers with GOLD stage I COPD.   
The contents of this Chapter have been accepted in Thorax and are currently in press. 
M  Kirby, A Owrangi, S Svenningsen, A Wheatley, HO Coxson, NAM Paterson, DG 
McCormack and G Parraga.  On the role of abnormal DLCO in ex-smokers without 
airflow limitation: Symptoms, exercise capacity and hyperpolarized helium-3 magnetic 
resonance imaging. Thorax (Accepted March 28, 2013). 
8 On the Role of abnormal DLCO in Ex-smokers Without 
Airflow Limitation: Symptoms, Exercise Capacity and 
Hyperpolarized Helium-3 Magnetic Resonance Imaging 
8.1 Introduction 
Chronic obstructive pulmonary disease (COPD) is characterized by chronic, progressive 
expiratory flow limitation that develops as a result of the lung’s inflammatory response to 
inhaled toxic gases and particles, primarily from tobacco smoke.1  In COPD, airflow 
limitation is caused by both small airway disease (obstructive bronchiolitis) and 
parenchymal destruction (emphysema),1 however, the relative contributions of these 
pathologies vary from person to person.   
When COPD is suspected based on symptoms, such as dyspnea, chronic cough or sputum 
production, and/or a history of exposure to risk factors,1 airflow limitation is measured 
using spirometry and severity is determined according to the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) criteria.1  This approach, however, has been 
acknowledged to potentially result in an over-diagnosis of COPD in the elderly,2 as well 
as under-diagnosis of mild or early stage COPD 3.   
The COPDGene study recently reported low forced expiratory volume in 1 second 
(FEV1) and normal FEV1/forced vital capacity (FVC) in ex-smokers with significant 
symptoms and decreased six-minute walk distance (6MWD) and defined these patients as 
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GOLD-Unclassified (GOLD-U).4  Until now, ex-smokers with GOLD-U or those with 
“non-obstructive” or “pure” emphysema without airflow limitation have been 
systematically excluded from COPD studies.  With respect to non-obstructive 
emphysema, there have been a few case reports5-7 and pilot studies8 that described 
significant smoking history, severe symptoms and abnormal diffusing capacity for carbon 
monoxide (DLCO)  in patients concomitant with normal expiratory airflow.  A recent 
study also reported that otherwise normal asymptomatic smokers with abnormal DLCO 
showed evidence of endothelial microparticles in the circulation – a marker of early lung 
destruction associated with emphysema.9  Although abnormal DLCO in ex-smokers is a 
valuable marker of lung function impairment, even in the absence of airflow limitation, 
the relationship between DLCO with other functional markers (i.e., symptoms and 
exercise limitation) is not well-understood. We hypothesized that subjects with abnormal 
DLCO without airflow limitation would have imaging evidence of early or mild 
emphysema with measureable functional consequences. 
Multi-detector computed tomography (CT) and hyperpolarized helium-3 (3He) magnetic 
resonance imaging (MRI) have been used independently to measure emphysema and 
airways disease as distinct phenotypes in COPD.10;11  In particular, hyperpolarized 3He 
MRI apparent diffusion coefficients (ADC),12;13 provide a way to sensitively measure 
regional lung tissue destruction, -the hallmark of emphysema.  Abnormally elevated 3He 
ADC have previously been reported in asymptomatic smokers without COPD,14;15 
although the relationship between 3He MRI ADC in early disease with symptoms and 
other physiological measurements has never been reported and their functional impact is 
not known.  To better understand the consequences of early or mild disease in ex-
smokers, here we evaluated well-established clinical, physiological as well as emerging 
imaging measurements in ex-smokers with normal spirometry but abnormal DLCO as well 
as ex-smokers with GOLD stage I COPD and those with normal spirometry and DLCO.    
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8.2 Materials and Methods 
8.2.1 Study Subjects 
All subjects provided written informed consent to the protocol approved by the local 
research ethics board and Health Canada, and the study was compliant with the Personal 
Information Protection and Electronic Documents Act (Canada) and the Health Insurance 
Portability and Accountability Act (USA).  Ex-smokers were recruited from a local 
tertiary care centre and by advertisement.  Thirty-eight subjects were enrolled who were 
ex-smokers without a diagnosis of COPD and 15 ex-smokers were enrolled with a 
previous diagnosis of GOLD stage I COPD,1 all of whom were 60-85 years of age, with a 
smoking history ≥ 10 pack -years.  The subjects without a diagnosis of COPD had no 
history of previous chronic or current respiratory disease and were classified according to 
ATS/ERS recommendations16 on the approximate lower limits of normal for DLCO17 such 
that normal DLCO ≥ 75%pred and abnormal DLCO < 75%pred. 
8.2.2 Spirometry, Plethysmography and other Tests 
Spirometry was performed using an EasyOne spirometer (ndd Medizintechnik AG, 
Zurich, CH) according to ATS guidelines.18  Lung volumes were measured using body 
plethysmography and DLCO was assessed using the attached gas analyzer (MedGraphics 
Corporation. 350 Oak Grove Parkway St. Paul, MN, USA).  The St Georges Respiratory 
Questionnaire (SGRQ) was administered19;20 and a standard six minute walk test 
(6MWT)21 was performed.  
8.2.3 Image Acquisition 
MRI was performed on a whole body 3.0 Tesla Discovery 750MR (General Electric 
Health Care, Milwaukee, WI) MRI system.22  3He gas was polarized to 30—40% 
(HeliSpin™) and doses (5mL/kg body weight) were administered in 1.0L Tedlar® bags 
diluted with medical grade nitrogen (N2) (Linde, Ontario, Canada).  3He MRI diffusion-
weighted images were acquired using a fast gradient-recalled-echo sequence immediately 
following inhalation of the 3He/N2 gas mixture during breath-hold conditions.22  Two 
interleaved images were acquired (14s total data acquisition, repetition time (TR)/echo 
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time (TE)/flip angle = 7.6 ms/3.7 ms/8o, field of view (FOV) = 40 x 40 cm, matrix 
128 x 128, 7 slices, 30 mm slice thickness, 0 gap), with and without additional diffusion 
sensitization with b = 1.6 s/cm2 (gradient amplitude (G) = 1.94 G/cm, rise and fall time = 
0.5 ms, gradient duration = 0.46 ms, diffusion time = 1.46 ms).   
CT was performed on a 64-slice Lightspeed VCT scanner (GEHC, Milwaukee, WI USA) 
(64×0.625 mm, 120 kVp, 100 effective mA, tube rotation time=500 ms, pitch=1.0).  A 
single spiral acquisition was acquired in breath-hold after inhalation of 1.0L of N2 from 
functional residual capacity.  Reconstruction was performed (1.25 mm) using a standard 
convolution kernel. 
To minimize the potential for differences in the levels of inspiration between 3He MRI 
and CT, extensive coaching was performed prior to the imaging sessions to ensure 
subjects could completely inspire the contents of the 1.0L bag.  The order of 3He MRI 
and CT acquisition was randomized for each subject. 
8.2.4 Image Analysis 
Regions of signal void were quantified as the 3He ventilation defect percent (VDP).23  
3He apparent diffusion coefficient (ADC) maps were also generated as previously 
described.24  Regional differences in ADC were evaluated in the anterior-posterior (AP) 
direction.25  The AP gradient (APG) was the slope of the line of best fit that described the 
change in ADC as a function of distance in centimeters.  Analysis of CT was performed 
using the Pulmonary Workstation 2.0 (VIDA Diagnostics, Inc., Coralville, IA).  Wall 
area percent (WA%) was measured for the segmental and subsegmental airways10 and the 
relative area with attenuation values below −950 HU (RA950) was generated.26   
8.2.5 Statistical Methods 
A multivariate analysis of variance was performed using IBM SPSS Statistics 20.0 (SPSS 
Inc., Chicago, IL, USA).  Univariate comparisons were performed using an unpaired two-
tailed t-test and Welch’s correction was used when the F-test for equal variances was 
significant using GraphPad Prism version 4.00 (GraphPad Software Inc, San Diego, CA, 
USA).  A Fisher’s exact test was performed for categorical variables.  Linear regression 
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(r2) and Pearson correlation coefficients ( ) were used to determine correlations using 
GraphPad Prism version 4.00.  Results were considered significant when the probability 
of making a Type I error was less than 5% (p < 0.05).   
8.3 Results 
We enrolled 53 ex-smokers, 38 subjects without a diagnosis of COPD and 15 subjects 
diagnosed with stage I COPD.  Of the 38 ex-smokers without COPD, half had normal 
DLCO without airflow obstruction (ND, n=19) and the other half had abnormal DLCO 
without airflow obstruction (AD, n=19).  Table 8-1 shows subject demographic data as 
well as the pulmonary function, SGRQ, 6MWD, CT and 3He MRI measurements for all 
subjects categorized according to spirometry and DLCO results.   
Subjects with abnormal DLCO without airflow obstruction (AD) were not significantly 
different from ex-smokers with normal DLCO (ND) and stage I COPD subjects with 
respect to age, BMI, pack-years, years since smoking cessation, the change in SpO2 after 
the 6MWT, CT WA% and 3He VDP.  However, there were significantly more female AD 
subjects than ND (p=.02) and stage I COPD (p=.01) subjects. 
Figure 8-1 shows the central coronal 3He MRI static ventilation image and 3He MRI 
ADC map for subjects with ND, AD and stage I COPD.  As shown in Table 8-1, AD 
subjects had significantly worse 3He ADC (0.30±0.03cm2/s, p=.01), 6MWD (341±95m, 
p=.008) and SGRQ total score (29±21, p=.01) compared with ND subjects, but no 
significant difference for RA950 (p=.53).  In comparison with stage I COPD, AD subjects 
had a significantly reduced 6MWD (341±95m, p=.005), FVC (93±12%pred, p=.001), 
RA950 (1.6±1.1, p=.0008) and ADC (0.30±0.03cm2/s, p=.02), and a significantly greater 
FEV1/FVC (80±7%, p<.0001) and no significant difference for SGRQ total score (p=.59). 
Figure 8-2A shows the mean ADC on a slice-by-slice basis in the anterior to posterior 
direction for ND, AD and stage I COPD subjects.  For AD ex-smokers, the ADC gradient 
in the anterior-posterior direction (ADC APG) was significantly lower than for ND 
(p=.02) and not significantly different from COPD subjects (p=.20).  Figure 8-2B shows 
the significant correlation between ADC APG and the 6MWD (r=-.51, p=.0002). 
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Figure 8-3 shows the correlations between 3He ADC and CT RA950 with DLCO, SGRQ 
and 6MWD.  There was a significant correlation between 3He ADC and DLCO (r=-0.55, 
p<0.0001) and SGRQ (r=0.34, p=0.02), but not 6MWD (r=-.17, p=0.24), and as shown in 
Figure 8-2B, the ADC APG was significantly correlated with 6MWD.  RA950 was 
significantly correlated with DLCO (r=-0.31, p=0.03); but not SGRQ (r=0.24, p=0.10); or 
6MWD (r=0.0013, p=0.99).   
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Table 8-1  Clinical, functional and radiographic measurements of asymptomatic ex-
smokers with normal DLCO and abnormal DLCO and with GOLD stage I COPD 
 ND 
(n=19) 
AD 
(n=19) 
Stage I 
COPD 
(n=15) 
Significance of 
Difference (p) 
ND-AD AD-COPD 
Subject Demographics 
Age yrs (±SD) 71 (7) 74 (7) 77 (5) 0.09 0.30 
Female Sex  3 11 2 0.02 0.01 
BMI kg/m2 (±SD) 29.5 (3.4) 28.6 (4.0) 28.4 (4.0) 0.46 0.91 
Pack yrs (±SD) 25 (12) 32 (23) 49 (36) 0.25 0.11 
Yrs since quit (±SD) 26 (9) 24 (14) 21 (14) 0.63 0.63 
Pulmonary Function Tests 
FEV1 %pred (±SD) 107 (13) 99 (12) 95 (13) 0.07 0.34 
FVC %pred (±SD) 98 (12) 93 (12) 108 (14) 0.16 0.001 
FEV1/FVC (±SD) 80 (6) 80 (7) 63 (5) 0.73 <0.0001 
IC %pred (±SD) 112 (17) 103 (22) 103 (17) 0.17 0.99 
RV %pred (±SD) 103 (17) 107 (25) 114 (29) 0.58 0.45 
TLC %pred (±SD) 101 (10) 101 (15) 109 (13) 0.96 0.12 
RV/TLC %pred (±SD) 101 (13) 104 (16) 103 (18) 0.49 0.77 
DLCO %pred (±SD) 89 (9) 59 (13) 68 (19) <0.0001 0.12 
6MWT 
Pre 6MWT Sp02 % (±SD) 97 (2) 95 (2)¥ 95 (2) 0.06 0.57 
Δ 6MWT Sp02 % (±SD) 0 (2)¥ 0 (2)‡ -1 (3) 0.55 0.25 
Distance m (±SD) 430 (99) 341 (95) 417 (41) 0.008 0.005 
SGRQ 
Symptoms (±SD) 18 (17)¥ 36 (30)‡ 36 (22) 0.04 0.99 
Activity Score (±SD) 19 (21)‡ 41 (24) 36 (25)+ 0.006 0.54 
Impact Score (±SD) 6 (11)‡ 17 (18) 15 (13)+ 0.04 0.68 
Total Score (±SD) 12 (14)* 29 (21)‡ 25 (17)+ 0.01 0.59 
CT Measurements 
RA950 (±SD) 1.36 (1.25)¥ 1.60 (1.06) 5.50 (3.16) 0.53 0.0008 
WA% (±SD) 57 (4) 59 (2) 58 (2) 0.17 0.23 
3He MRI Measurements 
ADC cm2/s (±SD) 0.27 (0.03) 0.30 (0.03)* 0.36 (0.08) 0.01 0.02 
VDP % (±SD) 6 (3)‡ 7 (4)* 9 (5) 0.40 0.07 
ND=Normal DLCO, AD=Abnormal DLCO, COPD=Chronic Obstructive Pulmonary 
Disease, BMI=Body Mass Index, FEV1=Forced Expiratory Volume in 1sec, FVC=Force 
Vital Capacity, IC=Inspiratory Capacity, RV=Residual Volume, TLC=Total Lung 
Capacity, DLCO=Diffusion capacity of the Lung for Carbon monoxide, 6MWT=6-min 
Walk Test, Sp02=Peripheral Oxygen Saturation, SGRQ=St. George’s Respiratory 
Questionnaire, RA950=Relative Area with attenuation values below −950 HU, HU15= 
lowest 15th percentile from the frequency distribution of HU, WA%=Wall area percent, 
ADC=Apparent Diffusion Coefficient, VDP=Ventilation defect percent. *n=16, ‡n=17, 
¥n=18, +n=14.  
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Figure 8-1  3He MRI static ventilation images and 3He ADC maps for a representative 
ND and two representative AD and COPD stage I ex-smokers. 
ND subject is a 70 yr old male FEV1=101%pred, FEV1/FVC=0.75, DLCO=113%pred, 3He 
ADC=0.26cm2/s, CT RA950=1.25.  AD subject 1 is a 74 yr old male FEV1=89%pred, 
FEV1/FVC=0.77, DLCO=41%pred, 3He ADC=0.31cm2/s, CT RA950=1.52; AD subject 2 is 
a 74 yr old male FEV1=95%pred, FEV1/FVC=0.85, DLCO=63%pred, 3He ADC=0.29cm2/s, 
CT RA950=0.52.  GOLD stage I COPD subject 1 is a 74 yr old male FEV1=86%pred, 
FEV1/FVC=0.59, DLCO=45%pred, 3He ADC=0.37cm2/s, CT RA950=6.14; GOLD stage I 
COPD subject 2 is a 78 yr old male FEV1=118%pred, FEV1/FVC=0.62, DLCO=71%pred, 
3He ADC=0.38cm2/s, CT RA950=5.52. 
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Figure 8-2 Regional 3He MRI ADC Anterior-Posterior Gradients (APG) for ND, AD and 
stage I COPD subjects and Correlation between 3He ADC APG with 6MWD 
A. Mean APG was statistically significantly different for AD and ND subjects (AD: 
APG=-3.55x10-4 ± 4.85x10-4 cm2/s/cm, ND: APG= -7.03x10-4 ± 3.03x10-4 
cm2/s/cm, p=0.02), but not between the AD and Stage I COPD subjects (COPD: 
APG=-5.58x10-4 ± 3.73x10-4 cm2/s/cm, p=0.20). Error bars represent the ADC 
standard deviation for each image slice. 
B. 3He APG ADC was significantly correlated with 6MWD (r=-0.51, p=0.0002, 
r2=0.26, p=0.0002, y=-0.02x+4.4).  Dotted lines represent the 95% confidence 
intervals of the regression. 
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Figure 8-3  Correlation between 3He ADC and CT RA950 with DLCO, SGRQ and 6MWD 
for ND, AD and stage I COPD subjects. 
A. 3He ADC was significantly correlated with DLCO (r=-0.55, p<0.0001, r2=0.31, 
p<0.0001, y=-0.0018x+0.44), SGRQ (r=0.34, p=0.02, r2=0.12, p=0.02, 
y=0.0012x+0.28), but not 6MWD (r=-0.17, p=0.24, r2=0.03, p=0.24, y=-
0.00013x+0.36). 
B. CT RA950 was significantly correlated with DLCO (r=-0.31, p=0.03, r2=0.09, 
p=0.02, y=-0.040x+5.42), but not with SGRQ (r=0.24, p=0.10, r2=0.06, p=0.10, 
y=-0.034x+1.71) and 6MWD (r=0.0013, p=0.99, r2<0.0001, p=0.99, 
y=0.00003x+2.5). 
Dotted lines represent the 95% confidence intervals of the regression. 
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8.4 Discussion 
To better understand the relationship between lung structural markers, symptoms and 
physiological measurements in ex-smokers, we evaluated 53 ex-smokers including 38 
subjects who did not have a diagnosis of COPD and 15 subjects with stage I COPD, and 
observed: 1) 19/38 ex-smokers showed normal spirometry and CT but abnormal DLCO 
and 19/38 ex-smokers showed normal spirometry, CT and DLCO, 2) subjects with 
abnormal DLCO had significantly worse 6MWD compared to stage I COPD ex-smokers 
and significantly worse 3He ADC, SGRQ and 6MWD compared to subjects with normal 
DLCO, and, 3) subjects with abnormal DLCO had significantly smaller 3He MRI ADC 
anterior-posterior gradients compared to subjects with normal DLCO. 
We were surprised that half of the ex-smokers without COPD showed abnormal DLCO 
and significantly worse 3He ADC, but with normal CT, which based on previous 
studies,14;15 was an unexpected result.  Although we were not able to confirm significant 
disease other than emphysema that could account for these findings, we note that a 
previous evaluation14 of 10 younger asymptomatic smokers (mean age=47 years, 
range=23-73) showed that 3 of 5 subjects aged 60yr or older also reported DLCO < 
75%pred.  In ex-smokers, abnormal DLCO is thought to reflect diminished lung surface 
area available for gas exchange, although DLCO also reflects the volume of blood in the 
pulmonary capillaries and thickness of the alveolar capillary membrane,27 related to 
bronchiectasis and interstitial lung disease.28  Abnormally low DLCO is also consistent 
with pulmonary vascular disease,29 and such patients exhibit normal spirometry, dyspnea 
upon exertion30 and a decline in oxygen saturation with exertion.31  In the current study, 
AD subjects did not show reduced oxygen saturation during the 6MWT nor did they 
report a history of pulmonary vascular disease, so there was no evidence to support the 
notion that pulmonary vascular disease was responsible for the abnormal exercise 
performance and dyspnea observed here.  Although DLCO is a very sensitive marker of 
emphysema in smokers,8 reproducibility can be low, and in some cases, low to moderate 
correlations have been reported between DLCO and pathological assessments of 
emphysema.32;33   
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Previous work by Woods and Hogg34 compared 3He ADC with histology measurements 
of emphysema in explanted lungs and showed that ADC values could be used to 
distinguish normal from emphysematous lung tissue with greater precision than the mean 
linear intercept measurement from histology samples.  Another previous study in COPD 
showed that while 3He ADC correlated significantly with CT measurements (i.e., RA950), 
stronger correlations were observed for 3He ADC and DLCO than for RA950 and DLCO.35   
In asymptomatic smokers, 3He ADC was shown to correlate with DLCO, but there was no 
significant correlation between DLCO and CT RA950.14  Finally, abnormally elevated 3He 
ADC values were previously observed in never-smokers exposed to significant second-
hand-smoke36 as compared to never-smokers with no such exposure.  Taken together, 
these previous findings support the observation here that elevated 3He ADC in ex-
smokers with abnormal DLCO may reflect mild emphysema not detected by CT.  Our 
observations are also consistent with previous reports5-8;37 and the identification of mild 
emphysema using histology that was not predicted using preoperative CT.38;39  While we 
cannot rule out the presence of small airways disease in subjects with AD, there was no 
significant difference between the AD and ND subjects for 3He VDP and CT WA%, both 
of which provide estimates of airways disease.  Taken together, these results suggest that 
3He ADC is sensitive to very mild emphysema in subjects with abnormal DLCO who have 
no CT evidence of airways disease or emphysema. 
Concomitant with significantly elevated 3He ADC, we observed significantly worse 
6MWD in AD as compared to COPD and ND ex-smokers.  This is an important finding 
and the first to provide evidence of a relationship between 3He MRI ADC reflective of 
early or mild emphysema and exercise capacity.  It is also important to note that the ratio 
of female/male ex-smokers with AD was 11/8 (1.4) and for ND, this ratio was 3/16 (0.2).  
Although the current study was not powered to evaluate sex differences, previous 
evidence suggests that female sex is significantly associated with early-onset COPD.40;41  
However, previous studies have also shown that emphysema dominates in males as 
compared to females,42 whereas here, the sex ratio was reversed.  We note that imaging 
was performed at a fixed volume and because there were more females in the AD group 
(who potentially had smaller lungs), we investigated the relationship between lung size 
and 3He ADC and observed no correlation for 3He ADC with height (r=-.36, p=.18), TLC 
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(r=.33, p=.21) or thoracic cavity volume (r=-.20, p=.45).  Therefore the elevated ADC in 
the AD subjects observed here was not related to lung size, and cannot explain the 
preponderance of female subjects in the AD subgroup.  Consistent with our findings, the 
6MWD in COPD was also previously shown to be lower for FEV1-matched females 
versus males.43   
We took advantage of the fact that 3He MRI diffusion-weighted images were acquired in 
the supine position and measured compression of the dependent lung due to gravity.  
Several sites have reported smaller 3He ADC in the dependent lung (or posterior slices) 
relative to the non-dependent lung,25;44;45 likely due to gravitational compression of the 
parenchyma. In COPD subjects,25;45 this anterior-to-posterior difference is significantly 
smaller and this is thought to be due to regional gas trapping that counteracts 
gravitational compression of the dependent regions.  Here, we observed that these 
gradients were significantly smaller in AD subjects compared to ND subjects suggesting 
that regional gas trapping was greater in the AD subgroup.   
Finally, we showed that 3He ADC was significantly correlated with SGRQ and that 3He 
ADC AP gradients were significantly correlated with the 6MWD.  The significant 
relationships between 3He ADC with respiratory symptoms and exercise capacity suggest 
that in early emphysema, symptomatic changes can go unnoticed in older patients even 
when standardized tests report significant changes in health-related quality of life and 
exercise capacity.  While elevated 3He ADC in asymptomatic ex-smokers was previously 
described,14;15 the imaging-to-exercise capacity and imaging-to-symptoms correlations 
observed here in very early emphysema are novel findings.  The unexpected finding of 
3He ADC anterior-posterior gradient correlations with 6MWD also provides more 
evidence about the role of mild emphysema and regional gas trapping that may together 
lead to exercise limitation even in early disease.  AD ex-smokers also reported SGRQ 
that was not significantly different from the stage I COPD ex-smokers, and worse than 
ND subjects, which supports previous reports of compromised health-related quality of 
life 46 and reduced work capacity in very early disease.47   
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This study was limited by the relatively small number of subjects evaluated, although we 
note that this is the single largest prospective study that directly compared CT, 
symptoms, exercise capacity and 3He MRI in ex-smokers with and without airflow 
obstruction.  We admit that we were surprised to find such a large proportion of 
asymptomatic ex-smokers without airflow limitation and abnormal DLCO in this study.  
This finding raises the important question as to whether this subgroup is atypical or 
perhaps this is a unique finding because “asymptomatic” ex-smokers are rarely 
administered SGRQ or the 6MWT.   Importantly, the selection criteria, manner and 
location for subject recruitment are those we have previously used for the recruitment of 
older ex-smokers, and typical of other studies.  It is possible that in this unique subgroup, 
patients were less likely to recognize and report symptoms.  Our results certainly raise 
many intriguing questions regarding whether these subjects are unusual or whether we 
have simply uncovered a group of older ex-smokers with both unrecognized mild 
emphysema and functional limitations.   
In summary, we evaluated 38 ex-smokers without airflow limitation and 15 ex-smokers 
with COPD.  In the absence of spirometry or CT abnormalities, half of the ex-smokers 
without COPD showed abnormal DLCO and abnormally elevated 3He ADC consistent 
with early or mild emphysema.  These subjects had significantly and markedly worse 
6MWD and SGRQ compared to ex-smokers with normal ADC and DLCO, and worse 
6MWD than subjects with COPD.  These findings provide a better understanding of 
abnormal DLCO in ex-smokers without COPD. 
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CHAPTER 9  
9 Conclusions and Future Directions 
In this final chapter, I will provide an overview and summary of the important findings 
and conclusions of Chapters 2-8.  I will also address the study specific limitations as well 
as general limitations of the hyperpolarized gas MRI studies presented and provide some 
potential solutions.  Finally, based on the findings and limitations discussed, I will 
outline a roadmap for future hyperpolarized gas MRI studies. 
9.1 Overview and Research Questions 
COPD is currently ranked the 4th leading cause of death worldwide,1 and despite the fact 
that the global burden of many other leading causes of deaths are declining,1 COPD 
remains largely under-diagnosed and under-treated.2;3  When COPD is suspected based 
on symptoms, such as dyspnea, chronic cough or sputum production, and/or a history of 
exposure to risk factors,4 airflow limitation is measured using spirometry and the 
presence of a post-bronchodilator FEV1/FVC <0.70 confirms the diagnosis of COPD.4;5  
However, this approach is limited for several reasons.  First, although it is utilized due to 
diagnostic simplicity and ease of use in the primary care setting, the fixed FEV1/FVC cut 
off has been acknowledged to potentially result in an over-diagnosis of COPD in the 
elderly,6 whom are expected to have a decline in lung function due to the normal aging 
process.7  Second, spirometry may be insensitive to mild or early disease changes.8  It is 
well known that the airways < 2mm in diameter are the major site of airway obstruction 
in COPD,9 and therefore disease may accumulate and progress to more severe states 
before detection with FEV1.  Third, chronic airflow limitation in COPD may be caused 
by small airways disease (obstructive bronchiolitis) or parenchyma destruction 
(emphysema) or some mixture of both of these underlying disease mechanisms.  
Therefore, FEV1 alone does not provide any information regarding the underlying disease 
mechanism responsible for the lung function impairment.  Finally, FEV1 measures the 
overall disease burden, and does not provide any information regarding which regions of 
the lung are most severely affected.  Clearly, it is important to identify the disease in its 
earliest possible stages for smoking cessation interventions to slow disease progression.  
For developing and evaluating treatments and interventions it is also critically important 
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to identify the underlying disease mechanisms and target the regional disease.  Therefore, 
it is because of these limitations that there is a continued need for the development of 
sensitive imaging approaches for regional and surrogate measurements of COPD. 
Chest x-ray was the first imaging modality introduced for the evaluation of COPD and 
although it is widely available, inexpensive, and allows visualisation of pulmonary 
structures, because chest x-ray is a planar imaging modality, it is not useful to establish a 
diagnosis of COPD5 and has been shown to be insensitive to early disease stages where 
disease-related structural changes may be subtle.10  Although there is no question that CT 
is superior to conventional x-ray imaging because it provides high resolution anatomical 
images and in three-dimensions, it provides no information regarding lung function and 
the radiation exposure from thoracic CT has been a major concern.  Although CT is not 
routinely recommended, it is useful in the differential diagnosis in COPD where 
concomitant diseases are present.5  Currently, the only clinical means for imaging lung 
ventilation is with lung scinitigraphy, however, it is limited by the need to inhale a 
radioactive substance and has low spatial resolution.  Therefore, a high resolution 
imaging method that does not involve the use of ionizing radiation that can evaluate both 
lung structure and function is needed. 
MRI with the inhaled hyperpolarized gases 3He and 129Xe provides high resolution 
images of pulmonary structure and function and does not require the use of x-rays or 
other ionizing radiation.  The overarching objective of this thesis was to generate 
hyperpolarized gas MRI measurements and measurement tools for the regional 
quantitative evaluation of hyperpolarized gas MRI with sufficient precision to evaluate 
COPD disease progression and treatment response.  The specific research questions 
investigated here included:  1) Are longitudinal changes in 3He MRI measurements in the 
COPD ex-smokers similar to those observed in elderly healthy never-smokers (Chapter 
2)?; 2) Can 3He MRI measurements derived from semi-automated segmentation methods 
be developed that have significantly reduced inter- and intra-observer variability than 
manual measurements and are not statistically significantly different from manual 
measurements (Chapter 3)?; 3)  Can the semi-automated 3He MRI measurements 
developed in Chapter 3 provide the necessary sensitivity as well as precision to detect any 
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potential regional functional lung changes after bronchodilator therapy in COPD subjects 
regardless of spirometry-based responder classification (Chapter 4)?; 4)  Are the regions 
of the lung that were newly ventilated following bronchodilator therapy in the same 
subjects evaluated in Chapter 4 more emphysematous than the remaining lung tissue, and 
can 3He ADC measure significant reductions in regional gas trapping following 
bronchodilator therapy (Chapter 5)?; 5)  Do the different properties of 129Xe gas result in 
significant differences in 129Xe compared to 3He gas distribution measurements in COPD 
(Chapter 6)?; 6)  Are the greater ventilation abnormalities for 129Xe compared to 3He 
MRI in COPD observed in Chapter 6 spatially correlated to emphysema  (Chapter 7)?; 
and, 7) Do ex-smokers with normal spirometry but abnormal DLCO have significantly 
worse symptoms, exercise capacity and 3He MRI ADC than ex-smokers with normal 
DLCO? 
9.2 Summary and Conclusions 
In Chapter 2 we quantitatively evaluated a small group of 15 COPD ex-smokers and five 
healthy volunteers over 2 years using hyperpolarized 3He MRI.  For COPD subjects, 
significant increases in 3He VDP and ADC were detected whereas there was no 
significant change in FEV1; healthy never-smokers showed no significant change in 
imaging or pulmonary function measurements at follow-up.  This finding suggests that 
regional 3He MRI measurements provide adequate sensitivity for detecting COPD 
changes over relatively short time periods, before significant changes in FEV1 can be 
detected.   
In Chapter 3 we aimed to improve intra- and inter-observer variability of 3He MRI 
segmentation by developing a semi-automated segmentation method.  The objective of 
this work was to compare the reproducibility of manual and semi-automated 
segmentation of 3He MRI ventilation measurements in subjects with a range of 
respiratory conditions (i.e., asthma, COPD and cystic fibrosis).  In 15 subjects we found 
that manual measurements and semi-automated measurements of 3He VDV were not 
significantly different and were strongly and significantly correlated. The semi-automated 
VDV had high inter-observer reproducibility and intra-observer reproducibility was 
significantly higher for semi-automated compared to manual measurements.  These 
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findings indicate that 3He MRI semi-automated segmentation provides excellent inter-
/intra-observer precision with high quantitative agreement with manual measurements 
enabling its use in longitudinal and serial studies. 
In Chapter 4 we evaluated a group of 14 COPD subjects using the 3He MRI semi-
automated measurements developed in Chapter 3 prior to and immediately following 
bronchodilator therapy.  Post-salbutamol, we observed significant improvements in 3He 
gas distribution measurements for all subjects.  Although five subjects were classified as 
bronchodilator responders and nine subjects were bronchodilator non-responders 
according to ATS/ERS criteria, there was no significant difference in the magnitude of 
the 3He MRI changes post-salbutamol between responder groups.  These results indicate 
that significant gas distribution improvements occur even in COPD subjects with 
minimal FEV1 or FVC response to bronchodilator therapy which is relevant to our 
understanding of the regional and functional effects of bronchodilators. 
In Chapter 5 we evaluated the same group of COPD ex-smokers evaluated using 3He 
MRI pre- and post-bronchodilator therapy in Chapter 4 using 3He MRI diffusion-
weighted imaging.  Using image registration/segmentation methods developed for 
quantifying ADC regionally, we found that the newly ventilated lung regions did not 
have significantly elevated ADC compared to the lung regions participating in ventilation 
before bronchodilator administration.  We also measured statistically significant 
differences between ADC in the most anterior and most posterior image slices post-
salbutamol, suggesting a reduction in regional gas trapping following bronchodilator 
therapy.  Regional evaluation of tissue microstructure using hyperpolarized 3He MRI 
ADC provides insights into lung alterations that accompany improvements in regional 
3He gas distribution after bronchodilator administration. 
In Chapter 6 we quantitatively compared hyperpolarized 3He and 129Xe MRI acquired 
within a few minutes in 8 healthy volunteers and 10 subjects with COPD, and evaluated 
the correlations between 3He and 129Xe MRI measurements with standard measurements 
of pulmonary function.  We found that there were significant and strong correlations 
between 129Xe and 3He VDP for all subjects, however, for the COPD subjects 129Xe VDP 
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was significantly greater than 3He VDP.  We also found there were similar and strong 
correlation for 129Xe and 3He VDP with FEV1 and for 129Xe and 3He ADC with DLCO.  
These findings suggest that the differences between 129Xe and 3He MRI VDP in COPD 
may reflect differences in the properties of the gases and physiological/anatomical 
abnormalities in COPD that are not seen in healthy volunteers.   
In Chapter 7 we aimed to better understand the morphological determinants for the 
ventilation differences observed between hyperpolarized 3He and 129Xe MRI in COPD 
found in Chapter 6 using 3He MRI diffusion-weighted imaging.  In the same 10 COPD 
ex-smokers in Chapter 6 and using the image registration/segmentation methods for 
quantifying ADC on a regional basis developed in Chapter 5, we found that the mean 
ADC in lung regions accessed by 3He gas only were statistically significantly greater than 
the mean ADC for lung regions accessed by both gases.  We also found that the 
difference between 3He and 129Xe ventilation was significantly correlated with the extent 
of emphysema measured using CT.  These findings indicate that the regions of decreased 
129Xe ventilation were spatially and significantly correlated with regions of increased 
pulmonary emphysema.  Therefore, it is most likely that the highly diffusive and less 
dense and viscous 3He gas may readily access the slower-filling emphysematous lung 
than 129Xe gas during the inhalation period and the breath-hold interval.   
In Chapter 8 we aimed to evaluate well-established clinical, physiological and emerging 
imaging measurements in 38 ex-smokers without airflow limitation and compared them 
with 15 ex-smokers with COPD.  In the absence of spirometry or CT abnormalities, half 
of the ex-smokers without COPD showed abnormally elevated 3He ADC and abnormal 
DLCO consistent with early or mild emphysema.  These subjects had significantly and 
markedly worse exercise capacity and symptoms compared with ex-smokers with normal 
ADC and DLCO, and worse exercise capacity than the subjects with COPD.  These novel 
findings provide evidence for the impact of mild or early stage emphysema and a better 
understanding of abnormal DLCO and hyperpolarized 3He MRI in ex-smokers without 
COPD. 
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9.3 Limitations 
In this section I will discuss some of the most significant limitations of the 3He MRI 
studies presented in Chapters 2-8, although the more detailed description of the study 
limitations were presented within the Chapters.  I will also outline how these limitations 
may be overcome in future studies.  Finally, I will end this section by describing the more 
general limitations common to each of these Chapters and introduce work that has yet to 
be done to overcome these limitations.   
9.3.1 Study Specific Limitations 
In the longitudinal study presented in Chapter 2, we did not acquire more established 
clinical measurements (ie., symptom scores and exercise tests) and therefore it is 
unknown whether these subjects had symptomatic worsening or a decline in exercise 
capacity over the two years that could be attributed to their disease progression.  In 
addition, CT images were also not acquired and therefore our results could not be directly 
compared to more established CT measurements, such as the percentage of low 
attenuation pixels (LAA%) as a measurement of the extent of emphysema or WA% as a 
measurement of airway wall thickness.  Clearly, a direct comparison of CT and 
hyperpolarized 3He MRI measurements in the same subjects would allow for a better 
understanding of the differences in measurement sensitivity these imaging modalities 
provide.  Moreover, the relatively small group of COPD subjects and healthy never-
smokers evaluated, and the relatively short period of follow-up certainly limits the 
applicability of our results.  Also, the comparison of current smokers with COPD, ex-
smokers with COPD and never-smokers may help to establish and directly compare rates 
of lung structural and functional decline.  Another important limitation of this study was 
the use of manual segmentation approaches.  Manual segmentation introduces inter- and 
intra-observer variability and therefore there is the potential for the changes measured 
over time to be due to the measurement error.  Although in this study, two independent 
observers evaluated the measurements at the baseline and the 2 year follow-up time point 
and both demonstrated statistically significant changes, segmentation methods with high 
precision are required to ensure that the changes measured over time represent 
physiological changes.  To overcome these limitations, larger studies of current and ex-
230 
 
smokers with COPD and healthy never-smokers should be followed longitudinally over 
multiple time-points and evaluated using hyperpolarized gas MRI and CT with automated 
segmentation approaches, as well as with symptom scores (St. George’s Respiratory 
Questionnaire) and tests of functional capacity (6 minute walk test).   
In Chapter 3, one of the important limitations of Chapter 2 was addressed.  We developed 
a semi-automated 3He MRI segmentation algorithm that provided excellent inter-/intra-
observer precision with high spatial and quantitative agreement with manual 
measurements enabling its use in longitudinal studies.  However, this segmentation 
algorithm is not without its own limitations.  First, the algorithm is not fully automated 
and therefore it requires some user intervention to remove the trachea as well as to 
manually select landmarks for registration.  Although this segmentation method has clear 
advantages over manual segmentation, automating these steps would clearly improve the 
reproducibility of the technique and reduce segmentation time.  One way to improve this 
technique is the simultaneous acquisition of 3He and 1H MRI,11 which would eliminate 
the registration step and improve reproducibility. 
In Chapter 4 and 5 we evaluated COPD subjects pre- and post-bronchodilator and 
demonstrated significant improvements in gas distribution to regions of the lung that 
were not more emphysematous than the remaining lung participating in gas distribution 
before bronchodilator use, however we did not acquire more established clinical 
measurements to determine whether these improvements in gas distribution were related 
to improvements in symptoms or exercise capacity.  Importantly, although 3He MRI in 
COPD has been shown to have high reproducibility for same-day repeat imaging as well 
as imaging over one week,12 the prospective inclusion of a control group would have 
strengthened the conclusion that the changes post-bronchodilator were directly 
attributable to bronchodilator treatment.  Also, studies have previously demonstrated 
significant changes in CT airway morphology measured in COPD after administration of 
a bronchodilator,13 and therefore acquiring CT in these subjects would have provided 
support for these findings as well as provide a better understanding of the relative 
sensitivities these imaging modalities provide for detecting changes following treatment.  
Also, the relatively small group of COPD subjects and the fact that the analysis was 
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restricted mainly to subjects with stage II and III COPD certainly limits the applicability 
of our results.  To overcome these limitations, larger studies evaluating COPD ex-
smokers randomized to either a control (pre- and post-placebo) or treatment group (pre- 
and post-bronchodilator) should be performed using hyperpolarized gas MRI and CT as 
well as symptom scores and tests of exercise capacity. 
Although Chapter 6 and 7 had the inclusion of CT measurements which were strengths of 
these studies, the acquisition of clinical measurements for direct comparison to 3He and 
129Xe MRI measurements were not acquired and may have aided in determining the 
clinical meaning of the differences observed.  Future studies should aim to evaluate the 
differences between 3He and 129Xe MRI in terms of their relationships with clinical 
measurements as well as the relative sensitivities for detecting improvements following 
treatment or interventions.  Also, there is significant work to be done to better understand 
how the different properties of 3He and 129Xe gas affect ventilation distribution and most 
importantly, what information these differences in ventilation distributions provide us 
regarding the sensitivity of the different gases and their mixtures for detecting airway and 
ventilation abnormalities.  Directly visualizing the distribution of the gases using 
mixtures of 3He and 129Xe with well-controlled viscosities and densities during a breath-
hold in the same subjects using time-resolved imaging sequences, as was recently 
performed with 3He MRI,46 could certainly be utilized to test some of our important 
hypotheses regarding delayed/collateral ventilation within emphysematous lung regions 
in COPD subjects.  These studies should be performed in a larger group of COPD 
subjects with varying stages of disease severity.   
In Chapter 8, we prospectively included 3He MRI, CT, SGRQ and the 6MWT which was 
an important strength of this study.  However, this study was limited by the relatively 
small number of subjects evaluated and due to the small subject number we were unable 
to evaluate sex differences.  Larger studies evaluating subjects with abnormal and normal 
DLCO without airflow limitation is required to evaluate whether emphysema dominates in 
females in early disease and whether females are more susceptible to develop early on-set 
COPD.  Moreover, it would be very important to longitudinally evaluate these subjects to 
determine whether the subjects with abnormal DLCO develop airflow limitation. 
232 
 
9.3.2 General Limitations 
Although in the last chapter of this thesis we prospectively acquired CT, SGRQ and the 
6MWT concurrently with 3He MRI, all of the previous studies in this thesis would have 
been strengthened by the inclusion of these more established measurements.  Moreover, 
although 3He ADC and CT measurements have been directly compared and shown to be 
significantly correlated in COPD subjects14 and asymptomatic smokers,15 there have been 
limited comparisons between 3He ventilation measurements and CT airway wall 
measurements in COPD.16 An important aim of future work should be to directly 
compare 3He MRI functional measurements and CT structural airway measurements in a 
large group of COPD subjects.  
Another important limitation of this work is that we do not have a clear understanding of 
the etiology of noble gas MRI ventilation defects.  It is hypothesized that 3He ventilation 
defects are caused by narrowed or constricted/occluded small airways, however, there is 
also the possibility that the ventilation abnormalities are due to mucous plugs.  Previous 
studies have demonstrated 3He MRI ventilation defect measurements were highly 
reproducible over 7-days in COPD,12 while poor 3He MRI reproducibility was shown in 
cystic fibrosis subjects over 7-days17 which was thought to be related to defective mucus 
clearance.  3He ventilation abnormalities in COPD may also be related to bullous disease 
or severe emphysema which would indicate that 3He ventilation defects reflect structural 
changes in the lung parenchyma rather than changes in the small airways.  Therefore, 
investigating the etiology of hyperpolarized MRI ventilation defects is important for our 
understanding of what this measurement represents in COPD subjects.   
9.4 Future Directions 
9.4.1 Airway Morphology and Hyperpolarized 3He MRI Ventilation 
Defects 
Although 3He MRI ventilation abnormalities in subjects with pulmonary disease has been 
shown to spatially correlate with ventilation abnormalities seen on xenon-133 
scintigraphy18 and correlate significantly with spirometric measurements of airflow 
limitation,19 we still do not have a clear understanding of the etiology of noble gas MRI 
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ventilation defects.  Depending on the respiratory disease, 3He ventilation defects could 
be caused by narrowed or constricted/occluded small airways, mucous plugs, bullous 
disease, severe emphysema or any combinations of these pathologies.  Therefore, 
investigating the etiology of hyperpolarized MRI ventilation defects is important for our 
understanding how this measurement can be used to monitor disease progression and 
response to treatment. 
Clearly, investigating the etiology of hyperpolarized gas MRI ventilation defects will 
require direct comparison with histology to fully uncover the underlying pathologies.  
Studies performed by Jason Woods and Jim Hogg20 have previously compared the 3He 
ADC with histology in explanted human lungs.  Explanted lungs from patients who 
underwent lung transplantation for advanced COPD and donor lungs that were not used 
for transplantation were evaluated using 3He diffusion-weighted MRI and histology.  
Woods and colleagues20 showed that the 3He ADC was significantly correlated with 
histology measurements (mean linear intercept and the surface area to lung volume ratio).  
Importantly, normal control lungs could be more clearly separated from emphysematous 
lungs using the 3He ADC compared to histology measurements, suggesting the 3He ADC 
is very sensitive to mild and moderate emphysematous tissue destruction.  Studies of this 
nature are required comparing 3He static ventilation imaging and histology in the 
ventilation defect regions as well as the regions of hypointense signal.  In addition, it 
would be useful to evaluate the airway dimensions using histology in airways proximal to 
3He ventilation abnormalities to confirm that 3He ventilation defects are due to narrowed 
or constricted/occluded small airways.  
However, before comparison between 3He MRI and histology is performed, comparisons 
between 3He MRI functional airway measurements (i.e., VDP) and CT structural airway 
measurements (i.e., WA%) may begin to tease apart the contributions of these different 
underlying disease changes.  Although in COPD, 3He ventilation defects may be caused 
by disease changes in either the lung parenchyma, the airways, or both, asthma is solely 
an airways disease.  In the following sections I will outline research that could be 
performed using MRI-CT comparisons to better understand the etiology of 3He 
ventilation defects in asthma and COPD. 
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9.4.1.1 CT Airway Morphology and Hyperpolarized 3He MRI 
Ventilation Defects in Asthma 
Asthma is a complex inflammatory disorder of the airways that is characterized by 
airway hyper-responsiveness and variable airflow obstruction.  The primary consequence 
of airway inflammation in asthmatic patients is airway smooth muscle hyperplasia and/or 
hypertrophy.21  This airway smooth muscle hyperplasia and hypertrophy, as well as 
epithelial basement membrane thickening, mucous gland and goblet cell hyperplasia, are 
part of the airway remodeling process that occurs in asthma that contributes to airway 
wall thickening and to a decrease in lumen diameter.   
There have been several studies performed in asthma using CT to investigate the 
relationship between airway remodeling with functional limitation.22-30  These studies 
haves shown strong relationships between CT structural airway measurements with 
inflammation,22;23 spirometry,22-27 and air trapping.22;28-30  Hyperpolarized 3He MRI has 
also been used to visualize heterogeneous and abnormal gas distribution in asthma28;31 
and 3He MRI gas distribution measurements were shown to significantly correlate with 
spirometry28;32;33 and disease severity. 32;34   
Therefore, in asthma the hypothesis is that the functional abnormalities observed with 
3He MRI are related to airways that are remodeled and/or constricted.  Using CT, the 
percentage of the total airway that was airway wall (WA%)  and lumen area can be 
measured35  up to the 6th generation airways.36  By registering hyperpolarized 3He MRI 
and CT acquired in the same asthmatic subjects at the same lung volume, the following 
research questions can be addressed: 
1) In asthmatics following 3He MRI and CT registration, can the CT airways feeding 
the regions of the lung where 3He MRI ventilation defects are observed be 
identified? 
2) Are the CT-derived airway wall measurements greater in asthmatics proximal to 
3He MRI ventilation defects compared to non-asthmatics and asthmatics with no 
ventilation defects? 
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3) Is there a significant relationship between the extent of airway wall thickening 
measured using CT with the volume of the 3He MRI ventilation defects in asthma? 
In a small proof-of-principle study of 18 asthmatics and 5 healthy volunteers, 3He MRI 
and CT in a region-of-interest (ROI) spatially related to 3He MRI ventilation defects was 
acquired, as shown in Figure 1.  Since there were no ventilation defects for the healthy 
volunteers, the CT ROI was selected at random.  CT analysis in the ROI showed that 
WA% was significantly greater (p=.002) and lumen area was significantly reduced 
(p=.02) for the asthmatics in comparison to the healthy volunteers.  Moreover, the extent 
of airway wall thickening measured using CT was significantly correlated with the extent 
of ventilation abnormalities measured using 3He MRI (r=.43, p=.04).  These findings 
provide a better understanding of the underlying airway spatial structure-function 
relationships in asthma and, importantly, suggest that there is a relationship between 
airways that are remodeled and/or constricted and 3He ventilation abnormalities.  
However, larger studies are required to confirm these important findings.  Also, the 
acquisition of whole lung CT images will allow for registration of the three-dimensional 
airway tree to 3He MRI for identification of the specific airway that feeds the 3He MRI 
ventilation defect region.  The identification of 3He MRI functional abnormalities and the 
airways responsible for these functional abnormalities may help guide therapy or airway 
interventions in asthmatic subjects, as well as aid in the evaluation of the airway 
interventions over time. 
 
 
 
 
 
Figure 9-1  CT and 3He MRI in Asthma 
A partial CT (as shown registered to the 3He MR image) was acquired in a region of 
interest that was selected based on the location of hyperpolarized 3He MRI ventilation 
defects for quantification of structural abnormalities.   
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9.4.1.2 CT Airway Morphology and Hyperpolarized 3He MRI 
Ventilation Defects in COPD 
As described above, and in contrast to asthma, 3He ventilation defects in COPD may be 
caused by narrowed or constricted/occluded small airways, mucous plugs, bullous 
disease, severe emphysema or any combinations of these pathologies.  Much of our 
understanding of small airways disease is from the early studies by Hogg and Macklem9 
that identified the small airways as the major site of airflow resistance in COPD.  The 
authors observed that the bronchioles were often narrowed and occluded with mucus 
plugging and defined these changes in the small airways as “small airways disease.”  
More recently, Hogg and colleagues37 evaluated the pathology of the small airways in 
relation to COPD severity, as measured by the GOLD COPD stages.5  These authors 
found that although the degree to which the lumen was filled with mucous significantly 
correlated with COPD severity, the strongest association with progression of COPD from 
GOLD state 0 to GOLD stage IV was with thickening of the airway wall.37  Therefore, it 
is hypothesized that in COPD subjects there is a significant relationship between airway 
wall thickness measured using CT and 3He MRI ventilation abnormalities.  Since bullous 
disease and emphysematous tissue destruction may also result in 3He gas distribution 
abnormalities in the lung, we hypothesize that the relationship between airway wall 
thickness measured using CT and 3He MRI ventilation abnormalities would be strongest 
in subjects without emphysema.  By registering hyperpolarized 3He MRI and CT 
acquired in the same COPD subjects at the same lung volume, the following research 
questions can be addressed: 
1) In COPD following 3He MRI and CT registration, can the CT airways feeding the 
regions of the lung where 3He MRI ventilation defects are observed be identified? 
2) Are the CT-derived airway wall measurements greater in COPD subjects 
proximal to 3He MRI ventilation defects compared to COPD subjects with no 
ventilation defects in the same lung region? 
3) Is there a significant relationship between the extent of airway wall thickening 
measured using CT with the volume of the 3He MRI ventilation defects in COPD? 
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4) Is the relationship between airway wall thickness measured using CT and 3He 
MRI ventilation abnormalities stronger in COPD subjects without emphysema 
compared to COPD subjects with emphysema?   
As part of a larger longitudinal study of 200 ex-smokers with and without COPD, we 
performed a preliminary analysis in the first 21 subjects comparing the functional 
abnormalities measured using 3He MRI with CT structural airway measurements and 
found that there was a significant relationship between 3He MRI VDV with CT airway 
wall area (Aaw) for the 5th generation (r=.72, p=.002) and 6th generation (r=.56, p=.03) 
airways, as shown in Figure 2.16  The quantitative evaluation of 3He MRI functional 
measurements with CT structural measurements in this large group of COPD subjects 
with varying stages of COPD and with varying extents of emphysema will provide a 
better understanding of the underlying disease changes responsible for the 3He ventilation 
defects in COPD. 
 
 
 
 
 
9.4.2 Hyperpolarized 3He MRI and CT COPD Phenotypes 
Although it is well known that the underlying disease mechanisms in COPD is small 
airways disease or emphysema, or some combination of both, patient-specific 
phenotyping continues to be a critical unmet clinical need that may help to guide patient 
therapy and management.   Moreover, spirometry provides only a global measurement of 
Figure 9-2  Evaluation of CT and 3He MRI in COPD 
A preliminary comparison of 3He MRI and CT in COPD subjects (A) showed a 
statistically significant correlation between 3He VDV and CT airway wall area (Aaw) for 
5th (r=.72, r2=.52, p=.002) and 6th (r=.56, r2=.31, p=.03) generation airways (B). 
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lung function and therefore the limitation of spirometry for differentiating these 
underlying pathologies or phenotypes has motivated the use of non-invasive imaging.   
Previous studies have demonstrated that these emphysema and airways disease dominant 
phenotypes can be distinguished by measuring LAA% as a measurement of emphysema 
and the WA% as a measurement of airways disease.35  It has been shown that although 
the combination of CT emphysema and airways measurements had the strongest 
correlation with FEV1, both measurements were also independently correlated.35  
However, thickening and narrowing of the small airways < 2 mm in diameter leads to the 
most important functional limitation in COPD,9 and CT is severely limited in that 
measurement of the small peripheral airways is not possible due to the CT resolution 
limits.   
Hyperpolarized noble gas MR imaging also has the potential to distinguish these distinct 
underlying phenotypes.  The 3He ADC has been shown to correlate significantly with  
histology measurements of emphysema in explanted lungs,20 and shown to correlate 
significantly with CT measurements and DLCO in COPD subjects14 and in asymptomatic 
smokers.15  Although the exact pathology underlying 3He ventilation defects has yet to be 
determined, as described above, significant correlations with xenon-133 scintigraphy18 
and FEV119 have been observed.  It is therefore hypothesized that 3He ventilation defects 
reflect airflow limitation that is caused by small airways disease.  Importantly, we have 
previously demonstrated in a small proof-of-principle study evaluating 20 subjects 
ranging from stage I to stage IV COPD evidence of either 3He VDP or ADC providing 
the main contribution to 3He MRI measured disease, or in other words, these COPD 
subjects showed evidence of having a single dominant disease phenotype.19  It was also 
suggested that the subjects with an imaging dominant phenotype showed decreased 
disease severity as measured by FEV1.  This interesting finding suggests that subjects 
may develop one disease phenotype in the early disease stages and then progress to a 
mixed disease phenotype and more severe disease over time. 
This very interesting hypothesis should be tested in a larger group of COPD subjects, 
ranging from stage I to stage IV disease.  The acquisition of CT for these subjects would 
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also allow for the relationship between 3He MRI and CT measurements of airways and 
emphysema phenotypes to be directly compared.  Importantly, the relationship between 
these imaging phenotypes with pulmonary function test measurements, symptom scores, 
and measurements of exercise tolerance would provide important information regarding 
the functional effect these underlying disease phenotypes have on the subject.  Also, 
these subjects should be followed longitudinally to determine how and if phenotypic 
dominance occurs in early disease and progresses to more severe mixed disease over 
time.   
9.4.3 Hyperpolarized 3He MRI Phenotypes of COPD: Relationship to 
Exacerbations 
In Appendix B we reported serial hyperpolarized 3He MRI over a four year period in a 77 
year old COPD ex-smoker prior to and following treatment for an acute exacerbation 
(AE) of COPD.  In this case study, 3He MRI showed improvements in gas distribution 
prior to improvements reflected by FEV1.  Importantly, it was also suggested that this 
subject had a worsening of 3He gas distribution 6 months prior to the exacerbation, 
although there was no change in the subjects clinical status until approximately one 
month before hospitalization when the subject complained of symptoms.  We suggested 
that 3He MRI may have reflected regional pulmonary decline before, or even in the 
absence of changes in FEV1.  From this case report several hypotheses and questions 
arose related to the time-course of COPD exacerbations that should be tested in a larger 
study that follows COPD subjects longitudinally.  The research questions that should be 
tested are: 
1) Is there a relationship between symptomatic and 3He MRI improvements following 
therapy, before changes in FEV1 are measured? 
2) Do COPD patients with specific imaging phenotypes have a propensity for increased 
exacerbation frequency? 
In a study currently underway, we aimed to determine if subjects that experienced an AE 
prior to or following hyperpolarized 3He MRI had a greater propensity for a specific 
imaging phenotype in comparison to subjects that did not experience an AE, and whether 
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there was a relationship between these imaging measurements with symptoms and 
functional limitation.  Based on the findings of the case report presented in Appendix B 
the demonstrated VDP worsening prior to an AE, we hypothesized that subjects that 
experienced an AE following the 3He MRI study would have significantly worse VDP 
than subjects that did not experience an AE.  To date 94 COPD subjects have underwent 
3He MRI, CT, spirometry/plethysmography, the St. George’s Respiratory Questionnaire 
(SGRQ) and the six-minute walk test (6MWT).  We defined an AE as a worsening of 
COPD symptoms that required hospitalization and was determined by examining patient 
records for up to 2 years prior to or following the study visit.  Subjects were divided into 
three groups:  no AE, AE prior to study visit and AE following study visit.  In this 
preliminary investigation we found that of the 94 COPD subjects evaluated, 8 subjects 
experienced a single AE 13±9 months prior to the study visit and 10 subjects experienced 
a single AE 7±8 months following the study visit.  Interestingly, we showed those 
subjects that experienced an AE following the study visit reported a significantly worse 
SGRQ score (p=.05), 6MWD (p=.02) and 3He VDP (p=.02) than the subjects that did not 
experience an AE (Figure 3), lending support to the hypothesis that 3He VDP may 
worsen prior to exacerbations in COPD.  However, the 2 year follow-up period is not 
complete for most of the COPD subjects evaluated and therefore it is important to 
continue to follow these subjects to determine the frequency of exacerbations as well as 
to determine if 3He MRI gas distribution improves following exacerbation treatment.  
This finding may have important implications for future COPD imaging studies 
evaluating the association between COPD phenotypes and exacerbation risk.  Clearly, 
predicting those COPD patients that are at the greatest risk for acute exacerbations will 
enable the targeting of these individuals for preventive therapy, or at least more 
aggressive monitoring.   
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9.4.4 Hyperpolarized Noble Gas MRI of Pediatric Lung Disease 
A major strength of MRI is that it does not require the use of ionizing radiation and 
provides regional structural and functional information simultaneously.  This is important 
for all longitudinal studies of lung disease, but this is especially the case in children with 
chronic life-threatening pulmonary disease.  Therefore, hyperpolarized noble gas MRI 
can be used to measure lung structure and function in young subjects and at multiple 
time-points.  However, despite the fact that the imaging procedure has been demonstrated 
to be feasible and well-tolerated in healthy non-sedated infants and children38;39 and 
infants and children with asthma and cystic fibrosis (CF),38;40-44  most 3He and 129Xe MRI 
studies to date have been performed in adults and experience in children has been largely 
limited to CF.  There is clearly considerable potential for hyperpolarized gas MRI to be 
used to evaluate CF and asthma, as well as other chronic lung diseases in the pediatric 
population, and therefore larger MRI studies in children are required.   
Figure 9-3  3He MRI static ventilation images and ADC maps for a representative 
subject that had an exacerbation and a representative subjects that did not have an 
exacerbation. 
Blue arrows indicate the large ventilation defects visually apparent in the subject that 
experienced an exacerbation. 
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9.4.4.1 Hyperpolarized Noble Gas MRI in Pediatric Cystic Fibrosis 
Although hyperpolarized 3He MRI experience is limited in the pediatric population and 
only moderate correlations have been shown between 3He MRI and spirometry in 
pediatric CF subjects,42;45 possibly due to the fact that children have difficulty performing 
the manoeuvres, 3He MRI has demonstrated regional changes in gas distribution in 
children following chest physiotherapy,43;44 following treatment with a bronchodilator 
and after mechanical airway clearance treatment.45   More recently, dramatic 
improvements in 3He gas distribution were visualized in children with CF following 
treatment with Ivacaftor, the first investigation to use hyperpolarized gas MRI to assess 
an investigational CF drug.40;46 
Although pulmonary function tests are still the mainstay for monitoring disease status and 
progression, and FEV1 is still the primary endpoint used and accepted by regulatory 
authorities for clinical trials of CF therapies, the limitations of standard pulmonary 
function test measurements and the clear advantages to using sensitive imaging 
biomarkers for evaluating the efficacy of novel therapies suggest this is likely a target 
application for hyperpolarized gas MRI.  It is clear from these previous 3He MRI studies 
in CF that the advantages of MRI for the quantitative, sensitive and regional evaluation of 
lung structure and function intensively in serial and longitudinal studies necessitates 
further investigation of pulmonary MRI in pediatric therapy studies. 
9.4.4.2 Hyperpolarized Noble Gas MRI in Pediatric Asthma 
Asthma is the most common chronic disease in the pediatric population and the 
prevalence of asthma continues to rise.47  Despite advances in drug therapy, a significant 
proportion of health care expenditure, morbidity and excess mortality are related to a 
small but significant number of patients with severe asthma symptoms that remain 
unresponsive to current treatments.  The development of new and improved asthma 
therapies and interventions are required to improve asthma symptoms and reduce the 
morbidity and mortality associated with asthma.  Moreover, the development of new 
therapies is going to require evaluation using sensitive tools that provide useful 
information regarding the effects of treatment on lung structure and function.  
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In preliminary studies utilizing hyperpolarized 3He MRI in asthmatics with abnormal 
spirometry, ventilation defects were observed that resolved and reappeared over a three 
week period.48  Other studies using 3He MRI in asthmatics also demonstrated 3He 
ventilation defects and showed that these defects increased in number and extent 
following an exercise challenge and methacholine administration.49 Importantly, 3He 
ventilation defect measures correlated significantly with spirometry32;49 and disease 
severity.32  It has also been demonstrated that many of the ventilation defects visible with 
3He MRI persist or recurred in the same location over time or with repeated 
bronchoconstriction,50;51 suggesting airway abnormalities are regional in nature.   
In a study by Fain and colleagues28 comparing hyperpolarized 3He MRI with chest CT in 
asthmatics, regions of the lung with 3He MRI ventilation defects were shown to spatially 
correlate with regions of hyperlucency on CT.  The authors also obtained inflammatory 
markers using bronchoscopy in these ventilation defect regions and detected an increase 
in inflammatory cell counts,28 suggesting these regional ventilation defects are likely 
related to airway inflammation and obstruction.  Another recent study52 showed that 3He 
ventilation defect measurements correlated significantly with specific airway resistance, 
symptoms and exhaled nitric oxide, also lending support to the notion that ventilation 
defects are likely related to inflammation and narrowing/obstruction of the airways. 
From this work it is clear that hyperpolarized gas MRI has many potential clinical 
applications in asthma.  The direct visualization of ventilation defects that recur in the 
same locations following provocation may help guide airway treatments and 
interventions to the regions within the lung or the specific airways that are hyper-
responsive.  However, nearly all 3He MRI studies have been performed with adult asthma 
subjects and therefore further studies evaluating regional 3He MRI structural and 
functional measurements at baseline and following provocation and treatment are 
required in the pediatric population.  
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9.4.4.3 Hyperpolarized Noble Gas MRI:  Lung Growth and 
Development  
Importantly, studies in healthy pediatric subjects showed that 3He MRI ADC increases 
with age,39 suggesting that diffusion-weighted MRI can be used to assess lung growth 
and alveolar enlargement.  Lung growth was also recently investigated using 
hyperpolarized 3He diffusion-weighed MRI by Butler and colleagues53 in a 33-year-old 
woman and demonstrated that this woman had an apparent 64% increase in the number of 
alveoli in her left lung 15 years following a right-sided pneumonectomy.  These very 
exciting studies suggest that diffusion-weighted MRI has the potential to evaluate lung 
growth and development in children and in particular, it may be used to evaluate non-
invasively and in vivo chronic lung diseases in children that affect the development of 
normal lung microstructure, such as bronchopulmonary dysplasia (BPD).  Although 
diffusion-weighted MRI has yet to be exploited in larger studies of pediatric diseases 
such as BPD, the promise remains for a non-invasive measurement that may regionally 
and longitudinally assess normal and abnormal lung growth and development. 
We believe that these important studies in children demonstrate the feasibility of 
hyperpolarized gas MRI to non-invasively measure disease morphological and functional 
consequences and to explore disease pathophysiology in vivo to potentially provide an 
improved understanding of pediatric lung disease.   
9.5 Significance and Impact 
Although FEV1 remains the primary outcome measure for assessing COPD progression 
and response to treatment, it is well recognized that COPD is a multi-component disease 
and, while FEV1 has its strengths, there is a continued and urgent need for additional 
pulmonary biomarkers for assessing COPD outcomes.  Here, we have demonstrated that 
regional 3He MRI measurements provide adequate sensitivity for detecting two important 
outcomes in COPD, namely evaluating significant changes over relatively short periods 
of time and evaluating changes following treatment.  Importantly, these 3He MRI 
measurement changes occurred in the absence of FEV1 changes, thus suggesting that 3He 
MR imaging biomarkers may have increased sensitivity to measuring outcomes in 
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COPD.  In this regard, we also identified ex-smokers with 3He MRI evidence of 
emphysema, symptoms and reduced exercise capacity with “normal” spirometry.  Taken 
together, these findings suggest that 3He MRI may provide the opportunity for measuring 
early disease changes in subjects with symptomatic changes, as well as measuring 
longitudinal and treatment changes, in the absence or possibly before changes in FEV1. 
In order to measure these important COPD outcomes, hyperpolarized gas MRI 
measurement tools for the regional quantitative evaluation with sufficient precision were 
needed.  We developed reproducible and robust hyperpolarized gas MRI 
registration/segmentation methods for generating measurements of pulmonary gas 
distribution that could be applied across many respiratory conditions, and also be used for 
larger scale pulmonary functional MRI studies.  We also developed image analysis tools 
for hyperpolarized gas diffusion-weighted MRI that provided a way to evaluate regional 
lung microstructure, and provided important insights into pulmonary structure-function 
on a regional basis.  These important findings indicate that hyperpolarized gas MRI can 
be used to improve our understanding of lung structural and functional changes in COPD. 
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APPENDIX A  
In Appendix A we aimed to establish imaging measurement reproducibility in adult cystic 
fibrosis subjects over a short period of time (7 ± 2 days) in the absence of therapeutic 
intervention using hyperpolarized 3He MRI.   
The contents of this Chapter have been previously published in Academic Radiology and 
permission to reproduce the article was granted by John Wiley and Sons and is provided 
in Appendix C. 
M Kirby, S Svenningsen, H Ahmed, N Paterson and G Parraga.  Quantitative Evaluation 
of Hyperpolarized Helium-3 Magnetic Resonance Imaging of Lung Function Variability 
in Cystic Fibrosis. Acad. Radiol. 2011; 18(8):1006-13. 
A Quantitative Evaluation of Hyperpolarized Helium-3 
Magnetic Resonance Imaging of Lung Function 
Variability in Cystic Fibrosis 
A.1 Introduction 
High resolution computed tomography (HRCT) is currently the gold standard imaging 
method for providing quantitative morphological measurements of lung abnormalities 
associated with cystic fibrosis (CF).  Scoring systems have been developed,1 for 
radiological interpretation of various pulmonary abnormalities, including bronchiectasis, 
mucous plugging, airway wall thickening, and air trapping.  Such scoring systems 
correlate with chest radiograph scores,1 pulmonary function tests,2 and clinical findings3 
and have been shown to be more sensitive than spirometry for detecting disease 
worsening.4  Despite these important advantages, the risk associated from repeated 
radiation exposure, particularly in monitoring disease progression and serial imaging in 
therapy studies, limits the use of CT in CF.  In addition, the relationship between lung 
functional changes and the structural, anatomical and morphological changes reflected by 
quantitative HRCT is still not completely understood.    
Hyperpolarized Helium-3 (3He) magnetic resonance imaging (MRI) provides high spatial 
and temporal resolution images of both lung structure and function5-10 without ionizing 
radiation.  Regional ventilation abnormalities can be clearly visualized as decreased or 
absent 3He signal in the lung that can be evaluated using quantitative scoring systems or 
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volumetric approaches.9;11   These measurements are sensitive to the pathological 
changes that accompany CF,12-18 have high same-day reproducibility in pediatric CF 
patients,18 and changes are clearly visible despite clinically normal spirometry results.12  
Because of previous same-day reproducibility18 and treatment12;16;18 studies in CF 
patients, we hypothesized that 3He MRI would provide the necessary and sufficient 
spatial and temporal sensitivity to detect day-to-day changes in lung function.   
There is an urgent requirement for precise and sensitive measurements or surrogates that 
can be used to determine pulmonary response to treatment and to monitor disease 
progression; imaging methods may be ideally positioned to provide some of these 
measurements.  Establishing imaging measurement reproducibility over time in the 
absence of therapeutic intervention is essential for future studies that aim to evaluate 
treatment changes.  Accordingly, the objective of this study was to evaluate lung function 
over a relatively short period of time (7 ± 2 days) using spirometry, plethysmography and 
hyperpolarized 3He MRI in adult CF patients with moderate lung function.  To our 
knowledge, this is the first reported study that quantitatively evaluates short-term lung 
functional variability in CF using 3He MRI.    
A.2 Materials and Methods 
A.1.1 Subjects 
Study subjects provided written informed consent to the study protocol approved by the 
local research ethics board and Health Canada.  The study was compliant with the 
Personal Information Protection and Electronic Documents Act (PIPEDA, Canada) and 
the Health Insurance Portability and Accountability Act (HIPAA, USA).  Subjects 
between the ages of 18 and 45 years, without claustrophobia or MRI contraindications 
and with baseline FEV1%pred > 60% at their last clinical visit were enrolled.  Study 
participation was also limited to those CF patients experiencing no more than three 
previous exacerbations (change in medication or hospitalization for CF) within the last 12 
months, as an indication of appropriate disease control.  A baseline and 7-day repeat 
testing paradigm was chosen to differentiate the day-to-day changes common in CF from 
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longer term alterations in lung physiology that accompany CF lung disease progression.  
All subjects were evaluated using spirometry and plethysmography 30 minutes prior to 
MRI and all subjects were evaluated on two separate occasions within 7 ± 2 days.  Digital 
pulse oximetry was used to measure arterial oxygen saturation (Sa02) for all subjects 
during scanning sessions.  An adverse event was considered to have occurred when Sa02 
decreased below 88% at any time during the scanning session.  Study withdrawal was 
required when Sa02 decreased to 80% for 10 seconds or longer.  
A.1.2 Pulmonary Function Tests 
Spirometry was performed using an ndd EasyOne spirometer (ndd Medizintechnik AG, 
Zurich, CH) reporting forced expiratory volume in 1 second (FEV1) and forced vital 
capacity (FVC) with a minimum of three acceptable spirometry maneuvers with the best 
FEV1 and FVC selected for analysis according to the American Thoracic Society (ATS) 
guidelines.  Total lung capacity (TLC), inspiratory capacity (IC), residual volume (RV), 
functional residual capacity (FRC), and diffusing capacity of carbon monoxide (DLCO) 
were measured using body plethysmography (MedGraphics Corporation, 350 Oak Grove 
Parkway St. Paul, MN USA).   
A.1.3 Image Acquisition 
MRI was performed on a whole body 3.0 Tesla (3T) Excite 12.0 MRI system (GEHC, 
Milwaukee, WI USA) with broadband imaging capability as previously described.10  All 
helium imaging employed a whole body gradient set with maximum gradient amplitude 
of 1.94 G/cm and a single channel, rigid elliptical transmit/receive chest coil (RAPID 
Biomedical GmbH, Wuerzburg Germany).  The basis frequency of the coil was 97.3 
MHz and excitation power was 3.2 kW using an AMT 3T90 RF power amplifier (GEHC, 
Milwaukee WI USA).  Subjects were positioned supine in the MR scanner and Sa02 was 
used to monitor arterial blood oxygenation levels during all MRI maneuvers.  For both 1H 
and 3He MRI, subjects were instructed by a pulmonary function technologist to inhale a 
gas mixture from a 1.0 L Tedlar bag (Jensen Inert Products, Coral Springs, FL) from 
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FRC, and image acquisition was performed under breath-hold conditions– a period of 8 
to 15s.   
Coronal proton (1H) MRI was performed prior to hyperpolarized 3He MRI with subjects 
scanned during breath-hold after inspiration of a 1.0 L 4He/N2 gas mixture using the 
whole body radiofrequency (RF) coil and 1H fast spoiled gradient recalled echo sequence 
(16s total data acquisition, repetition time (TR) / echo time (TE) / flip angle = 4.7 ms / 
1.2 ms / 30o, field-of-view (FOV) = 40 x 40 cm, matrix 256 x 128, 14 slices, 15 mm slice 
thickness, 0 gap), as previously described.10   
Prior to 3He MRI, a polarizer system (HeliSpin™, GEHC, Durham, NC) was used to 
polarize 3He gas to 30-40 %.  As previously described,10 hyperpolarized 3He MRI coronal 
static ventilation images were acquired in breath-hold after inspiration of a 1.0 L 3He/N2 
mixture (does 5 mL/kg body weight) (14s data acquisition, TR / TE / flip angle = 4.3 ms / 
1.4 ms / 7o, bandwidth = 31.25, FOV = 40 x 40 cm, matrix 128 x 128, 14 slices, 15 mm 
slice thickness, 0 gap). 
A.1.4 Image Analysis 
All 3He measurements were repeated four times to estimate observer reliability according 
using the approximation method developed by Walter et. al. 19  All measurements were 
performed by a single observer blinded to subject and time-point with both subjects and 
time-points randomized between each of the four repeated measurement trials to reduce 
any potential memory bias.  Additionally, each randomized time-point was analyzed 
independently and one day apart to minimize observer memory bias. 
The signal-to-noise ratio (SNR) for all images acquired was determined by calculating 
the mean signal intensity value within a 5 x 5 voxel region of interest (ROI) for four 
representative ROI within the lung parenchyma, and dividing by the standard deviation of 
the mean signal intensity values for noise inside a ROI of the same size within the image 
background where there was no lung structure.  SNR was determined for each slice and 
then averaged to obtain a single SNR value for each subject and time-point.  
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3He MRI pulmonary ventilation segmentation was performed with a semi-automated 
method generated using MATLAB R2007b (The Mathworks Inc., Natick, MA, USA), as 
previously described.20  Briefly, 3He MRI ventilation images were evaluated using a k-
means cluster algorithm,21 similar to previously described methods for 3He MRI 
segmentation,22-24 to classify the 3He MRI pixel intensity values into clusters ranging 
from 1 to 5, representing gradations of ventilation from unventilated to hyperventilated.  
To obtain the external contour of the thoracic cavity to differentiate ventilation defects 
from the edge of the lung, 1H MR images were segmented using a seeded region growing 
algorithm25 and registered to the segmented 3He MR ventilation images as previously 
described.26  The segmented 1H thoracic cavity volume was used to generate ventilation 
defect percent (VDP),9 representing a normalized 3He ventilation defect volume (VDV10 
or volume of cluster 1) for the lung. 
A.1.5 Statistical Methods 
Mean VDV and VDP for baseline and 7-days was calculated using the mean and standard 
deviation (SD) of four repeated measurements.  The smallest detectable difference 
(SDD), defined as the smallest difference that can be measured with prospectively 
determined confidence that is not due to measurement error (variability), was calculated 
using the baseline repeated 3He measurements according to Eliasziw et. al.27 and shown 
in Equation A1: 
raSEMzSDD int2α≥  (1) 
where αz  is 1.96 corresponding to a significance level of α =.05 and raSEM int  is the 
standard error of measurement due to intra-observer variability and is calculated as 
shown in Equation A2: 
2
int ˆ eraSEM σ=  
(2) 
where 2ˆ eσ  is the intra-observer repeated measures variance.  Multivariate analysis of 
variance (MANOVA) was performed for comparison of baseline and 7-day pulmonary 
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function measurements using SPSS 16.00 (SPSS Inc., Chicago, IL, USA LEAD 
Technologies, Inc., Chicago, IL).  For 3He MRI measurements, a three-way mixed design 
repeated measures analysis of variance (ANOVA) was used to determine the interactions 
between time-point (baseline and 7-day), repetition (four repeated measurements) and 
subject using SPSS 16.00.  The agreement between time-points for both pulmonary 
function and 3He MRI measurements was evaluated using Bland-Altman plots28 
generated using GraphPad Prism version 4.00 (GraphPad Software Inc, San Diego, CA, 
USA).  Linear regression (r2) and Spearman correlation coefficients (r) were used to 
determine the relationship between pulmonary function and 3He MRI measurements 
using SPSS 16.00.  A sample size ( n ) calculation29 was also performed to determine the 
number of subjects required in a controlled trial to detect a significant difference (δ) for 
VDP between baseline and follow-up with 95% confidence (α = 0.05, 96.1=αZ ) and 
80% power ( 20.0=β , 84.0=βZ ), according to Equation A3: 
2
22)(2
δ
βα DiffSDZZn
+
=  
(3) 
where DiffSD  is the standard deviation of the difference between baseline and follow-up.  
In all statistical analyses, results were considered significant when the probability of 
making a Type I error was less than 5% (p < 0.05).   
A.3  Results 
The demographic characteristics for 12 CF subjects enrolled (n=5 males, mean 
age=26±8, BMI=24±4) are provided in Table A1.  The first study visit was in September 
2007 and the last visit was in January 2010.  All subjects completed both scanning 
sessions and there were no serious or severe breath-hold-related or other adverse events 
reported, nor were there any other adverse events that required subjects to withdraw from 
the study.  Approximately one year after subject scanning, a single subject (Table A3, 
subject 1, female, age 24) died due to respiratory complications related to underlying CF.  
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Table A1 Subject Demographics 
 Subjects (±SD) [range] 
(n= 12) 
Age yrs 26 (8) [18-41] 
Male Sex 5 
BMI kg·m-2 24 (4) [18-30] 
FEV1 L 2.68 (0.66) [1.70-3.58] 
FEV1%pred 72 (14) [50-96] 
FVC L 3.87 (0.97) [2.87-5.65] 
FVC %pred 87 (12) [74-103] 
FEV1/FVC % 70 (12) [45-87] 
FEV1/FVC %pred 84 (13) [54-99] 
TLC L  6.52 (1.22) [5.15-8.95]† 
TLC %pred 108 (12) [96-128] 
IC L 2.98 (0.63) [1.88-3.67]† 
IC %pred 101 (20) [80-149]† 
FRC L 3.60 (1.04) [2.05-4.71]† 
FRC %pred 116 (28) [77-156]† 
RV L 2.51 (0.79) [1.51-3.82]† 
RV %pred 168 (41) [122-232]† 
DLCO 30.64 (6.39) [21.49-40]‡ 
DLCO%pred  105 (18) [87-138]‡ 
BMI=Body Mass Index, DLCO=Carbon Monoxide Diffusion Capacity of the lung, 
FEV1=Forced Expiratory Volume in 1s, FRC=Functional Residual Capacity, FVC= 
Forces Vital Capacity, IC= Inspiratory Capacity, %pred=Percent Predicted, RV= Reserve 
Volume, SD=Standard Deviation, TLC=Total Lung Capacity, ‡n=6, †n=9. 
Table A2 shows mean baseline and 7±2 day pulmonary function and 3He MRI 
measurements and Table A3 shows a subject listing of all pulmonary function and 3He 
MRI measurements for all subjects.  For baseline repeated measurements, the intra-
observer CV for both VDV and VDP was 0.04.  Based on the baseline intra-observer 
variance, the SDD or the minimum change in VDV and VDP that could be measured 
confidently in individual subjects that was not due to technological or observer 
measurement variability (measurement error) was 120ml and 2%, respectively.  As 
shown in Table A3, 8 of 12 subjects showed changes in both VDV and VDP over 7 days 
greater than or equal to the SDD.  
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Table A2 Baseline and 7-day pulmonary function and 3He MRI measurements 
 
Parameter 
Baseline 
(n=12) 
7-day 
(n=12) 
Mean 
Difference [p]* 
Pulmonary Function Measurements 
FEV1 (L) (±SD) 2.68 (0.66) 2.69 (0.54) -0.01 (0.19) [NS] 
FEV1%pred (±SD) 72 (14) 72 (12) 0 (6) [NS] 
FVC %pred (±SD) 87 (12) 86 (10) 0 (4) [NS] 
FEV1/FVC (± SD) 70 (12) 71 (11) -1 (4) [NS] 
TLC %pred (±SD) 108(12)† 113 (16)† -5 (7) [NS] 
IC %pred (±SD) 101 (20)† 103 (19)† -2 (14) [NS] 
FRC %pred (±SD) 116 (29)† 125 (32)† -9 (7) [NS] 
RV %pred (±SD) 168 (41)† 176 (58)† -8 (37) [NS] 
DLCO (%pred) (± SD) 106 (18)‡ 111 (13)‡ -5 (8) [NS] 
Hyperpolarized 3He MRI 
VDV L (±SD) 1.06 (0.56) 0.93 (.59)* 0.13 (0.25) [<.0001] 
VDP % (±SD)  20 (10) 17 (10)* 3 (4) [<.0001] 
DLCO=Carbon Monoxide Diffusion Capacity of the lung, FEV1=Forced Expiratory 
Volume in 1s, FRC=Functional Residual Capacity, FVC=Forces Vital Capacity, 
IC=Inspiratory Capacity, %pred=Percent Predicted, RV=Reserve Volume, SD=Standard 
Deviation, TLC=Total Lung Capacity, VDP=Ventilation Defect Percent, 
VDV=Ventilation Defect Volume, ‡n=8, †n=9. 
*Significance of difference (p<.05) was determined using a repeated measures ANOVA. 
There was no significant difference for pulmonary function measurements (p=.56) 
between time-points.  As shown in Table A2, significant differences were detected after 
7-days for both 3He VDV (130 ± 250ml, p<.0001) and VDP (3%± 4%, p<.0001), and a 
significant interaction between the changes measured after 7-days and subject was also 
observed (p<.0001, Figure A1), indicating that not all subjects showed a change over this 
time frame.  To underscore this point, Figure A1 shows center slice 3He ventilation 
images for three representative subjects at baseline and 7-days with subject numbers that 
correspond to the subject numbers shown in Table A2.  For subject (S1), very little 
change in 3He gas distribution is observed between the time-points, however the change 
in gas distribution after 7-days is readily apparent in subjects S2 and S3.  However, it is 
important to note that after conservatively comparing the 95% confidence intervals (CI) 
for baseline and 7-day 3He measurements, baseline and 7-day 95% CI overlapped for 
both VDV (baseline: [95% CI, 0.74L-1.38L], 7-day: [95% CI, 0.60L-1.26L]) and VDP 
(baseline: [95% CI, 15%-25%], 7-day: [95% CI, 12%-23%]).  Image signal-to-noise ratio 
(SNR) for all baseline and 7-day image pairs was not statistically significantly different 
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(p=.47), nor was there a significant relationship between the change in SNR and the 
change in VDV (r=-.29, p=.35).   
 
 
 
Figure A1 Baseline and 7-day 3He MRI static ventilation images for three representative CF 
subjects. 
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Shown in Figure A2, Bland-Altman analysis was also performed to evaluate differences 
between time-points for FEV1 (mean difference ( d )=0.01L, 95% CI =-0.37-0.39L) and 
no systematic bias was detected and differences were within the 95% limits of agreement 
for all but one subject.  However, Bland-Altman analysis also showed 7-day differences 
for 3He VDV ( d =-0.13L, 95% CI =-0.63–0.36L) and VDP ( d =-3%, 95% CI =-11–5%) 
with large 95% limits of agreement between the measurements.   
Figure A2 Bland-Altman plots of the 
differences between baseline and 7-day 
measurements. 
Scatterplots show the differences between 
baseline and 7-day FEV1, VDV and VDP 
for all subjects, against their mean. The 
mean difference (±SD) was 0.01L 
(0.19L) for FEV1 (lower limit=-.37L, 
upper limit=.39L) (A), -0.13L (0.25L) for 
VDV (lower limit=-.63L, upper 
limit=.36L) (B), and -3% (4%) for VDP 
(lower limit=-11%, upper limit=5%) (C).  
Solid lines indicate the mean difference 
and dotted lines indicate the 95% limits 
of agreement. 
262 
 
Table A3 shows the relationship between the baseline and 7-day pulmonary function and 
3He MRI measurements.  Figure 3 also shows the significant and moderate Spearman 
correlation between FEV1%pred and VDV (r=-.65, p=.001) and VDP (r=-.68, p<.0001).  
The relationship between baseline and 7-day measurements (Figure A3) was evaluated 
and showed a significant correlation for FEV1%pred (r=-.89, p<.0001), 3He VDV (r=.85, 
p=.001), and VDP (r=.94, p<.0001).  There were no significant correlations between the 
baseline and 7-day change in pulmonary function and the change in 3He measurements. 
Table A3 Subject listing of baseline and 7-day pulmonary function and hyperpolarized 
3He MRI measurements 
 Subject 
 1 2 3 4 5 6 7 8 9 10 11 12 Mean (± SD) 
Pulmonary Function Measurements 
Baseline             
FEV1 (L) 2.11 3.55 1.70 2.53 2.83 3.58 3.56 2.79 2.22 2.28 1.93 3.04 2.68 (0.66) 
FEV1%pred 50 78 54 74 79 81 79 82 69 55 61 96 72 (14) 
FVC (L) 3.41 4.87 3.06 2.92 3.55 5.65 4.88 3.52 2.87 5.02 2.96 3.77 3.87 (0.97) 
FVC%pred 65 89 79 75 87 103 90 90 74 103 81 103 87 (12) 
7-day             
FEV1 (L) 2.17 3.39 2.2 2.7 2.66 3.46 3.4 2.69 2.36 2.32 1.85 3.04 2.69 (0.54) 
FEV1%pred 51 74 69 79 75 78 75 79 73 56 58 96 72 (12) 
FVC (L) 3.69 4.75 3.39 3.05 3.49 5.31 4.82 3.34 3.05 4.87 2.83 3.76 3.86 (0.85) 
FVC%pred 70 87 87 78 85 96 89 86 79 100 77 102 86 (10) 
3He MRI Measurements 
Baseline             
VDV (L) 1.70 1.49 1.15 0.52 0.62 1.79 0.87 0.38 0.98 1.38 1.71 0.15 1.06 (0.56) 
VDP (%) 30 24 22 13 13 27 17 10 21 24 34 3 20 (9) 
7-day             
VDV (L) 1.80 1.16 1.61 0.30 0.46 1.31 0.52 0.33 0.65 1.36 1.51 0.14 0.93 (0.59) 
VDP (%) 30 18 27 7 10 25 10 8 11 22 31 3 17 (10) 
FEV1=Forced Expiratory Volume in 1s, FVC= Forced Vital Capacity, %pred=Percent 
Predicted, VDP=Ventilation Defect Percent, VDV=Ventilation Defect Volume 
 
We generated sample sizes required to detect significant differences in VDP in an 
interventional study.  Instead of assuming there would be no change in VDP over time in 
the absence of treatment, we used the mean difference over 7 days and the standard 
deviation of that difference measured in this study to generate sample sizes for the use of 
VDP.  Accordingly, to detect a significant 5%/7%/10% absolute change in VDP for a 
treatment group would require 60/15/5 subjects per group. 
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A.4  Discussion 
Functional imaging methods such as 3He MRI provide a way to perform intensive serial 
studies in individual patients to monitor therapy effects and disease changes and as well 
as repeated measurements in patient groups for therapy trials.  However, before 3He MRI 
measurements can be used as a complement to established endpoints, measurement 
sensitivity and precision must be determined.  In order to determine and compare the 
Figure A3 Relationship between baseline and 7-day for FEV1, 3He VDV and VDP. 
Baseline is significantly correlated with 7-day for FEV1 (r=-.89, p<.0001, r2=.84, p<.0001, 
y=0.79x+15) (A) and 3He VDP (r=.94, p<.0001, r2=.84, p<.0001, y=1.0x-3) (B).  Baseline 
and 7-day FEV1 is significantly correlated with 3He VDV (r=-.65, p=.001, r2=.49, 
p=.0001, y=-0.03x+3.23) (C) and VDP (r=-.68, p<.0001, r2=.55, p<.0001, y=-.54x+59) 
(D).  Dotted lines indicate the 95% confidence intervals. 
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variability of lung function measurements in CF, we evaluated 12 adult CF subjects with 
moderate lung function, using spirometry, plethysmography and 3He MRI, twice over 7 
days.  We made a number of important observations and report: 1) the SDD in 3He VDV 
and VDP for individual subjects, 2) highly correlated baseline and 7-day VDV and VDP 
but significant change in 3He MRI VDV and VDP, not reflected by changes in 
spirometric or plethysmographic measurements, 3) a significant and moderately strong 
relationship between FEV1 and 3He MRI functional measurements but not between the 
difference between time-points in FEV1 and 3He MRI measurement, and 4) sample sizes 
required to detect significant changes in 3He MRI VDP in a controlled clinical study. 
First we calculated the SDD for 3He VDV and VDP for an individual CF subject that was 
not due to measurement variability.  The relatively low SDD for 3He ventilation 
measurements was likely a consequence of the high precision of the 3He MRI 
measurement and the semi-automated image segmentation method used.   
Second, we observed statistically significant changes in mean 3He measurements in 7 
days, however no significant differences were detected using spirometry or 
plethysmography (and this study was not powered to detect such changes).  Although 
previous studies have demonstrated high same-day reproducibility in pediatric CF 
subjects,18 significant differences over short time periods in individuals with CF was not 
unexpected because the movement of mucus plugs and subsequent alterations of airway 
patency, could certainly result in 3He gas distribution changes.  However, the statistically 
significant and visually obvious change in 3He measurements we observed must be 
examined in light of previous reports of excellent 7-day 3He MRI reproducibility in 
COPD.7  The 7-day functional variability finding may reflect the greater contribution of 
defective mucus clearance to CF physiological variability and is important to consider 
when planning pulmonary functional imaging studies including 3He and 129Xe MRI that 
evaluate long-term treatment interventions.  The possibility exists that the differences 
measured, though small, were due to lung structural and functional changes that occurred 
over a one week period.  Certainly serial 3He MRI in COPD has revealed changes over a 
two-year time period with no concomitant change in FEV1.6  The results of the current 
study in CF indicate that 3He MRI sensitively quantified gas distribution changes that 
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occurred without changes detected in FEV1 suggesting it is possible to measure 
physiological changes that occur over short periods of time in CF.  Importantly, over half 
of the individual subjects (8/12) studied experienced a change in VDP and VDV greater 
than or equal to the SDD, over 7 days and these measurement changes were therefore 
unlikely due to measurement error.  The clinical meaning of this variability may be 
related to day to day variations in mucus redistribution.  As suggested by Bannier et. 
al.,12 mucus movement over short periods of time can potentially result in many small 
ventilation defects that traditional scoring or defect counting methods may not have the 
sensitivity to detect.   
In support of the finding of significant changes in mean 3He measurements over 7-days, 
Bland-Altman plots also identified a bias or improvement in 3He measurements between 
time-points.  This was unexpected as there was no significant difference between SNR 
for the image pairs to account for this difference and there was approximately a three 
year gap between the first and last subject imaging sessions, making it unlikely that the 
bias detected was due to technical or hardware issues at the second time-point for all 
subjects.  Whether the mean improvement in 3He gas distribution was due to the small 
number of subjects evaluated or related to improved therapy compliance for some 
subjects because of the 1-week study design cannot be ascertained by this study.   
We also reported a significant relationship between FEV1 and 3He functional 
measurements and this finding agrees with previous studies that have demonstrated the 
relationship between FEV1 and 3He measurements within a single day in both adult CF15 
and in pediatric CF patients.17;18  It is still unclear what the clinical meaning that 
ventilation distribution has in CF because 3He MRI measurements have not been 
validated using histology.  However it is possible that the ventilation measurements 
reported in this study reflect regional lung function and functional changes that occur on 
a day-to-day basis in CF.   
Finally, to use the current results as a guide for future studies, we estimated sample sizes 
required to detect significant differences in 3He VDP.  Relatively small sample sizes of 
60/15/5 subjects were estimated to be required per group to detect significant 
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5%/7%/10% absolute changes in VDP.  This suggests that 3He MRI can be considered 
when small sample sizes are necessitated such as in rare diseases with small patient 
populations, or in high cost per patient study designs. 
We acknowledge that this pilot study is limited by the small number and type of CF 
subjects studied.  The study subjects were recruited to represent CF subjects that would 
be appropriate candidates for therapy trials based on their FEV1, and therefore caution 
should be exercised in extrapolating these results to a pediatric population with less 
severe disease.  In addition, the interpretation and full understanding of the clinical 
relevance and meaning of 3He MRI measurements in CF patients is incomplete.  For 
example, the distribution of 3He gas within the lungs of CF patients is hypothesized to be 
related to mucous plugging and perhaps inflammation of the airways causing disruption 
in regional airflow.  However, histological validation or cross modality comparisons, 
such as with HRCT and the lung clearance index, are urgently required to identify the 
specific airway pathologies in and around ventilation defects.  We must also 
acknowledge that although we have taken into account the variability of the measurement 
technique over 7-days, we did not determine the reproducibility of the 3He measurements 
within the same-day, which is required to ensure that the differences observed here over 
7-days were not attributable to differences in the breath-hold maneuver, patient effort, or 
patient positioning between acquisitions.  However, a previous study evaluating 
measurement reproducibility in CF showed high same-day reproducibility, 18 lending 
strong support to the findings in this study over 7-days.  It is also important to note that 
while volumetric approaches may be more sensitive than visual scoring for quantifying 
changes in CF patients, certainly a regional analysis of the changes in ventilation 
distribution, as was recently shown by Woodhouse et. al.,18 would increase the sensitivity 
for detecting change and may be relevant in guiding therapies.  Another consideration is 
the limited 3He MRI access, although the development of hyperpolarized 129Xe MRI a 
less expensive and more readily available approach, is a promising alternative with which 
these reported findings can be directly tested.  
During progressive disease in CF, it is believed that adaptive remodeling of the lung 
airways and tissue occurs in response to bacterial/viral/fungal colonization, inflammation 
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and mucous plug occlusions.  Clinical research studies of CF continue to focus on FEV1, 
and in some cases high resolution or multi-detector x-ray CT methods to evaluate novel 
interventions and disease progression.  The results of the current study suggest that 3He 
MRI provides another imaging tool for the assessment of both airway and airspace 
changes in CF with sufficient precision and sensitivity to physiological lung functional 
changes for clinical research studies.  While much noble gas MRI pulmonary research is 
transitioning to 129Xe MRI, we believe the current results are applicable to its use as well.  
Moreover, both methods provide a relatively rapid and safe method of visualizing and 
quantifying both spatial and temporal lung structural and functional dynamics related to 
pulmonary disease.  In conclusion, our results indicated that 3He MRI detected significant 
changes in gas distribution in CF patients over a short 7-day period and these 
measurements can be considered as potential intermediate endpoints for evaluating 
functional lung changes with relatively small sample sizes. 
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APPENDIX B  
A case report of a COPD ex-smoker that was evaluated serially over 4 years using 
hyperpolarized 3He MRI, twice prior to and twice following an acute exacerbation 
requiring hospitalization is provided in Appendix B  
The contents of this Chapter have been previously published in the Journal of Magnetic 
Resonance in Medicine and permission to reproduce the article was granted by John 
Wiley and Sons and is provided in Appendix C. 
M Kirby, N Kanhere, R Etemad-Rezai, DG McCormack and G Parraga.  Hyperpolarized 
Helium-3 Magnetic Resonance Imaging of Chronic Obstructive Pulmonary Disease 
Exacerbation:  Case Report.  JMRI doi: 10.1002/jmri.23896. [Epub ahead of print Nov 2 
2012] 
 
B Hyperpolarized Helium-3 Magnetic Resonance Imaging 
of Chronic Obstructive Pulmonary Disease Exacerbation 
B.1  Introduction 
Chronic obstructive pulmonary disease (COPD) is the 4th leading cause of death 
worldwide and COPD exacerbations constitute a major burden on the health care 
system,1 and are associated with disease progression2 and reduced quality of life.3  The 
need for sensitive regional and surrogate measurements of COPD exacerbation risk and 
response to therapy continues to motivate the development of non-invasive and sensitive 
imaging approaches, such as hyperpolarized helium-3 (3He) magnetic resonance imaging 
(MRI).  Numerous studies have shown that 3He MRI measurements in COPD are highly 
reproducible,4;5 sensitive to early lung micro-structural changes,6;7 and significantly 
correlate with established measurements of pulmonary function,6;8 multi-slice computed 
tomography (CT) measurements9 and histology measurements of emphysema.10  
Furthermore, longitudinal 3He MRI of COPD has highlighted the sensitivity of the 
method to progressive worsening11 and shown regional improvements post-
bronchodilator12;13 and following interventions such as stent supported airway bypass.14  
Unfortunately, there have been few reports of the effect of such novel imaging results on 
therapeutic and patient care decision making.  Here, we report serial hyperpolarized 3He 
273 
 
MRI over a four year period in a 77 year old COPD ex-smoker including images acquired 
prior to and following treatment for an acute exacerbation (AE) of COPD. 
B.2  Case Report 
A 77 year old male with GOLD stage III COPD and a 20 pack-year smoking history, 
having ceased smoking 10 years prior, provided written informed consent to a 
longitudinal 3He MRI study that was Health Insurance Portability and Accountability Act 
(HIPAA) compliant and approved by a local ethics board.  Hyperpolarized 3He static 
ventilation and diffusion-weighted MRI was performed 25 minutes after 400μg 
salbutamol  administration in breath-hold after inspiration of a 1.0L gas mixture of 3He 
(5mL/kg body weight) and N2 gas from functional residual capacity (FRC) as previously 
described.15  3He gas was polarized to 30—40 % using a polarizer system (HeliSpin™, 
GEHC, Durham, NC).  Static ventilation images were acquired using a fast-gradient-
recalled-echo (FGRE) sequence (14s data acquisition, TR / TE / flip angle = 4.3 ms / 1.4 
ms / 7o, bandwidth = 31.25, FOV = 40 × 40 cm, matrix 128 × 128, 14 slices, 15 mm slice 
thickness, 0 gap) and diffusion-weighted images were acquired using a FGRE sequence 
with centric k-space sampling; two interleaved images were acquired (14s total data 
acquisition, TR/TE/flip angle = 7.6 ms/3.7 ms/8o, FOV = 40 x 40 cm, matrix 128 x 128, 7 
slices, 30 mm slice thickness), with and without additional diffusion sensitization (G = 
1.94 G/cm, rise and fall time = 0.5 ms, gradient duration = 0.46 ms, Δ = 1.46 ms, b = 1.6 
s/cm2).  It is important to note that pulse oximetry was used to measure arterial oxygen 
saturation (Sa02) during all imaging sessions.  No adverse events occurred during any 
imaging session for this subject and Sa02 remained above 88% at all times.  Proton (1H) 
MRI was also acquired with the same breath-hold volume within 5 min of 3He MRI as 
previously described15 to obtain an anatomical thoracic image to enable clear delineation 
of the thoracic cavity.  Registration and semi-automated segmentation of the 3He MRI 
functional and 1H MRI anatomical image for each time-point provided a way to generate 
the lung ventilation defect percent (VDP) as previously described.16;17  3He apparent 
diffusion coefficients (ADC) were generated from 3He diffusion-weighted imaging and 
ADC maps as previously described.13  Hyperpolarized  3He MRI measurement 
reproducibility in COPD was previously shown to be high at a number of independent 
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sites,4;5;9 and these results clearly provided good support for its use in serial studies of 
COPD.    
Approximately 2.5 years pre-AE, as shown in Table B1, the forced expiratory volume in 
1sec (FEV1) was 1.48L (41%pred), forced vital capacity (FVC) was 3.19L (66%pred), 
inspiratory capacity (IC) was 2.42L (64%pred) and FRC was 3.74L (95%pred).  As shown 
in Figure B1, 3He MRI revealed heterogeneous and abnormal gas distribution (whole 
lung VDP=16%) reflective of airway obstruction and Figure B2 provides an ADC map 
(whole lung ADC=0.34cm2/s) reflective of regional emphysema.   
Table B1 3He MRI and pulmonary function measurements in a single subject pre- and 
post-exacerbation 
 Pre-Exacerbation 
days [months] 
Post-Exacerbation 
days [months] 
Parameters - 886 [29] - 169 [6] + 8 + 477 [16] 
Pulmonary Function Tests     
FEV1 (%pred) 41 47 45 54 
FEF25% (%pred) - 19 23 34 
FEF50% (%pred) - 18 15 17 
FVC (%pred) 66 70 68 76 
FEV1/FVC (%) 46 49 48 51 
TLC (%pred) 78 73 78 74 
IC (%pred) 64 35 44 40 
FRC (%pred) 95 105 106 91 
RV (%pred) 94 76 113 85 
DLCO (%pred) - 36 - 34 
Hyperpolarized 3He MRI     
VDP (%) 16 29 20 14 
ADC (cm2/s) 0.34 0.38 - 0.34 
FEV1 = forced expiratory volume in one second, FEF25% = forced expiratory flow at 25% 
forced vital capacity (FVC), FEF50% = forced expiratory flow at 50% FVC, SVC = slow 
vital capacity, TLC = total lung capacity, IC = inspiratory Capacity, FRC = functional 
residual capacity, RV = residual volume, DLCO = carbon monoxide diffusion capacity of 
the lung, VDP = ventilation defect percent, ADC = apparent diffusion coefficient. 
Approximately 6 months pre-AE, 3He MRI (Table B1 and Figure B1) showed increased 
heterogeneity of gas distribution and increased VDP, suggestive of progressive 
worsening.  As shown in Figure B2, the elevated 3He ADC 6 months pre-AE was 
dominated by the contributions of the posterior lung slices.  Previous studies7 evaluating 
the anatomical distribution of 3He ADC in COPD and healthy volunteers have 
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demonstrated that the anterior-posterior gradient is significantly greater in healthy 
volunteers than in severe COPD subjects, suggesting dependent lung region gas trapping 
in contrast to progressive worsening of emphysema.  At the same time, measurements of 
gas trapping such as IC were also worse (Table B1).  Although there was worsening of 
both 3He MRI VDP and ADC, there was no change in the subject clinical status between 
the 29 and 6 months pre-AE time-points.  It is also important to note that there was 
sufficient image signal-to-noise-ratio (SNR) at all time-points (SNR>20).   
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Figure B1 Hyperpolarized 3He MRI pre- and post-exacerbation 
Hyperpolarized 3He MRI static ventilation images with the ventilation defect 
percent (VDP) shown below for the three centermost slices for a COPD subject 29 
and 6 months prior to hospitalization for an acute exacerbation with pneumonia 
and 8 days and 16 months following hospitalization.  The length of time prior to 
and following the acute exacerbation is provided in days and months in square 
brackets.  3He MRI shows a heterogeneous and abnormal gas distribution with 
signal voids or “defects” reflective of airway obstruction 29 months prior to 
hospitalization that was visually more heterogeneous 6 months prior to 
hospitalization.  Improvements in 3He gas distribution were observed 8 days post-
exacerbation that persisted 16 months post-exacerbation.   
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Figure B2 Hyperpolarized 3He MRI ADC of COPD subject pre- and post-
exacerbation 
A. 3He MRI ADC maps for the centermost slice for COPD subject 29 and 6 months 
prior to hospitalization for an acute exacerbation with pneumonia and 16 months 
following hospitalization.  The subject was unable to perform 3He MRI ADC 8 days 
following hospitalization.   
B. 3He ADC histograms for each slice in the posterior to anterior direction at the pre- 
and post-exacerbation time-points.   
C. Mean 3He ADC was 0.34cm2/s (mean ADC=0.34cm2/s, 95% confidence interval 
(CI)=0.32cm2/s-0.36cm2/s; linear regression slope=0.01, 95% CI=-0.002-0.02) at 29 
months pre-exacerbation and was elevated (mean ADC=0.38cm2/s, 95% 
CI=0.35cm2/s-0.40cm2/s; slope=-0.01, 95% CI=-0.03-0.008) at 6 months pre-
exacerbation.  The elevated ADC in the posterior slices suggests dependent lung 
region gas trapping.  At 16 months post-exacerbation, ADC values returned to 
baseline (mean ADC=0.34cm2/s, 95% CI=0.32cm2/s-0.34cm2/s; slope=0.005, 95% 
CI=-0.002-0.01). 
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Twenty-eight days prior to hospitalization, the subject complained of symptomatic 
worsening of COPD, characterized by increased shortness of breath and cough.  He was 
evaluated by a primary care physician and treated with levofloxacin 500mg for 10 days.  
Eighteen days later, he attended the emergency department with worsening symptoms 
and was hospitalized for COPD AE and treated with a course of 50mg of prednisone for 6 
days, 500mg of cefuroxime for 14 days and 250mg of erythromycin for 7 days.  Four 
days after discharge from hospital, the subject returned for 3He MRI and pulmonary 
function tests.  Although pulmonary function measurements were unchanged compared 
to 6 months prior (FEV1=45%pred, FEV1/FVC=48%), 3He MRI (Figure B1, 8 days post-
AE) showed gas distribution and VDP (VDP=20%) improvements.  Because of technical 
difficulties, 3He diffusion-weighted imaging was not performed at this time-point and 
therefore no ADC measurements were acquired.   
Approximately 16 months post-AE, visibly obvious improvements in gas distribution 
persisted and there was improved VDP, and improved FEV1, FVC, IC and FRC.  In 
addition, mean ADC also decreased to values that were the same as nearly 4 years earlier 
with a more normalized anterior-posterior ADC gradient reflecting diminished gas 
trapping7 compared to 6 months pre-AE. 
B.3  Discussion 
In this hyperpolarized 3He MRI study we evaluated a single COPD ex-smoker over 
nearly four years, including scans 6 months prior to and immediately following treatment 
for an acute exacerbation of COPD.  We observed visibly obvious improvements in 3He 
gas distribution immediately following exacerbation treatment, likely while the subject 
was still recovering, although no improvements were reflected by FEV1.  Improvements 
in 3He MRI VDP and ADC were also evident 16 months post-AE and these imaging 
improvements were mirrored by improved spirometry measurements.  Importantly, the 
change in the 3He VDP 6 months prior to the exacerbation compared to all other time-
points exceeded the smallest detectable difference of the measurement as previously 
reported,17 suggesting that the patient could have been worse 6 months before the 
exacerbation, although there was no change in the subjects clinical status until 
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approximately one month before hospitalization when the subject complained of 
symptoms.  It is important to note that the acute exacerbation may have been caused by 
infection since improvement was seen only after broad-spectrum antibiotic treatment, and 
therefore 3He MRI might not have predicted the exacerbation onset.  However, IC was 
also reduced 6 months prior to the exacerbation, and previous studies have demonstrated 
that IC can be used to reliably detect changes in end expiratory lung volume during 
COPD exacerbations.18  Taken together this suggests that MRI may have reflected 
regional pulmonary decline before, or even in the absence of changes in FEV1.  
Moreover, immediately after treatment for a COPD AE, spirometry measurements were 
relatively unchanged, although MRI showed substantive improvements.  
Several hypotheses and questions arise from our results that are related to the time-course 
of exacerbation treatment such as: 1) Is there a relationship between symptomatic and 
3He MRI improvements following therapy, before changes in FEV1 are measured?; 2)Do 
COPD patients with specific imaging phenotypes have a propensity for increased 
exacerbation frequency? We note that the potential for imaging surrogate endpoints as 
markers of future clinical outcomes was recently demonstrated in cystic fibrosis (CF), 
whereby the relationship between high-resolution computed tomography measurements 
and CF exacerbations was shown.19  Improvements in 3He gas distribution have also been 
demonstrated in the absence of concomitant improvements in spirometry in CF patients 
following chest physical therapy.20  We think these previous results and the current case 
study highlight the discordance between spirometry and exacerbations and the potential 
predictive relationship between imaging and clinical outcomes many years later.  In 
particular for hyperpolarized noble gas imaging, high short term reproducibility 4 coupled 
with the high sensitivity in longitudinal11 and other acute therapy studies,12;13 suggest that 
this may be an ideal imaging approach to study or identify COPD patients at high risk for 
exacerbation.  
We must acknowledge that this study was limited because 3He MRI and pulmonary 
function measurements were not acquired more close in time to the onset of the AE.  
Clearly, acquiring 3He MRI at time-points more closely timed to the clinical course 
would strengthen the findings of this investigation.  The limited and high cost of 3He gas 
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that which has restricted translation to specialized MR physics centers is another 
important limitation.  However, the development of hyperpolarized 129Xe MRI21;22 is a 
promising alternative with which these findings can be directly tested in a larger COPD 
patient population.   
It is nearly 2 decades since the potential for pulmonary functional imaging using inhaled 
noble gases was first described,21 and it is yet unclear what role this novel imaging tool 
might play in the management of patients with COPD.   Hyperpolarized 3He MRI is 
highly reproducible in COPD4;5;9 with a modest smallest detectable difference 
(SDD=0.16L for VDV)17 and this bodes well for serial studies in individual patients to 
monitor or perhaps predict disease worsening.  However, it has not yet been 
demonstrated how such structure-function measurements can be used to make or alter 
therapy decisions, nor do we fully understand the clinical meaning of 3He or 129Xe gas 
distribution measurements or the clinical relevance of their apparent worsening.  In this 
regard, the current case provides evidence that serial 3He MRI measurements of airway 
function (VDP) and parenchyma microstructure can be used to visualize regional changes 
in COPD subjects, with the potential to modify therapy.  However, it must be also noted 
that for the forseeable future, this imaging approach cannot be generalized to routine care 
or screening.  Clearly, however, larger scale studies are required to evaluate the effect on 
COPD outcomes of incorporating pulmonary functional imaging into regular clinical 
monitoring and visits.   
281 
 
B.4  References 
 (1)  Rabe KF, Hurd S, Anzueto A et al. Global strategy for the diagnosis, 
management, and prevention of chronic obstructive pulmonary disease: GOLD 
executive summary. Am J Respir Crit Care Med 2007; 176(6):532-555. 
 (2)  Donaldson GC, Seemungal TA, Bhowmik A et al. Relationship between 
exacerbation frequency and lung function decline in chronic obstructive 
pulmonary disease. Thorax 2002; 57(10):847-852. 
 (3)  Seemungal TA, Donaldson GC, Paul EA et al. Effect of exacerbation on 
quality of life in patients with chronic obstructive pulmonary disease. Am J 
Respir Crit Care Med 1998; 157(5 Pt 1):1418-1422. 
 (4)  Mathew L, Evans A, Ouriadov A et al. Hyperpolarized 3He magnetic 
resonance imaging of chronic obstructive pulmonary disease: reproducibility at 
3.0 tesla. Acad Radiol 2008; 15(10):1298-1311. 
 (5)  Morbach AE, Gast KK, Schmiedeskamp J et al. Diffusion-weighted MRI 
of the lung with hyperpolarized helium-3: a study of reproducibility. J Magn 
Reson Imaging 2005; 21(6):765-774. 
 (6)  Salerno M, de Lange EE, Altes TA et al. Emphysema: hyperpolarized 
helium 3 diffusion MR imaging of the lungs compared with spirometric indexes--
initial experience. Radiology 2002; 222(1):252-260. 
 (7)  Evans A, McCormack D, Ouriadov A et al. Anatomical distribution of 
3He apparent diffusion coefficients in severe chronic obstructive pulmonary 
disease. J Magn Reson Imaging 2007; 26(6):1537-1547. 
 (8)  Diaz S, Casselbrant I, Piitulainen E et al. Validity of apparent diffusion 
coefficient hyperpolarized 3He-MRI using MSCT and pulmonary function tests 
as references. Eur J Radiol 2009; 71(2):257-263. 
282 
 
 (9)  Diaz S, Casselbrant I, Piitulainen E et al. Hyperpolarized 3He apparent 
diffusion coefficient MRI of the lung: reproducibility and volume dependency in 
healthy volunteers and patients with emphysema. J Magn Reson Imaging 2008; 
27(4):763-770. 
 (10)  Woods JC, Choong CK, Yablonskiy DA et al. Hyperpolarized 3He 
diffusion MRI and histology in pulmonary emphysema. Magn Reson Med 2006; 
56(6):1293-1300. 
 (11)  Kirby M, Mathew L, Wheatley A et al. Chronic obstructive pulmonary 
disease: longitudinal hyperpolarized (3)He MR imaging. Radiology 2010; 
256(1):280-289. 
 (12)  Kirby M, Mathew L, Heydarian M et al. Chronic obstructive pulmonary 
disease: quantification of bronchodilator effects by using hyperpolarized (3)He 
MR imaging. Radiology 2011; 261(1):283-292. 
 (13)  Kirby M, Heydarian M, Wheatley A et al. Evaluating bronchodilator 
effects in chronic obstructive pulmonary disease using diffusion-weighted 
hyperpolarized helium-3 magnetic resonance imaging. J Appl Physiol 2012; 
112(4):651-657. 
 (14)  Mathew L, Kirby M, Farquhar D et al. Hyperpolarized 3He functional 
magnetic resonance imaging of bronchoscopic airway bypass in chronic 
obstructive pulmonary disease. Can Respir J 2012; 19(1):41-43. 
 (15)  Parraga G, Ouriadov A, Evans A et al. Hyperpolarized 3He ventilation 
defects and apparent diffusion coefficients in chronic obstructive pulmonary 
disease: preliminary results at 3.0 Tesla. Invest Radiol 2007; 42(6):384-391. 
 (16)  Mathew L, Kirby M, Etemad-Rezai R et al. Hyperpolarized (3)He 
magnetic resonance imaging: preliminary evaluation of phenotyping potential in 
chronic obstructive pulmonary disease. Eur J Radiol 2011; 79(1):140-146. 
283 
 
 (17)  Kirby M, Heydarian M, Svenningsen S et al. Hyperpolarized 3He 
magnetic resonance functional imaging semiautomated segmentation. Acad 
Radiol 2012; 19(2):141-152. 
 (18)  Parker CM, Voduc N, Aaron SD et al. Physiological changes during 
symptom recovery from moderate exacerbations of COPD. Eur Respir J 2005; 
26(3):420-428. 
 (19)  Brody AS, Sucharew H, Campbell JD et al. Computed tomography 
correlates with pulmonary exacerbations in children with cystic fibrosis. Am J 
Respir Crit Care Med 2005; 172(9):1128-1132. 
 (20)  Bannier E, Cieslar K, Mosbah K et al. Hyperpolarized 3He MR for 
sensitive imaging of ventilation function and treatment efficiency in young cystic 
fibrosis patients with normal lung function. Radiology 2010; 255(1):225-232. 
 (21)  Albert MS, Cates GD, Driehuys B et al. Biological magnetic resonance 
imaging using laser-polarized 129Xe. Nature 1994; 370(6486):199-201. 
 (22)  Mugler JP III, Mata JF, Wang HTJ et al. The apparent diffusion 
coefficient of 129-Xe in the lung: preliminary human results. 2004: 769. 
284 
 
APPENDIX C - PERMISSIONS FOR REPRODUCTION OF 
SCIENTIFIC ARTICLES 
285 
 
286 
 
287 
 
288 
 
289 
 
290 
 
291 
 
292 
 
293 
 
294 
 
 
295 
 
 
296 
 
 
 
297 
 
 
298 
 
 
299 
 
 
300 
 
APPENDIX D- HEALTH SCIENCE RESEARCH ETHICS BOARD 
APPROVAL NOTICES 
301 
 
 
302 
 
303 
 
304 
 
305 
 
APPENDIX E - CURRICULUM VITAE 
 
EDUCATION 
 
Sep. 2008 – 
present 
Doctor of Philosophy (Candidate) 
Department of Medical Biophysics 
The University of Western Ontario, London, Ontario, Canada  
Supervisor:  Dr. Grace Parraga 
Thesis:  ‘Hyperpolarized Helium-3 Magnetic Resonance Imaging of 
Chronic Obstructive Pulmonary Disease’ 
 
Sep. 2004 – 
Jul. 2008 
Bachelor of Science (Gold Medal for Honors Double Major in Applied 
Mathematics)    
Honors Double Major Applied Mathematics and Biology 
The University of Western Ontario, London, Ontario, Canada 
 
 
POSITIONS 
 
Sep. 2008 – 
present 
Research Assistant, Doctoral  
Department of Medical Biophysics 
The University of Western Ontario, London, Ontario, Canada  
Supervisor:  Dr. Grace Parraga 
Project:  ‘Hyperpolarized Helium-3 Magnetic Resonance Imaging of 
Chronic Obstructive Pulmonary Disease’ 
 
May 2008 – 
Sep. 2008 
Research Assistant, Summer Research Assistantship 
Supervisor:  Dr. Grace Parraga 
Project:  ‘Hyperpolarized Helium-3 Magnetic Resonance Imaging of 
Phenotyping Potential in Chronic Obstructive Pulmonary Disease’ 
 
 
ACADEMIC AWARDS, SCHOLARSHIPS and DISTINCTIONS 
 
Feb. 2013 3rd Annual Canadian Thoracic Society Poster Competition Finalist 
Top 30 abstracts out of all Canada-based trainees that submitted to the 
American Thoracic Society Meeting 2013 selected to compete in poster 
competition. 
National 
 
Jan. 2013
  
International Society for Magnetic Resonance in Medicine Educational 
Stipend Award 
Awarded to support the attendance of students, postdoctoral and 
clinical trainees to present abstracts at the scientific meeting. 
International 
306 
 
$440 USD  
 
Apr. 2013 CIHR IMPACT Strategic Training Initiatives in Health Research 
Program 
The University of British Columbia 
Awarded to high quality clinical and basic science post-doctoral 
fellows to create the next generation of investigators capable of 
developing and translating knowledge from bench to bedside with the 
outcome of improved cardio-pulmonary health status of the Canadian 
population. 
Institutional 
$52500 
 
Jun. 2012 Nellie Farthing Fellowship in the Medical Sciences Schulich School of 
Medicine & Dentistry, The University of Western Ontario 
Awarded to a full-time doctoral student in a Schulich School of 
Medicine & Dentistry graduate program for excellence in research. 
Institutional 
$3000 
 
Apr. 2012 Three Minute Thesis (3MT) Competition Finalist, The University of 
Western Ontario 
Awarded to the highest ranked graduate students for presentation of 
their research in 3 minutes or less to a panel of non-specialist judges 
and peers. 
Institutional 
$500 
 
Apr. 2012 American Thoracic Society Travel Award from the National 
Emphysema Foundation Honoring Claude Lenfant 
Awarded to support the attendance of fellows or in training members to 
present abstracts at the scientific meeting. 
International 
$500 USD 
 
Mar. 2012
  
International Society for Magnetic Resonance in Medicine Summa 
Cum Laude Award 
Awarded to student members whose abstract scored in the top 3% of 
all abstracts submitted to the same general category. 
International 
 
Feb. 2012
  
International Society for Magnetic Resonance in Medicine Educational 
Stipend Award 
Awarded to support the attendance of students, postdoctoral and 
clinical trainees to present abstracts at the scientific meeting. 
International 
307 
 
$540 USD  
 
Sep. 2011 –  
Sep. 2012
  
 
Schulich Graduate Scholarship, The University of Western Ontario 
Awarded to a full time graduate student for stipend support who has 
maintained an average of 80% or more. 
Institutional  
$7647.48 
 
Mar. 2011 1st Annual Canadian Thoracic Society Poster Competition Finalist 
Top 29 abstracts out of all Canada-based trainees that submitted to the 
American Thoracic Society Meeting 2011 selected to compete in poster 
competition. 
National 
 
Feb. 2011 International Society for Magnetic Resonance in Medicine Educational 
Stipend Award 
Awarded to support the attendance of students, postdoctoral and 
clinical trainees to present abstracts at the scientific meeting. 
International 
$450 USD 
 
Jan. 2011
  
3rd Japanese Society of Pulmonary Functional Imaging & 5th 
International Workshop for Pulmonary Functional Imaging Scientific 
Presentation Award 
Awarded in recognition of the excellence of a scientific paper 
presented orally 
International 
 
Sep. 2010 –  
Sep. 2011
  
 
Schulich Graduate Scholarship, The University of Western Ontario 
Awarded to a full time graduate student for stipend support who has 
maintained an average of 80% or more. 
Institutional  
$7376.46 
 
Mar. 2010
  
Margaret Moffat Research Day Travel Award, The University of 
Western Ontario 
Awarded to the student with the highest ranked poster in the Imaging 
category 
Institutional 
$500 
 
May 2010 – 
May 2013 
Natural Sciences and Engineering Research Council of Canada  (PGS-
Doctoral) 
National 
$63,000 
 
308 
 
Sep. 2009 –
Sep. 2010
  
 
Schulich Graduate Scholarship, The University of Western Ontario 
Awarded to a full time graduate student for stipend support who has 
maintained an average of 80% or more. 
Institutional  
$7080.87 
 
Jul. 2009
 
 
  
 
JR Cunningham Young Investigator Silver Medalist Award Winner 
Awarded to the top oral presentations in the Young Investigators' 
Symposium at the Canadian Organization of Medical Physic annual 
meeting. 
National  
$300 
 
Jun. 2009
  
RSNA Trainee Research Prize Competition Finalist 
Awarded to the highest ranked abstracts submissions for the RSNA 
Trainee Research Prize. 
International 
 
May 2009
  
JR Cunningham Young Investigator Finalist  
Awarded to the top 10 highest scored Young Investigator submission s 
for the Canadian Organization of Medical Physic annual meeting. 
National 
$175 
 
May 2009 – 
May 2010 
Ontario Graduate Scholarship (OGS) 
Provincial 
$15,000 
 
Sep. 2008 – 
Sep. 2010 
Canadian Institutes of Health Research Strategic Training Program in 
Vascular Research 
Institutional  
$20,000  
 
Sep. 2008 – 
Sep. 2009
  
 
Schulich Graduate Scholarship, The University of Western Ontario 
Awarded to a full time graduate student for stipend support who has 
maintained an average of 80% or more. 
Institutional  
$6,683.22 
 
Jul. 2008 Gold Medal for the Honors Double Major in Applied Mathematics, The 
University of Western Ontario 
Awarded to a full time student in the respective Honors program with 
the highest graduating average. 
Institutional  
 
May 2008, Dean’s Honor List 
309 
 
May 2007 Awarded to a full time student who has maintained an average of 80% 
or more. 
Institutional  
 
Sep. 2004 Western Scholarship of Distinction  
Awarded upon admission to Western students who have an admission 
average of 85-89.9%. 
Institutional  
$1,500 
 
Sep. 2004 The Queen Elizabeth II Aiming for the Top Scholarship 
Awarded to students who have shown academic excellence at the high 
school level. 
Institutional  
$3,500 
 
 
PUBLICATIONS and PRESENTATIONS 
 
A.  Refereed Journal Manuscripts (5 In Press, 14 published, 1 under review, 3 in 
preparation) 
In Press (5) 
1. M Kirby, A Owrangi, S Svenningsen, A Wheatley, HO Coxson, NAM Paterson, 
DG McCormack and G Parraga.  On the role of abnormal DLCO in ex-smokers 
without airflow limitation: Symptoms, exercise capacity and hyperpolarized 
helium-3 magnetic resonance imaging.  Thorax (Accepted March 28 2013). 
 
2. S Svenningsen, M Kirby, D Starr, D Leary, A Wheatley, GN Maksym, DG 
McCormack, and G Parraga. Evaluating Regional Bronchodilator Response in 
Asthma with 3He and 129Xe Magnetic Resonance Imaging.  JMRI (Accepted Feb 
12 2013). 
 
3. M Kirby and G Parraga.  Pulmonary Functional Imaging using Hyperpolarized 
Noble Gas MRI: Six years of Start-up Experience at a Single Site.  Acad. Radiol. 
(Accepted Feb 1 2013). 
 
4. A Ouriadov, A Farag, M Kirby, DG McCormack, G Parraga and GE Santyr.  
Lung Morphometry using Hyperpolarized 129Xe Apparent Diffusion Coefficient 
Anisotropy in Chronic Obstructive Pulmonary Disease.  MRM 
doi:10.1002/mrm.24595. [Epub ahead of print Jan 28 2013]. 
 
5. M Kirby, HO Coxson and G Parraga Pulmonary Functional Magnetic Resonance 
Imaging for Paediatric Lung Disease.  Paediatr Respir Rev (Accepted Jan 16 
2013) 
 
Published (14) 
310 
 
1. M Kirby, S Svenningsen, N Kanhere, A Owrangi, A Wheatley, HO Coxson, GE 
Santyr, NAM Paterson, DG McCormack and G Parraga.  Pulmonary Ventilation 
Visualized using Hyperpolarized Helium-3 and Xenon-129 Magnetic Resonance 
Imaging: Differences in COPD and Relationship to Emphysema. J Appl Physiol. 
2013;114(6):707-15. 
 
2. M Kirby, N Kanhere, R Etemad-Rezai, DG McCormack and G Parraga.  
Hyperpolarized Helium-3 Magnetic Resonance Imaging of Chronic Obstructive 
Pulmonary Disease Exacerbation:  Case Report.  JMRI doi: 10.1002/jmri.23896. 
[Epub ahead of print Nov 2 2012] 
 
3. M Kirby, DG McCormack and G Parraga.  Evidence for Adult Lung Growth in 
Humans.  N Engl J Med  2012; 367: 1566-1567. 
 
4. M Kirby, S Svenningsen, A Owrangi, A Wheatley, A Farag, A Ouriadov, GE 
Santyr, R Etemad-Rezai, HO Coxson, DG McCormack and G Parraga.  
Hyperpolarized Helium-3 and Xenon-129 Magnetic Resonance Imaging in 
Healthy Volunteers and Subjects with Chronic Obstructive Pulmonary Disease.  
Radiology. 2012; 265(2):600-10.  
 
5. S Costella, M Kirby, GN Maksym, DG McCormack, NAM Paterson and G 
Parraga.  Regional Pulmonary Functional Imaging Measurements in Asthma after 
Methacholine Challenge using Hyperpolarized 3He Magnetic Resonance Imaging.  
Respirology. 2012; 17(8):1237-1246.   
 
6. Y Shukla, A Wheatley, M Kirby, S Svenningsen, A Farag, G Santyr, NAM 
Paterson, DG McCormack and G Parraga.  Hyperpolarized 129Xe Magnetic 
Resonance Imaging: Tolerability in Healthy Volunteers and Subjects with 
Pulmonary Disease.  Acad. Radiol. 2012; 19(8):941-51.   
 
7. M Kirby, M Heydarian A Wheatley, R Etemad-Rezai, DG McCormack and G 
Parraga.  Evaluating Bronchodilator Effects in Chronic Obstructive Pulmonary 
Disease using Diffusion-Weighted Hyperpolarized Helium-3 Magnetic Resonance 
Imaging.  J. Appl. Physiol. 2012; 112(4):651-7. 
 
8. M Kirby, M Heydarian, S Svenningsen, A Wheatley, DG McCormack R 
Etemad-Rezai and G Parraga.  Hyperpolarized 3He Magnetic Resonance 
Functional Imaging Semiautomated Segmentation.  Acad. Radiol. 2012; 
19(2):141—52. 
 
9. L Mathew, M Kirby, D Farquahar, C Licskai, R Etemad-Rezai, DG McCormack, 
and G Parraga.  Hyperpolarized 3He Magnetic Resonance Imaging of 
Bronchoscopic Airway Bypass in COPD.  Can. Resp. J. 2012; 19(1):41-3.  
 
10. M Kirby, L Mathew, M Heydarian, R Etemad-Rezai, DG McCormack and G 
Parraga. Chronic obstructive pulmonary disease: quantification of bronchodilator 
311 
 
effects by using hyperpolarized ³He MR imaging. Radiology 2011; 261(1):283-
92. 
 
11.  M Kirby, S Svenningsen, H Ahmed, NAM Paterson and G Parraga.  
Quantitative Evaluation of Hyperpolarized Helium-3 Magnetic Resonance 
Imaging of Lung Function Variability in Cystic Fibrosis. Acad. Radiol. 2011; 
18(8):1006-13.  
 
12. M Kirby, AM Owrangi, J Wang, S Costella, S Choy, DG McCormack and G 
Parraga.  Pulmonary Magnetic Resonance Imaging of Obstructive Airways 
Disease.  Minerva Pnemologica 2011; 50(1): 17-29. 
 
13.  L Mathew, M Kirby, R Etemad-Rezai, A Wheatley, DG McCormack and G 
Parraga.  Hyperpolarized 3He Magnetic Resonance Imaging:  Preliminary 
Evaluation of Phenotyping Potential in Chronic Obstructive Pulmonary Disease.  
Eur J Radiol. 2011; 79(1):140-6.  
 
14. M Kirby, L Mathew, A Wheatley, GE Santyr, DG McCormack and G Parraga.  
Chronic Obstructive Pulmonary Disease:  Longitudinal Hyperpolarized 3He MR 
Imaging.  Radiology 2010; 256(1): 280-9. 
 
Under Review (1) 
1. M Kirby, A Ouriadov, S Svenningsen, A Owrangi, A Wheatley, A Farag, GE 
Santyr, DG McCormack and G Parraga.  Diffusion-Weighted Hyperpolarized 
Helium-3 and Xenon-129 Magnetic Resonance Imaging in Never-smokers and 
Ex-smokers with Chronic Obstructive Pulmonary Disease.  Academic Radiology 
 
In Preparation (3) 
1. D Pike, M Kirby, C Neron, D Buchanan, JD Spence, NAM Paterson, A 
Wheatley, HO Coxson, DG McCormack and G Parraga.  Hyperpolarized Helium-
3 Magnetic Resonance Imaging of Pulmonary Structure and Function in Ex-
smokers with Carotid Atherosclerosis.  Respirology 
2. S Svenningsen, D Starr, HO Coxson, DG McCormack, NAM Paterson, M Kirby 
and G Parraga.  Structural Determinants of Hyperpolarized 3He Magnetic 
Resonance Imaging Ventilation Defects in Asthma. Radiology 
 
3. M Kirby, L Villemaire, H Ahmed, NAM Paterson, DG McCormack JF Lewis 
and G Parraga.  Diffusion-Weighted Hyperpolarized Helium-3 Magnetic 
Resonance Imaging of Cystic Fibrosis.  JAP 
 
B.  Published Refereed Conference Papers (2) 
1. M Heydarian, M Kirby, A Wheatley, A Fenster, G Parraga.  Two and Three-
Dimensional Segmentation of Hyperpolarized 3He Magnetic Resonance 
Functional Imaging.  Proc SPIE 2012 Vol. 8317, 83171C-1-83171C-9. 
 
312 
 
2. M Kirby, A Wheatley, DG McCormack and G Parraga.  Development of Image 
processing methods to quantify Spatial and Temporal Ventilation Dynamics using 
Hyperpolarized 3He magnetic resonance imaging.  Proc SPIE 2010 Vol. 7626, 
762605-1-762605-9. 
 
C.  Peer Reviewed Published Conference Abstracts (23) 
1. A Youn, M Kirby, A Wheatley, J Lewis, DG McCormack and G Parraga.  
Hyperpolarized Helium-3 and Xenon-129 Magnetic Resonance Functional 
Imaging in Adult Cystic Fibrosis.  International Conference of the American 
Thoracic Society Meeting Proceedings 2012 
 
2. M Kirby, A Wheatley, A Farag, A Ouriadov, GE Santyr DG McCormack and G 
Parraga.   Hyperpolarized Helium-3 and Xenon-129 Magnetic Resonance 
Functional Imaging in Healthy Volunteers and Subjects with Chronic Obstructive 
Pulmonary Disease.  International Conference of the American Thoracic Society 
Meeting Proceedings 2012 
 
3. M Kirby, C Neron, JD Spence, NAM Paterson, D Buchanan, A Wheatley, HO 
Coxson, DG McCormack and G Parraga.  Hyperpolarized Helium-3 Magnetic 
Resonance Imaging of Pulmonary Structure and Function in Ex-smokers with 
Carotid Atherosclerosis.  International Conference of the American Thoracic 
Society Meeting Proceedings 2012 
 
4. N Kanhere, M Kirby, A Wheatley, GE Santyr, DG McCormack, GB Rodrigues, 
G Parraga and L Mathew.  Hyperpolarized Helium-3 and Xenon-129 Magnetic 
Resonance Imaging of Radiation-induced Lung Injury.  International Conference 
of the American Thoracic Society Meeting Proceedings 2012 
 
5. S Svenningsen, M Kirby, A Wheatley, A Ouriadov, GE Santyr, DG McCormack 
and G Parraga.  Hyperpolarized 3He and 129Xe Magnetic Resonance Imaging of 
Asthma.  International Conference of the American Thoracic Society Meeting 
Proceedings 2012 
 
6. DG McCormack, S Halko, S McKay, M Kirby, S Svenningsen, A Wheatley, A 
Farag, GE Santyr and G Parraga.  Hyperpolarized 129Xe MRI Feasibility, Subject 
Safety and Tolerability: At the doorstep of Clinical Translation? International 
Conference of the American Thoracic Society Meeting Proceedings 2012 
 
7. M Kirby, A Wheatley, A Farag, A Ouriadov, GE Santyr DG McCormack and G 
Parraga.  Hyperpolarized Helium-3 and Xenon-129 Magnetic Resonance Imaging 
of Elderly Never-smokers and Ex-smokers with Chronic Obstructive Pulmonary 
Disease.  International Society for Magnetic Resonance in Medicine Meeting 
Proceedings 2012 
 
8. S Svenningsen, M Kirby, A Wheatley, A Farag, A Ouriadov, GE Santyr, DG 
McCormack and G Parraga. Anatomical Distribution of Hyperpolarized 3He and 
313 
 
129Xe MRI Apparent Diffusion Coefficients in Asthma.  International Society for 
Magnetic Resonance in Medicine Meeting Proceedings 2012 
 
9. A Ouriadov, A Farag, M Kirby, DG McCormack, G Parraga and G Santyr. 
Hyperpolarized 129Xe Apparent Diffusion Coefficient Anisotropy in Chronic 
Obstructive Pulmonary Disease.  International Society for Magnetic Resonance in 
Medicine Meeting Proceedings 2012 
 
10. N Kanhere, M Kirby, A Wheatley, A Ouriadov, GE Santyr, DG McCormack and 
G Parraga.  Reproducibility of Hyperpolarized Xenon-129 Magnetic Resonance 
Imaging of Chronic Obstructive Pulmonary Disease.  International Society for 
Magnetic Resonance in Medicine Meeting Proceedings 2012 
 
11. M Heydarian, M Kirby, A Wheatley, A Fenster and G Parraga.  Two and Three-
Dimensional Segmentation of Hyperpolarized 3He Magnetic Resonance 
Functional Imaging. Society of Photographic Instrumentation Engineers 
Proceedings 2012 
 
12. M Kirby, L Mathew, D Farquhar, C Licskai, R McFadden, DG McCormack and 
G Parraga.  Hyperpolarized 3He Magnetic Resonance Imaging Biomarkers of 
Bronchoscopic Airway Bypass in COPD.  International Conference of the 
American Thoracic Society Meeting Proceedings 2011 
 
13. M Kirby, N Krowchuk, A Wheatley, DG McCormack, HO Coxson and G 
Parraga.  Evaluation of COPD Airway Function and Structure using 
Hyperpolarized 3He Magnetic Resonance Imaging and x-ray Computed 
Tomography.  International Conference of the American Thoracic Society 
Meeting Proceedings 2011 
 
14. S Svenningsen, M Kirby, H Ahmed, NAM Paterson and G Parraga. Evaluation of 
Short Term Reproducibility of Hyperpolarized Helium-3 Magnetic Resonance 
Imaging in Adult Cystic Fibrosis using a Semi-Automated Segmentation Tool. 
International Society for Magnetic Resonance in Medicine Proceedings 2011 
 
15. M Kirby, R Etemad-Rezai, DG McCormack and G Parraga.  Evaluating 
Bronchodilator Effects in Chronic Obstructive Pulmonary Disease using 
Hyperpolarized Helium-3 Magnetic Resonance Imaging.  International Society 
for Magnetic Resonance in Medicine Proceedings 2011 
 
16. M Kirby, A Wheatley, R Etemad-Rezai, PD Pare, HO Coxson, JC Hogg, DG 
McCormack and G Parraga.  Regional Quantification of Hyperpolarized Helium-3 
Magnetic Resonance Imaging Apparent Diffusion Coefficients:  What does 
Bronchodilator Administration in COPD Accomplish?  3rd Japanese Society of 
Pulmonary Functional Imaging and 5th International Workshop for Pulmonary 
Functional Imaging Proceedings 2011 
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17. L Mathew, M Kirby, R Etemad-Rezai, DG McCormack and G Parraga.  
Hyperpolarized 3He Magnetic Resonance Imaging Chronic Obstructive 
Pulmonary Disease Phenotypes. International Conference of the American 
Thoracic Society Proceedings 2010  
 
18. M Kirby, A Wheatley, DG McCormack and G Parraga.   Development and 
application of methods to quantify spatial and temporal hyperpolarized 3He MRI 
ventilation dynamics: preliminary results in chronic obstructive pulmonary 
disease. Society of Photographic Instrumentation Engineers Proceedings 2010 
 
19. M Kirby, L Mathew, A Wheatley, DG McCormack and G Parraga.  Longitudinal 
Hyperpolarized 3He Magnetic Resonance Imaging of Chronic Obstructive 
Pulmonary Disease, Interactions:  Canadian Medical Physics Newsletter Volume 
56, Issue 1, pp. 13-22 (01/10). 
 
20. M Kirby, A Wheatley, R Etemad-Rezai, DG McCormack and G Parraga.   
Hyperpolarized Helium-3 Magnetic Resonance Imaging Spatial and Temporal 
Ventilation Dynamics in Chronic Obstruction Pulmonary Disease post 
Bronchodilator. Radiological Society of North America Proceedings 2009. 
 
21. M Kirby, L Mathew, A Wheatley, DG McCormack and G Parraga.  Longitudinal 
Hyperpolarized 3He Magnetic Resonance Imaging of Chronic Obstructive 
Pulmonary Disease. The Canadian Organization of Medical Physicists 
Proceedings 2009 
 
22. M Kirby, A Wheatley, DG McCormack and G Parraga.  Hyperpolarized Helium-
3 Magnetic Resonance Imaging Ventilation Heterogeneity in Chronic Obstructive 
Pulmonary Disease. International Conference of the American Thoracic Society 
Proceedings 2009 
 
23. M Kirby, L Mathew, A Wheatley, DG McCormack and G Parraga.  Longitudinal 
Hyperpolarized Helium-3 Magnetic Resonance Imaging of Chronic Obstructive 
Pulmonary Disease: Two year Follow-up Evaluation. International Conference of 
the American Thoracic Society Proceedings 2009 
 
D.  Peer Reviewed Oral Presentations (19) *presenter 
1. M Kirby*, L Villemaire, H Ahmed, N.A. Paterson, D.G. McCormack, J.F. Lewis 
and G Parraga.   Diffusion-Weighted Hyperpolarized Helium-3 Magnetic 
Resonance Imaging in Adult Cystic Fibrosis.  International Conference of the 
American Thoracic Society Meeting, Philadelphia, Pennsylvania, USA (05/13) 
 
2. S Svenningsen*, M Kirby, S Choy, A Wheatley, D.G. McCormack and G 
Parraga.  Temporal-Spatial Maps of Asthma Ventilation to Identify Therapy 
Targets.  International Conference of the American Thoracic Society Meeting, 
Philadelphia, Pennsylvania, USA (05/13) 
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3. M Kirby*, S Svenningsen, A Ouriadov, GE Santyr,  D.G. McCormack and G 
Parraga.  Diffusion-weighted Hyperpolarized 3He and 129Xe Magnetic Resonance 
Imaging of Elderly Never-smokers and Ex-smokers with Chronic Obstructive 
Pulmonary Disease.  International Society for Magnetic Resonance in Medicine 
Meeting, Salt Lake City, Utah, USA (05/13) 
 
4. M Kirby*, S Svenningsen, A Wheatley, A Farag, A Ouriadov, GE Santyr, D.G. 
McCormack and G Parraga.  Hyperpolarized Helium-3 and Xenon-129 Magnetic 
Resonance Imaging in Healthy Volunteers and Subjects with Chronic Obstructive 
Pulmonary Disease.  London Health Research Day, London, Ontario, Canada 
(03/13) 
 
5. M Kirby*, S Svenningsen, A Wheatley, A Farag, A Ouriadov, GE Santyr, D.G. 
McCormack and G Parraga.  Hyperpolarized Helium-3 and Xenon-129 Magnetic 
Resonance Imaging in Healthy Volunteers and Subjects with Chronic Obstructive 
Pulmonary Disease.  Imaging Network Ontario Symposium, Toronto, Ontario, 
Canada (02/13) 
 
6. S Svenningsen*, D Starr, HO Coxson, NAM Paterson, DG McCormack, M 
Kirby and G Parraga.  Asthma Airway Morphology and Hyperpolarized 3He 
Magnetic Resonance Imaging Ventilation Defects.  Imaging Network Ontario 
Symposium, Toronto, Ontario, Canada (02/13) 
 
7. M Kirby*, A Wheatley, DG McCormack, G Parraga.  Imaging of lung function 
using hyperpolarized helium.  European Respiratory Society, Vienna, Austria 
(09/12) 
 
8. A Youn*, M Kirby, A Wheatley, J Lewis, DG McCormack and G Parraga.  
Hyperpolarized Helium-3 and Xenon-129 Magnetic Resonance Functional 
Imaging in Adult Cystic Fibrosis.  International Conference of the American 
Thoracic Society Meeting, San Francisco, California, USA (05/12) 
 
9. M Kirby*, A Wheatley, A Farag, A Ouriadov, GE Santyr DG McCormack and G 
Parraga.   Hyperpolarized Helium-3 and Xenon-129 Magnetic Resonance 
Functional Imaging in Healthy Volunteers and Subjects with Chronic Obstructive 
Pulmonary Disease.  International Conference of the American Thoracic Society 
Meeting, San Francisco, California, USA (05/12) 
 
10. M Kirby*, A Wheatley, A Farag, A Ouriadov, GE Santyr DG McCormack and G 
Parraga.  Hyperpolarized Helium-3 and Xenon-129 Magnetic Resonance Imaging 
of  Elderly Never-smokers and Ex-smokers with Chronic Obstructive Pulmonary 
Disease.  International Society for Magnetic Resonance in Medicine, Melbourne, 
Australia (05/12) 
 
11. M Kirby*, R Etemad-Rezai, DG McCormack and G Parraga.  Evaluating 
Bronchodilator Effects in Chronic Obstructive Pulmonary Disease using 
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Hyperpolarized Helium-3 Magnetic Resonance Imaging.    Imaging Network 
Ontario Symposium, Toronto, Ontario, Canada (02/12) 
 
12. S Svenningsen*, M Kirby, A Wheatley, A Ouriadov, GE Santyr, DG 
McCormack and G Parraga.  Reproducibility of Hyperpolarized Helium-3 
Magnetic Resonance Imaging in Adult Cystic Fibrosis using a Semi-Automated 
Segmentation Tool.  Imaging Network Ontario Symposium, Toronto, Ontario, 
Canada (02/12) 
 
13. M Heydarian, M Kirby*, A Wheatley, A Fenster, G Parraga.  Two and Three-
Dimensional Segmentation of Hyperpolarized 3He Magnetic Resonance 
Functional Imaging.  Society of Photographic Instrumentation Engineers, San 
Diego, California, USA (02/12) 
 
14. M Kirby*, M Heydarian, A Wheatley, R Etemad-Rezai, DG McCormack and G 
Parraga.  Development and Application of Novel Hyperpolarized 3He Magnetic 
Resonance Imaging Segmentation to Measure Acute Treatment Effects in 
Pulmonary Disease, The Canadian Organization of Medical Physicists, 
Vancouver, British Columbia, Canada (07/11) 
 
15. M Kirby*, A Wheatley, R Etemad-Rezai, PD Pare, HO Coxson, JC Hogg, DG 
McCormack and G Parraga.  Regional Quantification of Hyperpolarized Helium-3 
Magnetic Resonance Imaging Apparent Diffusion Coefficients:  What does 
Bronchodilator Administration in COPD Accomplish?  3rd Japanese Society of 
Pulmonary Functional Imaging and 5th International Workshop for Pulmonary 
Functional Imaging, Awaji, Japan (01/11) 
 
16. M Kirby*, A Wheatley, DG McCormack and G Parraga.   Development of Image 
processing methods to quantify Spatial and Temporal Ventilation Dynamics using 
Hyperpolarized 3He magnetic resonance imaging, Society of Photographic 
Instrumentation Engineers, San Diego, California, USA (02/10) 
 
17. M Kirby*, A Wheatley, R Etemad-Rezai, DG McCormack and G Parraga.   
Hyperpolarized Helium-3 Magnetic Resonance Imaging Spatial and Temporal 
Ventilation Dynamics in Chronic Obstruction Pulmonary Disease post 
Bronchodilator, Radiological Society of North America, Chicago, Illinois, USA 
(11/09) 
 
18. M Kirby*, L Mathew, A Wheatley, DG McCormack and G Parraga.  
Longitudinal Hyperpolarized 3He Magnetic Resonance Imaging of Chronic 
Obstructive Pulmonary Disease, The Canadian Organization of Medical 
Physicists, Victoria, British Columbia, Canada (07/09) 
 
19. M Kirby, A Wheatley, G Santyr, DG McCormack and G Parraga*.  Visualizing 
and Quantifying Hyperpolarized 3He Magnetic Resonance Imaging Ventilation in 
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COPD pre- and post-Salbutamol.  International Summit on Future of Quantitative 
and Functional Lung Imaging Meeting, Iowa City, Iowa, USA, (10/08) 
 
E.  Peer Reviewed Poster Presentations (52) 
1. K Sheikh, S Svenningsen, M Kirby, D.G. McCormack and G Parraga.  
Hyperpolarized 3He Magnetic Resonance Imaging ADC Gradients in Healthy 
Elderly Never-Smokers. International Society for Magnetic Resonance in 
Medicine Meeting, Salt Lake City, Utah, USA (05/13) 
 
2. S Svenningsen, D Starr, HO Coxson, NAM Paterson, DG McCormack, M Kirby 
and G Parraga.  Asthma Airway Morphology and Hyperpolarized 3He Magnetic 
Resonance Imaging Ventilation Defects.  International Society for Magnetic 
Resonance in Medicine Meeting, Salt Lake City, Utah, USA (05/13) 
 
3. D Pike, M Kirby, A Wheatley, D.G. McCormack and G Parraga. Evaluation of 
Airway Morphology in Chronic Obstructive Pulmonary Disease of 
Hyperpolarized Helium-3 Magnetic Resonance Imaging and Computed 
Tomography. International Society for Magnetic Resonance in Medicine Meeting, 
Salt Lake City, Utah, USA (05/13) 
 
4. N Kanhere, A Hasany, M Kirby, J Suggett, DG McCormack, G Parraga. 
Hyperpolarized 3He Magnetic Resonance Imaging following Oscillatory Positive 
Expiratory Pressure Treatment in GOLD stage II and III COPD.  International 
Conference of the American Thoracic Society Meeting, Philadelphia, 
Pennsylvania, USA (05/13) 
 
5. M Kirby, N Kanhere, D Pike, A Wheatley, N.A. Paterson, D.G. McCormack and 
G Parraga.  Hyperpolarized Helium-3 Magnetic Resonance Imaging Phenotypes 
of Chronic Obstructive Pulmonary Disease: Relationship to Exacerbations.  
International Conference of the American Thoracic Society Meeting, 
Philadelphia, Pennsylvania, USA (05/13) 
 
6. K Sheikh, S Svenningsen, M Kirby, D.G. McCormack and G Parraga.  What is 
the Relationship between Hyperpolarized 3He MRI Measurements, Airborne 
Toxin Exposure, and Exercise Capacity in Healthy Elderly Never-Smokers?  
International Conference of the American Thoracic Society Meeting, 
Philadelphia, Pennsylvania, USA (05/13) 
 
7. K Sheikh, S Svenningsen, M Kirby, D.G. McCormack and G Parraga. 
Hyperpolarized 3He MRI Ventilation Defects in Healthy Elderly Never-Smokers: 
Response to Deep Inspiration and Salbutamol. International Conference of the 
American Thoracic Society Meeting, Philadelphia, Pennsylvania, USA (05/13) 
 
8. D Pike, M Kirby, K Sheikh, D Buchanan, C Neron, J.D. Spence, N.A. Paterson, 
H.O. Coxson, D.G. McCormack and G Parraga.  Airways Disease in 
Asymptomatic Ex-smokers without Airflow Limitation: Relationship to Carotid 
318 
 
Atherosclerosis.  International Conference of the American Thoracic Society 
Meeting, Philadelphia, Pennsylvania, USA (05/13) 
 
9. AM Owrangi, M Kirby, R Etemad-Rezai, DG McCormack, HO Coxson, IA 
Cunningham and G Parraga.  Computed Tomography Density Histogram 
Analysis to Evaluate Pulmonary Emphysema in Ex-smokers.  International 
Conference of the American Thoracic Society Meeting, Philadelphia, 
Pennsylvania, USA (05/13) 
 
10. K Sheikh, S Svenningsen, M Kirby, D.G. McCormack and G Parraga.  What is 
the Relationship between Hyperpolarized 3He MRI Measurements and Exercise 
Capacity in Healthy Elderly Never-Smokers?  London Health Research Day, 
London, Ontario (03/13) 
 
11. D Pike, M Kirby, K Sheikh, D Buchanan, C Neron, JD Spence, NAM Paterson, 
HO Coxson, DG McCormack  and G Parraga. Airways Disease in Asymptomatic 
Ex-smokers without Airflow Limitation: Relationship to Carotid Atherosclerosis.  
London Health Research Day, London, Ontario (03/13) 
 
12. S Svenningsen, D Starr, HO Coxson, NAM Paterson, DG McCormack, M Kirby 
and G Parraga.  Asthma Airway Morphology and Hyperpolarized 3He Magnetic 
Resonance Imaging Ventilation Defects.  London Health Research Day, London, 
Ontario (03/13) 
 
13. K Sheikh, S Svenningsen, M Kirby, D.G. McCormack and G Parraga.  What is 
the Relationship between Hyperpolarized 3He MRI Measurements and Exercise 
Capacity in Healthy Elderly Never-Smokers?  Imaging Network Ontario 
Symposium, Toronto, Ontario, Canada (02/13) 
 
14. K Sheikh, S Svenningsen, M Kirby, D.G. McCormack , G Parraga. 
Hyperpolarized 3He MRI Ventilation Defects in Healthy Elderly Never-Smokers: 
Response to Deep Inspiration and Salbutamol. Imaging Network Ontario 
Symposium, Toronto, Ontario, Canada (02/13) 
 
15. D Pike, M Kirby, K Sheikh, D Buchanan, C Neron, JD Spence, NAM Paterson, 
HO Coxson, DG McCormack  and G Parraga. Airways Disease in Asymptomatic 
Ex-smokers without Airflow Limitation: Relationship to Carotid Atherosclerosis.  
Imaging Network Ontario Symposium, Toronto, Ontario, Canada (02/13) 
 
16. N Kanhere, A Hasany, M Kirby, J Suggett, DG McCormack, G Parraga. 
Hyperpolarized 3He Magnetic Resonance Imaging following Oscillatory Positive 
Expiratory Pressure Treatment in GOLD stage II and III COPD.  Imaging 
Network Ontario Symposium, Toronto, Ontario, Canada (02/13) 
 
17. M Kirby, C Neron, JD Spence, NAM Paterson, D Buchanan, A Wheatley, HO 
Coxson, DG McCormack and G Parraga.  Hyperpolarized Helium-3 Magnetic 
319 
 
Resonance Imaging of Pulmonary Structure and Function in Ex-smokers with 
Carotid Atherosclerosis.  London Imaging Discovery Day, London, Ontario, 
Canada (06/12) 
 
18. M Kirby, C Neron, JD Spence, NAM Paterson, D Buchanan, A Wheatley, HO 
Coxson, DG McCormack and G Parraga.  Hyperpolarized Helium-3 Magnetic 
Resonance Imaging of Pulmonary Structure and Function in Ex-smokers with 
Carotid Atherosclerosis.  International Conference of the American Thoracic 
Society Meeting, San Francisco, California, USA (05/12) 
 
19. N Kanhere, M Kirby, A Wheatley, GE Santyr, DG McCormack, GB Rodrigues, 
G Parraga and L Mathew.  Hyperpolarized Helium-3 and Xenon-129 Magnetic 
Resonance Imaging of Radiation-induced Lung Injury.  International Conference 
of the American Thoracic Society Meeting, San Francisco, California, USA 
(05/12) 
 
20. S Svenningsen, M Kirby, A Wheatley, A Ouriadov, GE Santyr, DG McCormack 
and G Parraga.  Hyperpolarized 3He and 129Xe Magnetic Resonance Imaging of 
Asthma.  International Conference of the American Thoracic Society Meeting, 
San Francisco, California, USA (05/12) 
 
21. DG McCormack, S Halko, S McKay, M Kirby, S Svenningsen, A Wheatley, A 
Farag, GE Santyr and G Parraga.  Hyperpolarized 129Xe MRI  Feasibility, Subject 
Safety and Tolerability: At the doorstep of Clinical Translation? International 
Conference of the American Thoracic Society Meeting, San Francisco, California, 
USA (05/12) 
 
22. S Svenningsen, M Kirby, A Wheatley, A Farag, A Ouriadov, GE Santyr, DG 
McCormack and G Parraga. Anatomical Distribution of Hyperpolarized 3He and 
129Xe MRI Apparent Diffusion Coefficients in Asthma.  International Society for 
Magnetic Resonance in Medicine, Melbourne, Australia (05/12) 
 
23. A Ouriadov, A Farag, M Kirby, DG McCormack, G Parraga and G Santyr. 
Hyperpolarized 129Xe Apparent Diffusion Coefficient Anisotropy in Chronic 
Obstructive Pulmonary Disease.  International Society for Magnetic Resonance in 
Medicine, Melbourne, Australia (05/12) 
 
24. N Kanhere, M Kirby, A Wheatley, A Ouriadov, GE Santyr, DG McCormack and 
G Parraga.  Reproducibility of Hyperpolarized Xenon-129 Magnetic Resonance 
Imaging of Chronic Obstructive Pulmonary Disease.  International Society for 
Magnetic Resonance in Medicine, Melbourne, Australia (05/12) 
 
25. M Kirby, L Mathew, M Heydarian, R Etemad-Rezai, DG McCormack and G 
Parraga..  Evaluating Bronchodilator Effects in Chronic Obstructive Pulmonary 
Disease using Hyperpolarized Helium-3 Magnetic Resonance Imaging.  London 
Healthy Research Day, London, Ontario, Canada (03/12) 
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26. N Kanhere, M Kirby, A Wheatley, A Ouriadov, GE Santyr, DG McCormack and 
G Parraga.  Reproducibility of Hyperpolarized Xenon-129 Magnetic Resonance 
Imaging of Chronic Obstructive Pulmonary Disease.  London Healthy Research 
Day, London, Ontario, Canada (03/12) 
 
27. S Svenningsen, M Kirby, A Wheatley, A Ouriadov, GE Santyr, DG McCormack 
and G Parraga.  Comparison of Hyperpolarized 3He and 129Xe Magnetic 
Resonance Imaging of Asthma:  Pre- and Post-Salbutamol.  London Healthy 
Research Day, London, Ontario, Canada (03/12) 
 
28. M Kirby, L Mathew, M Heydarian, R Etemad-Rezai, DG McCormack and G 
Parraga..  Evaluating Bronchodilator Effects in Chronic Obstructive Pulmonary 
Disease using Hyperpolarized Helium-3 Magnetic Resonance Imaging.  Imaging 
Network Ontario Symposium, Toronto, Ontario, Canada (02/12) 
 
29. N Kanhere, M Kirby, A Wheatley, A Ouriadov, GE Santyr, DG McCormack and 
G Parraga.  Reproducibility of Hyperpolarized Xenon-129 Magnetic Resonance 
Imaging of Chronic Obstructive Pulmonary Disease.  Reproducibility of 
Hyperpolarized Xenon-129 Magnetic Resonance Imaging of Chronic Obstructive 
Pulmonary Disease.  Imaging Network Ontario Symposium, Toronto, Ontario, 
Canada (02/12) 
 
30. S Svenningsen, M Kirby, A Wheatley, A Ouriadov, GE Santyr, DG McCormack 
and G Parraga.  Reproducibility of Hyperpolarized Helium-3 Magnetic Resonance 
Imaging in Adult Cystic Fibrosis using a Semi-Automated Segmentation Tool.  
Imaging Network Ontario Symposium, Toronto, Ontario, Canada (02/12) 
 
31. M Kirby, L Mathew, M Heydarian, R Etemad-Rezai, DG McCormack and G 
Parraga..  Evaluating Bronchodilator Effects in Chronic Obstructive Pulmonary 
Disease using Hyperpolarized Helium-3 Magnetic Resonance Imaging.  London 
Imaging Discovery Day, London, Ontario, Canada (06/11) 
 
32. M Kirby, L Mathew, D. Farquhar, C. Licskai, R McFadden, DG McCormack, G 
Parraga.  Hyperpolarized 3He Magnetic Resonance Imaging Biomarkers of 
Bronchoscopic Airway Bypass in COPD.  International Conference of the 
American Thoracic Society Meeting, Denver, Colorado, USA (05/11) 
 
33. M Kirby, N. Krowchuk, A Wheatley, DG McCormack, H Coxson, G Parraga.  
Evaluation of COPD Airway Function and Structure using Hyperpolarized 3He 
Magnetic Resonance Imaging and x-ray Computed Tomography.  International 
Conference of the American Thoracic Society Meeting, Denver, Colorado, USA 
(05/11) 
 
34. M Kirby, N. Krowchuk, A Wheatley, DG McCormack, H Coxson, G Parraga.  
Evaluation of COPD Airway Function and Structure using Hyperpolarized 3He 
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Magnetic Resonance Imaging and x-ray Computed Tomography.  1st Annual 
Canadian Thoracic Society Poster Competition, Denver, Colorado, USA (05/11) 
 
35. S Svenningsen, M Kirby, H Ahmed, N Paterson, G Parraga. Evaluation of Short 
Term Reproducibility of Hyperpolarized Helium-3 Magnetic Resonance Imaging 
in Adult Cystic Fibrosis using a Semi-Automated Segmentation Tool. 
International Society for Magnetic Resonance in Medicine, Montreal, Quebec, 
Canada (05/11) 
 
36. M Kirby, R Etemad-Rezai, DG McCormack and G Parraga.  Evaluating 
Bronchodilator Effects in Chronic Obstructive Pulmonary Disease using 
Hyperpolarized Helium-3 Magnetic Resonance Imaging.  International Society 
for Magnetic Resonance in Medicine, Montreal, Quebec, Canada (05/11) 
 
37. M Kirby, L Mathew, M Heydarian, R Etemad-Rezai, DG McCormack and G 
Parraga. Evaluating Bronchodilator Effects in Chronic Obstructive Pulmonary 
Disease Quantified using Hyperpolarized Helium-3 Magnetic Resonance 
Imaging.  Margaret Moffat Research Day, London, Ontario, Canada (03/11) 
 
38. L Mathew, M Kirby, R Etemad-Rezai, D G McCormack, G Parraga.  
Hyperpolarized 3He Magnetic Resonance Imaging Biomarkers of Bronchoscopic 
Airway Bypass in COPD.  5th International Workshop for Pulmonary Functional 
Imaging, Awaji, Japan (01/11) 
 
39. SE Costella, S Choy, M Kirby, A Wheatley, R Etemad-Rezai, DG McCormack, 
G Parraga.  Hyperpolarized 3He MRI Apparent Diffusion Coefficients as a Probe 
of Airway Function in Asthma After Methacholine Challenge and Recovery.  5th 
International Workshop for Pulmonary Functional Imaging, Awaji, Japan (01/11) 
 
40. M Heydarian, M Kirby, S Choy, A Wheatley, S Costella, R Etemad-Rezai, DG 
McCormack, G Parraga.  Semi-Automated Segmentation of Lung Ventilation 
using Hyperpolarized Heliium-3 Magnetic Resonance Imaging, Biomedical 
Engineering Society, Austin, Texas, (09/10) 
 
41. M Kirby, L Mathew, A Wheatley, DG McCormack and G Parraga.  Inter-
Observer Reproducibility of Longitudinal Hyperpolarized Helium-3 Magnetic 
Resonance Imaging of Chronic Obstructive Pulmonary Disease. London Imaging 
Discovery Day, London, Ontario, Canada (06/10) 
 
42. L Mathew, M Kirby, R Etemad-Rezai, DG McCormack, G Parraga.  
Characterization of Hyperpolarized Helium-3 Magnetic Resonance Imaging 
Phenotype Dominant COPD. International Conference of the American Thoracic 
Society, New Orleans, Louisiana, USA (05/10) 
 
43. M Kirby, L Mathew, A Wheatley, DG McCormack and G Parraga.  Inter-
Observer Reproducibility of Longitudinal Hyperpolarized Helium-3 Magnetic 
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Resonance Imaging of Chronic Obstructive Pulmonary Disease.  International 
Society for Magnetic Resonance in Medicine, Stockholm, Sweden (05/10) 
 
44. M Kirby, L Mathew, A Wheatley, DG McCormack and G Parraga.  Inter-
Observer Reproducibility of Longitudinal Hyperpolarized Helium-3 Magnetic 
Resonance Imaging of Chronic Obstructive Pulmonary Disease.  Margaret Moffat 
Research Day, London, Ontario, Canada (03/10) 
 
45. M Kirby, L Mathew, A Wheatley, DG McCormack and G Parraga.  Inter-
Observer Reproducibility of Longitudinal Hyperpolarized Helium-3 Magnetic 
Resonance Imaging of Chronic Obstructive Pulmonary Disease.  Lawson 
Research Day, London, Ontario, Canada (03/10) 
 
46. A Wheatley, H Ahmed, S Choy, M Kirby and G Parraga.  Development and 
Application of Texture Analysis Tools for Hyperpolarized Helium-3 Magnetic 
Resonance Lung Imaging, The International Workshop for Pulmonary Functional 
Imaging, Boston, Massachusetts, USA (09/09) 
 
47. M Kirby, L Mathew, A Wheatley, DG McCormack and G Parraga.  Chronic 
Obstructive Pulmonary Disease Progression Detected by Hyperpolarized Helium-
3 Magnetic Resonance Imaging, London Imaging Discovery Day, London, 
Ontario, Canada (06/09) 
 
48. M Kirby, A Wheatley, DG McCormack and G Parraga.  Hyperpolarized Helium-
3 Magnetic Resonance Imaging Ventilation Heterogeneity in Chronic Obstructive 
Pulmonary Disease, London Imaging Discovery Day, London, Ontario, Canada 
(06/09) 
 
49. M Kirby, A Wheatley, DG McCormack and G Parraga.  Hyperpolarized Helium-
3 Magnetic Resonance Imaging Ventilation Heterogeneity in Chronic Obstructive 
Pulmonary Disease, International Conference of the American Thoracic Society 
Meeting, San Diego, California, USA (05/09) 
 
50. M Kirby, L Mathew, A Wheatley, DG McCormack and G Parraga.  Longitudinal 
Hyperpolarized Helium-3 Magnetic Resonance Imaging of Chronic Obstructive 
Pulmonary Disease: Two year Follow-up Evaluation, International Conference of 
the American Thoracic Society Meeting, San Diego, California, USA (05/09) 
 
51. H Ahmed, M Kirby*, L Mathew, S Choy, A Wheatley, G Santyr, R McFadden, 
NAM Paterson, J Lewis, R Veldhuizen, G Rodrigues, G Bauman, C Licskai, R 
Etemad-Rezai, DG McCormack and G Parraga.  Hyperpolarized 3He Magnetic 
Resonance Imaging:  Novel Imaging Endpoints for Respiratory Research, 
Canadian Respiratory Conference, Toronto, Ontario, Canada (04/09) 
 
52. M Kirby, L Mathew, A Wheatley, DG McCormack and G Parraga.  Chronic 
Obstructive Pulmonary Disease Progression Detected by Hyperpolarized Helium-
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3 Magnetic Resonance Imaging, Margaret Moffat Research Day, London, 
Ontario, Canada (03/09) 
 
 
F.  Invited Presentations (4) 
1. M Kirby, N Kanhere, D Pike, A Wheatley, N.A. Paterson, D.G. McCormack and 
G Parraga.  Hyperpolarized Helium-3 Magnetic Resonance Imaging Phenotypes 
of Chronic Obstructive Pulmonary Disease: Relationship to Exacerbations.  3rd 
Annual Canadian Thoracic Society Poster Competition, Philadelphia, 
Pennsylvania, USA (05/13) 
 
2. M Kirby, A Wheatley, DG McCormack, G Parraga.  Imaging of lung function 
using hyperpolarized helium.  European Respiratory Society, Vienna, Austria 
(09/12) 
 
3. M Kirby, L Mathew, A Wheatley, DG McCormack, G Parraga.  Hyperpolarized 
Helium-3 Magnetic Resonance Imaging of Chronic Obstructive Pulmonary 
Disease.  A.C. Burton Day, London, Ontario, Canada (04/11) 
 
4. M Kirby, N. Krowchuk, A Wheatley, DG McCormack, H Coxson, G Parraga.  
Evaluation of COPD Airway Function and Structure using Hyperpolarized 3He 
Magnetic Resonance Imaging and x-ray Computed Tomography.  1st Annual 
Canadian Thoracic Society Poster Competition, Denver, Colorado, USA (05/11) 
 
 
POST-GRADUATE EDUCATION DEVELOPMENT 
Oct. 2012 –  
Nov. 2012 
Graduate Student Supervisor 
Resident:  Aasim Hasany, 2nd year Internal Medicine, UWO 
6 Week Project:  ‘Longitudinal Study of Oscillatory Positive 
Expiratory Pressure (oPEP) in Stable COPD’ 
Poster Presentation ImNO: N Kanhere, A Hasany, M Kirby, J 
Suggett, DG McCormack, G Parraga. Hyperpolarized 3He Magnetic 
Resonance Imaging following Oscillatory Positive Expiratory Pressure 
Treatment in GOLD stage II and III COPD.  Imaging Network Ontario 
Symposium, Toronto, Ontario, Canada (02/13) 
 
May 2012 –  
Aug. 2012 
Graduate Student Supervisor 
Medical Student:  Lauren Villemaire, 2nd year Medicine, UWO 
Project: ‘Hyperpolarized Helium-3 Diffusion-Weighted Magnetic 
Resonance Imaging of Cystic Fibrosis’ 
Poster Presentation ATS: M Kirby, L Villemaire, H Ahmed, N.A. 
Paterson, D.G. McCormack, J.F. Lewis and G Parraga.   Diffusion-
Weighted Hyperpolarized Helium-3 Magnetic Resonance Imaging in 
Adult Cystic Fibrosis.  International Conference of the American 
Thoracic Society Meeting, Philadelphia, Pennsylvania, USA (05/13) 
Manuscript in Preparation:  M Kirby, L Villemaire, H Ahmed, NAM 
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Paterson, DG McCormack JF Lewis and G Parraga.  Diffusion-
Weighted Hyperpolarized Helium-3 Magnetic Resonance Imaging of 
Cystic Fibrosis.  JAP 
 
Jan. 2012 –   
Feb. 2012 
Graduate Student Supervisor 
Resident:  Yaj Shukla, 2nd year Internal Medicine, UWO 
6 Week Project:  ‘Hyperpolarized 129Xe Magnetic Resonance Imaging: 
Tolerability in Healthy Volunteers and Subjects with Pulmonary 
Disease’ 
Published Manuscript:  Y Shukla, A Wheatley, M Kirby, S 
Svenningsen, A Farag, G Santyr, NAM Paterson, DG McCormack and 
G Parraga.  Hyperpolarized 129Xe Magnetic Resonance Imaging: 
Tolerability in Healthy Volunteers and Subjects with Pulmonary 
Disease.  Acad. Radiol. 2012; 19(8):941-51.   
 
Jan. 2012 –   
Feb. 2012 
Graduate Student Supervisor 
Resident:  Andrew Youn, 2nd year Internal Medicine, UWO 
6 Week Project:  ‘Hyperpolarized Helium-3 and Xenon-129 Magnetic 
Resonance Functional Imaging in Adult Cystic Fibrosis’ 
Oral Presentation ATS: A Youn, M Kirby, A Wheatley, J Lewis, DG 
McCormack and G Parraga.  Hyperpolarized Helium-3 and Xenon-129 
Magnetic Resonance Functional Imaging in Adult Cystic Fibrosis.  
International Conference of the American Thoracic Society Meeting, 
San Francisco, California, USA (05/12) 
 
Jun. 2011 3D Slicer Workshop 
Instructor:  Dr. Ron Kikinis 
Objective:  Introduction to the 3D Slicer environment, as well as to 
illustrate the ability to integrate with ITK and Python modules. 
 
Jun. 2011 –  
Aug. 2011  
Graduate Student Supervisor 
Medical Student:  Casey Neron, 2nd year Medicine, UWO 
8 Week Project:  ‘Evaluating the Relationship between Atherosclerosis 
and Lung Function in Subjects with Smoking Histories’ 
Poster Presentation ATS: M Kirby, C Neron, JD Spence, NAM 
Paterson, D Buchanan, A Wheatley, HO Coxson, DG McCormack and 
G Parraga  Hyperpolarized Helium-3 Magnetic Resonance Imaging of 
Pulmonary Structure and Function in Ex-smokers with Carotid 
Atherosclerosis.  International Conference of the American Thoracic 
Society Meeting, San Francisco, California, USA (05/12) 
Manuscript in Preparation:  D Pike, M Kirby, C Neron, D Buchanan, 
JD Spence, NAM Paterson, A Wheatley, HO Coxson, DG McCormack 
and G Parraga.  Hyperpolarized Helium-3 Magnetic Resonance 
Imaging of Pulmonary Structure and Function in Ex-smokers with 
Carotid Atherosclerosis.  Respirology 
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Sep. 2010 –  
Apr. 2011  
Graduate Student Supervisor 
Undergraduate Student:  Sarah Svenningsen, 4th year Medical 
Biophysics, UWO 
Thesis Project:  ‘Quantitative Evaluation of Hyperpolarized Helium-3 
Magnetic Resonance Imaging of Lung Function Variability in Cystic 
Fibrosis’ 
Poster Presentation ISMRM: S Svenningsen, M Kirby, A Wheatley, 
A Ouriadov, GE Santyr, DG McCormack and G Parraga.  
Reproducibility of Hyperpolarized Helium-3 Magnetic Resonance 
Imaging in Adult Cystic Fibrosis using a Semi-Automated 
Segmentation Tool.  Imaging Network Ontario, Toronto, Ontario, 
Canada (02/12) 
Published Manuscript:  M Kirby, S Svenningsen, H Ahmed, N 
Paterson and G Parraga.  Quantitative Evaluation of Hyperpolarized 
Helium-3 Magnetic Resonance Imaging of Lung Function Variability 
in Cystic Fibrosis. Acad. Radiol. 2011; 18(8):1006-13.  
 
Sep. 2010 –  
Dec. 2010 
  
Graduate Teaching Assistant 
3505F Mathematical Transform Applications in Medical Biophysics 
Department of Medical Biophysics 
The University of Western Ontario, London, Ontario, Canada 
 
Sep. 2009 –  
Dec. 2009 
  
Graduate Teaching Assistant 
3505F Mathematical Transform Applications in Medical Biophysics 
Department of Medical Biophysics 
The University of Western Ontario, London, Ontario, Canada 
 
 
RELEVANT GRADUATE COURSES 
Department of Medical Biophysics 
The University of Western Ontario, London, Ontario, Canada 
 
Sep. 2009 –  
Apr. 2010 
BIOPHYS 9663 
BIOPHYS 9516 
BIOPHYS 9662 
BIOPHYS 9509 
MRI Physics  
Imaging Principles  
Nuclear Magnetic Resonance Imaging 
Digital Image Processing  
 
Sep. 2008 – 
Apr. 2009 
BIOPHYS 9515 
VASCPROG 9560 
VASCPROG 9603 
BIOPHYS 9513 
BIOPHYS 9522 
Medical Imaging  
Vascular Imaging  
Research Ethics  
Scientific Communication  
Inferencing from data analysis  
 
 
PROFESSIONAL MEMEBERSHIPS 
2010 – 2011 Biomedical Engineering Society 
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Student Member  
2009 – present Canadian Thoracic Society 
Student Member 
2008 – present American Thoracic Society 
Student Member 
2008 – present  International Society of Magnetic Resonance in Medicine 
Student Member 
2008 – present Canadian Organization of Physicists in Medicine 
Student Member 
 
 
LEADERSHIP and VOLUNTEER ACTIVITIES 
2013 Volunteer, Let’s Talk Science 
Member, Biomedical Imaging Research Centre (BIRC) 
Member, Network of Imaging Students (NOISe) 
 
2012 Volunteer, Canadian Cancer Society, Relay for Life 
Volunteer, Let’s Talk Science 
Member, Biomedical Imaging Research Centre (BIRC) 
Member, Network of Imaging Students (NOISe) 
 
2011 Volunteer, Let’s Talk Science 
Member, Biomedical Imaging Research Centre (BIRC) 
Member, Network of Imaging Students (NOISe) 
 
2010
  
Member, Biomedical Imaging Research Centre (BIRC) 
Member, Network of Imaging Students (NOISe) 
 
2009
  
Volunteer, Doors open London, Robarts Research Institute 
Member, Network of Imaging Students (NOISe) 
 
2008 Member, Network of Imaging Students (NOISe) 
 
